Estimating kinetic parameters from dynamic contrast-diffusable tracer: Standardized quantities and symbols

Journal of Magnetic Resonance Imaging 10, 223-232

DOI: 10.1002/(sici)1522-2586(199909)10:3<223::aid-jmri2>3.0.co;2-s

Citation Report

#	Article	IF	CITATIONS
1	Gadolinium-enhanced plaque imaging., 0,, 288-301.		0
2	GREEN'S MATRICES OF BOUNDARY VALUE PROBLEMS FOR PETROVSKIĬ PARABOLIC SYSTEMS OF GENERAL FORM. I. Sbornik: Mathematics, 1982, 42, 93-144.	0.2	5
4	Key factors in the acquisition of contrast kinetic data for oncology. Journal of Magnetic Resonance Imaging, 1999, 10, 254-259.	1.9	346
5	MR imaging of tumor microcirculation: Promise for the new millenium. Journal of Magnetic Resonance Imaging, 1999, 10, 903-907.	1.9	212
6	Dynamic contrast-enhanced MR imaging. Cancer Imaging, 2000, 1, 52-63.	1.2	7
7	<title>Accurate estimation of contrast agent dynamics in fast contrast-enhanced MRI</title> ., 2000, , .		O
8	Simultaneous MRI measurement of blood flow, blood volume, and capillary permeability in mammary tumors using two different contrast agents. Journal of Magnetic Resonance Imaging, 2000, 12, 991-1003.	1.9	128
9	Determination of the MRI contrast agent concentration time course in vivo following bolus injection: Effect of equilibrium transcytolemmal water exchange. Magnetic Resonance in Medicine, 2000, 44, 563-574.	1.9	199
11	Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. Magnetic Resonance Imaging, 2000, 18, 765-776.	1.0	104
12	Analysis of the Look-Locker T1 mapping sequence in dynamic contrast uptake studies: simulation and in vivo validation. Magnetic Resonance Imaging, 2000, 18, 947-954.	1.0	28
13	Pharmacokinetic analysis of glioma compartments with dynamic Gd-DTPA-enhanced magnetic resonance imaging. Magnetic Resonance Imaging, 2000, 18, 1201-1214.	1.0	91
14	Evolution from empirical dynamic contrast-enhanced magnetic resonance imaging to pharmacokinetic MRI. Advanced Drug Delivery Reviews, 2000, 41, 91-110.	6.6	59
15	Preclinical MRI experience in imaging angiogenesis. Cancer and Metastasis Reviews, 2000, 19, 39-43.	2.7	27
16	Measurement of the arterial input function using changes in T/sub $2/*$ in the aorta for dynamic contrast-enhanced MR imaging of cancerous lesions in the rat., 0 ,,.		O
17	Spectroscopical Measurements of Ablation Plasma Generated by an Excimer Laser from Functionally Graded Materials. Japanese Journal of Applied Physics, 2000, 39, 5263-5267.	0.8	5
18	Contrast-enhanced magnetic resonance imaging of the breast. European Journal of Radiology, 2000, 34, 208-219.	1.2	77
19	Breast imaging technology Application of magnetic resonance imaging to angiogenesis in breast cancer. Breast Cancer Research, 2000, 3, 22-7.	2.2	57
20	Application of CT in the investigation of angiogenesis in oncology. Academic Radiology, 2000, 7, 840-850.	1.3	211

#	Article	IF	Citations
21	In vivo monitoring of tumor angiogenesis with MR imaging. Academic Radiology, 2000, 7, 812-823.	1.3	117
23	Dynamic Contrast-enhanced MRI Studies in Oncology with an Emphasis on Quantification, Validation and Human Studies. Clinical Radiology, 2001, 56, 607-620.	0.5	220
24	Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Oncology. Topics in Magnetic Resonance Imaging, 2001, 12, 301-308.	0.7	145
25	Tumor volume or dynamic contrast-enhanced MRI for prediction of clinical outcome of Ewing sarcoma family of tumors. Pediatric Radiology, 2001, 31, 518-523.	1.1	35
26	Synovial sarcoma: dynamic contrast-enhanced MR imaging features. Skeletal Radiology, 2001, 30, 25-30.	1.2	47
27	Nichtinvasive Untersuchung der Mikrozirkulation von neoplastischen Erkrankungen. Onkologe, 2001, 7, 1134-1144.	0.7	4
28	Comparison of plasma and peritoneal concentrations of various categories of MRI blood pool agents in a murine experimental pharmacokinetic model. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2001, 12, 82-87.	1.1	25
29	Serial changes in tumor oxygenation during the early phase of radiation therapy in cervical cancer—are we quantitating hypoxia change? re: Lyng et al., IJROBP 2000; 46:935–946. International Journal of Radiation Oncology Biology Physics, 2001, 49, 282-285.	0.4	2
30	Comparison of plasma and peritoneal concentrations of various categories of MRI blood pool agents in a murine experimental pharmacokinetic model. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2001, 12, 82-87.	1.1	0
31	Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd-DTPA-enhanced MR imaging. Journal of Magnetic Resonance Imaging, 2001, 14, 750-756.	1.9	71
32	Myocardial flow reserve parametric map, assessed by first-pass MRI compartmental analysis at the chronic stage of infarction. Journal of Magnetic Resonance Imaging, 2001, 13, 352-360.	1.9	17
33	Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. Journal of Magnetic Resonance Imaging, 2001, 13, 607-614.	1.9	106
34	Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. Journal of Magnetic Resonance Imaging, 2001, 14, 457-463.	1.9	174
35	Dynamic contrast-enhanced MRI using Gd-DTPA: Interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. Magnetic Resonance in Medicine, 2001, 45, 1030-1038.	1.9	147
36	Quantification of the effect of water exchange in dynamic contrast MRI perfusion measurements in the brain and heart. Magnetic Resonance in Medicine, 2001, 46, 272-281.	1.9	101
37	A pharmacokinetic model for quantitative evaluation of spinal cord injury with dynamic contrast-enhanced magnetic resonance imaging. Magnetic Resonance in Medicine, 2001, 46, 1099-1106.	1.9	36
38	Comparison of dynamic contrast-enhanced MRI with WHO tumor grading for gliomas. European Radiology, 2001, 11, 1231-1241.	2.3	98
39	Comparison of pharmacokinetic MRI and [18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience. European Radiology, 2001, 11, 2058-2070.	2.3	45

#	ARTICLE	IF	CITATIONS
40	Developments in nuclear magnetic resonance imaging and spectroscopy: Application to radiation oncology*. Seminars in Radiation Oncology, 2001, 11, 3-15.	1.0	20
41	Magnetic resonance imaging applications in the evaluation of tumor angiogenesis*. Seminars in Radiation Oncology, 2001, $11,70-82$.	1.0	55
42	Intensity-modulated Parametric Mapping for Simultaneous Display of Rapid Dynamic and High-Spatial-Resolution Breast MR Imaging Data. Radiographics, 2001, 21, 217-226.	1.4	48
43	Effects of Androgen Deprivation on Prostatic Morphology and Vascular Permeability Evaluated with MR Imaging. Radiology, 2001, 218, 365-374.	3. 6	143
44	In vivo imaging of blood-spinal cord barrier permeability with dynamic contrast enhanced MRI of spinal cord injury. , 0 , , .		0
45	Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Journal of Clinical Oncology, 2002, 20, 3826-3840.	0.8	150
46	Steady-state and Dynamic Contrast MR Imaging of Human Prostate Cancer Xenograft Tumors: A Comparative Study. Technology in Cancer Research and Treatment, 2002, 1, 489-495.	0.8	12
47	Acute Cardiac Transplant Rejection: Detection and Grading with MR Imaging with a Blood Pool Contrast Agent—Experimental Study in the Rat. Radiology, 2002, 225, 97-103.	3. 6	30
48	Measurement of Volumetric and Vascular Changes with Dynamic Contrast Enhanced MRI for Cancer Therapy Monitoring. Technology in Cancer Research and Treatment, 2002, 1, 479-488.	0.8	9
49	Pharmacokinetic Modeling of Gd-DTPA Extravasation in Brain Tumors. Investigative Radiology, 2002, 37, 562-570.	3.5	23
50	Gadobenate Dimeglumine in MRI of Acute Myocardial Infarction. Investigative Radiology, 2002, 37, 135-145.	3.5	13
51	Identifying Tumor Vascular Permeability Heterogeneity With Magnetic Resonance Imaging Contrast Agents. Investigative Radiology, 2002, 37, 178-192.	3.5	21
52	ARMA modeling for estimation of permeability from perfusion MRI. , 0 , , .		0
53	Functional MRI for anticancer therapy assessment. European Journal of Cancer, 2002, 38, 2116-2127.	1.3	96
54	Hypoxia imaging in brain tumors. Neuroimaging Clinics of North America, 2002, 12, 537-552.	0.5	46
55	Diffusion-weighted MRI in the characterization of soft-tissue tumors. Journal of Magnetic Resonance Imaging, 2002, 15, 302-307.	1.9	171
56	Dynamic contrast-enhanced MRI in clinical oncology: Current status and future directions. Journal of Magnetic Resonance Imaging, 2002, 16, 407-422.	1.9	415
57	Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhancedT1-weighted MRI. Magnetic Resonance in Medicine, 2002, 47, 601-606.	1.9	257

#	ARTICLE	IF	CITATIONS
58	Transcytolemmal water exchange and its affect on the determination of contrast agent concentration in vivo. Magnetic Resonance in Medicine, 2002, 47, 420-421.	1.9	32
59	Mapping myocardial perfusion with an intravascular MR contrast agent: Robustness of deconvolution methods at various blood flows. Magnetic Resonance in Medicine, 2002, 48, 166-179.	1.9	36
60	Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. NMR in Biomedicine, 2002, 15, 164-173.	1.6	81
61	Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR in Biomedicine, 2002, 15, 132-142.	1.6	323
62	Reproducibility of quantitative dynamic MRI of normal human tissues. NMR in Biomedicine, 2002, 15, 143-153.	1.6	183
63	Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR in Biomedicine, 2002, 15, 89-98.	1.6	104
64	Applications of sliding window reconstruction with cartesian sampling for dynamic contrast enhanced MRI. NMR in Biomedicine, 2002, 15, 174-183.	1.6	68
65	Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR in Biomedicine, 2002, 15, 154-163.	1.6	250
67	Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. British Journal of Surgery, 2002, 88, 1628-1636.	0.1	212
68	Neural network-based segmentation of dynamic MR mammographic images. Magnetic Resonance Imaging, 2002, 20, 147-154.	1.0	50
69	MRI measurement of blood-brain barrier permeability following spontaneous reperfusion in the starch microsphere model of ischemia. Magnetic Resonance Imaging, 2002, 20, 221-230.	1.0	44
70	In vivo assessment of blood-spinal cord barrier permeability: serial dynamic contrast enhanced MRI of spinal cord injury. Magnetic Resonance Imaging, 2002, 20, 337-341.	1.0	43
71	Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1185-1191.	0.4	111
72	Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. International Journal of Radiation Oncology Biology Physics, 2002, 54, 759-767.	0.4	165
73	Effect of breathing a hyperoxic hypercapnic gas mixture on the oxygenation of meningiomas; preliminary results. Journal of Neuro-Oncology, 2002, 57, 127-132.	1.4	8
74	MR Imaging-guided Focused Ultrasound Surgery of Breast Cancer: Correlation of Dynamic Contrast-enhanced MRI with Histopathologic Findings. Breast Cancer Research and Treatment, 2003, 82, 93-101.	1.1	132
75	Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. European Radiology, 2003, 13, 80-87.	2.3	84
76	A physiologic model of capillary-tissue exchange for dynamic contrast-enhanced imaging of tumor microcirculation. IEEE Transactions on Biomedical Engineering, 2003, 50, 159-167.	2.5	65

#	ARTICLE	IF	CITATIONS
77	Dynamic MRI of breast hardness following radiation treatment. Journal of Magnetic Resonance Imaging, 2003, 17, 427-434.	1.9	16
78	Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. Journal of Magnetic Resonance Imaging, 2003, 17, 509-520.	1.9	401
79	Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases. Journal of Magnetic Resonance Imaging, 2003, 18, 315-320.	1.9	45
80	Determining and optimizing the precision of quantitative measurements of perfusion from dynamic contrast enhanced MRI. Journal of Magnetic Resonance Imaging, 2003, 18, 575-584.	1.9	69
81	High-resolution assessment of blood flow in murine RIF-1 tumors by monitoring uptake of H217O with protonT1?-weighted imaging. Magnetic Resonance in Medicine, 2003, 49, 1-6.	1.9	27
82	Albumin-binding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model. Magnetic Resonance in Medicine, 2003, 49, 586-590.	1.9	32
83	Capillarization of the sinusoids in liver fibrosis: Noninvasive assessment with contrast-enhanced MRI in the rabbit. Magnetic Resonance in Medicine, 2003, 49, 692-699.	1.9	92
84	Comparison of temporal filtering methods for dynamic contrast MRI myocardial perfusion studies. Magnetic Resonance in Medicine, 2003, 49, 895-902.	1.9	28
85	Patlak plots of Gd-DTPA MRI data yield blood-brain transfer constants concordant with those of 14C-sucrose in areas of blood-brain opening. Magnetic Resonance in Medicine, 2003, 50, 283-292.	1.9	171
86	Variation of the relaxographic ?shutter-speed? for transcytolemmal water exchange affects the CR bolus-tracking curve shape. Magnetic Resonance in Medicine, 2003, 50, 1151-1169.	1.9	171
87	New hybrid technique for accurate and reproducible quantitation of dynamic contrast-enhanced MRI data. Magnetic Resonance in Medicine, 2003, 50, 1286-1295.	1.9	30
88	Detecting early response to cyclophosphamide treatment of RIF-1 tumors using selective multiple quantum spectroscopy (SelMQC) and dynamic contrast enhanced imaging. NMR in Biomedicine, 2003, 16, 102-111.	1.6	31
89	Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts. Magnetic Resonance Imaging, 2003, 21, 475-482.	1.0	52
90	Quantitative assessment of Gd-DTPA contrast agent from signal enhancement: an in-vitro study. Magnetic Resonance Imaging, 2003, 21, 637-643.	1.0	42
91	Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media. Magnetic Resonance Imaging, 2003, 21, 845-851.	1.0	75
92	Comparison of intermittent-bolus contrast imaging with conventional power Doppler sonography: quantification of tumour perfusion in small animals. Ultrasound in Medicine and Biology, 2003, 29, 1093-1103.	0.7	53
93	Increased brain injury and vascular leakage after pretreatment with p38-inhibitor SB203580 in transient ischemia. Acta Neurologica Scandinavica, 2003, 108, 339-345.	1.0	45
94	Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. British Journal of Cancer, 2003, 89, 1889-1895.	2.9	124

#	Article	IF	CITATIONS
95	Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. International Journal of Radiation Oncology Biology Physics, 2003, 56, 958-965.	0.4	221
96	Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. British Journal of Radiology, 2003, 76, S87-S91.	1.0	121
97	Functional Response of Tumor Vasculature to PaCO2: Determination of Total and Microvascular Blood Volume by MRI. Neoplasia, 2003, 5, 330-338.	2.3	28
98	Dynamic contrast-enhanced MR studies. Academic Radiology, 2003, 10, 961-962.	1.3	0
99	Newer MR imaging techniques for head and neck. Magnetic Resonance Imaging Clinics of North America, 2003, 11, 449-469.	0.6	30
100	Discrimination of Prostate Cancer from Normal Peripheral Zone and Central Gland Tissue by Using Dynamic Contrast-enhanced MR Imaging. Radiology, 2003, 229, 248-254.	3.6	375
101	T2- andT2*-W DCE-MRI: Blood Perfusion and Volume Estimation using Bolus Tracking., 0,, 365-412.		6
102	Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies. Journal of Clinical Oncology, 2003, 21, 3955-3964.	0.8	648
103	Osteogenic and Ewing Sarcomas: Estimation of Necrotic Fraction during Induction Chemotherapy with Dynamic Contrast-enhanced MR Imaging. Radiology, 2003, 228, 271-278.	3.6	119
104	Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood Flow. Journal of Clinical Oncology, 2003, 21, 4428-4438.	0.8	300
105	Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging. Journal of Clinical Oncology, 2003, 21, 2831-2842.	0.8	328
106	Structural, Functional, and Molecular MR Imaging of the Microvasculature. Annual Review of Biomedical Engineering, 2003, 5, 29-56.	5.7	65
107	Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development. British Journal of Radiology, 2003, 76, S83-S86.	1.0	23
108	Functional CT imaging of prostate cancer. Physics in Medicine and Biology, 2003, 48, 3085-3100.	1.6	53
109	MRI for assessing antivascular cancer treatments. British Journal of Radiology, 2003, 76, S60-S80.	1.0	131
110	Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. British Journal of Radiology, 2003, 76, 153-162.	1.0	126
111	Molecular imagingin vivo: an introduction. British Journal of Radiology, 2003, 76, S98-S109.	1.0	37
112	Simultaneous mapping of blood volume and endothelial permeability surface area product in gliomas using iterative analysis of first-pass dynamic contrast enhanced MRI data. British Journal of Radiology, 2003, 76, 39-51.	1.0	62

#	Article	IF	CITATIONS
113	Imaging microvascular structure with contrast enhanced MRI. British Journal of Radiology, 2003, 76, S159-S173.	1.0	37
114	Molecular imaging in oncology. Cancer Imaging, 2004, 4, 162-173.	1.2	4
115	Changes in the Pharmacokinetics of Gd-DTPA in Experimental Tumors after Charged Particle Radiation: Comparison with \hat{I}^3 -Ray Radiation. Journal of Radiation Research, 2004, 45, 261-267.	0.8	0
116	Molecular and Functional Imaging of Cancer: Advances in MRI and MRS. Methods in Enzymology, 2004, 386, 1-58.	0.4	74
117	Methods for Modeling and Predicting Mechanical Deformations of the Breast under External Perturbations. Handbook of Numerical Analysis, 2004, , 591-656.	0.9	0
118	The effects of renal variation upon measurements of perfusion and leakage volume in breast tumours. Physics in Medicine and Biology, 2004, 49, 2041-2051.	1.6	18
119	Physiological noise in murine solid tumours using T2*-weighted gradient-echo imaging: a marker of tumour acute hypoxia?. Physics in Medicine and Biology, 2004, 49, 3389-3411.	1.6	106
120	Dynamic Contrast-enhanced CT of Intracranial Meningioma: Comparison of Distributed and Compartmental Tracer Kinetic Models—Initial Results. Radiology, 2004, 232, 921-930.	3.6	49
121	Effect of Calcium Channel Blockers on Vertebral Bone Marrow Perfusion of the Lumbar Spine. Radiology, 2004, 231, 24-30.	3.6	19
122	Analysis of dynamic contrast enhanced MRI. British Journal of Radiology, 2004, 77, S154-S166.	1.0	69
123	High-Resolution Magnetic Resonance Imaging of Disparities in the Transcapillary Transfer Rates in Orthotopically Inoculated Invasive Breast Tumors. Cancer Research, 2004, 64, 3155-3161.	0.4	33
124	Evaluation of three different kinetic models for use with myocardial perfusion MRI data. , 2004, 2004, 1922-4.		3
125	The development and application of functional nuclear magnetic resonance toin vivotherapeutic anticancer research. British Journal of Radiology, 2004, 77, 296-307.	1.0	8
126	Can in Vivo Assessment of Tissue Hemodynamics with Dynamic Contrast-enhanced CT Be Used in the Diagnosis of Tumors and Monitoring of Cancer Therapy Outcomes?. Radiology, 2004, 232, 631-632.	3.6	4
127	Src family kinase-inhibitor PP2 reduces focal ischemic brain injury. Acta Neurologica Scandinavica, 2004, 110, 175-179.	1.0	56
128	Dynamic magnetic resonance imaging of tumor perfusion. IEEE Engineering in Medicine and Biology Magazine, 2004, 23, 65-83.	1.1	155
129	Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI. European Radiology, 2004, 14, 1793-801.	2.3	60
130	The relationship between vascular and metabolic characteristics of primary breast tumours. European Radiology, 2004, 14, 2038-2045.	2.3	104

#	Article	IF	Citations
131	Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging. Breast Cancer Research and Treatment, 2004, 83, 67-76.	1.1	225
132	Magnetic resonance imaging contrast-enhanced relaxometry of breast tumors: an MRI multicenter investigation concerning 100 patients. Magnetic Resonance Imaging, 2004, 22, 475-481.	1.0	38
133	BOLD MRI response to hypercapnic hyperoxia in patients with meningiomas: correlation with Gadolinium-DTPA uptake rate. Magnetic Resonance Imaging, 2004, 22, 761-767.	1.0	36
134	Quantification of dynamic contrast-enhanced MR imaging of the knee in children with juvenile rheumatoid arthritis based on pharmacokinetic modeling. Magnetic Resonance Imaging, 2004, 22, 1201-1210.	1.0	57
135	Dynamic MRI in indirect estimation of microvessel density, histologic grade, and prognosis in colorectal adenocarcinomas. Abdominal Imaging, 2004, 29, 166-172.	2.0	67
137	Magnetic resonance imaging of psoriatic arthritis: Insight from traditional and three-dimensional analysis. Current Rheumatology Reports, 2004, 6, 317-321.	2.1	27
138	A comparison of Ktransmeasurements obtained with conventional and first pass pharmacokinetic models in human gliomas. Journal of Magnetic Resonance Imaging, 2004, 19, 527-536.	1.9	60
139	Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. Journal of Magnetic Resonance Imaging, 2004, 20, 122-128.	1.9	113
140	Spatio-temporal bandwidth-based acquisition for dynamic contrast-enhanced magnetic resonance imaging. Journal of Magnetic Resonance Imaging, 2004, 20, 129-137.	1.9	14
141	Assessment of skeletal muscle perfusion by contrast medium first-pass magnetic resonance imaging: Technical feasibility and preliminary experience in healthy volunteers. Journal of Magnetic Resonance Imaging, 2004, 20, 111-121.	1.9	32
142	Combined quantitative dynamic contrast-enhanced MR imaging and 1H MR spectroscopic imaging of human prostate cancer. Journal of Magnetic Resonance Imaging, 2004, 20, 279-287.	1.9	160
143	Evaluation of heart perfusion in patients with acute myocardial infarction using dynamic contrast-enhanced magnetic resonance imaging. Journal of Magnetic Resonance Imaging, 2004, 20, 403-410.	1.9	21
144	Algorithms for calculation of kinetic parameters from T1-weighted dynamic contrast-enhanced magnetic resonance imaging. Journal of Magnetic Resonance Imaging, 2004, 20, 723-729.	1.9	21
145	Comparative study of methods for determining vascular permeability and blood volume in human gliomas. Journal of Magnetic Resonance Imaging, 2004, 20, 748-757.	1.9	90
146	New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors. Magnetic Resonance in Medicine, 2004, 51, 487-494.	1.9	80
147	Efficient method for calculating kinetic parameters usingT1-weighted dynamic contrast-enhanced magnetic resonance imaging. Magnetic Resonance in Medicine, 2004, 51, 858-862.	1.9	161
148	Improvement in breast lesion characterization with dynamic contrast-enhanced MRI using pharmacokinetic modeling and bookendT1 measurements. Magnetic Resonance in Medicine, 2004, 51, 1066-1070.	1.9	32
149	Measuring blood volume and vascular transfer constant from dynamic,T2*-weighted contrast-enhanced MRI. Magnetic Resonance in Medicine, 2004, 51, 961-968.	1.9	140

#	Article	IF	CITATIONS
150	Simultaneous measurement of arterial input function and tumor pharmacokinetics in mice by dynamic contrast enhanced imaging: Effects of transcytolemmal water exchange. Magnetic Resonance in Medicine, 2004, 52, 248-257.	1.9	86
151	Measurement of tumor interstitial volume fraction: Method and implication for drug delivery. Magnetic Resonance in Medicine, 2004, 52, 485-494.	1.9	34
152	Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced MRI studies: Fundamental concepts and simulations. Magnetic Resonance in Medicine, 2004, 52, 1110-1117.	1.9	101
153	A method for interleaved acquisition of a vascular input function for dynamic contrast-enhanced MRI in experimental rat tumours. NMR in Biomedicine, 2004, 17, 132-143.	1.6	21
154	A modified logistic model to describe gadolinium kinetics in breast tumors. Magnetic Resonance Imaging, 2004, 22, 467-473.	1.0	41
155	Dynamic MR imaging of brain tumors in low field using undersampled projection reconstruction. Magnetic Resonance Imaging, 2004, 22, 799-805.	1.0	5
156	Conventional MR imaging with simultaneous measurements of cerebral blood volume and vascular permeability in ganglioglioma. Magnetic Resonance Imaging, 2004, 22, 599-606.	1.0	27
157	Evaluation of reproducibility for perfusion assessment of tumors in MRI. , 0, , .		0
158	The role of imaging in the clinical development of antiangiogenic agents. Hematology/Oncology Clinics of North America, 2004, 18, 1183-1206.	0.9	16
159	Prostate Cancer: Evaluation of Vascular Characteristics with Dynamic Contrast-enhanced T1-weighted MR Imaging—Initial Experience. Radiology, 2004, 233, 709-715.	3 . 6	204
160	Assessment of Perfusion by Dynamic Contrast-Enhanced Imaging Using a Deconvolution Approach Based on Regression and Singular Value Decomposition. IEEE Transactions on Medical Imaging, 2004, 23, 1532-1542.	5 . 4	37
161	A comparison of pharmacokinetic models of dynamic contrast enhanced MRI., 0,,.		10
162	Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resistance Updates, 2004, 7, 125-138.	6.5	73
163	Extraskeletal osteosarcoma: report of a case with unusual imaging features and histopathological correlation. European Journal of Radiology Extra, 2004, 49, 97-102.	0.1	8
164	Dynamic Contrast-Enhanced MR Imaging. Topics in Magnetic Resonance Imaging, 2004, 15, 71-77.	0.7	20
165	Dynamic Magnetic Resonance Tomography and Proton Magnetic Resonance Spectroscopy of Prostate Cancers in Rats Treated by Radiotherapy. Investigative Radiology, 2004, 39, 34-44.	3.5	33
166	In and Ex Vivo MR Evaluation of Acute Myocardial Ischemia in Pigs by Determining R1 in Steady State After the Administration of the Intravascular Contrast Agent NC100150 Injection. Investigative Radiology, 2004, 39, 479-486.	3 . 5	15
167	Improved Perfusion and Tracer Kinetic Imaging Using Parallel Imaging. Topics in Magnetic Resonance Imaging, 2004, 15, 245-255.	0.7	16

#	Article	IF	CITATIONS
168	Perfusion MR Imaging of Extracranial Tumor Angiogenesis. Topics in Magnetic Resonance Imaging, 2004, 15, 41-57.	0.7	63
169	Identifiability analysis of the standard pharmacokinetic models in DCE MR imaging of tumours. , 2004, 2004, 1040-3.		0
170	An Introduction to Dynamic Contrast-Enhanced MRI in Oncology. , 2005, , 1-22.		15
171	Dynamic Contrast-Enhanced MRI of Prostate Cancer., 2005, , 191-213.		2
172	Novel Imaging Agents for Molecular MR Imaging of Cancer. , 2005, , 1309-1341.		0
173	Extended Kalman filtering for the modeling and analysis of ICG pharmacokinetics using NIR optical methods., 2005, 5693, 17.		0
174	Classification of Signal-Time Curves Obtained by Dynamic Magnetic Resonance Mammography. Investigative Radiology, 2005, 40, 442-447.	3.5	22
175	Quantification of Gd-BOPTA Uptake and Biliary Excretion From Dynamic Magnetic Resonance Imaging in Rat Livers. Investigative Radiology, 2005, 40, 705-714.	3.5	21
176	Dynamic Magnetic Resonance Imaging in Breast Cancer., 2005,, 145-173.		2
177	Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI. Magnetic Resonance Imaging, 2005, 23, 833-841.	1.0	74
178	Implementation of a rapid inversion-prepared dual-contrast gradient echo sequence for quantitative dynamic contrast-enhanced magnetic resonance imaging of the human prostate. Magnetic Resonance Imaging, 2005, 23, 983-990.	1.0	16
179	Intravascular contrast agent–enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1208-1215.	0.4	26
180	Early reoxygenation in tumors after irradiation: Determining factors and consequences for radiotherapy regimens using daily multiple fractions. International Journal of Radiation Oncology Biology Physics, 2005, 63, 901-910.	0.4	84
181	Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1309-1315.	0.4	128
182	Vascular disrupting agents: a new class of drug in cancer therapy. Clinical Oncology, 2005, 17, 277-290.	0.6	123
183	Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume. Journal of Clinical Oncology, 2005, 23, 973-981.	0.8	167
184	Serial tumour blood-flow measurements in androgen-dependent and -independent Shionogi tumour models. BJU International, 2005, 95, 644-649.	1.3	4
185	The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. British Journal of Cancer, 2005, 92, 1599-1610.	2.9	487

#	Article	IF	CITATIONS
186	Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR in Biomedicine, 2005, 18, 173-185.	1.6	85
187	Magnetic resonance imaging reveals functional diversity of the vasculature in benign and malignant breast lesions. Cancer, 2005, 104, 708-718.	2.0	89
188	Comparison of tumor blood perfusion assessed by dynamic contrast-enhanced MRI with tumor blood supply assessed by invasive imaging. Journal of Magnetic Resonance Imaging, 2005, 21, 272-281.	1.9	40
189	Dynamic Gd-DTPA enhanced MRI as a surrogate marker of angiogenesis in tissue-engineered bladder constructs: A feasibility study in rabbits. Journal of Magnetic Resonance Imaging, 2005, 21, 415-423.	1.9	23
190	Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: Assessment by voxel analysis of dynamic contrast-enhanced MRI. Journal of Magnetic Resonance Imaging, 2005, 22, 511-519.	1.9	58
191	Mixture model approach to tumor classification based on pharmacokinetic measures of tumor permeability. Journal of Magnetic Resonance Imaging, 2005, 22, 549-558.	1.9	6
192	Effect of intravascular-to-extravascular water exchange on the determination of blood-to-tissue transfer constant by magnetic resonance imaging. Magnetic Resonance in Medicine, 2005, 53, 282-293.	1.9	36
193	Shutter-speed analysis of contrast reagent bolus-tracking data: Preliminary observations in benign and malignant breast disease. Magnetic Resonance in Medicine, 2005, 53, 724-729.	1.9	67
194	Improving the reliability of obtaining tumor hemodynamic parameters in the presence of contrast agent extravasation. Magnetic Resonance in Medicine, 2005, 53, 1307-1316.	1.9	72
195	Measurement of skeletal muscle perfusion during postischemic reactive hyperemia using contrast-enhanced MRI with a step-input function. Magnetic Resonance in Medicine, 2005, 54, 289-298.	1.9	57
196	Quantifying dynamic contrast-enhanced MRI of the knee in children with juvenile rheumatoid arthritis using an arterial input function (AIF) extracted from popliteal artery enhancement, and the effect of the choice of the AIF on the kinetic parameters. Magnetic Resonance in Medicine, 2005, 54, 560-568.	1.9	36
197	Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdominal Imaging, 2005, 30, 325-342.	2.0	116
198	Extracting and visualizing physiological parameters using dynamic contrast-enhanced magnetic resonance imaging of the breast. Medical Image Analysis, 2005, 9, 315-329.	7.0	67
199	Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magnetic Resonance Imaging, 2005, 23, 519-529.	1.0	254
200	Consensus Recommendations for Acquisition of Dynamic Contrasted-Enhanced MRI Data in Oncology. , 2005 , , $109-113$.		3
201	Tumor Radiosensitization by Antiinflammatory Drugs: Evidence for a New Mechanism Involving the Oxygen Effect. Cancer Research, 2005, 65, 7911-7916.	0.4	79
202	Use of Dynamic Contrast-Enhanced MRI in Multi-Centre Trials with Particular Reference to Breast Cancer Screening in Women at Genetic Risk., 2005,, 265-279.		0
203	Dynamic Contrast-Enhanced MR Imaging for Predicting Tumor Control in Patients with Cervical Cancer. Medical Radiology, 2005, , 175-189.	0.0	1

#	Article	IF	CITATIONS
204	Dynamic Contrast-Enhanced MR Imaging in Musculoskeletal Tumors. , 2005, , 215-237.		4
205	Imaging Techniques for Dynamic Susceptibility Contrast-Enhanced MRI. Medical Radiology, 2005, , 95-108.	0.0	1
208	Current Issues in the Utility of Blood Oxygen Level Dependent MRI for the Assessment of Modulations in Tumor Oxygenation. Current Medical Imaging, 2005, 1, 229-243.	0.4	48
209	Pharmacokinetic Parameters Analyzed from MR Contrast Enhancement Kinetics of Multiple Malignant and Benign Breast Lesions Detected in the Same Patients. Technology in Cancer Research and Treatment, 2005, 4, 255-263.	0.8	15
210	MRI in the detection and management of breast cancer. Expert Review of Anticancer Therapy, 2005, 5, 239-252.	1.1	19
211	A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer. Clinical Cancer Research, 2005, 11, 3369-3376.	3.2	195
212	Use of Magnetic Resonance Imaging to Assess Blood-Brain/Blood-Glioma Barrier Opening During Conformal Radiotherapy. Journal of Clinical Oncology, 2005, 23, 4127-4136.	0.8	149
213	The Role of Blood-Brain Barrier Permeability in Brain Tumor Imaging and Therapeutics. American Journal of Roentgenology, 2005, 185, 763-767.	1.0	82
214	Effect of Vascular Targeting Agent in Rat Tumor Model: Dynamic Contrast-enhanced versus Diffusion-weighted MR Imaging. Radiology, 2005, 237, 492-499.	3.6	158
215	Gadopentetate Dimeglumine and FDG Uptake in Liver Metastases of Colorectal Carcinoma as Determined with MR Imaging and PET. Radiology, 2005, 237, 181-188.	3.6	20
216	Differentiation of Prostate Cancer from Normal Prostate Tissue in an Animal Model: Conventional MRI and Dynamic Contrast-enhanced MRI. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2005, 177, 935-939.	0.7	10
217	Functional modeling for liver imaging and nodule characterization. Proc Int Symp Image Signal Process Anal, 2005, , .	0.0	0
218	Inter-Operator Variability in Perfusion Assessment of Tumors in MRI Using Automated AIF Detection. Lecture Notes in Computer Science, 2005, 8, 451-458.	1.0	8
219	Tracer Kinetic Modelling for T1-Weighted DCE-MRI. , 2005, , 81-92.		41
220	Analysis of ICG Pharmacokinetics in Cancerous Tumors using NIR Optical Methods., 2005, 2006, 62-5.		5
221	Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI. British Journal of Cancer, 2005, 93, 979-985.	2.9	30
222	Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study. Journal of Clinical Oncology, 2005, 23, 5464-5473.	0.8	271
223	Characterizing Extravascular Fluid Transport of Macromolecules in the Tumor Interstitium by Magnetic Resonance Imaging. Cancer Research, 2005, 65, 1425-1432.	0.4	61

#	Article	IF	CITATIONS
224	Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416. Clinical Cancer Research, 2005, 11, 7938-7944.	3.2	47
225	Molecular MR Imaging Probes. Proceedings of the IEEE, 2005, 93, 800-808.	16.4	7
226	Molecular Imaging of Cancer: Applications of Magnetic Resonance Methods. Proceedings of the IEEE, 2005, 93, 784-799.	16.4	17
227	Technical and Practical Considerations for Permeability Modeling of Dynamic Contrast Enhanced MRI. Academic Radiology, 2005, 12, S34-S37.	1.3	2
228	Imaging Angiogenesis: Applications and Potential for Drug Development. Journal of the National Cancer Institute, 2005, 97, 172-187.	3.0	312
230	Dynamic Contrast-enhanced MR Imaging Kinetic Parameters and Molecular Weight of Dendritic Contrast Agents in Tumor Angiogenesis in Mice. Radiology, 2005, 235, 65-72.	3.6	106
231	Tracer Kinetic Model-Driven Registration for Dynamic Contrast Enhanced MRI Time Series. Lecture Notes in Computer Science, 2005, 8, 91-98.	1.0	11
232	Dynamic contrast-enhanced magnetic resonance imaging: a non-invasive method to evaluate significant differences between malignant and normal tissue. European Journal of Radiology, 2005, 53, 514-519.	1.2	30
233	Prostate Cancer: Precision of Integrating Functional MR Imaging with Radiation Therapy Treatment by Using Fiducial Gold Markers. Radiology, 2005, 236, 311-317.	3.6	58
234	The use of the Levenberg–Marquardt curve-fitting algorithm in pharmacokinetic modelling of DCE-MRI data. Physics in Medicine and Biology, 2005, 50, N85-N92.	1.6	84
235	Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. International Journal of Radiation Biology, 2006, 82, 699-757.	1.0	561
236	Low-Density Lipoprotein Nanoparticles as Magnetic Resonance Imaging Contrast Agents. Neoplasia, 2006, 8, 488-498.	2.3	98
237	Stroke Imaging at 3.0 T. Neuroimaging Clinics of North America, 2006, 16, 343-366.	0.5	8
238	Comparison of the Performance of Tracer Kinetic Model-Driven Registration for Dynamic Contrast Enhanced MRI Using Different Models of Contrast Enhancement. Academic Radiology, 2006, 13, 1112-1123.	1.3	43
239	Bayesian Methods for Pharmacokinetic Models in Dynamic Contrast-Enhanced Magnetic Resonance Imaging. IEEE Transactions on Medical Imaging, 2006, 25, 1627-1636.	5.4	80
240	NG2 expression regulates vascular morphology and function in human brain tumours. Neurolmage, 2006, 29, 965-976.	2.1	35
241	Cerebral perfusion mapping using a robust and efficient method for deconvolution analysis of dynamic contrast-enhanced images. Neurolmage, 2006, 32, 643-653.	2.1	27
242	Dynamic Contrast Enhanced Magnetic Resonance Imaging as a Biological Marker to Noninvasively Assess the Effect of Finasteride on Prostatic Suburethral Microcirculation. Journal of Urology, 2006, 176, 2299-2304.	0.2	3

#	ARTICLE	IF	CITATIONS
243	Fluctuations inpO2in Irradiated Human Melanoma Xenografts. Radiation Research, 2006, 165, 16-25.	0.7	50
244	Prostate Cancer Localization with Dynamic Contrast-enhanced MR Imaging and Proton MR Spectroscopic Imaging. Radiology, 2006, 241, 449-458.	3.6	506
245	Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis. Physics in Medicine and Biology, 2006, 51, 3593-3602.	1.6	115
246	Dynamic Contrast-Enhanced Magnetic Resonance Imaging As an Imaging Biomarker. Journal of Clinical Oncology, 2006, 24, 3293-3298.	0.8	374
247	Estimation of contrast agent concentration in intra- and extra-vascular spaces of brain tissue. Mathematical Biosciences, 2006, 204, 102-118.	0.9	4
248	Imaging the Effects of Vasculature-targeting Agents. , 2006, , 277-304.		1
249	Tumor infiltration of bone marrow in patients with hemato-logical malignancies: dynamic contrast-enhanced magnetic resonance imaging. Chinese Medical Journal, 2006, 119, 1256-1262.	0.9	7
251	Correlation Between Estimates of Tumor Perfusion From Microbubble Contrast-Enhanced Sonography and Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Journal of Ultrasound in Medicine, 2006, 25, 487-497.	0.8	39
252	Visualization of suspicious lesions in breast MRI based on intelligent neural systems. , 2006, , .		0
253	Contrast-Enhanced Magnetic Resonance Imaging of Central Nervous System Tumors. Topics in Magnetic Resonance Imaging, 2006, 17, 89-106.	0.7	56
254	CNS Tumors. Topics in Magnetic Resonance Imaging, 2006, 17, 63-68.	0.7	9
255	Importance of Parametric Mapping and Deconvolution in Analyzing Magnetic Resonance Myocardial Perfusion Images. Investigative Radiology, 2006, 41, 374-383.	3.5	8
256	Determination of Pharmacokinetic Parameters in DCE MRI. Investigative Radiology, 2006, 41, 536-543.	3.5	45
257	Assessing Tumor Angiogenesis with Dynamic Contrast Enhanced Magnetic Resonance Imaging. AIP Conference Proceedings, 2006, , .	0.3	0
258	A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging. British Journal of Cancer, 2006, 94, 1420-1427.	2.9	55
259	Model Selection in Magnetic Resonance Imaging Measurements of Vascular Permeability: Gadomer in a 9L Model of Rat Cerebral Tumor. Journal of Cerebral Blood Flow and Metabolism, 2006, 26, 310-320.	2.4	119
260	Combined T2* and T1 measurements for improved perfusion and permeability studies in high field using dynamic contrast enhancement. European Radiology, 2006, 16, 2083-2091.	2.3	67
261	Imaging vascular physiology to monitor cancer treatment. Critical Reviews in Oncology/Hematology, 2006, 58, 95-113.	2.0	53

#	Article	IF	Citations
262	Multi-Slice DCE-MRI Data Using P760 Distinguishes Between Metastatic and Non-Metastatic Rodent Prostate Tumors. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2006, 19, 15-21.	1.1	9
263	Improved Discrimination of Breast Lesions Using Selective Sampling of Segmented MR Images. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2006, 19, 34-40.	1.1	1
264	The effect of MR contrast medium dose on pituitary gland enhancement, microlesion enhancement and pituitary gland-to-lesion contrast conspicuity. Neuroradiology, 2006, 48, 449-459.	1.1	4
265	Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment. Abdominal Imaging, 2006, 31, 188-193.	2.0	163
266	The application of NMR in tumor angiogenesis research. Progress in Nuclear Magnetic Resonance Spectroscopy, 2006, 49, 27-44.	3.9	15
267	Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI. Magnetic Resonance Imaging, 2006, 24, 721-725.	1.0	12
268	Extended Kalman Filtering for the Modeling and Analysis of ICG Pharmacokinetics in Cancerous Tumors Using NIR Optical Methods. IEEE Transactions on Biomedical Engineering, 2006, 53, 1861-1871.	2.5	48
269	MR in oncology drug development. NMR in Biomedicine, 2006, 19, 681-689.	1.6	23
270	Vascular perfusion of human lung cancer in a rat orthotopic model using dynamic contrast-enhanced magnetic resonance imaging. International Journal of Cancer, 2006, 119, 365-372.	2.3	3
271	Noninvasive 1H/13C magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide. Magnetic Resonance in Medicine, 2006, 55, 755-761.	1.9	24
272	Comparison of MRI and positron emission tomography for measuring myocardial perfusion reserve in healthy humans. Magnetic Resonance in Medicine, 2006, 55, 772-779.	1.9	56
273	Iterative blind deconvolution in magnetic resonance brain perfusion imaging. Magnetic Resonance in Medicine, 2006, 55, 805-815.	1.9	26
274	Assessment of fraction of radiobiologically hypoxic cells in human melanoma xenografts by dynamic contrast-enhanced MRI. Magnetic Resonance in Medicine, 2006, 55, 874-882.	1.9	40
275	Measurement of kinetic parameters in skeletal muscle by magnetic resonance imaging with an intravascular agent. Magnetic Resonance in Medicine, 2006, 55, 1114-1123.	1.9	34
276	Complex relationship between changes in oxygenation status and changes in R*2: The case of insulin and NS-398, two inhibitors of oxygen consumption. Magnetic Resonance in Medicine, 2006, 56, 637-643.	1.9	18
277	Comparison of errors associated with single- and multi-bolus injection protocols in low-temporal-resolution dynamic contrast-enhanced tracer kinetic analysis. Magnetic Resonance in Medicine, 2006, 56, 611-619.	1.9	32
278	Determination of the maturity and functionality of tumor vasculature by MRI: Correlation between BOLD-MRI and DCE-MRI using P792 in experimental fibrosarcoma tumors. Magnetic Resonance in Medicine, 2006, 56, 1041-1049.	1.9	39
279	Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. Journal of Magnetic Resonance Imaging, 2006, 23, 554-563.	1.9	145

#	ARTICLE	IF	CITATIONS
280	Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis—Correlation with biopsy and histopathology. Journal of Magnetic Resonance Imaging, 2006, 24, 108-113.	1.9	251
281	Estimate of vascular permeability and cerebral blood volume using Gd-DTPA contrast enhancement and dynamic T2*-weighted MRI. Journal of Magnetic Resonance Imaging, 2006, 24, 288-296.	1.9	40
282	Model-free parameters from dynamic contrast-enhanced-MRI: Sensitivity to EES volume fraction and bolus timing. Journal of Magnetic Resonance Imaging, 2006, 24, 586-594.	1.9	25
283	Repeatability of a reference region model for analysis of murine DCE-MRI data at 7T. Journal of Magnetic Resonance Imaging, 2006, 24, 1140-1147.	1.9	56
284	Model-based registration for dynamic cardiac perfusion MRI. Journal of Magnetic Resonance Imaging, 2006, 24, 1062-1070.	1.9	62
285	MR Imaging in Primary Headaches. Radiology, 2006, 238, 754-755.	3.6	1
286	Assessing Tumor Perfusion and Treatment Response in Rectal Cancer. Radiology, 2006, 238, 756-757.	3.6	3
287	Has the Time Arrived to Image Placental Perfusion?. Radiology, 2006, 241, 633-634.	3.6	5
288	Magnetic Resonance Imaging Workbench: Analysis and Visualization of Dynamic Contrast-enhanced MR Imaging Data. Radiographics, 2006, 26, 621-632.	1.4	82
289	Feasibility and measurement precision of 3D quantitative blood flow mapping of the prostate using dynamic contrast-enhanced multi-slice CT. Physics in Medicine and Biology, 2006, 51, 4329-4343.	1.6	20
290	A method for pharmacokinetic modelling of dynamic contrast enhanced MRI studies of rapidly enhancing lesions acquired in a clinical setting. Physics in Medicine and Biology, 2006, 51, N187-N197.	1.6	9
291	Physiologic and Metabolic Magnetic Resonance Imaging in Gliomas. Journal of Clinical Oncology, 2006, 24, 1228-1235.	0.8	90
292	Prediction of Clinicopathologic Response of Breast Cancer to Primary Chemotherapy at Contrast-enhanced MR Imaging: Initial Clinical Results. Radiology, 2006, 239, 361-374.	3.6	224
293	Dynamic Contrast-Enhanced MRI Quantification of Synovium Microcirculation in Experimental Arthritis. American Journal of Roentgenology, 2006, 186, 1165-1171.	1.0	17
295	Inflammation in Carotid Atherosclerotic Plaque: A Dynamic Contrast-enhanced MR Imaging Study. Radiology, 2006, 241, 459-468.	3.6	275
296	Minimally Invasive Pharmacokinetic and Pharmacodynamic Technologies in Hypothesis-Testing Clinical Trials of Innovative Therapies. Journal of the National Cancer Institute, 2006, 98, 580-598.	3.0	189
297	Antiangiogenic activity of the selective cyclooxygenase 2 inhibitor rofecoxib in human colorectal cancer liver metastases. Gut, 2006, 55, 1058-1059.	6.1	10
298	Diffusion-weighted and Perfusion MR Imaging for Brain Tumor Characterization and Assessment of Treatment Response. Radiology, 2006, 239, 632-649.	3.6	359

#	Article	IF	CITATIONS
299	Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers. Current Cancer Drug Targets, 2006, 6, 455-489.	0.8	36
300	Glioma assessment using quantitative blood volume maps generated by T1-weighted dynamic contrast-enhanced magnetic resonance imaging: a receiver operating characteristic study. Acta Radiologica, 2006, 47, 303-310.	0.5	63
301	Bayesian Estimation of Smooth Parameter Maps for Dynamic Contrast-Enhanced MR Images with Block-ICM. , 0 , , .		4
302	Adapting radiotherapy to hypoxic tumours. Physics in Medicine and Biology, 2006, 51, 4903-4921.	1.6	70
303	Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration. Annals of Oncology, 2006, 17, 1393-1398.	0.6	27
304	Bayesian estimation of pharmacokinetic parameters for DCE-MRI with a robust treatment of enhancement onset time. Physics in Medicine and Biology, 2007, 52, 2393-2408.	1.6	34
305	Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessing Tumor Vascularity and Vascular Effects of Targeted Therapies in Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 770s-776s.	3.2	119
306	Reference tissue quantification of DCE-MRI data without a contrast agent calibration. Physics in Medicine and Biology, 2007, 52, 589-601.	1.6	36
307	Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology:Theory, Data Acquisition,Analysis, and Examples. Current Medical Imaging, 2007, 3, 91-107.	0.4	325
308	Effect of dietary tetradecylthioacetic acid on colon cancer growth studied by dynamic contrast enhanced MRI. Cancer Biology and Therapy, 2007, 6, 1810-1816.	1.5	12
309	Assessment of Lung Cancer Perfusion by Using Patlak Analysis: What Do We Measure?. Radiology, 2007, 243, 907-908.	3.6	15
310	Registration of dynamic contrast-enhanced MRI using a progressive principal component registration (PPCR). Physics in Medicine and Biology, 2007, 52, 5147-5156.	1.6	89
311	Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Clinical Cancer Research, 2007, 13, 3449-3459.	3.2	293
312	Comparison of cerebral blood volume maps generated fromT2* andT1weighted MRI data in intra-axial cerebral tumours. British Journal of Radiology, 2007, 80, 161-168.	1.0	28
313	Visualization of quantitative breast DCE-MRI functional parametric maps by dedicated image processing. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2007, 2007, 55-8.	0.5	0
314	SIMULATION OF HEPATOCELLULAR CARCINOMA IN MRI BY COMBINED MACROVASCULAR AND PHARMACOKINETIC MODELS. , 2007, , .		2
315	The Current Status of Breast MR Imaging Part I. Choice of Technique, Image Interpretation, Diagnostic Accuracy, and Transfer to Clinical Practice. Radiology, 2007, 244, 356-378.	3.6	679
316	Measuring Elevated Microvascular Permeability and Predicting Hemorrhagic Transformation in Acute Ischemic Stroke Using First-Pass Dynamic Perfusion CT Imaging. American Journal of Neuroradiology, 2007, 28, 1292-1298.	1.2	90

#	Article	IF	CITATIONS
317	Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2007, 13, 2128-2135.	3.2	136
318	Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes. Multiple Sclerosis Journal, 2007, 13, 884-894.	1.4	51
319	Reproducibility of reference tissue quantification of dynamic contrast-enhanced data: comparison with a fixed vascular input function. Physics in Medicine and Biology, 2007, 52, 75-89.	1.6	52
320	Lung inflammation and vascular remodeling after repeated allergen challenge detected noninvasively by MRI. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L644-L653.	1.3	39
321	Effect of calibration on computerized analysis of prostate lesions using quantitative dynamic contrast-enhanced magnetic resonance imaging., 2007,,.		2
322	Imaging Biomarker Applications in Oncology Drug Development. Drug Information Journal, 2007, 41, 561-572.	0.5	1
323	IN VIVO IMAGING IN A MURINE MODEL OF GLIOBLASTOMA. Neurosurgery, 2007, 60, 360-371.	0.6	37
324	Assessment of the Vascularity of Uterine Leiomyomas Using Double-Echo Dynamic Perfusion-Weighted MRI With the First-Pass Pharmacokinetic Model. Investigative Radiology, 2007, 42, 629-635.	3.5	7
325	Usage of the T1 effect of an iron oxide contrast agent in an animal model to quantify myocardial blood flow by MRI. European Journal of Radiology, 2007, 62, 247-256.	1.2	5
326	Dynamic contrast enhanced MRI in prostate cancer. European Journal of Radiology, 2007, 63, 335-350.	1.2	196
327	Optimal breathing protocol for dynamic contrast-enhanced MRI of solitary pulmonary nodules at 3T. European Journal of Radiology, 2007, 64, 397-400.	1.2	4
328	Effect of heterogeneous vasculature on interstitial transport within a solid tumor. Microvascular Research, 2007, 73, 224-236.	1.1	98
329	Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncology, The, 2007, 8, 63-74.	5.1	249
330	Quantitative Analysis of Dynamic Contrast-Enhanced MRI Datasets of the Metacarpophalangeal Joints. Academic Radiology, 2007, 14, 1189-1200.	1.3	27
331	In Vivo Imaging of Cancer Therapy. , 2007, , .		6
332	DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. British Journal of Cancer, 2007, 96, 189-195.	2.9	467
333	Alpha-v Integrins as Therapeutic Targets in Oncology. Cancer Investigation, 2007, 25, 632-646.	0.6	94
334	The role of advanced MR imaging in understanding brain tumour pathology. British Journal of Neurosurgery, 2007, 21, 562-575.	0.4	44

#	Article	IF	CITATIONS
335	8A-5 Simultaneous Contrast Ultrasound and DCE MRI for Improved Breast Tumour Characterization: Demonstration of Technical Feasibility. Proceedings IEEE Ultrasonics Symposium, 2007, , .	0.0	0
336	STEP: SPATIAL-TEMPORAL ENHANCEMENT PATTERN, FOR MR-BASED BREAST TUMOR DIAGNOSIS., 2007,,.		7
337	Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2931-2937.	1.8	189
338	Correlation of MRI Biomarkers with Tumor Necrosis in Hras5 Tumor Xenograft in Athymic Rats. Neoplasia, 2007, 9, 382-391.	2.3	32
339	Dynamic Contrast-Enhanced MRI of Prostate Cancer at 3 T: A Study of Pharmacokinetic Parameters. American Journal of Roentgenology, 2007, 189, W192-W201.	1.0	235
340	MR Imaging of the Prostate: 1.5T versus 3T. Magnetic Resonance Imaging Clinics of North America, 2007, 15, 433-448.	0.6	31
341	Monitoring Breast Cancer Response to Neoadjuvant Systemic Chemotherapy Using Parametric Contrast-Enhanced MRI: A Pilot Study. Academic Radiology, 2007, 14, 561-573.	1.3	44
342	Multimodality imaging of head and neck cancer. Cancer Imaging, 2007, 7, S37-S46.	1.2	13
343	Measuring Tumor Perfusion in Control and Treated Murine Tumors. Journal of Ultrasound in Medicine, 2007, 26, 749-756.	0.8	54
344	The biologic basis of in vivo angiogenesis imaging. Frontiers in Bioscience - Landmark, 2007, 12, 3601.	3.0	35
345	Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR in Biomedicine, 2007, 20, 128-140.	1.6	49
346	Dynamic contrast-enhanced MRI of muscle perfusion combined with MR angiography of collateral artery growth in a femoral artery ligation model. NMR in Biomedicine, 2007, 20, 717-725.	1.6	20
347	In Vivo mouse imaging and spectroscopy in drug discovery. NMR in Biomedicine, 2007, 20, 154-185.	1.6	104
348	Comparison of a reference region model with direct measurement of an AIF in the analysis of DCE-MRI data. Magnetic Resonance in Medicine, 2007, 57, 353-361.	1.9	86
349	Assessment of the morphological and functional effects of the anti-angiogenic agent SU11657 on 9L gliosarcoma vasculature using dynamic susceptibility contrast MRI. Magnetic Resonance in Medicine, 2007, 57, 680-687.	1.9	45
350	Multiple reference tissue method for contrast agent arterial input function estimation. Magnetic Resonance in Medicine, 2007, 58, 1266-1275.	1.9	72
351	MRI estimation of contrast agent concentration in tissue using a neural network approach. Magnetic Resonance in Medicine, 2007, 58, 290-297.	1.9	17
352	On the identifiability of pharmacokinetic parameters in dynamic contrastâ€enhanced imaging. Magnetic Resonance in Medicine, 2007, 58, 425-429.	1.9	53

#	Article	IF	CITATIONS
353	Feasibility of multipleâ€mouse dynamic contrastâ€enhanced MRI. Magnetic Resonance in Medicine, 2007, 58, 610-615.	1.9	18
354	Pharmacokinetic modeling of dynamic contrastâ€enhanced MRI of the hand and wrist in rheumatoid arthritis and the response to antiâ€ŧumor necrosis factorâ€ἷ± therapy. Magnetic Resonance in Medicine, 2007, 58, 482-489.	1.9	49
355	Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging. Magnetic Resonance in Medicine, 2007, 58, 572-581.	1.9	42
356	Fluctuations in tumor blood perfusion assessed by dynamic contrastâ€enhanced MRI. Magnetic Resonance in Medicine, 2007, 58, 473-481.	1.9	50
357	Incorporating contrast agent diffusion into the analysis of DCEâ€MRI data. Magnetic Resonance in Medicine, 2007, 58, 1124-1134.	1.9	47
358	Tracer kinetic model–driven registration for dynamic contrastâ€enhanced MRI timeâ€series data. Magnetic Resonance in Medicine, 2007, 58, 1010-1019.	1.9	71
359	Correlations between dynamic contrast-enhanced magnetic resonance imaging–derived measures of tumor microvasculature and interstitial fluid pressure in patients with cervical cancer. Journal of Magnetic Resonance Imaging, 2007, 25, 153-159.	1.9	51
360	Dynamic contrast-enhanced MRI study of male pelvic perfusion at 3T: Preliminary clinical report. Journal of Magnetic Resonance Imaging, 2007, 25, 160-169.	1.9	8
361	Dynamic contrastâ€enhanced magnetic resonance imaging of human melanoma xenografts with necrotic regions. Journal of Magnetic Resonance Imaging, 2007, 26, 133-143.	1.9	16
362	MRI of tumor angiogenesis. Journal of Magnetic Resonance Imaging, 2007, 26, 235-249.	1.9	253
363	Dynamic T ₁ mapping predicts outcome of chemoradiation therapy in primary rectal carcinoma: Sequence implementation and data analysis. Journal of Magnetic Resonance Imaging, 2007, 26, 662-671.	1.9	50
364	MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. Journal of Magnetic Resonance Imaging, 2007, 26, 615-623.	1.9	77
365	Comparison of region-of-interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas. Journal of Magnetic Resonance Imaging, 2007, 26, 1053-1063.	1.9	80
366	Assessment of microvascular density, extracellular volume fraction, and radiobiological hypoxia in human melanoma xenografts by dynamic contrastâ€enhanced MRI. Journal of Magnetic Resonance Imaging, 2007, 26, 1033-1042.	1.9	22
367	Transcytolemmal water exchange in pharmacokinetic analysis of dynamic contrastâ€enhanced MRI data in squamous cell carcinoma of the head and neck. Journal of Magnetic Resonance Imaging, 2007, 26, 1607-1617.	1.9	57
368	Radiotherapy Adapted to Spatial and Temporal Variability in Tumor Hypoxia. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1496-1504.	0.4	70
369	Assessment of Tumor Response to the Vascular Disrupting Agents 5,6-Dimethylxanthenone-4-Acetic Acid or Combretastatin-A4-Phosphate by Intrinsic Susceptibility Magnetic Resonance Imaging. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1238-1245.	0.4	15
370	Spatial and temporal resolution effects on dynamic contrast-enhanced magnetic resonance mammography. Magnetic Resonance Imaging, 2007, 25, 14-34.	1.0	8

#	Article	IF	CITATIONS
371	Diagnosis of suspicious breast lesions using an empirical mathematical model for dynamic contrast-enhanced MRI. Magnetic Resonance Imaging, 2007, 25, 593-603.	1.0	56
372	Magnetic resonance imaging measurements of vascular permeability and extracellular volume fraction of breast tumors by dynamic Gd-DTPA-enhanced relaxometry. Magnetic Resonance Imaging, 2007, 25, 293-302.	1.0	33
373	Pixel-by-pixel analysis of DCE MRI curve patterns and an illustration of its application to the imaging of the musculoskeletal system. Magnetic Resonance Imaging, 2007, 25, 604-612.	1.0	92
374	Water diffusion-exchange effect on the paramagnetic relaxation enhancement in off-resonance rotating frame. Journal of Magnetic Resonance, 2007, 186, 259-272.	1.2	4
375	An orthotopic xenograft model of intraneural NF1 MPNST suggests a potential association between steroid hormones and tumor cell proliferation. Laboratory Investigation, 2007, 87, 1092-1102.	1.7	33
376	Dynamic MRI signals in the second week of radiotherapy relate to treatment outcomes of hepatocellular carcinoma: a preliminary result. Liver International, 2007, 27, 516-528.	1.9	14
377	AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. Cancer Cell, 2007, 11, 83-95.	7.7	1,675
378	Dynamic contrast-enhanced MR imaging in cancer. Radiography, 2007, 13, e45-e53.	1.1	4
379	MRI observation of the light-induced release of a contrast agent from photo-controllable polymer micelles. Physics in Medicine and Biology, 2007, 52, N249-N255.	1.6	23
380	The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. European Radiology, 2007, 17, 1700-1713.	2.3	72
381	Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging. European Radiology, 2007, 17, 2136-2148.	2.3	65
382	MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature. Breast Cancer Research and Treatment, 2007, 107, 1-14.	1.1	236
384	Simultaneous dynamic T 1 and T 2 * measurement for AIF assessment combined with DCE MRI in a mouse tumor model. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2007, 20, 193-203.	1.1	35
385	Kinetic Modeling of Contrast-Enhanced MRI: An Automated Technique for Assessing Inflammation in the Rheumatoid Arthritis Wrist. Annals of Biomedical Engineering, 2007, 35, 781-795.	1.3	13
386	Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magnetic Resonance Imaging, 2007, 25, 1-13.	1.0	291
387	Early Prediction of Outcome in Advanced Head-and-Neck Cancer Based on Tumor Blood Volume Alterations During Therapy: A Prospective Study. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1287-1290.	0.4	119
388	Non-invasive assessment of tumor neovasculature: techniques and clinical applications. Cancer and Metastasis Reviews, 2008, 27, 615-630.	2.7	46
389	Imaging hemodynamics. Cancer and Metastasis Reviews, 2008, 27, 589-613.	2.7	20

#	Article	IF	CITATIONS
390	Mechanisms of enhanced tumoricidal efficacy of multiple small dosages of ranpirnase, the novel cytotoxic ribonuclease, on lung cancer. Cancer Chemotherapy and Pharmacology, 2008, 62, 337-346.	1.1	7
391	Imaging and targeted agents in gastrointestinal cancers: overview on perfusion- and diffusion-weighted magnetic resonance imaging and angiogenesis inhibitors. Targeted Oncology, 2008, 3, 101-110.	1.7	1
392	The Evaluation of Esophageal Adenocarcinoma Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Journal of Gastrointestinal Surgery, 2008, 12, 166-175.	0.9	35
393	An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2008, 21, 411-421.	1.1	27
394	MR pharmacokinetic modeling of the patellar cartilage differentiates normal from pathological conditions. Journal of Magnetic Resonance Imaging, 2008, 27, 171-177.	1.9	31
395	New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues. Journal of Magnetic Resonance Imaging, 2008, 27, 581-589.	1.9	46
396	Capillary permeability and extracellular volume fraction in uterine cervical cancer as patient outcome predictors: Measurements by using dynamic MRI spinâ€lattice relaxometry. Journal of Magnetic Resonance Imaging, 2008, 27, 846-853.	1.9	3
397	Dynamic contrastâ€enhanced quantitative perfusion measurement of the brain using <i>T</i> ₁ â€weighted MRI at 3T. Journal of Magnetic Resonance Imaging, 2008, 27, 754-762.	1.9	71
398	MRI measurement of change in vascular parameters in the 9L rat cerebral tumor after dexamethasone administration. Journal of Magnetic Resonance Imaging, 2008, 27, 1430-1438.	1.9	22
399	Independent component analysis of dynamic contrastâ€enhanced magnetic resonance images of breast carcinoma: A feasibility study. Journal of Magnetic Resonance Imaging, 2008, 28, 271-277.	1.9	12
400	Transvascular and interstitial transport in rat hepatocellular carcinomas: Dynamic contrastâ€enhanced MRI assessment with low―and high―molecular weight agents. Journal of Magnetic Resonance Imaging, 2008, 28, 906-914.	1.9	23
401	Limitations of dynamic contrastâ€enhanced MRI in monitoring radiationâ€induced changes in the fraction of radiobiologically hypoxic cells in human melanoma xenografts. Journal of Magnetic Resonance Imaging, 2008, 28, 1209-1218.	1.9	6
402	Incorporating the effects of transcytolemmal water exchange in a reference region model for DCEâ€MRI analysis: Theory, simulations, and experimental results. Magnetic Resonance in Medicine, 2008, 59, 326-335.	1.9	37
403	Quantification of viable tumor microvascular characteristics by multispectral analysis. Magnetic Resonance in Medicine, 2008, 60, 64-72.	1.9	48
404	MR imaging of adventitial vasa vasorum in carotid atherosclerosis. Magnetic Resonance in Medicine, 2008, 59, 507-514.	1.9	181
405	System identification theory in pharmacokinetic modeling of dynamic contrastâ€enhanced MRI: Influence of contrast injection. Magnetic Resonance in Medicine, 2008, 59, 1111-1119.	1.9	39
406	Improving the pharmacokinetic parameter measurement in dynamic contrastâ€enhanced MRI by use of the arterial input function: Theory and clinical application. Magnetic Resonance in Medicine, 2008, 59, 1448-1456.	1.9	23
407	Fourâ€dimensional transcatheter intraarterial perfusion (TRIP)â€MRI for monitoring liver tumor embolization in VX2 rabbits. Magnetic Resonance in Medicine, 2008, 60, 970-975.	1.9	17

#	Article	IF	CITATIONS
408	Cellularâ€interstitial water exchange and its effect on the determination of contrast agent concentration in vivo: Dynamic contrastâ€enhanced MRI of human internal obturator muscle. Magnetic Resonance in Medicine, 2008, 60, 1011-1019.	1.9	71
409	Pharmacokinetic modeling of delayed gadolinium enhancement in the myocardium. Magnetic Resonance in Medicine, 2008, 60, 1524-1530.	1.9	28
410	Characterization of tumor angiogenesis with dynamic contrastâ€enhanced MRI and biodegradable macromolecular contrast agents in mice. Magnetic Resonance in Medicine, 2008, 60, 1347-1352.	1.9	32
411	Dynamic contrastâ€enhanced MRI diagnostics in oncology via principal component analysis. Journal of Chemometrics, 2008, 22, 708-716.	0.7	12
412	Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol). NMR in Biomedicine, 2008, 21, 42-52.	1.6	41
413	Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal <i>in vivo</i> and <i>ex vivo</i> study. NMR in Biomedicine, 2008, 21, 1043-1056.	1.6	98
414	Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. Magnetic Resonance Imaging, 2008, 26, 1071-1080.	1.0	100
415	Model-based simulation of dynamic magnetic resonance imaging signals. Biomedical Signal Processing and Control, 2008, 3, 305-311.	3.5	2
416	Model-free visualization of suspicious lesions in breast MRI based on supervised and unsupervised learning. Engineering Applications of Artificial Intelligence, 2008, 21, 129-140.	4.3	27
417	Preclinical Studies to Predict Efficacy of Vascular Changes Induced by Combretastatin A-4 Disodium Phosphate in Patients. International Journal of Radiation Oncology Biology Physics, 2008, 70, 859-866.	0.4	19
418	Assessment of extravascular extracellular space fraction in human melanoma xenografts by DCE-MRI and kinetic modeling. Magnetic Resonance Imaging, 2008, 26, 160-170.	1.0	48
419	Delineation and segmentation of cerebral tumors by mapping blood-brain barrier disruption with dynamic contrast-enhanced CT and tracer kinetics modeling–a feasibility study. European Radiology, 2008, 18, 143-151.	2.3	8
420	Contrast-enhanced magnetic resonance imaging of the breast: the value of pharmacokinetic parameters derived from fast dynamic imaging during initial enhancement in classifying lesions. European Radiology, 2008, 18, 1123-1133.	2.3	54
421	Murine liver implantation of radiation-induced fibrosarcoma: characterization with MR imaging, microangiography and histopathology. European Radiology, 2008, 18, 1422-1430.	2.3	22
422	Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study. British Journal of Cancer, 2008, 99, 321-326.	2.9	22
423	Multiparametric Magnetic Resonance Imaging of the Prostate: Current Status in Prostate Cancer Detection, Localization, and Staging. Seminars in Roentgenology, 2008, 43, 303-313.	0.2	21
424	Quantitative dynamic contrast-enhanced MRI for the assessment of mandibular invasion by squamous cell carcinoma. Oral Oncology, 2008, 44, 1147-1154.	0.8	33
425	Functional MR Imaging of the Uterus. Magnetic Resonance Imaging Clinics of North America, 2008, 16, 673-684.	0.6	9

#	Article	IF	CITATIONS
426	Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced MRI. Medical Physics, 2008, 35, 888-899.	1.6	81
427	Tumor Vascularity Assessed By Magnetic Resonance Imaging and Intravital Microscopy Imaging. Neoplasia, 2008, 10, 354-362.	2.3	62
428	Non-invasive imaging of barriers to drug delivery in tumors. Microvascular Research, 2008, 76, 94-103.	1.1	31
430	Quantitative 2- and 3-dimensional analysis of pharmacokinetic model-derived variables for breast lesions in dynamic, contrast-enhanced MR mammography. European Journal of Radiology, 2008, 66, 300-308.	1.2	24
431	Pharmacokinetic MR analysis of the cartilage is influenced by field strength. European Journal of Radiology, 2008, 67, 448-452.	1.2	14
432	Late tissue effects following radiotherapy and neoadjuvant hormone therapy of the prostate measured with quantitative magnetic resonance imaging. Radiotherapy and Oncology, 2008, 88, 127-134.	0.3	26
433	Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. Journal of Translational Medicine, 2008, 6, 80.	1.8	234
434	Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncology, The, 2008, 9, 766-776.	5.1	150
435	Diffusion and Perfusion MR Imaging of the Prostate. Magnetic Resonance Imaging Clinics of North America, 2008, 16, 685-695.	0.6	73
436	Assessment of Renal Function with Dynamic Contrast-Enhanced MR Imaging. Magnetic Resonance Imaging Clinics of North America, 2008, 16, 597-611.	0.6	63
438	BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy. Cancer Research, 2008, 68, 4774-4782.	0.4	929
439	Has Molecular and Cellular Imaging Enhanced Drug Discovery and Drug Development?. Drugs in R and D, 2008, 9, 351-368.	1.1	26
440	Assessment of Fraction of Hypoxic Cells in Human Tumor Xenografts with Necrotic Regions by Dynamic Contrast-Enhanced MRI. Radiation Research, 2008, 169, 689-699.	0.7	19
441	Computationally efficient vascular input function models for quantitative kinetic modelling using DCE-MRI. Physics in Medicine and Biology, 2008, 53, 1225-1239.	1.6	114
443	Uncertainty and bias in contrast concentration measurements using spoiled gradient echo pulse sequences. Physics in Medicine and Biology, 2008, 53, 2345-2373.	1.6	186
444	Expanded pharmacokinetic model for population studies in breast MRI. Proceedings of SPIE, 2008, , .	0.8	0
445	Monitoring Pc 4-mediated photodynamic therapy of U87 tumors with dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) in the athymic nude rat. Proceedings of SPIE, 2008, , .	0.8	1
446	Determining glioma response to radiation therapy using recombinant peptides. Expert Review of Anticancer Therapy, 2008, 8, 1787-1796.	1.1	3

#	Article	IF	CITATIONS
447	Review: Tumor Vasculature and Microenvironment Normalization: A Possible Mechanism of Antiangiogenesis Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 661-668.	0.7	30
448	Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and Doxorubicin. Clinical Cancer Research, 2008, 14, 7260-7271.	3.2	43
449	Use of H215O-PET and DCE-MRI to Measure Tumor Blood Flow. Oncologist, 2008, 13, 631-644.	1.9	63
450	Detection of Breast Malignancy. , 2008, , 519-528.		2
451	Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy. Acta Oncol \tilde{A}^3 gica, 2008, 47, 1257-1264.	0.8	7
452	Segmentation of dynamic contrast enhanced magnetic resonance imaging data. Acta Oncol $ ilde{A}^3$ gica, 2008, 47, 1265-1270.	0.8	11
453	Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI. British Journal of Radiology, 2008, 81, 120-128.	1.0	44
454	Predicting Grade of Cerebral Glioma Using Vascular-Space Occupancy MR Imaging. American Journal of Neuroradiology, 2008, 29, 373-378.	1.2	28
455	Dynamic NMR effects in breast cancer dynamic-contrast-enhanced MRI. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17937-17942.	3.3	69
456	Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma. Journal of Clinical Oncology, 2008, 26, 4572-4578.	0.8	219
457	Quantitative Estimation of Permeability Surface-Area Product in Astroglial Brain Tumors Using Perfusion CT and Correlation with Histopathologic Grade. American Journal of Neuroradiology, 2008, 29, 694-700.	1.2	125
458	Detection of Neovessels in Atherosclerotic Plaques of Rabbits Using Dynamic Contrast Enhanced MRI and 18F-FDG PET. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1311-1317.	1.1	127
459	The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17943-17948.	3.3	85
460	Hepatic Metastases: In Vivo Assessment of Perfusion Parameters at Dynamic Contrast-enhanced MR Imaging with Dual-Input Two-Compartment Tracer Kinetics Model. Radiology, 2008, 249, 307-320.	3.6	94
461	Are Measurements from Two Commercial Software Packages Interchangeable? Possibly, If Like Is Compared with Like. Radiology, 2008, 246, 642-643.	3.6	4
462	Breast Lesions. , 2008, , 529-538.		0
463	Glandular Function in Sjögren Syndrome: Assessment with Dynamic Contrast-enhanced MR Imaging and Tracer Kinetic Modeling—Initial Experience. Radiology, 2008, 246, 845-853.	3.6	27
464	Invasive Breast Cancer: Predicting Disease Recurrence by Using High-Spatial-Resolution Signal Enhancement Ratio Imaging. Radiology, 2008, 248, 79-87.	3.6	53

#	Article	IF	CITATIONS
465	Multiphasic contrast injection for improved precision of parameter estimates in functional CT. Medical Physics, 2008, 35, 5921-5933.	1.6	7
466	Incorporating a vascular term into a reference region model for the analysis of DCE-MRI data: a simulation study. Physics in Medicine and Biology, 2008, 53, 2617-2631.	1.6	23
467	Pancreatic Perfusion: Noninvasive Quantitative Assessment with Dynamic Contrast-enhanced MR Imaging without and with Secretin Stimulation in Healthy Volunteers—Initial Results. Radiology, 2008, 247, 115-121.	3.6	48
468	Liver tumor assessment with DCE-MRI. , 2008, , .		1
469	Automatic liver tumor diagnosis with Dynamic-Contrast Enhanced MRI., 2008,,.		1
470	Perfusion measurement using DCE-MRI: Implications for hyperthermia. International Journal of Hyperthermia, 2008, 24, 91-96.	1.1	27
471	Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Musculoskeletal System: Basic Principles and Clinical Applications in Bone Sarcomas and Rheumatoid Arthritis., 2008,, 729-748.		0
472	Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth. Blood, 2008, 112, 1904-1911.	0.6	47
473	Temporal Constraints in Renal Perfusion Imaging With a 2-Compartment Model. Investigative Radiology, 2008, 43, 120-128.	3.5	60
476	Evaluation of Normal Prostate Tissue, Chronic Prostatitis, and Prostate Cancer by Quantitative Perfusion Analysis Using a Dynamic Contrast-Enhanced Inversion-Prepared Dual-Contrast Gradient Echo Sequence. Investigative Radiology, 2008, 43, 481-487.	3.5	7 5
477	Dynamic Contrast-Enhanced Magnetic Resonance Imaging in the Evaluation of the Prostate. Topics in Magnetic Resonance Imaging, 2008, 19, 273-284.	0.7	46
478	Computed Tomography Perfusion Using First Pass Methods for Lung Nodule Characterization. Investigative Radiology, 2008, 43, 349-358.	3.5	50
479	Post-Treatment Changes in Tumor Microenvironment. , 2008, , 235-248.		2
480	Role of Imaging Biomarkers in Drug Development. , 2008, , 139-159.		1
481	Magnetic resonance perfusion imaging in neuro-oncology. Cancer Imaging, 2008, 8, 186-199.	1.2	23
482	Extended Kalman Filtering for the Modeling and Estimation of ICG Pharmacokinetics in Cancerous Tumors Using NIR Measurements., 0,,.		0
483	The role of dynamic contrast enhanced MR imaging in cancer diagnosis and treatment. Diagnostic and Interventional Radiology, 2009, 16, 186-92.	0.7	82
484	Advanced imaging techniques in brain tumors. Cancer Imaging, 2009, 9, S4-S9.	1.2	37

#	Article	IF	CITATIONS
485	DCE-MRI Data Analysis for Cancer Area Classification. Methods of Information in Medicine, 2009, 48, 248-253.	0.7	9
486	Breaching the Blood-Brain Barrier as a Gate to Psychiatric Disorder. Cardiovascular Psychiatry and Neurology, 2009, 2009, 1-7.	0.8	88
487	Imaging perfusion and blood–brain barrier permeability using T1-weighted dynamic contrast-enhanced MR imaging. , 0, , 113-128.		1
488	Perfusion MR imaging in adult neoplasia. , 0, , 341-368.		0
489	Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. Journal of Clinical Oncology, 2009, 27, 3027-3035.	0.8	467
490	Effect of VEGF Treatment on the Blood-Spinal Cord Barrier Permeability in Experimental Spinal Cord Injury: Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Journal of Neurotrauma, 2009, 26, 1005-1016.	1.7	48
491	Interindividual variability of arterial impulse response to intravenous injection of nonionic contrast agent (Iohexol) in DCE T study. Medical Physics, 2009, 36, 4791-4802.	1.6	5
492	Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17898-17903.	3.3	87
493	Limitations of single slice dynamic contrast enhanced MR in pharmacokinetic modeling of bone sarcomas. Acta Radiologica, 2009, 50, 512-520.	0.5	9
494	Quantitative magnetic resonance and optical imaging biomarkers of melanoma metastatic potential. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6608-6613.	3.3	86
495	Prostate Gland., 2009,, 559-598.		0
496	Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor α and c-Myc. Endocrine-Related Cancer, 2009, 16, 819-834.	1.6	33
497	Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Annals of Oncology, 2009, 20, 1589-1595.	0.6	148
498	Optimizing functional parameter accuracy for breath-hold DCE-MRI of liver tumours. Physics in Medicine and Biology, 2009, 54, 2197-2215.	1.6	28
499	Prostate MR Imaging: Tissue Characterization with Pharmacokinetic Volume and Blood Flow Parameters and Correlation with Histologic Parameters. Radiology, 2009, 252, 101-108.	3.6	54
500	Magnetic Resonance Imaging Defines Cervicovaginal Anatomy, Cancer, and VEGF Trap Antiangiogenic Efficacy in Estrogen-Treated K14-HPV16 Transgenic Mice. Cancer Research, 2009, 69, 7945-7952.	0.4	8
501	Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers. Journal of Nuclear Medicine, 2009, 50, 239-249.	2.8	73
502	Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging. Clinical Cancer Research, 2009, 15, 6674-6682.	3.2	142

#	Article	IF	CITATIONS
503	Dynamic contrast-enhanced and T2-weighted magnetic resonance imaging study of the correlation between tumour angiogenesis and growth kinetics. Laboratory Animals, 2009, 43, 53-59.	0.5	6
504	Tumor tissue analysis by self organizing maps from combined DCE-/DSC-MRI data. , 2009, , .		1
505	Model-based reconstruction for undersampled dynamic contrast-enhanced MRI. Proceedings of SPIE, 2009, , .	0.8	1
507	lmaging of Tumor Angiogenesis: Functional or Targeted?. American Journal of Roentgenology, 2009, 193, 304-313.	1.0	88
508	Mapping the Zonal Organization of Tumor Perfusion and Permeability in a Rat Glioma Model by Using Dynamic Contrast-enhanced Synchrotron Radiation CT. Radiology, 2009, 250, 692-702.	3.6	31
509	Dynamic contrast-enhanced MRI for prostate cancer localization. British Journal of Radiology, 2009, 82, 148-156.	1.0	93
510	Dysferlin-deficient Muscular Dystrophy: Gadofluorine M Suitability at MR Imaging in a Mouse Model. Radiology, 2009, 250, 87-94.	3.6	12
511	Rheumatoid Synovial Inflammation: Pixel-by-Pixel Dynamic Contrast-enhanced MR Imaging Time-Intensity Curve Shape Analysis—A Feasibility Study. Radiology, 2009, 253, 234-240.	3.6	40
512	A theoretical framework to model DSC-MRI data acquired in the presence of contrast agent extravasation. Physics in Medicine and Biology, 2009, 54, 5749-5766.	1.6	56
513	A "Vascular Normalization Index―as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients. Cancer Research, 2009, 69, 5296-5300.	0.4	369
514	Dynamic MRI and CAD vs. Choline MRS: Where is the detection level for a lesion characterisation in prostate cancer?. International Journal of Radiation Biology, 2009, 85, 814-824.	1.0	32
515	Automatic selection of arterial input function using tri-exponential models. , 2009, , .		1
516	Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies. Journal of Clinical Oncology, 2009, 27, 4718-4726.	0.8	87
517	Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging. Radiology, 2009, 253, 486-496.	3.6	365
518	Perfusion CT: Noninvasive Surrogate Marker for Stratification of Pancreatic Cancer Response to Concurrent Chemo- and Radiation Therapy. Radiology, 2009, 250, 110-117.	3.6	134
520	Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice. Journal of Clinical Oncology, 2009, 27, 2542-2552.	0.8	285
521	Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for Prediction of Radiation-Induced Neurocognitive Dysfunction. Clinical Cancer Research, 2009, 15, 1747-1754.	3.2	59
522	Chemotherapy Response Monitoring of Colorectal Liver Metastases by Dynamic Gd-DTPA–Enhanced MRI Perfusion Parameters and 18F-FDG PET Metabolic Rate. Journal of Nuclear Medicine, 2009, 50, 1777-1784.	2.8	29

#	Article	IF	CITATIONS
523	Subchondral fluid dynamics in a model of osteoarthritis: use of dynamic contrast-enhanced magnetic resonance imaging. Osteoarthritis and Cartilage, 2009, 17, 1350-1355.	0.6	42
525	Functional and Metabolic Magnetic Resonance Imaging and Positron Emission Tomography for Tumor Volume Definition in High-Grade Gliomas. Seminars in Radiation Oncology, 2009, 19, 155-162.	1.0	14
526	Quantitative Analysis of Dynamic Contrast-Enhanced MR Images Based on Bayesian P-Splines. IEEE Transactions on Medical Imaging, 2009, 28, 789-798.	5.4	35
527	Developing DCE-CT to Quantify Intra-Tumor Heterogeneity in Breast Tumors With Differing Angiogenic Phenotype. IEEE Transactions on Medical Imaging, 2009, 28, 861-871.	5.4	35
528	A Novel Estimation Method for Physiological Parameters in Dynamic Contrast-Enhanced MRI: Application of a Distributed Parameter Model Using Fourier-Domain Calculations. IEEE Transactions on Medical Imaging, 2009, 28, 1375-1383.	5.4	32
529	Estimating Kinetic Parameter Maps From Dynamic Contrast-Enhanced MRI Using Spatial Prior Knowledge. IEEE Transactions on Medical Imaging, 2009, 28, 1534-1547.	5.4	44
530	Breast Tumor Analysis in Dynamic Contrast Enhanced MRI Using Texture Features and Wavelet Transform. IEEE Journal on Selected Topics in Signal Processing, 2009, 3, 94-100.	7.3	66
531	Placental Morphologic and Functional Imaging in High-Risk Pregnancies. Seminars in Perinatology, 2009, 33, 270-280.	1.1	25
532	<i>In vitro</i> setup to study permeability characteristics of contrast agents by MRI. Contrast Media and Molecular Imaging, 2009, 4, 66-72.	0.4	11
533	DCEâ€MRI in experimental chronic pancreatitis. Contrast Media and Molecular Imaging, 2009, 4, 127-134.	0.4	6
534	Magnetic resonance imaging as a biomarker in renal cell carcinoma. Cancer, 2009, 115, 2334-2345.	2.0	77
535	Improved bolus arrival time and arterial input function estimation for tracer kinetic analysis in DCEâ€MRI. Journal of Magnetic Resonance Imaging, 2009, 29, 166-176.	1.9	64
536	Benign prostatic hyperplasia: Evaluation of T ₁ , T ₂ , and microvascular characteristics with T ₁ â€weighted dynamic contrastâ€enhanced MRI. Journal of Magnetic Resonance Imaging, 2009, 29, 641-648.	1.9	48
537	DCEâ€MRI pixelâ€byâ€pixel quantitative curve pattern analysis and its application to osteosarcoma. Journal of Magnetic Resonance Imaging, 2009, 30, 177-184.	1.9	21
538	Relationship of temporal resolution to diagnostic performance for dynamic contrast enhanced MRI of the breast. Journal of Magnetic Resonance Imaging, 2009, 30, 999-1004.	1.9	163
539	Principal component analysis of breast DCEâ€MRI adjusted with a modelâ€based method. Journal of Magnetic Resonance Imaging, 2009, 30, 989-998.	1.9	36
540	A Bayesian hierarchical model for the analysis of a longitudinal dynamic contrastâ€enhanced MRI oncology study. Magnetic Resonance in Medicine, 2009, 61, 163-174.	1.9	29
541	Modeling of contrast agent kinetics in the lung using <i>T</i> ₁ â€weighted dynamic contrastâ€enhanced MRI. Magnetic Resonance in Medicine, 2009, 61, 1507-1514.	1.9	58

#	Article	IF	CITATIONS
542	Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced–MRI analysis. Magnetic Resonance in Medicine, 2009, 61, 851-859.	1.9	46
543	Highâ€resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI. Magnetic Resonance in Medicine, 2009, 61, 615-625.	1.9	45
544	Regional pulmonary blood flow: Comparison of dynamic contrastâ€enhanced MR perfusion and phaseâ€contrast MR. Magnetic Resonance in Medicine, 2009, 61, 1249-1254.	1.9	7
545	A new approach to analysis of the impulse response function (IRF) in dynamic contrastâ€enhanced MRI (DCEMRI): A simulation study. Magnetic Resonance in Medicine, 2009, 62, 229-239.	1.9	10
546	Quantification of cerebral blood flow, cerebral blood volume, and blood–brainâ€barrier leakage with DCEâ€MRI. Magnetic Resonance in Medicine, 2009, 62, 205-217.	1.9	225
547	Reliability of pharmacokinetic parameters: Small vs. mediumâ€sized contrast agents. Magnetic Resonance in Medicine, 2009, 62, 779-787.	1.9	30
548	Modelâ€based blind estimation of kinetic parameters in dynamic contrast enhanced (DCE)â€MRI. Magnetic Resonance in Medicine, 2009, 62, 1477-1486.	1.9	61
549	Measurement of brain perfusion, blood volume, and bloodâ€brain barrier permeability, using dynamic contrastâ€enhanced <i>T</i> ₁ â€weighted MRI at 3 tesla. Magnetic Resonance in Medicine, 2009, 62, 1270-1281.	1.9	185
550	Modelâ€based and modelâ€free parametric analysis of breast dynamicâ€contrastâ€enhanced MRI. NMR in Biomedicine, 2009, 22, 40-53.	1.6	48
551	Molecular and functional imaging of breast cancer. NMR in Biomedicine, 2009, 22, 92-103.	1.6	35
552	Recent advances in breast MRI and MRS. NMR in Biomedicine, 2009, 22, 3-16.	1.6	63
553	Dynamic contrastâ€enhanced MRI in the diagnosis and management of breast cancer. NMR in Biomedicine, 2009, 22, 28-39.	1.6	164
554	Firstâ€pass dynamic contrastâ€enhanced MRI with extravasating contrast reagent: evidence for human myocardial capillary recruitment in adenosineâ€induced hyperemia. NMR in Biomedicine, 2009, 22, 148-157.	1.6	39
555	Blood–spinal cord barrier permeability in experimental spinal cord injury: dynamic contrastâ€enhanced MRI. NMR in Biomedicine, 2009, 22, 332-341.	1.6	83
556	Optimization of Perfusion CT Protocol for Imaging of Extracranial Head and Neck Tumors. Journal of Digital Imaging, 2009, 22, 437-448.	1.6	12
557	Simultaneous Quantification of Perfusion and Permeability in the Prostate Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging with an Inversion-Prepared Dual-Contrast Sequence. Annals of Biomedical Engineering, 2009, 37, 749-762.	1.3	39
558	Region of interest and pixel-by-pixel analysis of dynamic contrast enhanced magnetic resonance imaging parameters and time–intensity curve shapes: a comparison in chondroid tumors. Magnetic Resonance Imaging, 2009, 27, 62-68.	1.0	15
559	Prediction of early response to radiotherapy of uterine carcinoma with dynamic contrast-enhanced MR imaging using pixel analysis of MR perfusion imaging. Magnetic Resonance Imaging, 2009, 27, 370-376.	1.0	9

#	Article	IF	Citations
560	Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate. Magnetic Resonance Imaging, 2009, 27, 377-384.	1.0	45
561	Dynamic contrast-enhanced magnetic resonance imaging parameters independent of baseline T10 values. Magnetic Resonance Imaging, 2009, 27, 1208-1215.	1.0	11
562	An Exploratory Study Into the Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging or Perfusion Computed Tomography for Detection of Intratumoral Hypoxia in Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 74, 29-37.	0.4	82
563	Assessment of Hypoxia in Human Cervical Carcinoma Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. International Journal of Radiation Oncology Biology Physics, 2009, 73, 838-845.	0.4	23
564	Detecting Vascular-Targeting Effects of the Hypoxic Cytotoxin Tirapazamine in Tumor Xenografts Using Magnetic Resonance Imaging. International Journal of Radiation Oncology Biology Physics, 2009, 74, 957-965.	0.4	6
565	Tumor Characterization with Dynamic Contrast Enhanced Magnetic Resonance Imaging and Biodegradable Macromolecular Contrast Agents in Mice. Pharmaceutical Research, 2009, 26, 2202-2208.	1.7	18
566	Biomarkers in abdominal imaging. Abdominal Imaging, 2009, 34, 663-667.	2.0	23
567	Characterization of Tumor Angiogenesis in Rat Brain Using Iron-Based Vessel Size Index MRI in Combination with Gadolinium-Based Dynamic Contrast-Enhanced MRI. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 1714-1726.	2.4	65
568	The parametric response map is an imaging biomarker for early cancer treatment outcome. Nature Medicine, 2009, 15, 572-576.	15.2	187
569	Biomarkers of response and resistance to antiangiogenic therapy. Nature Reviews Clinical Oncology, 2009, 6, 327-338.	12.5	541
570	Quantifying Disease Activity and Damage by Imaging in Rheumatoid Arthritis and Osteoarthritis. Annals of the New York Academy of Sciences, 2009, 1154, 207-238.	1.8	17
571	Imaging techniques to evaluate the response to treatment in oncology: Current standards and perspectives. Critical Reviews in Oncology/Hematology, 2009, 72, 217-238.	2.0	125
572	Blood–brain barrier breakdown-inducing astrocytic transformation: Novel targets for the prevention of epilepsy. Epilepsy Research, 2009, 85, 142-149.	0.8	238
573	Semiquantitative and Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging Measurements Predict Radiation Response in Cervix Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 74, 766-773.	0.4	140
574	A Combined Pharmacokinetic and Radiologic Assessment of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Predicts Response to Chemoradiation in Locally Advanced Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 611-617.	0.4	54
575	Glucosamine sulfate effect on the degenerated patellar cartilage: preliminary findings by pharmacokinetic magnetic resonance modeling. European Radiology, 2009, 19, 1512-1518.	2.3	16
576	Mural Crohn Disease: Correlation of Dynamic Contrast-enhanced MR Imaging Findings with Angiogenesis and Inflammation at Histologic Examination—Pilot Study. Radiology, 2009, 251, 369-379.	3.6	122
577	Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treatment Reviews, 2009, 35, 309-321.	3.4	151

#	Article	IF	Citations
579	Post-ischemic leakiness of the blood–brain barrier: A quantitative and systematic assessment by Patlak plots. Experimental Neurology, 2009, 219, 328-333.	2.0	57
581	Fundamentals of Quantitative Dynamic Contrast-Enhanced MR Imaging. Magnetic Resonance Imaging Clinics of North America, 2009, 17, 277-289.	0.6	109
582	A functional form for injected MRI Gd-chelate contrast agent concentration incorporating recirculation, extravasation and excretion. Physics in Medicine and Biology, 2009, 54, 2933-2949.	1.6	18
583	Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. Journal of Translational Medicine, 2009, 7, 33.	1.8	19
584	Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. Journal of Translational Medicine, 2009, 7, 77.	1.8	70
585	Dynamic Contrast-Enhanced Breast MR Imaging. Magnetic Resonance Imaging Clinics of North America, 2009, 17, 351-362.	0.6	64
587	Effect of Nanoparticle and Aggregate Size on the Relaxometric Properties of MR Contrast Agents Based on High Quality Magnetite Nanoparticles. Journal of Physical Chemistry B, 2009, 113, 7033-7039.	1.2	131
588	Dendrimer., 2008,, 839-839.		0
590	Quantitative Imaging to Assess Tumor Response to Therapy: Common Themes of Measurement, Truth Data, and Error Sources. Translational Oncology, 2009, 2, 198-210.	1.7	49
591	Molecular probes for the in vivo imaging of cancer. Molecular BioSystems, 2009, 5, 1279.	2.9	65
592	Dynamic contrast-enhanced magnetic resonance imaging of tumor interstitial fluid pressure. Radiotherapy and Oncology, 2009, 91, 107-113.	0.3	39
593	Difficulties and potential of correlating local recurrences in prostate cancer with the delivered local dose. Radiotherapy and Oncology, 2009, 93, 180-184.	0.3	17
594	DCEMRI of spontaneous canine tumors during fractionated radiotherapy: A pharmacokinetic analysis. Radiotherapy and Oncology, 2009, 93, 618-624.	0.3	10
595	MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: The feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Radiotherapy and Oncology, 2009, 93, 241-245.	0.3	38
596	Predicting Control of Primary Tumor and Survival by DCE MRI During Early Therapy in Cervical Cancer. Investigative Radiology, 2009, 44, 343-350.	3.5	91
597	Dynamic Contrast-Enhanced MR Imaging in the Evaluation of Patients with Prostate Cancer. Magnetic Resonance Imaging Clinics of North America, 2009, 17, 363-383.	0.6	34
598	COMPARISON BETWEEN PERFUSION-CT AND DYNAMIC CONTRAST-ENHANCED MRI IN RECTAL CANCER. Radiotherapy and Oncology, 2009, 92, S81.	0.3	0
599	Quantitative Analysis of Dynamic Contrast Enhanced MRI for Assessment of Bowel Inflammation in Crohn's Disease. Academic Radiology, 2009, 16, 1223-1230.	1.3	58

#	Article	IF	CITATIONS
600	Multiparametric Magnetic Resonance Imaging of Breast Cancer. Journal of the American College of Radiology, 2009, 6, 523-526.	0.9	12
601	Magnetic Resonance Perfusion and Permeability Imaging in Brain Tumors. Neuroimaging Clinics of North America, 2009, 19, 527-557.	0.5	131
602	Dynamic Contrast-Enhanced MR Imaging of the Liver: Current Status and Future Directions. Magnetic Resonance Imaging Clinics of North America, 2009, 17, 339-349.	0.6	59
604	Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Tumors: Preclinical Validation of Parametric Images. Radiation Research, 2009, 172, 339-347.	0.7	43
605	Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Prostate Cancer. Topics in Magnetic Resonance Imaging, 2009, 20, 105-112.	0.7	14
606	Sonographic Assessment of Tumor Response. Ultrasound Quarterly, 2009, 25, 175-183.	0.3	20
607	Dynamic Contrast-enhanced Magnetic Resonance Imaging as a Predictor of Clinical Outcome in Canine Spontaneous Soft Tissue Sarcomas Treated with Thermoradiotherapy. Clinical Cancer Research, 2009, 15, 4993-5001.	3.2	32
608	Analysis of Prostate DCE-MRI. Investigative Radiology, 2009, 44, 577-584.	3.5	42
610	Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood, 2009, 113, 3161-3167.	0.6	75
611	Onset and Maintenance of Angiogenesis in Biomaterials: In Vivo Assessment by Dynamic Contrast-Enhanced MRI. Tissue Engineering - Part C: Methods, 2009, 15, 455-462.	1.1	12
612	The Immunocompromised Host: Central Nervous System. , 2009, , 1315-1323.		0
613	STEP: Spatiotemporal enhancement pattern for MRâ€based breast tumor diagnosis. Medical Physics, 2009, 36, 3192-3204.	1.6	67
614	Automated segmentation of reference tissue for prostate cancer localization in dynamic contrast enhanced MRI. Proceedings of SPIE, 2010, , .	0.8	0
615	Principal Component Analysis of Dynamic Contrast Enhanced MRI in Human Prostate Cancer. Investigative Radiology, 2010, 45, 174-181.	3.5	25
616	A Systematic Review of the Literature on the Effects of Dexamethasone on the Brain From In Vivo Human-Based Studies: Implications for Physiological Brain Imaging of Patients With Intracranial Tumors. Neurosurgery, 2010, 67, 1799-1815.	0.6	54
617	Intraindividual In Vivo Comparison of Gadolinium Contrast Agents for Pharmacokinetic Analysis Using Dynamic Contrast Enhanced Magnetic Resonance Imaging. Investigative Radiology, 2010, 45, 233-244.	3.5	14
618	Feasibility of 3T Dynamic Contrast-Enhanced Magnetic Resonance-Guided Biopsy in Localizing Local Recurrence of Prostate Cancer After External Beam Radiation Therapy. Investigative Radiology, 2010, 45, 121-125.	3.5	56
619	Dynamic contrast enhanced–MRI in head and neck cancer patients: Variability of the precontrast longitudinal relaxation time. Medical Physics, 2010, 37, 2683-2692.	1.6	12

#	Article	IF	CITATIONS
620	Optimized pharmacokinetic modeling for the detection of perfusion differences in skeletal muscle with DCEâ€MRI: Effect of contrast agent size. Medical Physics, 2010, 37, 5746-5755.	1.6	20
621	Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia. Haematologica, 2010, 95, 1420-1424.	1.7	17
623	Simulation-based comparison of two approaches frequently used for dynamic contrast-enhanced MRI. European Radiology, 2010, 20, 432-442.	2.3	73
624	Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours. European Radiology, 2010, 20, 2013-2026.	2.3	34
625	An exploratory pilot study into the association between microcirculatory parameters derived by MRI-based pharmacokinetic analysis and glucose utilization estimated by PET-CT imaging in head and neck cancer. European Radiology, 2010, 20, 2358-2366.	2.3	37
626	Dynamic CT perfusion imaging of intra-axial brain tumours: differentiation of high-grade gliomas from primary CNS lymphomas. European Radiology, 2010, 20, 2482-2490.	2.3	48
627	Polydisulfideâ€based Biodegradable Macromolecular Magnetic Resonance Imaging Contrast Agents. Israel Journal of Chemistry, 2010, 50, 220-232.	1.0	22
628	Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 164-182.	3.3	64
629	Focal Salvage Guided by T2-Weighted and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prostate Cancer Recurrences. International Journal of Radiation Oncology Biology Physics, 2010, 76, 741-746.	0.4	59
630	Noninvasive Assessment of Tumor Microenvironment Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging and 18F-Fluoromisonidazole Positron Emission Tomography Imaging in Neck Nodal Metastases. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1403-1410.	0.4	102
631	Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T $\hat{a}\in$ " quantitative correlation with biopsy. Magnetic Resonance Imaging, 2010, 28, 621-628.	1.0	71
632	Reproducibility of the gadolinium concentration measurements and of the fitting parameters of the vascular input function in the superior sagittal sinus in a patient population. Magnetic Resonance Imaging, 2010, 28, 1420-1430.	1.0	68
633	Dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) of atherosclerotic plaque angiogenesis. Angiogenesis, 2010, 13, 87-99.	3.7	47
634	Magnetic resonance imaging of brain angiogenesis after stroke. Angiogenesis, 2010, 13, 101-111.	3.7	76
635	White paper on imaging biomarkers. Insights Into Imaging, 2010, 1, 42-45.	1.6	61
636	Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. Targeted Oncology, 2010, 5, 39-52.	1.7	95
637	Imaging Prostate Cancer: An Update on Positron Emission Tomography and Magnetic Resonance Imaging. Current Urology Reports, 2010, 11, 180-190.	1.0	44
638	Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurology, The, 2010, 9, 906-920.	4.9	335

#	Article	IF	CITATIONS
639	Response to Letter Regarding Article: "Developing DCE-CT to Quantify Intra-Tumor Heterogeneity in Breast Tumors With Differing Angiogenic Phenotype― IEEE Transactions on Medical Imaging, 2010, 29, 1089-1092.	5.4	2
640	Template-Based B_{1} Inhomogeneity Correction in 3T MRI Brain Studies. IEEE Transactions on Medical Imaging, 2010, 29, 1927-1941.	5.4	9
642	The Tumor Microenvironment in Non–Small-Cell Lung Cancer. Seminars in Radiation Oncology, 2010, 20, 156-163.	1.0	108
643	Measurement of MRI enhancement kinetics for evaluation of inflammatory activity in Crohn's disease. Clinical Imaging, 2010, 34, 29-35.	0.8	18
644	RGS4 Controls Renal Blood Flow and Inhibits Cyclosporine-Mediated Nephrotoxicity. American Journal of Transplantation, 2010, 10, 231-241.	2.6	22
645	Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, <i>ex vivo</i> HR MAS, and <i>in vivo</i> ¹ H MRS. NMR in Biomedicine, 2010, 23, 56-65.	1.6	40
646	Fast, reproducible measurement of the vascular input function in mice using constrained reconstruction and cardiac sampling. NMR in Biomedicine, 2011, 24, 373-384.	1.6	10
647	Pharmacokinetics of contrast agents targeted to the tumor vasculature in molecular magnetic resonance imaging. Contrast Media and Molecular Imaging, 2010, 5, 9-17.	0.4	13
648	Assessment of tumor angiogenesis: dynamic contrastâ€enhanced MRI with paramagnetic nanoparticles compared with Gdâ€DTPA in a rabbit Vxâ€2 tumor model. Contrast Media and Molecular Imaging, 2010, 5, 155-161.	0.4	9
649	Surrogate MR markers of response to chemo―or radiotherapy in association with coâ€ŧreatments: a retrospective analysis of multiâ€modal studies. Contrast Media and Molecular Imaging, 2010, 5, 323-332.	0.4	24
650	Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination. International Journal of Cancer, 2010, 127, 1535-1546.	2.3	153
651	Arterial spin labeling at ultraâ€high field: All that glitters is not gold. International Journal of Imaging Systems and Technology, 2010, 20, 62-70.	2.7	30
652	Measuring perfusion and permeability in renal cell carcinoma with dynamic contrastâ€enhanced MRI: A pilot study. Journal of Magnetic Resonance Imaging, 2010, 31, 490-501.	1.9	64
653	Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma. Journal of Magnetic Resonance Imaging, 2010, 31, 1106-1116.	1.9	22
654	Pharmacokinetic mapping for lesion classification in dynamic breast MRI. Journal of Magnetic Resonance Imaging, 2010, 31, 1371-1378.	1.9	52
655	Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibilityâ€weighted MRI parameters in the benign and malignant human prostate. Journal of Magnetic Resonance Imaging, 2010, 32, 155-164.	1.9	47
656	Feasibility of FAIR imaging for evaluating tumor perfusion. Journal of Magnetic Resonance Imaging, 2010, 32, 738-744.	1.9	8
657	Toward local arterial input functions in dynamic contrastâ€enhanced MRI. Journal of Magnetic Resonance Imaging, 2010, 32, 924-934.	1.9	23

#	Article	IF	CITATIONS
658	The influence of temporal resolution in determining pharmacokinetic parameters from DCE-MRI data. Magnetic Resonance in Medicine, 2010, 63, 811-816.	1.9	63
659	A comparison of tracer kinetic models for <i>T</i> ₁ -weighted dynamic contrast-enhanced MRI: Application in carcinoma of the cervix. Magnetic Resonance in Medicine, 2010, 63, 691-700.	1.9	92
660	High-resolution magnetic resonance colonography and dynamic contrast-enhanced magnetic resonance imaging in a murine model of colitis. Magnetic Resonance in Medicine, 2010, 63, 922-929.	1.9	31
661	Comparison of myocardial perfusion estimates from dynamic contrastâ€enhanced magnetic resonance imaging with four quantitative analysis methods. Magnetic Resonance in Medicine, 2010, 64, 125-137.	1.9	69
662	Dynamic contrast-enhanced MRI in ovarian cancer: Initial experience at 3 tesla in primary and metastatic disease. Magnetic Resonance in Medicine, 2010, 63, 1044-1049.	1.9	44
663	An automated method for nonparametric kinetic analysis of clinical DCEâ€MRI data: Application to glioblastoma treated with bevacizumab. Magnetic Resonance in Medicine, 2010, 63, 1366-1375.	1.9	33
664	Comparison of quantitative parameters in cervix cancer measured by dynamic contrast–enhanced MRI and CT. Magnetic Resonance in Medicine, 2010, 63, 1601-1609.	1.9	31
665	Noncompartmental kinetic analysis of DCEâ€MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab. Magnetic Resonance in Medicine, 2010, 64, 408-417.	1.9	30
666	Measurement of perfusion and permeability from dynamic contrastâ€enhanced MRI in normal and pathological vertebral bone marrow. Magnetic Resonance in Medicine, 2010, 64, 115-124.	1.9	24
667	Tracer kinetic analysis of dynamic contrastâ€enhanced MRI and CT bladder cancer data: A preliminary comparison to assess the magnitude of water exchange effects. Magnetic Resonance in Medicine, 2010, 64, 595-603.	1.9	35
668	Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis. Magnetic Resonance in Medicine, 2010, 63, 1637-1647.	1.9	47
669	Bayesian estimation of changes in transverse relaxation rates. Magnetic Resonance in Medicine, 2010, 64, 914-921.	1.9	28
670	Reconstruction of dynamic contrast enhanced magnetic resonance imaging of the breast with temporal constraints. Magnetic Resonance Imaging, 2010, 28, 637-645.	1.0	54
671	Dynamic-contrast-enhanced-MRI with extravasating contrast reagent: Rat cerebral glioma blood volume determination. Journal of Magnetic Resonance, 2010, 206, 190-199.	1.2	47
672	Compartmental modelling for magnetic resonance renography. Zeitschrift Fur Medizinische Physik, 2010, 20, 101-114.	0.6	18
673	Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: Current status and perspectives. Critical Reviews in Oncology/Hematology, 2010, 73, 202-212.	2.0	64
674	Can DCEMRI assess the effect of green tea on the angiogenic properties of rodent prostate tumors?. Physica Medica, 2010, 26, 111-116.	0.4	4
675	Comparison Between Perfusion Computed Tomography and Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 400-408.	0.4	30

#	Article	IF	CITATIONS
676	Quantification of myocardial perfusion using CMR with a radial data acquisition: comparison with a dual-bolus method. Journal of Cardiovascular Magnetic Resonance, 2010, 12, 45.	1.6	24
677	DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING OF CANINE BRAIN TUMORS. Veterinary Radiology and Ultrasound, 2010, 51, 122-9.	0.4	27
678	Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. British Journal of Cancer, 2010, 103, 52-60.	2.9	74
679	Noninvasive methods of measuring bone blood perfusion. Annals of the New York Academy of Sciences, 2010, 1192, 95-102.	1.8	64
680	Functional Principal Component Analyses of Biomedical Images as Outcome Measures. Journal of the Royal Statistical Society Series C: Applied Statistics, 2010, 59, 57-76.	0.5	5
681	Determination of Glomerular Filtration Rate Using Dynamic CT-Angiography. Investigative Radiology, 2010, 45, 387-392.	3.5	29
682	Quantitative Whole Heart Stress Perfusion CT Imaging as Noninvasive Assessment of Hemodynamics in Coronary Artery Stenosis. Investigative Radiology, 2010, 45, 298-305.	3.5	106
683	Perfusion magnetic resonance imaging of the liver. World Journal of Gastroenterology, 2010, 16, 1598.	1.4	103
684	Molecular and Clinical Aspects of Targeting the VEGF Pathway in Tumors. Journal of Oncology, 2010, 2010, 1-12.	0.6	19
685	Review: Treatment monitoring of paranasal sinus tumors by magnetic resonance imaging. Cancer lmaging, 2010, 10, 183-193.	1.2	18
686	Combined PET/MR Imaging $\hat{a}\in$ " Technology and Applications. Technology in Cancer Research and Treatment, 2010, 9, 5-20.	0.8	60
687	Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2010, 28, 207-214.	0.8	232
688	Integrated Software Environment Based on COMKAT for Analyzing Tracer Pharmacokinetics with Molecular Imaging. Journal of Nuclear Medicine, 2010, 51, 77-84.	2.8	20
689	Applications of molecular MRI and optical imaging in cancer. Future Medicinal Chemistry, 2010, 2, 975-988.	1.1	48
690	Applications of Molecular Imaging. Progress in Molecular Biology and Translational Science, 2010, 95, 237-298.	0.9	22
691	Renal and Perfusion Imaging at 3 T. Topics in Magnetic Resonance Imaging, 2010, 21, 157-163.	0.7	2
692	Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01. Journal of Clinical Oncology, 2010, 28, 21-28.	0.8	172
693	Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G ₁ Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2. Journal of Clinical Oncology, 2010, 28, 780-787.	0.8	498

#	Article	IF	CITATIONS
694	Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. Annals of Oncology, 2010, 21, 1982-1989.	0.6	27
695	A quantitative study of grade of gliomas by applying dynamic contrast-enhanced MR imaging technique. , 2010, , .		1
696	Magnetic resonance imaging: A potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancer. International Journal of Hyperthermia, 2010, 26, 625-637.	1.1	9
697	Spinal Cord Blood Flow and Blood Vessel Permeability Measured by Dynamic Computed Tomography Imaging in Rats after Localized Delivery of Fibroblast Growth Factor. Journal of Neurotrauma, 2010, 27, 2041-2053.	1.7	32
698	Quantification of DCE-MRI: Pharmacokinetic parameter ratio between TOI and RR in reference region model., 2010, 2010, 2837-40.		0
699	Evaluation of model-independent deconvolution techniques to estimate blood perfusion., 2010, 2010, 2602-7.		3
700	MRI for men undergoing active surveillance or with rising PSA and negative biopsies. Nature Reviews Urology, 2010, 7, 543-551.	1.9	22
701	Noninvasive detection of temozolomide in brain tumor xenografts by magnetic resonance spectroscopyâ€. Neuro-Oncology, 2010, 12, 71-79.	0.6	11
702	Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation. International Journal of Hyperthermia, 2010, 26, 499-513.	1.1	93
703	A model-constrained Monte Carlo method for blind arterial input function estimation in dynamic contrast-enhanced MRI: I. Simulations. Physics in Medicine and Biology, 2010, 55, 4783-4806.	1.6	37
704	The use of a reference tissue arterial input function with low-temporal-resolution DCE-MRI data. Physics in Medicine and Biology, 2010, 55, 4871-4883.	1.6	24
705	Magnetic resonance imaging of hypoxic injury to the murine placenta. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 298, R312-R319.	0.9	54
706	Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2010, 16, 311-319.	3.2	157
707	Characterization of tumor microvascular structure and permeability: comparison between magnetic resonance imaging and intravital confocal imaging. Journal of Biomedical Optics, 2010, 15, 036004.	1.4	31
708	Dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) for the assessment of Pc 4-sensitized photodynamic therapy of a U87-derived glioma model in the athymic nude rat. Proceedings of SPIE, 2010, , .	0.8	0
709	A model-constrained Monte Carlo method for blind arterial input function estimation in dynamic contrast-enhanced MRI: II.In vivoresults. Physics in Medicine and Biology, 2010, 55, 4807-4823.	1.6	39
710	Permeability assessment of the focused ultrasound-induced blood–brain barrier opening using dynamic contrast-enhanced MRI. Physics in Medicine and Biology, 2010, 55, 5451-5466.	1.6	74
711	Characterizing early contrast uptake of ductal carcinomain situwith high temporal resolution dynamic contrast-enhanced MRI of the breast: a pilot study. Physics in Medicine and Biology, 2010, 55, N473-N485.	1.6	32

#	ARTICLE	IF	CITATIONS
712	Error estimation for perfusion parameters obtained using the two-compartment exchange model in dynamic contrast-enhanced MRI: a simulation study. Physics in Medicine and Biology, 2010, 55, 6431-6443.	1.6	30
713	Measurement of cerebral perfusion using MRI. Imaging in Medicine, 2010, 2, 41-61.	0.0	3
714	Differentiation of Prostate Cancer From Normal Prostate Tissue: Role of Hotspots in Pharmacokinetic MRI and Histologic Evaluation. American Journal of Roentgenology, 2010, 194, 675-681.	1.0	21
715	MRI in the early identification and classification of high-risk atherosclerotic carotid plaques. Imaging in Medicine, 2010, 2, 63-75.	0.0	44
716	Quantitative Analysis of Clinical Dynamic Contrast-enhanced MR Imaging for Evaluating Treatment Response in Human Breast Cancer. Radiology, 2010, 257, 47-55.	3.6	33
717	Dynamic Contrast-enhanced CT for Prostate Cancer: Relationship between Image Noise, Voxel Size, and Repeatability. Radiology, 2010, 256, 976-984.	3.6	27
718	Prostate Cancer: Differentiation of Central Gland Cancer from Benign Prostatic Hyperplasia by Using Diffusion-weighted and Dynamic Contrast-enhanced MR Imaging. Radiology, 2010, 257, 715-723.	3.6	278
719	Invited Commentary. Radiographics, 2010, 30, 716-719.	1.4	5
720	Pancreatic Cancer: Utility of Dynamic Contrast-enhanced MR Imaging in Assessment of Antiangiogenic Therapy. Radiology, 2010, 256, 441-449.	3.6	100
721	Assessment of the <i>In vivo</i> Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models. Clinical Cancer Research, 2010, 16, 2989-2998.	3.2	42
722	Candidate Biomarkers of Extravascular Extracellular Space: A Direct Comparison of Apparent Diffusion Coefficient and Dynamic Contrast-Enhanced MR Imagingâ€"Derived Measurement of the Volume of the Extravascular Extracellular Space in Glioblastoma Multiforme. American Journal of Neuroradiology, 2010, 31, 549-553.	1.2	61
723	Abstract No. 329: Hybrid reference tissue calibrated dual-bolus 3D quantitative dynamic contrast-enhanced MRI in a rabbit VX2 tumor model. Journal of Vascular and Interventional Radiology, 2010, 21, S124.	0.2	0
724	Comparison between Population Average and Experimentally Measured Arterial Input Function in Predicting Biopsy Results in Prostate Cancer. Academic Radiology, 2010, 17, 520-525.	1.3	41
725	Radiological Assessment of Gynecologic Malignancies. PET Clinics, 2010, 5, 407-423.	1.5	2
726	Sensitivity of Quantitative Metrics Derived from DCE MRI and a Pharmacokinetic Model to Image Quality and Acquisition Parameters. Academic Radiology, 2010, 17, 468-478.	1.3	41
727	Sustained Expression of Vascular Endothelial Growth Factor and Angiopoietin-1 Improves Blood–Spinal Cord Barrier Integrity and Functional Recovery after Spinal Cord Injury. Journal of Neurotrauma, 2010, 27, 2067-2076.	1.7	56
728	Nosological analysis of MRI tissue perfusion parameters obtained using the unicompartmental and pharmacokinetic models in cerebral glioblastomas. Radiologia, 2010, 52, 432-441.	0.3	5
729	Longitudinal Magnetic Resonance Imaging-Based Assessment of Vascular Changes and Radiation Response in Androgen-Sensitive Prostate Carcinoma Xenografts under Androgen-Exposed and Androgen-Deprived Conditions. Neoplasia, 2010, 12, 818-825.	2.3	12

#	ARTICLE	IF	CITATIONS
730	Combined PET/MRI: one step further in multimodality imaging. Trends in Molecular Medicine, 2010, 16, 508-515.	3.5	121
731	Toward clinical application of manganese-enhanced MRI of retinal function. Brain Research Bulletin, 2010, 81, 333-338.	1.4	30
732	An introduction to functional and molecular imaging with MRI. Clinical Radiology, 2010, 65, 557-566.	0.5	54
733	Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. European Journal of Cancer, 2010, 46, 198-206.	1.3	50
734	Perfusion maps of the whole liver based on high temporal and spatial resolution contrast-enhanced MRI (4D THRIVE): Feasibility and initial results in focal liver lesions. European Journal of Radiology, 2010, 74, 529-535.	1.2	17
735	Technical aspects of MR perfusion. European Journal of Radiology, 2010, 76, 304-313.	1.2	137
736	Combined diffusion-weighted and dynamic contrast-enhanced imaging of patients with acute osteoporotic vertebral fractures. European Journal of Radiology, 2010, 76, 298-303.	1.2	43
737	Dynamic in vivo imaging of cerebral blood flow and blood–brain barrier permeability. NeuroImage, 2010, 49, 337-344.	2.1	42
738	Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: Sequential perfusion-CT findings. Radiotherapy and Oncology, 2010, 94, 156-160.	0.3	31
739	The use of probability maps to deal with the uncertainties in prostate cancer delineation. Radiotherapy and Oncology, 2010, 94, 168-172.	0.3	19
740	Validation of functional imaging with pathology for tumor delineation in the prostate. Radiotherapy and Oncology, 2010, 94, 145-150.	0.3	97
741	Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients. Radiotherapy and Oncology, 2010, 95, 185-190.	0.3	219
742	Dynamic contrast-enhanced magnetic resonance imaging of human cervical carcinoma xenografts: Pharmacokinetic analysis and correlation to tumor histomorphology. Radiotherapy and Oncology, 2010, 97, 217-224.	0.3	13
743	Quantitative assessment of hypoxia in melanoma xenografts by dynamic contrast-enhanced magnetic resonance imaging: Intradermal versus intramuscular tumors. Radiotherapy and Oncology, 2010, 97, 233-238.	0.3	21
745	Diffusion-Weighted MR Imaging. Medical Radiology, 2010, , .	0.0	16
746	Advances in Computational Biology. Advances in Experimental Medicine and Biology, 2010, , .	0.8	2
747	Imaging of Brain Tumors: Perfusion/Permeability. Neuroimaging Clinics of North America, 2010, 20, 337-353.	0.5	38
748	Two Non-linear Parametric Models of Contrast Enhancement for DCE-MRI of the Breast Amenable to Fitting Using Linear Least Squares. , 2010 , , .		1

#	Article	lF	Citations
749	In-vivo quantitative permeability assessment of the focused-ultrasound-induced blood-brain barrier opening using dynamic contrast-enhanced MRI. , 2010 , , .		1
750	Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates. Acta Oncol $ ilde{A}^3$ gica, 2010, 49, 906-913.	0.8	22
751	Imaging tumour physiology and vasculature to predict and assess response to heat. International Journal of Hyperthermia, 2010, 26, 264-272.	1.1	5
752	MRI of Stroke Recovery. Stroke, 2010, 41, 410-414.	1.0	44
753	Pharmacokinetic analysis and k-means clustering of DCEMR images for radiotherapy outcome prediction of advanced cervical cancers. Acta Oncol \tilde{A}^3 gica, 2011, 50, 859-865.	0.8	19
7 54	Magnetic resonance imaging of tumor necrosis. Acta Oncol $ ilde{A}^3$ gica, 2011, 50, 427-434.	0.8	32
755	Spatiotemporal analysis of tumor uptake patterns in dynamic 18FDG-PET and dynamic contrast enhanced CT. Acta Oncol \tilde{A}^3 gica, 2011, 50, 873-882.	0.8	12
756	Noninvasive Monitoring of Therapy-Induced Microvascular Changes in a Pancreatic Cancer Model Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging with P846, a New Low-Diffusible Gadolinium-Based Contrast Agent. Radiation Research, 2011, 175, 10-20.	0.7	14
757	Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3749-3754.	3.3	552
758	Imaging hypoxia in gliomas. British Journal of Radiology, 2011, 84, S145-S158.	1.0	66
759	Prostate Cancer: Multiparametric MR Imaging for Detection, Localization, and Staging. Radiology, 2011, 261, 46-66.	3.6	618
760	Radiological Assessment of Gynecologic Malignancies. Obstetrics and Gynecology Clinics of North America, 2011, 38, 45-68.	0.7	27
761	Advancements in MR Imaging of the Prostate: From Diagnosis to Interventions. Radiographics, 2011, 31, 677-703.	1.4	215
762	IRM fonctionnelleÂ: nouvel outil pour prédire la réponse des cancers du col utérin à la chimioradiothérapie concomitanteÂ?. Imagerie De La Femme, 2011, 21, 143-147.	0.0	2
763	Measuring Permeability in Acute Ischemic Stroke. Neuroimaging Clinics of North America, 2011, 21, 315-325.	0.5	26
764	Imaging in Renal CellÂCarcinoma. Hematology/Oncology Clinics of North America, 2011, 25, 687-715.	0.9	21
765	Opportunities and pitfalls of cancer imaging in clinical trials. Nature Reviews Clinical Oncology, 2011, 8, 517-527.	12.5	31
766	Diffusion-Weighted and Dynamic Contrast-Enhanced MRI of Prostate Cancer: Correlation of Quantitative MR Parameters With Gleason Score and Tumor Angiogenesis. American Journal of Roentgenology, 2011, 197, 1382-1390.	1.0	221

#	Article	IF	Citations
767	Vascular and Metabolic Response to Bevacizumab-Containing Regimens in Two Patients With Colorectal Liver Metastases Measured by Dynamic Contrast-Enhanced MRI and Dynamic 18F-FDG-PET. Clinical Colorectal Cancer, 2011, 10, E1-E5.	1.0	16
769	Dendrimer., 2011,, 1080-1080.		0
770	Difluoromethylornithine., 2011, , 1117-1117.		0
771	Functional MRI for tumor delineation in prostate radiation therapy. Imaging in Medicine, 2011, 3, 219-231.	0.0	11
772	Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. International Journal of Radiation Biology, 2011, 87, 1126-1134.	1.0	19
773	Contrast enhanced MR imaging of female pelvic cancers: Established methods and emerging applications. European Journal of Radiology, 2011, 78, 2-11.	1.2	20
774	Evaluation of inflammatory status of atherosclerotic carotid plaque before thromboendarterectomy using delayed contrast-enhanced subtracted images after magnetic resonance angiography. European Journal of Radiology, 2011, 80, e373-e380.	1.2	13
775	Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. Journal of Hepatology, 2011, 55, 858-865.	1.8	114
776	Blood–brain barrier impairment is functionally correlated with clinical severity in patients of multiple system atrophy. Neurobiology of Aging, 2011, 32, 2183-2189.	1.5	33
777	DNA Vaccine. , 2011, , 1144-1144.		0
778	Functional magnetic resonance: biomarkers of response in breast cancer. Breast Cancer Research, 2011, 13, 204.	2.2	61
779	First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Annals of Oncology, 2011, 22, 559-566.	0.6	70
780	Intra-arterial brachytherapy of hepatic malignancies: watch the flow. Nature Reviews Clinical Oncology, 2011, 8, 115-120.	12.5	24
781	Differentiation between hypoxic and non-hypoxic experimental tumors by dynamic contrast-enhanced magnetic resonance imaging. Radiotherapy and Oncology, 2011, 98, 360-364.	0.3	34
782	Assessment of tumor hypoxia and interstitial fluid pressure by gadomelitol-based dynamic contrast-enhanced magnetic resonance imaging. Radiotherapy and Oncology, 2011, 101, 217-222.	0.3	10
783	MRI to quantify early radiation-induced changes in the salivary glands. Radiotherapy and Oncology, 2011, 100, 386-389.	0.3	32
784	Perfusion Estimated With Rapid Dynamic Contrast-Enhanced Magnetic Resonance Imaging Correlates Inversely With Vascular Endothelial Growth Factor Expression and Pimonidazole Staining in Head-and-Neck Cancer: A Pilot Study. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1176-1183.	0.4	63
785	Principles and Technical Aspects of Perfusion Magnetic Resonance Imaging. Journal of the Korean Society of Magnetic Resonance in Medicine, 2011, 15, 91.	0.1	6

#	Article	IF	CITATIONS
786	Dynamic Contrast Enhanced Magnetic Resonance Imaging in Rectal Cancer., 2011, , .		3
787	MR imaging and MR-guided biopsy of the prostate at 3T., 0,, 178-196.		0
788	BIOMARKERS AND PUBLIC–PRIVATE PARTNERSHIPS. , O, , 193-194.		0
789	Evaluation of Antiangiogenic Effects of a New Synthetic Candidate Drug KR-31831 on Xenografted Ovarian Carcinoma Using Dynamic Contrast Enhanced MRI. Korean Journal of Radiology, 2011, 12, 602.	1.5	12
790	Investigation of <i>In Vivo</i> Targeting Kinetics of \hat{l}_{\pm} _v \hat{l}^{2} ₃ -Specific Superparamagnetic Nanoprobes by Time-Resolved MRI. Theranostics, 2011, 1, 263-273.	4.6	36
791	Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. Cancer Imaging, 2011, 11, 259-265.	1.2	37
792	Correlations of 3T DCE-MRI Quantitative Parameters with Microvessel Density in a Human-Colorectal-Cancer Xenograft Mouse Model. Korean Journal of Radiology, 2011, 12, 722.	1.5	20
793	IMAGING BIOMARKERS IN DRUG DEVELOPMENT: CASE STUDIES. , 0, , 222-264.		1
794	Sensitivity of MRI Tumor Biomarkers to VEGFR Inhibitor Therapy in an Orthotopic Mouse Glioma Model. PLoS ONE, 2011, 6, e17228.	1.1	27
795	A Systems Approach for Tumor Pharmacokinetics. PLoS ONE, 2011, 6, e24696.	1.1	101
796	Assessing Antiangiogenic Therapy Response by DCE-MRI: Development of a Physiology Driven Multi-Compartment Model Using Population Pharmacometrics. PLoS ONE, 2011, 6, e26366.	1.1	8
797	Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Molecular Imaging, 2011, 10, 7290.2010.00040.	0.7	23
798	Advances in imaging angiogenesis and inflammation in atherosclerosis. Thrombosis and Haemostasis, 2011, 105, 820-827.	1.8	15
799	Pharmacokinetics of Contrast Media in Humans. Investigative Radiology, 2011, 46, 576-585.	3.5	23
800	Free-Breathing Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging in a Rat Liver Tumor Model Using Dynamic Radial T1 Mapping. Investigative Radiology, 2011, 46, 624-631.	3 . 5	17
801	A Useful Tool for the Initial Assessment of Blood–Brain Barrier Permeability After Traumatic Brain Injury in Rabbits: Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Journal of Trauma, 2011, 71, 1645-1651.	2.3	15
802	Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Evaluating Intraosseous Cleft Formation in Patients With Osteoporotic Vertebral Compression Fractures Before Vertebroplasty. Spine, 2011, 36, 1244-1250.	1.0	12
803	Head and Neck Cancer as a Model for Advances in Imaging Prognosis, Early Assessment, and Posttherapy Evaluation. Cancer Journal (Sudbury, Mass), 2011, 17, 159-165.	1.0	10

#	Article	IF	CITATIONS
804	Dynamic Contrast-Enhanced Magnetic Resonance Imaging Predicts Immediate Therapeutic Response of Magnetic Resonance-Guided High-Intensity Focused Ultrasound Ablation of Symptomatic Uterine Fibroids. Investigative Radiology, 2011, 46, 639-647.	3.5	59
805	Update on vascular disrupting agents for cancer therapy. Therapy: Open Access in Clinical Medicine, 2011, 8, 403-413.	0.2	1
806	Experimental Investigations of Nonlinearities and Destruction Mechanisms of an Experimental Phospholipid-Based Ultrasound Contrast Agent: Erratum. Investigative Radiology, 2011, 46, 600.	3.5	0
807	Quantification of Supra-Aortic Arterial Wall Inflammation in Patients With Arteritis Using High Resolution Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Investigative Radiology, 2011, 46, 594-599.	3.5	14
808	Functional and Structural Characteristics of Tumor Angiogenesis in Lung Cancers Overexpressing Different VEGF Isoforms Assessed by DCE- and SSCE-MRI. PLoS ONE, 2011, 6, e16062.	1.1	36
809	Development and characterization of a dynamic lesion phantom for the quantitative evaluation of dynamic contrast-enhanced MRI. Medical Physics, 2011, 38, 5601-5611.	1.6	13
810	An anthropomorphic phantom for quantitative evaluation of breast MRI. Medical Physics, 2011, 38, 743-753.	1.6	35
811	Use of dynamic contrastâ€enhanced magnetic resonance imaging to evaluate the microcirculation of lower extremity muscles in patients with Type 2 diabetes. Diabetic Medicine, 2011, 28, 618-621.	1.2	5
812	T ₁ - and T ₂ *-Dominant Extravasation Correction in DSC-MRI: Part IIâ€"Predicting Patient Outcome after a Single Dose of Cediranib in Recurrent Glioblastoma Patients. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 2054-2064.	2.4	35
813	T ₁ - and T* ₂ -Dominant Extravasation Correction in DSC-MRI: Part lâ€"Theoretical Considerations and Implications for Assessment of Tumor Hemodynamic Properties. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 2041-2053.	2.4	100
814	Molecular MRI assessment of vascular endothelial growth factor receptor-2 in rat C6 gliomas. Journal of Cellular and Molecular Medicine, 2011, 15, 837-849.	1.6	18
815	Studies of pathology and VEGF expression in rabbit cerebrospinal fluid metastasis: application of dynamic contrast-enhanced MRI. Magnetic Resonance Imaging, 2011, 29, 1101-1109.	1.0	3
816	The Promise of Dynamic Contrast-Enhanced Imaging in Radiation Therapy. Seminars in Radiation Oncology, 2011, 21, 147-156.	1.0	99
817	Tissue-Specific Compartmental Analysis for Dynamic Contrast-Enhanced MR Imaging of Complex Tumors. IEEE Transactions on Medical Imaging, 2011, 30, 2044-2058.	5.4	58
818	Value of multiparametric prostate MRI of the peripheral zone. Zeitschrift Fur Medizinische Physik, 2011, 21, 198-205.	0.6	18
819	Single blind randomized Phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials, 2011, 12, 255.	0.7	156
820	Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors. Critical Reviews in Oncology/Hematology, 2011, 80, 40-53.	2.0	63
821	Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion. Neuro-Oncology, 2011, 13, 1037-1046.	0.6	103

#	Article	IF	CITATIONS
822	Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. European Radiology, 2011, 21, 616-626.	2.3	110
823	Prediction and monitoring of the response to chemoradiotherapy in oral squamous cell carcinomas using a pharmacokinetic analysis based on the dynamic contrast-enhanced MR imaging findings. European Radiology, 2011, 21, 1699-1708.	2.3	20
824	Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. European Radiology, 2011, 21, 1970-1978.	2.3	79
825	Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response. Annals of Surgical Oncology, 2011, 18, 2192-2199.	0.7	76
826	DCE-MRI Detects Early Vascular Response in Breast Tumor Xenografts Following Anti-DR5 Therapy. Molecular Imaging and Biology, 2011, 13, 94-103.	1.3	28
827	Precision analysis of kinetic modelling estimates in dynamic contrast enhanced MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2011, 24, 51-66.	1.1	18
828	Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2011, 24, 225-232.	1.1	14
829	Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids. Angiogenesis, 2011, 14, 143-153.	3.7	13
830	Limitations of the permeability-limited compartment model in estimating vascular permeability and interstitial volume fraction in DCE-MRI. Magnetic Resonance Imaging, 2011, 29, 639-649.	1.0	4
831	Advances in MRI-Based Detection of Cerebrovascular Changes after Experimental Traumatic Brain Injury. Translational Stroke Research, 2011, 2, 524-532.	2.3	9
832	Classification of breast lesions based on a dual S-shaped logistic model in dynamic contrast enhanced magnetic resonance imaging. Science China Life Sciences, 2011, 54, 889-896.	2.3	3
833	Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore Câ,,¢), doxorubicin (Caelyx®) or vincristine. BMC Cancer, 2011, 11, 124.	1.1	49
834	Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study. Radiation Oncology, 2011, 6, 65.	1.2	25
835	Dynamic contrastâ€enhanced MRI of primary rectal cancer: Quantitative correlation with positron emission tomography/computed tomography. Journal of Magnetic Resonance Imaging, 2011, 33, 340-347.	1.9	16
836	Active Crohn's Disease in the small bowel: Evaluation by diffusion weighted imaging and quantitative dynamic contrast enhanced MR imaging. Journal of Magnetic Resonance Imaging, 2011, 33, 615-624.	1.9	188
837	Degenerative endplate changes of the lumbosacral spine: Dynamic contrastâ€enhanced MRI profiles related to age, sex, and spinal level. Journal of Magnetic Resonance Imaging, 2011, 33, 382-389.	1.9	12
838	Quantitative analysis of vertebral bone marrow perfusion using dynamic contrastâ€enhanced MRI: Initial results in osteoporotic patients with acute vertebral fracture. Journal of Magnetic Resonance Imaging, 2011, 33, 676-683.	1.9	32
839	Suppression of vascular enhancement artifacts through the use of a multiband, selectively spoiled radiofrequency excitation pulse. Journal of Magnetic Resonance Imaging, 2011, 33, 1256-1261.	1.9	3

#	Article	IF	CITATIONS
840	Dualâ€temporal resolution dynamic contrastâ€enhanced MRI protocol for blood–brain barrier permeability measurement in enhancing multiple sclerosis lesions. Journal of Magnetic Resonance Imaging, 2011, 33, 1291-1300.	1.9	42
841	Comparison of enhancement characteristics between invasive lobular carcinoma and invasive ductal carcinoma. Journal of Magnetic Resonance Imaging, 2011, 34, 293-300.	1.9	19
842	Diffusionâ€weighted and dynamic contrastâ€enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients. Journal of Magnetic Resonance Imaging, 2011, 34, 1099-1109.	1.9	60
843	Modelâ€based, semiquantitative and time intensity curve shape analysis of dynamic contrastâ€enhanced MRI: A comparison in patients undergoing antiangiogenic treatment for recurrent glioma. Journal of Magnetic Resonance Imaging, 2011, 34, 1303-1312.	1.9	23
844	Fundamentals of tracer kinetics for dynamic contrastâ€enhanced MRI. Journal of Magnetic Resonance Imaging, 2011, 34, 1262-1276.	1.9	105
845	Reference regionâ€based pharmacokinetic modeling in quantitative dynamic contractâ€enhanced MRI allows robust treatment monitoring in a rat liver tumor model despite cardiovascular changes. Magnetic Resonance in Medicine, 2011, 65, 229-238.	1.9	10
846	The effect of blood inflow and <i>B</i> ₁ â€field inhomogeneity on measurement of the arterial input function in axial 3D spoiled gradient echo dynamic contrastâ€enhanced MRI. Magnetic Resonance in Medicine, 2011, 65, 108-119.	1.9	61
847	Validity of perfusion parameters obtained using the modified Tofts model: A simulation study. Magnetic Resonance in Medicine, 2011, 65, 1491-1497.	1.9	40
848	Comparison of dynamic contrastâ€enhanced MRI and dynamic contrastâ€enhanced CT biomarkers in bladder cancer. Magnetic Resonance in Medicine, 2011, 66, 219-226.	1.9	20
849	Ischemiaâ€reperfusion injury in rat skeletal muscle assessed with <i>T</i> ₂ â€weighted and dynamic contrastâ€enhanced MRI. Magnetic Resonance in Medicine, 2011, 66, 528-537.	1.9	36
850	Extended graphical model for analysis of dynamic contrastâ€enhanced MRI. Magnetic Resonance in Medicine, 2011, 66, 868-878.	1.9	20
851	Permeability dependence study of the focused ultrasoundâ€induced blood–brain barrier opening at distinct pressures and microbubble diameters using DCEâ€MRI. Magnetic Resonance in Medicine, 2011, 66, 821-830.	1.9	83
852	On the scope and interpretation of the Tofts models for DCEâ€MRI. Magnetic Resonance in Medicine, 2011, 66, 735-745.	1.9	295
853	Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis. Magnetic Resonance in Medicine, 2011, 65, 889-899.	1.9	10
854	The concordance of MRI and quantitative autoradiography estimates of the transvascular transfer rate constant of albumin in a rat brain tumor model. Magnetic Resonance in Medicine, 2011, 66, 1422-1431.	1.9	8
855	The blood–spinal cord barrier: Morphology and Clinical Implications. Annals of Neurology, 2011, 70, 194-206.	2.8	341
856	Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by ¹ H MRS. NMR in Biomedicine, 2011, 24, 316-324.	1.6	48
857	A comparative study of dynamic contrastâ€enhanced MRI parameters as biomarkers for antiâ€angiogenic drug therapy. NMR in Biomedicine, 2011, 24, 1169-1180.	1.6	15

#	Article	IF	CITATIONS
858	MRI & amp; MRS assessment of the role of the tumour microenvironment in response to therapy. NMR in Biomedicine, 2011, 24, 612-635.	1.6	15
859	MRI in breast cancer therapy monitoring. NMR in Biomedicine, 2011, 24, 712-720.	1.6	42
860	Antivascular Effects of Neoadjuvant Androgen Deprivation for Prostate Cancer: An In Vivo Human Study Using Susceptibility and Relaxivity Dynamic MRI. International Journal of Radiation Oncology Biology Physics, 2011, 80, 721-727.	0.4	54
861	Interstitial Fluid Pressure and Vascularity of Intradermal and Intramuscular Human Tumor Xenografts. International Journal of Radiation Oncology Biology Physics, 2011, 80, 258-264.	0.4	19
862	Assessment of Tumor Radioresponsiveness and Metastatic Potential by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. International Journal of Radiation Oncology Biology Physics, 2011, 81, 255-261.	0.4	32
863	Pseudo ground truth based nonrigid registration of myocardial perfusion MRI. Medical Image Analysis, 2011, 15, 449-459.	7.0	10
864	Novel Ultrasound and DCE-MRI Analyses After Antiangiogenic Treatment With a Selective VEGF Receptor Inhibitor. Ultrasound in Medicine and Biology, 2011, 37, 909-921.	0.7	7
865	Phenomenological universalities: a novel tool for the analysis of dynamic contrast enhancement in magnetic resonance imaging. Physics in Medicine and Biology, 2011, 56, 573-586.	1.6	17
866	Use of a capillary input function with cardiac output for the estimation of lesion pharmacokinetic parameters: preliminary results on a breast cancer patient. Physics in Medicine and Biology, 2011, 56, 1743-1753.	1.6	2
867	Prediction of Disease-Free Survival in Patients with Squamous Cell Carcinomas of the Head and Neck Using Dynamic Contrast-Enhanced MR Imaging. American Journal of Neuroradiology, 2011, 32, 778-784.	1.2	83
868	Carotid Artery Atherosclerosis: Effect of Intensive Lipid Therapy on the Vasa Vasorumâ€"Evaluation by Using Dynamic Contrast-enhanced MR Imaging. Radiology, 2011, 260, 224-231.	3.6	77
870	Discrimination of Benign and Malignant Breast Lesions by Using Shutter-Speed Dynamic Contrast-enhanced MR Imaging. Radiology, 2011, 261, 394-403.	3.6	87
871	Development of a platform for co-registered ultrasound and MR contrast imaging in vivo. Physics in Medicine and Biology, 2011, 56, 861-877.	1.6	14
872	Improved Perfusion MR Imaging Assessment of Intracerebral Tumor Blood Volume and Antiangiogenic Therapy Efficacy in a Rat Model with Ferumoxytol. Radiology, 2011, 261, 796-804.	3.6	46
873	The effect of motion correction on pharmacokinetic parameter estimation in dynamic-contrast-enhanced MRI. Physics in Medicine and Biology, 2011, 56, 7693-7708.	1.6	37
874	Quantitative DCE-MRI modeling on tumor diagnosis and treatment effect evaluation. , $2011, \ldots$		0
875	Dynamic Contrast-enhanced MR Imaging Measurement of Vertebral Bone Marrow Perfusion May Be Indicator of Outcome of Acute Myeloid Leukemia Patients in Remission. Radiology, 2011, 258, 821-831.	3.6	44
876	Areas Suspicious for Prostate Cancer: MR–guided Biopsy in Patients with at Least One Transrectal US-guided Biopsy with a Negative Finding—Multiparametric MR Imaging for Detection and Biopsy Planning. Radiology, 2011, 259, 162-172.	3.6	175

#	Article	IF	CITATIONS
877	Dynamic Gadolinium-Enhanced Perfusion MRI of Prostate Cancer: Assessment of Response to Hypofractionated Robotic Stereotactic Body Radiation Therapy. American Journal of Roentgenology, 2011, 197, 907-915.	1.0	28
878	A task-based approach to parametric imaging with dynamic contrast enhanced MRI., 2011, , .		0
879	Estimation of physiological parameters in the subspace of arterial input function in dynamic contrast-enhanced magnetic resonance imaging. , $2011,\ldots$		2
880	Functional Imaging for Assessing Tumor Response in Cancer of the Cervix. Women's Health, 2011, 7, 487-497.	0.7	10
881	Tumoral and Nontumoral Pancreas: Correlation between Quantitative Dynamic Contrast-enhanced MR Imaging and Histopathologic Parameters. Radiology, 2011, 261, 456-466.	3.6	84
882	Liver Metastasis: Biology and Clinical Management. Cancer Metastasis - Biology and Treatment, 2011, , .	0.1	6
883	Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2011, 29, 2689-2695.	0.8	204
884	Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies. Journal of Clinical Oncology, 2011, 29, 1271-1279.	0.8	189
885	Multimodality Assessment of Brain Tumors and Tumor Recurrence. Journal of Nuclear Medicine, 2011, 52, 1585-1600.	2.8	125
886	Blood-Brain Barrier Breakdown and Blood-Brain Communication in Neurological and Psychiatric Diseases. Cardiovascular Psychiatry and Neurology, 2011, 2011, 1-2.	0.8	13
887	Vascular Pathology and Blood-Brain Barrier Disruption in Cognitive and Psychiatric Complications of Type 2 Diabetes Mellitus. Cardiovascular Psychiatry and Neurology, 2011, 2011, 1-10.	0.8	78
888	The Blood-Brain Barrier and Microvascular Water Exchange in Alzheimer's Disease. Cardiovascular Psychiatry and Neurology, 2011, 2011, 1-9.	0.8	23
889	Monitoring Response to Antiangiogenic Therapy in Nonâ€"Small Cell Lung Cancer Using Imaging Markers Derived from PET and Dynamic Contrast-Enhanced MRI. Journal of Nuclear Medicine, 2011, 52, 48-55.	2.8	98
890	Flip angle optimization for dynamic contrast-enhanced MRI-studies with spoiled gradient echo pulse sequences. Physics in Medicine and Biology, 2011, 56, 5373-5395.	1.6	22
891	Dynamic contrast-enhanced imaging techniques: CT and MRI. British Journal of Radiology, 2011, 84, S112-S120.	1.0	156
892	Multicentre imaging measurements for oncology and in the brain. British Journal of Radiology, 2011, 84, S213-S226.	1.0	34
893	Detection of Small Hepatocellular Carcinoma: Intraindividual Comparison of Gadoxetic Acid-Enhanced MRI at 3.0 and 1.5 T: Erratum. Investigative Radiology, 2011, 46, 600.	3.5	0
894	Feasibility of a Pneumatically Actuated MR-compatible Robot for Transrectal Prostate Biopsy Guidance. Radiology, 2011, 260, 241-247.	3.6	80

#	Article	IF	Citations
895	Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer. Prostate Cancer and Prostatic Diseases, 2011, 14, 232-237.	2.0	103
896	3-T Dynamic Contrast-Enhanced MRI of the Breast: Pharmacokinetic Parameters Versus Conventional Kinetic Curve Analysis. American Journal of Roentgenology, 2011, 197, 1498-1505.	1.0	98
897	Clinical MRI of the Abdomen. , 2011, , .		12
898	Quantifying Tumor Vascular Heterogeneity with Dynamic Contrast-Enhanced Magnetic Resonance Imaging: A Review. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-12.	3.0	100
899	The precision of pharmacokinetic parameters in dynamic contrast-enhanced magnetic resonance imaging: the effect of sampling frequency and duration. Physics in Medicine and Biology, 2011, 56, 5665-5678.	1.6	25
900	Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Blood Oxygenation Level-Dependent Magnetic Resonance Imaging for the Assessment of Changes in Tumor Biology With Treatment. Journal of the National Cancer Institute Monographs, 2011, 2011, 103-107.	0.9	32
901	Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging of bone marrow in healthy individuals. Acta Radiologica, 2011, 52, 324-330.	0.5	36
902	Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and Gene Expression Profiles. Journal of the National Cancer Institute Monographs, 2011, 2011, 71-74.	0.9	42
903	Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer. Clinical Cancer Research, 2012, 18, 3428-3439.	3.2	158
904	Molecular Imaging in Therapeutic Efficacy Assessment of Targeted Therapy for Nonsmall Cell Lung Cancer. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-10.	3.0	2
905	Quantitative MRI measurements of the Achilles tendon in spondyloarthritis using ultrashort echo times. British Journal of Radiology, 2012, 85, e293-e299.	1.0	8
906	Radiation-induced brain injury: A review. Frontiers in Oncology, 2012, 2, 73.	1.3	501
907	Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. Annals of Oncology, 2012, 23, 1030-1036.	0.6	90
908	Reproducibility and Comparison of DCE-MRI and DCE-CT Perfusion Parameters in a Rat Tumor Model. Technology in Cancer Research and Treatment, 2012, 11, 279-288.	0.8	25
909	Multiparametric MRI and prostate cancer diagnosis and risk stratification. Current Opinion in Urology, 2012, 22, 310-315.	0.9	105
910	New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Annals of Oncology, 2012, 23, 570-576.	0.6	69
911	Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer. Clinical Cancer Research, 2012, 18, 1404-1414.	3.2	77
912	Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectin–Positive Metastatic Human Melanoma Xenografts. Cancer Research, 2012, 72, 1814-1824.	0.4	86

#	Article	IF	CITATIONS
913	Volumetric MR-guided High-Intensity Focused Ultrasound Ablation with a One-Layer Strategy to Treat Large Uterine Fibroids: Initial Clinical Outcomes. Radiology, 2012, 263, 600-609.	3.6	68
914	MR Imaging of Treated Prostate Cancer. Radiology, 2012, 262, 26-42.	3.6	120
915	An approach to identify, from DCE MRI, significant subvolumes of tumors related to outcomes in	1.6	59
916	Imaging the Efficacy of Anti-Inflammatory Liposomes in a Rabbit Model of Atherosclerosis by Non-Invasive Imaging. Methods in Enzymology, 2012, 508, 211-228.	0.4	26
917	Magnetic resonance pharmacokinetic imaging clusterization of hepatocellular carcinomas as a means to grade tumor aggressiveness. Expert Review of Gastroenterology and Hepatology, 2012, 6, 711-716.	1.4	3
918	X-ray Computed Tomography Principles and Contrast Agents. , 2012, , 795-827.		2
919	Correlation of Microcirculatory Parameters Derived from the Generalized Kinetic and Distributed Parameter Models: A Perfusion CT Study. , 2012, , .		0
920	GADOLINIUM(Gd)-BASED AND ION OXIDE NANOPARTICLE CONTRAST AGENTS FOR PRE-CLINICAL AND CLINICAL MAGNETIC RESONANCE IMAGING (MRI) RESEARCH. Cosmos, 2012, 08, 103-119.	0.4	1
921	MMP-9 from sublethally irradiated tumor promotes Lewis lung carcinoma cell invasiveness and pulmonary metastasis. Oncogene, 2012, 31, 458-468.	2.6	50
922	Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. British Journal of Cancer, 2012, 106, 1926-1933.	2.9	105
923	Dynamic Contrast-Enhanced MRI for Assessing Therapeutic Response of Choroidal Neovascularization in a Rat Model., 2012, 53, 7693.		3
924	Neoadjuvant Chemotherapy in Breast Cancer: Prediction of Pathologic Response with PET/CT and Dynamic Contrast-enhanced MR Imaging—Prospective Assessment. Radiology, 2012, 263, 53-63.	3.6	113
925	Advances in noninvasive imaging for evaluating clinical risk and guiding therapy in carotid atherosclerosis. Expert Review of Cardiovascular Therapy, 2012, 10, 37-53.	0.6	16
926	Dynamics of Rabbit Brain Edema in Focal Lesion and Perilesion Area after Traumatic Brain Injury: A MRI Study. Journal of Neurotrauma, 2012, 29, 2413-2420.	1.7	49
927	Combination therapy of radiofrequency ablation and bevacizumab monitored with power Doppler ultrasound in a murine model of hepatocellular carcinoma. International Journal of Hyperthermia, 2012, 28, 766-775.	1.1	10
928	Diagnostic Accuracy of Dynamic Contrast-Enhanced MR Imaging Using a Phase-Derived Vascular Input Function in the Preoperative Grading of Gliomas. American Journal of Neuroradiology, 2012, 33, 1539-1545.	1.2	35
929	Theoretical Compartment Modeling of DCE-MRI Data Based on the Transport across Physiological Barriers in the Brain. Computational and Mathematical Methods in Medicine, 2012, 2012, 1-6.	0.7	1
930	Characteristics of synovial inflammation in early arthritis analysed by pixel-by-pixel time-intensity curve shape analysis. Rheumatology, 2012, 51, 1240-1245.	0.9	22

#	Article	IF	CITATIONS
931	Retinoblastoma: Value of Dynamic Contrast-Enhanced MR Imaging and Correlation with Tumor Angiogenesis. American Journal of Neuroradiology, 2012, 33, 2129-2135.	1.2	15
932	The Akaike information criterion in DCE-MRI: Does it improve the haemodynamic parameter estimates?. Physics in Medicine and Biology, 2012, 57, 3609-3628.	1.6	21
933	Advanced Ovarian Cancer: Multiparametric MR Imaging Demonstrates Response- and Metastasis-specific Effects. Radiology, 2012, 263, 149-159.	3. 6	89
934	In Vivo Imaging of Neurovascular Remodeling After Stroke. Stroke, 2012, 43, 3436-3441.	1.0	24
935	Monitoring Brain Repair in Stroke Using Advanced Magnetic Resonance Imaging. Stroke, 2012, 43, 3124-3131.	1.0	18
936	T1-Weighted MR Contrast Agents for Cancer Research. , 2012, , 611-658.		1
937	Blood-Brain-Barrier Imaging in Brain Tumors: Concepts and Methods. Neurographics, 2012, 2, 48-59.	0.0	9
938	Quantification of Perfusion and Permeability in Multiple Sclerosis. Investigative Radiology, 2012, 47, 252-258.	3.5	86
939	Monitoring Molecular, Functional and Morphologic Aspects of Bone Metastases Using Non-Invasive Imaging. Current Pharmaceutical Biotechnology, 2012, 13, 584-594.	0.9	8
940	Using contrast agents to obtain maps of regional perfusion and capillary wall permeability. Imaging in Medicine, 2012, 4, 423-442.	0.0	6
941	Tracer Kinetic Model Selection for Dynamic Contrast-Enhanced Computed Tomography Imaging of Prostate Cancer. Investigative Radiology, 2012, 47, 41-48.	3.5	19
942	Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers. Anti-Cancer Drugs, 2012, 23, 12-21.	0.7	11
943	Molecular Imaging of Fibrin in a Breast Cancer Xenograft Mouse Model. Investigative Radiology, 2012, 47, 553-558.	3.5	29
944	Decision support system for localizing prostate cancer based on multiparametric magnetic resonance imaging. Medical Physics, 2012, 39, 4093-4103.	1.6	63
945	Quantification of Antiangiogenic and Antivascular Drug Activity by Kinetic Analysis of DCE-MRI Data. Clinical Pharmacology and Therapeutics, 2012, 92, 118-124.	2.3	16
946	Recent Advances in Contrast-Enhanced near Infrared Diffuse Optical Imaging of Diseases Using Indocyanine Green. Journal of Near Infrared Spectroscopy, 2012, 20, 203-221.	0.8	18
947	Quantification of DCE-MRI: A validation of three techniques with 3D-histology. , 2012, , .		1
948	Angiogenesis in prostate cancer: onset, progression and imaging. BJU International, 2012, 110, E794-808.	1.3	150

#	Article	IF	CITATIONS
949	Effect of Small-Molecule–Binding Affinity on Tumor Uptake <i>In Vivo</i> : A Systematic Study Using a Pretargeted Bispecific Antibody. Molecular Cancer Therapeutics, 2012, 11, 1365-1372.	1.9	37
950	Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nature Reviews Clinical Oncology, 2012, 9, 167-177.	12.5	318
951	Heuristic linear mapping of physiological parameters in dynamic contrastâ€enhanced MRI without T ₁ measurement and contrast agent concentration. Journal of Magnetic Resonance Imaging, 2012, 35, 916-925.	1.9	3
952	Dynamic contrast-enhanced 3-T MR imaging in cervical cancer before and after concurrent chemoradiotherapy. European Radiology, 2012, 22, 2533-2539.	2.3	53
953	Repeated Positron Emission Tomography-Computed Tomography and Perfusion-Computed Tomography Imaging in Rectal Cancer: Fluorodeoxyglucose Uptake Corresponds With Tumor Perfusion. International Journal of Radiation Oncology Biology Physics, 2012, 82, 849-855.	0.4	11
954	Tumor Metabolism and Perfusion in Head and Neck Squamous Cell Carcinoma: Pretreatment Multimodality Imaging With 1H Magnetic Resonance Spectroscopy, Dynamic Contrast-Enhanced MRI, and [18F]FDG-PET. International Journal of Radiation Oncology Biology Physics, 2012, 82, 299-307.	0.4	87
955	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Predictor of Outcome in Head-and-Neck Squamous Cell Carcinoma Patients With Nodal Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1837-1844.	0.4	137
956	Hypoxic Prostate/Muscle Po2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results. International Journal of Radiation Oncology Biology Physics, 2012, 82, e433-e439.	0.4	69
957	Dynamic Contrast-Enhanced MRI in Head-and-Neck Cancer: The Impact of Region of Interest Selection on the Intra- and Interpatient Variability of Pharmacokinetic Parameters. International Journal of Radiation Oncology Biology Physics, 2012, 82, e345-e350.	0.4	22
958	Pathologic Validation of a Model Based on Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Tumor Delineation in the Prostate Peripheral Zone. International Journal of Radiation Oncology Biology Physics, 2012, 82, e537-e544.	0.4	68
959	Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Metastatic Potential of Melanoma Xenografts. International Journal of Radiation Oncology Biology Physics, 2012, 83, e121-e127.	0.4	6
960	A mechanistic compartmental model for total antibody uptake in tumors. Journal of Theoretical Biology, 2012, 314, 57-68.	0.8	85
961	Assessment of hypoxia and radiation response in intramuscular experimental tumors by dynamic contrast-enhanced magnetic resonance imaging. Radiotherapy and Oncology, 2012, 102, 429-435.	0.3	32
962	Comparisons of the Efficacy of a Jak1/2 Inhibitor (AZD1480) with a VEGF Signaling Inhibitor (Cediranib) and Sham Treatments in Mouse Tumors Using DCE-MRI, DW-MRI, and Histology. Neoplasia, 2012, 14, 54-64.	2.3	35
963	Quantification of cerebral tumour blood flow and permeability with T1-weighted dynamic contrast enhanced MRI: A feasibility study. Journal of Neuroradiology, 2012, 39, 227-235.	0.6	10
964	Mapping Tumor Hypoxia In Vivo Using Pattern Recognition of Dynamic Contrast-enhanced MRI Data. Translational Oncology, 2012, 5, 437-IN2.	1.7	55
965	Imaging Radiation-Induced Normal Tissue Injury. Radiation Research, 2012, 177, 449-466.	0.7	74
966	Applications of Imaging Technology in Radiation Research. Radiation Research, 2012, 177, 387-397.	0.7	12

#	Article	IF	CITATIONS
967	Tumor Imaging., 2012,, 353-368.		0
968	Comparison between PUN and Tofts models in the quantification of dynamic contrast-enhanced MR imaging. Physics in Medicine and Biology, 2012, 57, 8443-8453.	1.6	11
969	Distribution of intravascular and extravascular extracellular volume fractions for neovascularization assessment by dynamic contrast-enhanced magnetic resonance imaging. , 2012, , .		1
970	Principles of Magnetic Resonance Imaging. Radiation Research, 2012, 177, 331-348.	0.7	12
971	Overview of Dynamic Contrast-Enhanced MRI in Prostate Cancer Diagnosis and Management. American Journal of Roentgenology, 2012, 198, 1277-1288.	1.0	248
972	The effect of hormonal treatment on conspicuity of prostate cancer: Implications for focal boosting radiotherapy. Radiotherapy and Oncology, 2012, 103, 233-238.	0.3	17
973	Multi-modal Imaging of Angiogenesis in a Nude Rat Model of Breast Cancer Bone Metastasis Using Magnetic Resonance Imaging, Volumetric Computed Tomography and Ultrasound. Journal of Visualized Experiments, 2012, , e4178.	0.2	10
974	Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study. Journal of Hepatology, 2012, 56, 1097-1103.	1.8	91
975	Temporal/spatial resolution improvement of in vivo DCE-MRI with compressed sensing-optimized FLASH. Magnetic Resonance Imaging, 2012, 30, 741-752.	1.0	26
976	A five-colour colour-coded mapping method for DCE-MRI analysis of head and neck tumours. Clinical Radiology, 2012, 67, 216-223.	0.5	17
977	Endorectal 3D T2-weighted 1mm-slice thickness MRI for prostate cancer staging at 1.5Tesla: Should we reconsider the indirects signs of extracapsular extension according to the D'Amico tumor risk criteria?. European Journal of Radiology, 2012, 81, e591-e597.	1.2	55
978	Evaluation of pancreatic cancer by multiple breath-hold dynamic contrast-enhanced magnetic resonance imaging at 3.0 T. European Journal of Radiology, 2012, 81, e917-e922.	1.2	17
979	Practical medical applications of quantitative MR relaxometry. Journal of Magnetic Resonance Imaging, 2012, 36, 805-824.	1.9	176
980	Imaging the Laboratory Mouse in vivo. , 2012, , 761-780.		1
981	Nanoprobes for hybrid SPECT/MR molecular imaging. Nanomedicine, 2012, 7, 719-733.	1.7	21
982	Magnetic Resonance Spectroscopy of Cancer Metabolism and Response to Therapy. Radiation Research, 2012, 177, 398-435.	0.7	16
983	Advances in oncologic imaging. Ca-A Cancer Journal for Clinicians, 2012, 62, 364-393.	157.7	53
984	Clinical imaging of tumor angiogenesis. Future Oncology, 2012, 8, 1443-1459.	1.1	15

#	Article	IF	Citations
985	Tumour response prediction by diffusion-weighted MR imaging: Ready for clinical use?. Critical Reviews in Oncology/Hematology, 2012, 83, 194-207.	2.0	61
986	Prediction and monitoring of treatment effect using T1-weighted dynamic contrast-enhanced magnetic resonance imaging in colorectal liver metastases: Potential of whole tumour ROI and selective ROI analysis. European Journal of Radiology, 2012, 81, 3870-3876.	1.2	29
987	Correlation of a priori DCE-MRI and 1H-MRS data with molecular markers in neck nodal metastases: Initial analysis. Oral Oncology, 2012, 48, 717-722.	0.8	53
988	Imaging biomarkers, quantitative imaging, and bioengineering. Radiologia, 2012, 54, 269-278.	0.3	24
989	The effect of temporal sampling on quantitative pharmacokinetic and three-time-point analysis of breast DCE-MRI. Magnetic Resonance Imaging, 2012, 30, 934-943.	1.0	13
990	Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model. Magnetic Resonance Imaging, 2012, 30, 1002-1009.	1.0	23
991	A feasible high spatiotemporal resolution breast DCE-MRI protocol for clinical settings. Magnetic Resonance Imaging, 2012, 30, 1257-1267.	1.0	60
992	Functional MRI for radiotherapy dose painting. Magnetic Resonance Imaging, 2012, 30, 1216-1223.	1.0	136
993	Signal-to-noise ratio, contrast-to-noise ratio and pharmacokinetic modeling considerations in dynamic contrast-enhanced magnetic resonance imaging. Magnetic Resonance Imaging, 2012, 30, 1313-1322.	1.0	44
994	Role of convection and diffusion on DCE-MRI parameters in low leakiness KHT sarcomas. Microvascular Research, 2012, 84, 306-313.	1.1	16
995	A MRI phantom for cardiac perfusion simulation. , 2012, , .		4
996	PET/MRI for Neurologic Applications. Journal of Nuclear Medicine, 2012, 53, 1916-1925.	2.8	237
997	Hyperbranched Polyglycerols as Trimodal Imaging Agents: Design, Biocompatibility, and Tumor Uptake. Bioconjugate Chemistry, 2012, 23, 372-381.	1.8	45
998	Response to Treatment: The Role of Imaging. , 2012, , 15-37.		5
999	Radiology: Criteria for Determining Response to Treatment and Recurrence of High-Grade Gliomas. Neurosurgery Clinics of North America, 2012, 23, 269-276.	0.8	3
1000	EP-1096 EXTERNAL BEAM RADIOTHERAPY FOR PROSTATE CANCER: THE POTENTIAL FOR DOSE ESCALATION. Radiotherapy and Oncology, 2012, 103, S424.	0.3	0
1001	Advanced Techniques Using Contrast Media in Neuroimaging. Magnetic Resonance Imaging Clinics of North America, 2012, 20, 699-713.	0.6	17
1002	Tracer kinetic modelling in MRI: estimating perfusion and capillary permeability. Physics in Medicine and Biology, 2012, 57, R1-R33.	1.6	289

#	Article	IF	CITATIONS
1003	Targeted drug delivery by high intensity focused ultrasound mediated hyperthermia combined with temperature-sensitive liposomes: Computational modelling and preliminary <i>in vivo</i> validation. International Journal of Hyperthermia, 2012, 28, 337-348.	1.1	127
1004	Preclinical evaluation of Gd-DTPA and gadomelitol as contrast agents in DCE-MRI of cervical carcinoma interstitial fluid pressure. BMC Cancer, 2012, 12, 544.	1.1	16
1005	Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer. Radiation Oncology, 2012, 7, 75.	1.2	25
1006	Dynamic Contrast-Enhanced MRI Assessment of Hyperemic Fractional Microvascular Blood Plasma Volume in Peripheral Arterial Disease: Initial Findings. PLoS ONE, 2012, 7, e37756.	1.1	12
1007	Comparison of Conventional Chemotherapy, Stealth Liposomes and Temperature-Sensitive Liposomes in a Mathematical Model. PLoS ONE, 2012, 7, e47453.	1.1	82
1008	Arrival Time Correction for Dynamic Susceptibility Contrast MR Permeability Imaging in Stroke Patients. PLoS ONE, 2012, 7, e52656.	1.1	32
1009	Targeting Tumor Perfusion and Oxygenation to Improve the Outcome of Anticancer Therapy1. Frontiers in Pharmacology, 2012, 3, 94.	1.6	80
1010	The Principal of Dynamic Contrast Enhanced MRI, the Method of Pharmacokinetic Analysis, and Its Application in the Head and Neck Region. International Journal of Dentistry, 2012, 2012, 1-10.	0.5	33
1011	Imaging-Based Tumor Treatment Response Evaluation: Review of Conventional, New, and Emerging Concepts. Korean Journal of Radiology, 2012, 13, 371.	1.5	72
1012	Pilot study on evaluation of any correlation between MR perfusion (Ktrans) and diffusion (apparent) Tj ETQq1 1).784314 r 1.2	gBT /Overlo
1012 1013	Pilot study on evaluation of any correlation between MR perfusion (Ktrans) and diffusion (apparent) Tj ETQq1 10 Practical Dynamic Contrast Enhanced MRI in Small Animal Models of Cancer: Data Acquisition, Data Analysis, and Interpretation. Pharmaceutics, 2012, 4, 442-478.	2.0	gBT /Overlo
	Practical Dynamic Contrast Enhanced MRI in Small Animal Models of Cancer: Data Acquisition, Data	1,2	17
1013	Practical Dynamic Contrast Enhanced MRI in Small Animal Models of Cancer: Data Acquisition, Data Analysis, and Interpretation. Pharmaceutics, 2012, 4, 442-478. Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of	2.0	68
1013 1014	Practical Dynamic Contrast Enhanced MRI in Small Animal Models of Cancer: Data Acquisition, Data Analysis, and Interpretation. Pharmaceutics, 2012, 4, 442-478. Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments. Pharmaceutics, 2012, 4, 563-589. Evaluation of Concanavalin A-induced Acute Liver Injury in Rats using an Empirical Mathematical Model and Dynamic Contrast-enhanced MR Imaging with Gd-EOB-DTPA. Magnetic Resonance in Medical	2.0	68
1013 1014 1015	Practical Dynamic Contrast Enhanced MRI in Small Animal Models of Cancer: Data Acquisition, Data Analysis, and Interpretation. Pharmaceutics, 2012, 4, 442-478. Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments. Pharmaceutics, 2012, 4, 563-589. Evaluation of Concanavalin A-induced Acute Liver Injury in Rats using an Empirical Mathematical Model and Dynamic Contrast-enhanced MR Imaging with Gd-EOB-DTPA. Magnetic Resonance in Medical Sciences, 2012, 11, 53-60. Quantitative Assessment of Tumor Responses after Radiation Therapy in a DLD-1 Colon Cancer Mouse Model Using Serial Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Yonsei Medical Journal,	2.0	68 35 15
1013 1014 1015 1016	Practical Dynamic Contrast Enhanced MRI in Small Animal Models of Cancer: Data Acquisition, Data Analysis, and Interpretation. Pharmaceutics, 2012, 4, 442-478. Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments. Pharmaceutics, 2012, 4, 563-589. Evaluation of Concanavalin A-induced Acute Liver Injury in Rats using an Empirical Mathematical Model and Dynamic Contrast-enhanced MR Imaging with Gd-EOB-DTPA. Magnetic Resonance in Medical Sciences, 2012, 11, 53-60. Quantitative Assessment of Tumor Responses after Radiation Therapy in a DLD-1 Colon Cancer Mouse Model Using Serial Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Yonsei Medical Journal, 2012, 53, 1147.	2.0 2.0 1.1	68 35 15
1013 1014 1015 1016	Practical Dynamic Contrast Enhanced MRI in Small Animal Models of Cancer: Data Acquisition, Data Analysis, and Interpretation. Pharmaceutics, 2012, 4, 442-478. Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments. Pharmaceutics, 2012, 4, 563-589. Evaluation of Concanavalin A-induced Acute Liver Injury in Rats using an Empirical Mathematical Model and Dynamic Contrast-enhanced MR Imaging with Gd-EOB-DTPA. Magnetic Resonance in Medical Sciences, 2012, 11, 53-60. Quantitative Assessment of Tumor Responses after Radiation Therapy in a DLD-1 Colon Cancer Mouse Model Using Serial Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Yonsei Medical Journal, 2012, 53, 1147. Evaluation of therapeutic effect of tumor-targeted therapy. OncoTargets and Therapy, 2012, 5, 191.	2.0 2.0 1.1 0.9	68 35 15 7

#	Article	IF	CITATIONS
1021	Tumor response assessments with diffusion and perfusion MRI. Journal of Magnetic Resonance Imaging, 2012, 35, 745-763.	1.9	150
1022	Ultrahighâ€field DCEâ€MRI of angiogenesis in a novel angiogenesis mouse model. Journal of Magnetic Resonance Imaging, 2012, 35, 703-710.	1.9	10
1023	Perfusion parameters analysis of the vertebral bone marrow in patients with Ph ^{1â^'} chronic myeloproliferative neoplasms (Ph ^{neg} MPN): A dynamic contrastâ€enhanced MRI (DCEâ€MRI) study. Journal of Magnetic Resonance Imaging, 2012, 35, 696-702.	1.9	10
1024	In vivo MRI and histopathological assessment of tumor microenvironment in luminalâ€like and basalâ€like breast cancer xenografts. Journal of Magnetic Resonance Imaging, 2012, 35, 1098-1107.	1.9	27
1025	Multiparametric MRI maps for detection and grading of dominant prostate tumors. Journal of Magnetic Resonance Imaging, 2012, 35, 1403-1413.	1.9	52
1026	Correlation of perfusion parameters on dynamic contrastâ€enhanced MRI with prognostic factors and subtypes of breast cancers. Journal of Magnetic Resonance Imaging, 2012, 36, 145-151.	1.9	123
1027	Dynamic contrastâ€enhanced MRI in advanced nonsmallâ€cell lung cancer patients treated with firstâ€line bevacizumab, gemcitabine, and cisplatin. Journal of Magnetic Resonance Imaging, 2012, 36, 387-396.	1.9	51
1028	Pharmacokinetic analysis based on dynamic contrastâ€enhanced MRI for evaluating tumor response to preoperative therapy for oral cancer. Journal of Magnetic Resonance Imaging, 2012, 36, 589-597.	1.9	49
1029	Washout gradient in dynamic contrastâ€enhanced MRI is associated with tumor aggressiveness of prostate cancer. Journal of Magnetic Resonance Imaging, 2012, 36, 912-919.	1.9	63
1030	Assessment of liver function in thioacetamideâ€induced rat acute liver injury using an empirical mathematical model and dynamic contrastâ€enhanced MRI with Gdâ€EOBâ€DTPA. Journal of Magnetic Resonance Imaging, 2012, 36, 1483-1489.	1.9	14
1031	Model selection for DCEâ€₹1 studies in glioblastoma. Magnetic Resonance in Medicine, 2012, 68, 241-251.	1.9	74
1032	An improved coverage and spatial resolutionâ€"using dual injection dynamic contrastâ€enhanced (ICEâ€DICE) MRI: A novel dynamic contrastâ€enhanced technique for cerebral tumors. Magnetic Resonance in Medicine, 2012, 68, 452-462.	1.9	30
1033	Blind estimation of the arterial input function in dynamic contrastâ€enhanced MRI using purity maximization. Magnetic Resonance in Medicine, 2012, 68, 1439-1449.	1.9	16
1034	A unified impulse response model for DCEâ€MRI. Magnetic Resonance in Medicine, 2012, 68, 1632-1646.	1.9	50
1035	Pharmacokinetic parameters from 3â€Tesla DCEâ€MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. International Journal of Cancer, 2012, 130, 2359-2365.	2.3	59
1036	Dynamic contrastâ€enhanced magnetic resonance imaging as a prognostic factor in predicting eventâ€free and overall survival in pediatric patients with osteosarcoma. Cancer, 2012, 118, 3776-3785.	2.0	95
1037	MRI of Blood–Brain Barrier Permeability in Cerebral Ischemia. Translational Stroke Research, 2012, 3, 56-64.	2.3	17
1038	Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. Journal of Neuro-Oncology, 2012, 109, 105-114.	1.4	42

#	Article	IF	CITATIONS
1039	New acquisition techniques: fields of application. Abdominal Imaging, 2012, 37, 155-163.	2.0	10
1040	Radical prostatectomy: value of prostate MRI in surgical planning. Abdominal Imaging, 2012, 37, 664-674.	2.0	36
1041	Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. European Radiology, 2012, 22, 821-831.	2.3	121
1042	Precise measurement of renal filtration and vascular parameters using a two-compartment model for dynamic contrast-enhanced MRI of the kidney gives realistic normal values. European Radiology, 2012, 22, 1320-1330.	2.3	41
1043	Perfusion MRI for the prediction of treatment response after preoperative chemoradiotherapy in locally advanced rectal cancer. European Radiology, 2012, 22, 1693-1700.	2.3	83
1044	Arterial input function calculation in dynamic contrast-enhanced MRI: an in vivo validation study using co-registered contrast-enhanced ultrasound imaging. European Radiology, 2012, 22, 1735-1747.	2.3	12
1045	Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. European Radiology, 2012, 22, 1451-1464.	2.3	138
1046	Quantification of brain edema and hemorrhage by MRI after experimental traumatic brain injury in rabbits predicts subsequent functional outcome. Neurological Sciences, 2012, 33, 731-740.	0.9	13
1047	Evaluation of DCE-MRI postprocessing techniques to assess metastatic bone marrow in patients with prostate cancer. Clinical Imaging, 2012, 36, 308-315.	0.8	14
1048	Estradiol modulates post-ischemic cerebral vascular remodeling and improves long-term functional outcome in a rat model of stroke. Brain Research, 2012, 1461, 76-86.	1.1	18
1050	Preliminary MRI Quality Assessment and Device Acceptance Guidelines for a Multicenter Bioclinical Study: The GO Glioblastoma Project. Journal of Neuroimaging, 2012, 22, 336-342.	1.0	3
1052	Predictive and Prognostic Role of Functional Imaging of Head and Neck Squamous Cell Carcinomas. Seminars in Radiation Oncology, 2012, 22, 220-232.	1.0	31
1053	An analysis of the pharmacokinetic parameter ratios in DCE-MRI using the reference region model. Magnetic Resonance Imaging, 2012, 30, 26-35.	1.0	11
1054	Classification of breast mass lesions using model-based analysis of the characteristic kinetic curve derived from fuzzy c-means clustering. Magnetic Resonance Imaging, 2012, 30, 312-322.	1.0	23
1055	Angiogenesis imaging by spatiotemporal analysis of ultrasound contrast agent dispersion kinetics. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2012, 59, 621-629.	1.7	66
1056	Single-Channel Blind Estimation of Arterial Input Function and Tissue Impulse Response in DCE-MRI. IEEE Transactions on Biomedical Engineering, 2012, 59, 1012-1021.	2.5	29
1057	Myocardial Blood Flow Quantification From MRI by Deconvolution Using an Exponential Approximation Basis. IEEE Transactions on Biomedical Engineering, 2012, 59, 2060-2067.	2.5	22
1058	A quantitative comparison of the influence of individual versus populationâ€derived vascular input functions on dynamic contrast enhancedâ€MRI in small animals. Magnetic Resonance in Medicine, 2012, 67, 226-236.	1.9	48

#	Article	IF	CITATIONS
1059	The influence of radial undersampling schemes on compressed sensing reconstruction in breast MRI. Magnetic Resonance in Medicine, 2012, 67, 363-377.	1.9	77
1060	Dynamic contrastâ€enhancedâ€MRI of tumor hypoxia. Magnetic Resonance in Medicine, 2012, 67, 519-530.	1.9	57
1061	Value of Multiparametric MRI in the Work-up of Prostate Cancer. Current Urology Reports, 2012, 13, 82-92.	1.0	36
1062	Intravoxel incoherent motion MR imaging for prostate cancer: An evaluation of perfusion fraction and diffusion coefficient derived from different $\langle i \rangle b \langle i \rangle \hat{a} \in V$ alue combinations. Magnetic Resonance in Medicine, 2013, 69, 553-562.	1.9	169
1063	Uncertainty estimation in dynamic contrastâ€enhanced MRI. Magnetic Resonance in Medicine, 2013, 69, 992-1002.	1.9	20
1064	Assessing the reproducibility of dynamic contrast enhanced magnetic resonance imaging in a murine model of breast cancer. Magnetic Resonance in Medicine, 2013, 69, 1721-1734.	1.9	25
1065	Quantitative imaging assessment of blood-brain barrier permeability in humans. Fluids and Barriers of the CNS, 2013, 10, 9.	2.4	60
1066	Tracer-kinetic modeling of dynamic contrast-enhanced MRI and CT: a primer. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 281-300.	0.8	93
1067	Prostate Cancer Diagnosis. , 2013, , .		3
1068	Prebiopsy Magnetic Resonance Imaging and Prostate Cancer Detection: Comparison of Random and Targeted Biopsies. Journal of Urology, 2013, 189, 493-499.	0.2	248
1069	Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. Journal of Hematology and Oncology, 2013, 6, 51.	6.9	47
1070	A prostate cancer computer-aided diagnosis system using multimodal magnetic resonance imaging and targeted biopsy labels. , 2013, , .		22
1071	Functional and Molecular Imaging: Applications for Diagnosis and Staging of Localised Prostate Cancer. Clinical Oncology, 2013, 25, 451-460.	0.6	16
1072	Three-dimensional whole-liver perfusion magnetic resonance imaging in patients with hepatocellular carcinomas and colorectal hepatic metastases. BMC Gastroenterology, 2013, 13, 53.	0.8	10
1073	Clinical feasibility of pulmonary perfusion analysis using dynamic computed tomography and a gamma residue function. Japanese Journal of Radiology, 2013, 31, 243-252.	1.0	1
1074	Pattern analysis accounts for heterogeneity observed in MRI studies of tumor angiogenesis. Magnetic Resonance in Medicine, 2013, 70, 1481-1490.	1.9	9
1075	Non-invasive imaging of glioma vessel size and densities in correlation with tumour cell proliferation by small animal PET and MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1595-1606.	3.3	15
1076	Functional and molecular imaging of localized and recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 48-59.	3.3	26

#	Article	IF	CITATIONS
1077	Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. European Radiology, 2013, 23, 2916-2925.	2.3	36
1078	Dynamic MR imaging of osteoid osteomas: correlation of semiquantitative and quantitative perfusion parameters with patient symptoms and treatment outcome. European Radiology, 2013, 23, 2602-2611.	2.3	31
1079	Dynamic contrast-enhanced magnetic resonance imaging for characterising nasopharyngeal carcinoma: comparison of semiquantitative and quantitative parameters and correlation with tumour stage. European Radiology, 2013, 23, 1495-1502.	2.3	44
1080	Free-breathing dynamic contrast-enhanced MRI of the abdomen and chest using a radial gradient echo sequence with K-space weighted image contrast (KWIC). European Radiology, 2013, 23, 1352-1360.	2.3	52
1081	Assessment of dynamic contrast-enhanced magnetic resonance imaging in the differentiation of malignant from benign orbital masses. European Journal of Radiology, 2013, 82, 1506-1511.	1.2	58
1082	Use of Tracer Kinetic Models for Selection of Semi-Quantitative Features for DCE-MRI Data Classification. Applied Magnetic Resonance, 2013, 44, 1311-1324.	0.6	26
1083	SHILO, a novel dual imaging approach for simultaneous HI-/LOw temporal (Low-/Hi-spatial) resolution imaging for vascular dynamic contrast enhanced cardiovascular magnetic resonance: numerical simulations and feasibility in the carotid arteries. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 42.	1.6	18
1084	Inter―and intra―ater reproducibility of quantitative dynamic contrast enhanced MRI using TWIST perfusion data in a uterine fibroid model. Journal of Magnetic Resonance Imaging, 2013, 38, 329-335.	1.9	17
1085	Imagerie de la perfusion tissulaire et de la perméabilité. Diagnostic and Interventional Imaging, 2013, 94, 1184-1202.	0.0	1
1086	Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome. Radiotherapy and Oncology, 2013, 107, 117-122.	0.3	73
1087	Role of Imaging as an Adjunct or Replacement for Biopsy: American Experience. , 2013, , 309-336.		1
1088	Multiparametric Magnetic Resonance Imaging Approaches in Focal Prostate Cancer Therapy. , 2013, , 173-202.		1
1089	Differentiation of myeloma and metastatic cancer in the spine using dynamic contrast-enhanced MRI. Magnetic Resonance Imaging, 2013, 31, 1285-1291.	1.0	37
1090	Comparison of Three Different MR Perfusion Techniques and MR Spectroscopy for Multiparametric Assessment in Distinguishing Recurrent High-Grade Gliomas from Stable Disease. Academic Radiology, 2013, 20, 1557-1565.	1.3	93
1091	A new user-friendly visual environment for breast MRI data analysis. Computer Methods and Programs in Biomedicine, 2013, 110, 411-423.	2.6	3
1092	Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. European Journal of Radiology, 2013, 82, 2161-2168.	1.2	45
1093	Advanced Techniques in Pediatric Abdominopelvic Oncologic Magnetic Resonance Imaging. Magnetic Resonance Imaging Clinics of North America, 2013, 21, 829-841.	0.6	5
1094	A comprehensive nonâ€invasive framework for automated evaluation of acute renal transplant rejection using DCEâ€MRI. NMR in Biomedicine, 2013, 26, 1460-1470.	1.6	52

#	ARTICLE	IF	CITATIONS
1097	SCUBE3 regulation of early lung cancer angiogenesis and metastatic progression. Clinical and Experimental Metastasis, 2013, 30, 741-752.	1.7	24
1098	Magnetic resonance imaging identifies early effects of sunitinib treatment in human melanoma xenografts. Journal of Experimental and Clinical Cancer Research, 2013, 32, 93.	3.5	25
1099	The complementary roles of dynamic contrast-enhanced MRI and 18F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1884-1893.	3.3	57
1101	Tumor perfusion imaging predicts the intra-tumoral accumulation of liposomes. Journal of Controlled Release, 2013, 172, 351-357.	4.8	49
1102	Drug delivery to the brain by focused ultrasound induced blood–brain barrier disruption: Quantitative evaluation of enhanced permeability of cerebral vasculature using two-photon microscopy. Journal of Controlled Release, 2013, 172, 274-280.	4.8	100
1103	Quantitative multiparametric MRI of ovarian cancer. Journal of Magnetic Resonance Imaging, 2013, 38, 1501-1509.	1.9	38
1104	A Fast Nonlinear Regression Method for Estimating Permeability in CT Perfusion Imaging. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1743-1751.	2.4	22
1105	Combined Diffusion-Weighted, Blood Oxygen Level–Dependent, and Dynamic Contrast-Enhanced MRI for Characterization and Differentiation of Renal Cell Carcinoma. Academic Radiology, 2013, 20, 685-693.	1.3	25
1106	Classic models for dynamic contrastâ€enhanced MRI. NMR in Biomedicine, 2013, 26, 1004-1027.	1.6	324
1107	Assessment of gadoxetate DCEâ€MRI as a biomarker of hepatobiliary transporter inhibition. NMR in Biomedicine, 2013, 26, 1258-1270.	1.6	44
1108	Model selection in measures of vascular parameters using dynamic contrastâ€enhanced MRI: experimental and clinical applications. NMR in Biomedicine, 2013, 26, 1028-1041.	1.6	86
1109	A comparison of dynamic contrastâ€enhanced <scp>CT</scp> and <scp>MR</scp> imagingâ€derived measurements in patients with cervical cancer. Clinical Physiology and Functional Imaging, 2013, 33, 150-161.	0.5	9
1110	MR Perfusion Imaging. Medical Radiology, 2013, , 75-98.	0.0	2
1111	Optimizing MRI scan time in the computation of pharmacokinetic parameters (K ^{trans}) in breast cancer diagnosis. Journal of Magnetic Resonance Imaging, 2013, 38, 573-579.	1.9	15
1112	Information Criteria for Dynamic Contrast-Enhanced Magnetic Resonance Imaging., 2013,,.		1
1113	Conversion of arterial input functions for dual pharmacokinetic modeling using Gdâ€DTPA/MRI and ¹⁸ Fâ€FDG/PET. Magnetic Resonance in Medicine, 2013, 69, 781-792.	1.9	33
1114	Computed Tomography and Magnetic Resonance Imaging. Recent Results in Cancer Research, 2013, 187, 3-63.	1.8	6
1115	Multifunctional Magnetic Resonance Imaging Probes. Recent Results in Cancer Research, 2013, 187, 151-190.	1.8	6

#	Article	IF	CITATIONS
1116	Solid Pancreatic Lesions: Characterization by Using Timing Bolus Dynamic Contrast-enhanced MR Imaging Assessmentâ€"A Preliminary Study. Radiology, 2013, 266, 185-196.	3.6	74
1117	Quantitative Imaging Biomarkers: The Application of Advanced Image Processing and Analysis to Clinical and Preclinical Decision Making. Journal of Digital Imaging, 2013, 26, 97-108.	1.6	65
1118	Impact of transvascular and cellular–interstitial water exchange on dynamic contrastâ€enhanced magnetic resonance imaging estimates of blood to tissue transfer constant and blood plasma volume. Journal of Magnetic Resonance Imaging, 2013, 37, 435-444.	1.9	16
1119	Gadolinium-Based Contrast Agents for Vessel Wall Magnetic Resonance Imaging (MRI) of Atherosclerosis. Current Cardiovascular Imaging Reports, 2013, 6, 11-24.	0.4	22
1120	The Microenvironment of Cervical Carcinoma Xenografts: Associations with Lymph Node Metastasis and Its Assessment by DCE-MRI. Translational Oncology, 2013, 6, 607-617.	1.7	21
1121	Assessment of Prostate Cancer Aggressiveness Using Dynamic Contrast-enhanced Magnetic Resonance Imaging at 3 T. European Urology, 2013, 64, 448-455.	0.9	152
1122	Perfusion and vascular permeability: Basic concepts and measurement in DCE-CT and DCE-MRI. Diagnostic and Interventional Imaging, 2013, 94, 1187-1204.	1.8	213
1123	Physiological Imaging-Defined, Response-Driven Subvolumes of a Tumor. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1383-1390.	0.4	14
1124	Simultaneous magnetic resonance angiography and perfusion (MRAP) measurement: Initial application in lower extremity skeletal muscle. Journal of Magnetic Resonance Imaging, 2013, 38, 1237-1244.	1.9	18
1125	Modifications in Dynamic Contrast-Enhanced Magnetic Resonance Imaging Parameters After α-Particle-Emitting 227Th-trastuzumab Therapy of HER2-Expressing Ovarian Cancer Xenografts. International Journal of Radiation Oncology Biology Physics, 2013, 87, 153-159.	0.4	9
1126	Low-grade and anaplastic oligodendrogliomas: Differences in tumour microvascular permeability evaluated with dynamic contrast-enhanced magnetic resonance imaging. Journal of Clinical Neuroscience, 2013, 20, 1110-1113.	0.8	21
1127	Inhibition of SUR1 Decreases the Vascular Permeability of Cerebral Metastases. Neoplasia, 2013, 15, 535-543.	2.3	49
1128	Noninvasive Monitoring of Microvascular Changes With Partial Irradiation Using Dynamic Contrast-Enhanced and Blood Oxygen Level-Dependent Magnetic Resonance Imaging. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1367-1374.	0.4	17
1129	An empirical mathematical model applied to quantitative evaluation of thioacetamide-induced acute liver injury in rats by use of dynamic contrast-enhanced computed tomography. Radiological Physics and Technology, 2013, 6, 115-120.	1.0	3
1130	Perfusion MRI: The Five Most Frequently Asked Technical Questions. American Journal of Roentgenology, 2013, 200, 24-34.	1.0	296
1131	A reference agent model for DCE MRI can be used to quantify the relative vascular permeability of two MRI contrast agents. Magnetic Resonance Imaging, 2013, 31, 900-910.	1.0	7
1132	Multiparametric Magnetic Resonance Imaging of the Prostate. Magnetic Resonance Imaging Clinics of North America, 2013, 21, 409-426.	0.6	14
1133	Posttreatment Evaluation of Central Nervous System Gliomas. Magnetic Resonance Imaging Clinics of North America, 2013, 21, 241-268.	0.6	11

#	Article	IF	Citations
1134	Diseases of the Female Pelvis. Magnetic Resonance Imaging Clinics of North America, 2013, 21, 447-469.	0.6	7
1135	A linear algorithm of the reference region model for DCE-MRI is robust and relaxes requirements for temporal resolution. Magnetic Resonance Imaging, 2013, 31, 497-507.	1.0	33
1136	Dynamic Contrast-enhanced MR Imaging of Carotid Atherosclerotic Plaque: Model Selection, Reproducibility, and Validation. Radiology, 2013, 266, 271-279.	3.6	79
1137	Monitoring Anti-Angiogenic Therapy in Colorectal Cancer Murine Model using Dynamic Contrast-Enhanced MRI — Comparing Pixel-by-Pixel with Region of Interest Analysis. Technology in Cancer Research and Treatment, 2013, 12, 71-78.	0.8	9
1138	MRI for response assessment in metastatic bone disease. European Radiology, 2013, 23, 1986-1997.	2.3	87
1139	Multiparametric MRI of prostate cancer: An update on stateâ€ofâ€theâ€art techniques and their performance in detecting and localizing prostate cancer. Journal of Magnetic Resonance Imaging, 2013, 37, 1035-1054.	1.9	192
1140	MRI of ovarian masses. Journal of Magnetic Resonance Imaging, 2013, 37, 265-281.	1.9	43
1141	Quantitative Analysis of Acute Benign and Malignant Vertebral Body Fractures Using Dynamic Contrast-Enhanced MRI. American Journal of Roentgenology, 2013, 200, W635-W643.	1.0	18
1143	UMMPerfusion: an Open Source Software Tool Towards Quantitative MRI Perfusion Analysis in Clinical Routine. Journal of Digital Imaging, 2013, 26, 344-352.	1.6	57
1144	Water signal attenuation by D ₂ 0 infusion as a novel contrast mechanism for ¹ H perfusion MRI. NMR in Biomedicine, 2013, 26, 692-698.	1.6	13
1145	Acute effects of pelvic irradiation on the adult uterus revealed by dynamic contrast-enhanced MRI. British Journal of Radiology, 2013, 86, 20130334.	1.0	13
1146	Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI. Investigational New Drugs, 2013, 31, 1097-1106.	1.2	29
1147	Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications. NMR in Biomedicine, 2013, 26, 1042-1049.	1.6	84
1148	A dedicated automated injection system for dynamic contrastâ€enhanced MRI experiments in mice. Journal of Magnetic Resonance Imaging, 2013, 37, 746-751.	1.9	2
1149	Quantitative firstâ€pass perfusion MRI of the mouse myocardium. Magnetic Resonance in Medicine, 2013, 69, 1735-1744.	1.9	23
1150	Characterization of estrogenâ€receptorâ€targeted contrast agents in solution, breast cancer cells, and tumors in vivo. Magnetic Resonance in Medicine, 2013, 70, 193-206.	1.9	5
1151	Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatric Blood and Cancer, 2013, 60, 396-401.	0.8	67
1152	<scp>DCE</scp> â€ <scp>MRI</scp> : a review and applications in veterinary oncology. Veterinary and Comparative Oncology, 2013, 11, 87-100.	0.8	14

#	Article	IF	Citations
1153	Differentiation of Benign and Malignant Vertebral Compression Fractures. Medical Radiology, 2013, , 145-174.	0.0	0
1154	Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, 1059-1066.	2.2	60
1155	Reproducibility of Dynamic Contrast-enhanced MR Imaging. Part II. Comparison of Intra- and Interobserver Variability with Manual Region of Interest Placement versus Semiautomatic Lesion Segmentation and Histogram Analysis. Radiology, 2013, 266, 812-821.	3.6	137
1156	Reproducibility of Dynamic Contrast-enhanced MR Imaging. Part I. Perfusion Characteristics in the Female Pelvis by Using Multiple Computer-aided Diagnosis Perfusion Analysis Solutions. Radiology, 2013, 266, 801-811.	3.6	108
1157	Quantitative Analysis of Multiparametric Prostate MR Images: Differentiation between Prostate Cancer and Normal Tissue and Correlation with Gleason Score—A Computer-aided Diagnosis Development Study. Radiology, 2013, 267, 787-796.	3.6	229
1158	Dynamic Contrast-Enhanced MRI in Determining Disease Activity in Perianal Fistulizing Crohn Disease: A Pilot Study. American Journal of Roentgenology, 2013, 200, W170-W177.	1.0	32
1159	Evaluation of the Kinetic Properties of Background Parenchymal Enhancement throughout the Phases of the Menstrual Cycle. Radiology, 2013, 268, 356-365.	3.6	40
1160	Prostate Cancer: Computer-aided Diagnosis with Multiparametric 3-T MR Imaging—Effect on Observer Performance. Radiology, 2013, 266, 521-530.	3.6	103
1162	Assessment of Skeletal Muscle Microperfusion Using MRI. Medical Radiology, 2013, , 87-114.	0.0	0
1163	Transition Zone Prostate Cancer: Detection and Localization with 3-T Multiparametric MR Imaging. Radiology, 2013, 266, 207-217.	3.6	222
1164	MRI for Response Assessment In Oncologic Bone Marrow Lesions. Medical Radiology, 2013, , 121-143.	0.0	1
1165	Primary Colorectal Cancer: Use of Kinetic Modeling of Dynamic Contrast-enhanced CT Data to Predict Clinical Outcome. Radiology, 2013, 267, 145-154.	3.6	25
1166	Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro-Oncology, 2013, 15, 515-534.	0.6	254
1167	Assessment of the interstitial fluid pressure of tumors by dynamic contrast-enhanced magnetic resonance imaging with contrast agents of different molecular weights. Acta Oncológica, 2013, 52, 627-635.	0.8	20
1168	Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of tumors: A preclinical study of cervical carcinoma and melanoma xenografts. Acta Oncológica, 2013, 52, 604-611.	0.8	15
1169	Modeling of nanotherapeutics delivery based on tumor perfusion. New Journal of Physics, 2013, 15, 055004.	1.2	33
1170	Ultra-high field 1H magnetic resonance imaging approaches for acute hypoxia. Acta Oncol \tilde{A}^3 gica, 2013, 52, 1287-1292.	0.8	5
1171	Pharmacodynamic Analysis of Magnetic Resonance Imaging-Monitored Focused Ultrasound-Induced Blood-Brain Barrier Opening for Drug Delivery to Brain Tumors. BioMed Research International, 2013, 2013, 1-13.	0.9	31

#	Article	IF	CITATIONS
1172	The Potential for an Enhanced Role for MRI in Radiation-Therapy Treatment Planning. Technology in Cancer Research and Treatment, 2013, 12, 429-446.	0.8	162
1173	Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma. Neuro-Oncology, 2013, 15, 1673-1683.	0.6	20
1174	Phase I Trial of Preoperative Chemoradiation plus Sorafenib for High-Risk Extremity Soft Tissue Sarcomas with Dynamic Contrast-Enhanced MRI Correlates. Clinical Cancer Research, 2013, 19, 6902-6911.	3.2	61
1175	Dynamic Contrast-Enhanced Computed Tomography to Assess Antitumor Treatment Effects. Investigative Radiology, 2013, 48, 715-721.	3.5	7
1176	Perfusion MRI at rest in subacute and chronic myocardial infarct. Acta Radiologica, 2013, 54, 401-411.	0.5	4
1177	A diffusion-compensated model for the analysis of DCE-MRI data: theory, simulations and experimental results. Physics in Medicine and Biology, 2013, 58, 1983-1998.	1.6	20
1178	Contrast-enhanced ultrasound imaging for the detection of transient dynamics of blood-brain barrier opening induced by focused ultrasound. , $2013, , .$		0
1179	Role of quantitative pharmacokinetic parameter (transfer constant: Ktrans) in the characterization of breast lesions on MRI. Indian Journal of Radiology and Imaging, 2013, 23, 19-25.	0.3	18
1180	Transmit field inhomogeneity and T ₁ estimation errors in breast DCEâ€MRI at 3 tesla. Journal of Magnetic Resonance Imaging, 2013, 38, 454-459.	1.9	59
1181	Absolute quantification of myocardial blood flow with constrained estimation of the arterial input function. Journal of Magnetic Resonance Imaging, 2013, 38, 603-609.	1.9	5
1182	Advanced MRI in malignant neoplasms of the uterus. Journal of Magnetic Resonance Imaging, 2013, 37, 249-264.	1.9	23
1183	MRIâ€based prediction of pulsed highâ€intensity focused ultrasound effect on tissue transport in rabbit muscle. Journal of Magnetic Resonance Imaging, 2013, 38, 1094-1102.	1.9	10
1184	Modeling DCEâ€MRI at low temporal resolution: A case study on rheumatoid arthritis. Journal of Magnetic Resonance Imaging, 2013, 38, 1554-1563.	1.9	7
1185	Prostate cancer localization by novel magnetic resonance dispersion imaging., 2013, 2013, 2603-6.		3
1186	Sampling requirements in DCEâ€MRI based analysis of high grade gliomas: Simulations and clinical results. Journal of Magnetic Resonance Imaging, 2013, 37, 818-829.	1.9	29
1187	Subcompartmentalization of extracellular extravascular space (EES) into permeability and leaky space with local arterial input function (AIF) results in improved discrimination between high―and lowâ€grade glioma using dynamic contrast―nhanced (DCE) MRI. Journal of Magnetic Resonance Imaging, 2013. 38, 677-688.	1.9	29
1188	Regional heterogeneity changes in DCEâ€MRI as response to isolated limb perfusion in experimental softâ€tissue sarcomas. Contrast Media and Molecular Imaging, 2013, 8, 340-349.	0.4	13
1189	Lowâ€molecular contrast agent dynamic contrastâ€enhanced (DCE)â€MRI and diffusionâ€weighted (DW)â€MRI i early assessment of bevacizumab treatment in breast cancer xenografts. Journal of Magnetic Resonance Imaging, 2013, 38, 1043-1053.	in 1.9	34

#	Article	IF	CITATIONS
1190	Robust estimation of MRI myocardial perfusion parameters., 2013, 2013, 4382-5.		0
1191	Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours. British Journal of Cancer, 2013, 108, 58-63.	2.9	19
1192	Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. Therapeutic Advances in Gastroenterology, 2013, 6, 459-473.	1.4	27
1193	Survival Outcomes of Breast Cancer Patients Who Receive Neoadjuvant Chemotherapy: Association with Dynamic Contrast-enhanced MR Imaging with Computer-aided Evaluation. Radiology, 2013, 268, 662-672.	3.6	47
1194	Standardization of Radiological Evaluation of Dynamic Contrast Enhanced MRI: Application in Breast Cancer Diagnosis. TCRT Express, 2013, 13, 445-54.	1.5	7
1195	MR perfusion imaging in oncology: neuro applications. , 2013, , 204-237.		2
1196	Interscanner Comparison of Dynamic Contrast-Enhanced MRI in Prostate Cancer. Investigative Radiology, 2013, 48, 92-97.	3.5	20
1197	Iterative multiple reference tissue method for estimating pharmacokinetic parameters on prostate DCE MRI. Proceedings of SPIE, 2013, , .	0.8	0
1198	Reproducibility and biological basis of in vivo <i>T</i> ₂ * magnetic resonance imaging of liver metastasis of colorectal cancer. Magnetic Resonance in Medicine, 2013, 70, 1145-1152.	1.9	3
1199	Simultaneous T ₁ and B ₁ ⁺ Mapping Using Reference Region Variable Flip Angle Imaging. Magnetic Resonance in Medicine, 2013, 70, 954-961.	1.9	24
1200	Measurement of Blood Perfusion in Spinal Metastases With Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Spine, 2013, 38, E1418-E1424.	1.0	58
1201	Bone Marrow Enhancement During Time-Resolved Magnetic Resonance Angiography of the Pelvis. Journal of Computer Assisted Tomography, 2013, 37, 458-462.	0.5	0
1202	A comparison of radial keyhole strategies for high spatial and temporal resolution 4D contrast-enhanced MRI in small animal tumor models. Medical Physics, 2013, 40, 022304.	1.6	23
1203	DCE-MRI defined subvolumes of a brain metastatic lesion by principle component analysis and fuzzy-c-means clustering for response assessment of radiation therapy. Medical Physics, 2013, 41, 011708.	1.6	13
1204	Usefulness of Tissue Permeability Factor in Differentiating Benign and Malignant Pulmonary Lesions on Dynamic Contrast-Enhanced MRI. Journal of the Korean Society of Radiology, 2013, 69, 57.	0.1	1
1205	Dynamic Contrast-Enhanced MRI for Monitoring Antiangiogenic Treatment: Determination of Accurate and Reliable Perfusion Parameters in a Longitudinal Study of a Mouse Xenograft Model. Korean Journal of Radiology, 2013, 14, 589.	1.5	7
1206	Perfusion Parameters of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients with Rectal Cancer: Correlation with Microvascular Density and Vascular Endothelial Growth Factor Expression. Korean Journal of Radiology, 2013, 14, 878.	1.5	31
1207	The Use of Dynamic Tracer Concentration in Veins for Quantitative DCE-MRI Kinetic Analysis in Head and Neck. PLoS ONE, 2013, 8, e59885.	1.1	7

#	Article	IF	CITATIONS
1208	Dynamic Contrast-Enhanced MR Imaging Predicts Local Control in Oropharyngeal or Hypopharyngeal Squamous Cell Carcinoma Treated with Chemoradiotherapy. PLoS ONE, 2013, 8, e72230.	1.1	49
1209	Can DCE-MRI Explain the Heterogeneity in Radiopeptide Uptake Imaged by SPECT in a Pancreatic Neuroendocrine Tumor Model?. PLoS ONE, 2013, 8, e77076.	1.1	18
1210	Combining Antiangiogenic Therapy with Adoptive Cell Immunotherapy Exerts Better Antitumor Effects in Non-Small Cell Lung Cancer Models. PLoS ONE, 2013, 8, e65757.	1.1	49
1211	Measurement of Blood-Brain Barrier Permeability with T $<$ sub $>$ 1 $<$ /sub $>$ -Weighted Dynamic Contrast-Enhanced MRI in Brain Tumors: A Comparative Study with Two Different Algorithms. ISRN Neuroscience, 2013, 2013, 1-6.	1.5	22
1212	Use of dynamic contrast enhanced time intensity curve shape analysis in MRI: theory and practice. Reports in Medical Imaging, $0, 71$.	0.8	24
1213	DCE-MRI: acquisition and analysis techniques. , 2013, , 58-74.		15
1214	MR perfusion imaging in breast cancer. , 0, , 255-280.		0
1215	Correlations of Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Morphologic, Angiogenic, and Molecular Prognostic Factors in Rectal Cancer. Yonsei Medical Journal, 2013, 54, 123.	0.9	27
1216	Glioma Grading Capability: Comparisons among Parameters from Dynamic Contrast-Enhanced MRI and ADC Value on DWI. Korean Journal of Radiology, 2013, 14, 487.	1.5	67
1218	Quantitative Mapping of Angiogenesis by Magnetic Resonance Imaging. , 2013, , .		O
1219	Perfusion Magnetic Resonance Imaging: A Comprehensive Update on Principles and Techniques. Korean Journal of Radiology, 2014, 15, 554.	1.5	177
1220	Reproducibility of Magnetic Resonance Perfusion Imaging. PLoS ONE, 2014, 9, e89797.	1.1	15
1221	Quantitative Serial MRI of the Treated Fibroid Uterus. PLoS ONE, 2014, 9, e89809.	1.1	6
1222	Tumor Vascularity and Glucose Metabolism Correlated in Adenocarcinoma, but Not in Squamous Cell Carcinoma of the Lung. PLoS ONE, 2014, 9, e91649.	1.1	15
1223	Pharmacokinetic Changes Induced by Focused Ultrasound in Glioma-Bearing Rats as Measured by Dynamic Contrast-Enhanced MRI. PLoS ONE, 2014, 9, e92910.	1.1	15
1224	Focused Ultrasound Simultaneous Irradiation/MRI Imaging, and Two-Stage General Kinetic Model. PLoS ONE, 2014, 9, e100280.	1.1	1
1225	Clinical Utility of Multimodality Imaging with Dynamic Contrast-Enhanced MRI, Diffusion-Weighted MRI, and 18F-FDG PET/CT for the Prediction of Neck Control in Oropharyngeal or Hypopharyngeal Squamous Cell Carcinoma Treated with Chemoradiation. PLoS ONE, 2014, 9, e115933.	1.1	53
1227	Contrast-Enhanced Ultrasound Imaging for the Detection of Focused Ultrasound-Induced Blood-Brain Barrier Opening. Theranostics, 2014, 4, 1014-1025.	4.6	43

#	Article	IF	CITATIONS
1228	Diffusion-weighted and Dynamic Contrast-enhanced MRI of Metastatic Bone Tumors: Correlation of the Apparent Diffusion Coefficient, Ktransand vevalues. Journal of the Korean Society of Magnetic Resonance in Medicine, 2014, 18, 25.	0.1	4
1229	Targeting hypoxia-inducible factor- $1\hat{1}$ (HIF- $1\hat{1}$) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab. Oncotarget, 2014, 5, 10280-10292.	0.8	49
1230	Perfusion Imaging and Hyperpolarized Agents for MRI. , 2014, , 37-53.		0
1231	Models and methods for analyzing DCEâ€MRI: A review. Medical Physics, 2014, 41, 124301.	1.6	225
1232	MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy. Neuro-Oncology, 2014, 16, 868-879.	0.6	39
1233	Noninvasive assessment of perfusion in virus-associated VX2 tumors using MR spin labeling technique. Radiology of Infectious Diseases, 2014, 1, 17-21.	2.4	1
1234	Blood–Brain Barrier Imaging in Human Neuropathologies. Archives of Medical Research, 2014, 45, 646-652.	1.5	43
1235	Closed-form solution of the convolution integral in the magnetic resonance dispersion model for quantitative assessment of angiogenesis., 2014, 2014, 4272-5.		0
1236	Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer. Clinical Cancer Research, 2014, 20, 480-489.	3.2	52
1237	Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas. British Journal of Cancer, 2014, 110, 107-114.	2.9	49
1238	Microvascular MRI and Unsupervised Clustering Yields Histology-Resembling Images in Two Rat Models of Glioma. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1354-1362.	2.4	23
1239	Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. Leukemia, 2014, 28, 413-416.	3.3	24
1240	Tracer kinetic model selection for dynamic contrast-enhanced magnetic resonance imaging of locally advanced cervical cancer. Acta Oncol \tilde{A}^3 gica, 2014, 53, 1064-1072.	0.8	21
1242	Quantitative identification of magnetic resonance imaging features of prostate cancer response following laser ablation and radical prostatectomy. Journal of Medical Imaging, 2014, 1, 035001.	0.8	11
1243	Improved parameter extraction and classification for dynamic contrast enhanced MRI of prostate. , 2014, , .		3
1244	Multi-modal pharmacokinetic modelling for DCE-MRI: using diffusion weighted imaging to constrain the local arterial input function. Proceedings of SPIE, 2014 , , .	0.8	0
1245	Distinguishing prostate cancer from benign confounders via a cascaded classifier on multi-parametric MRI. Proceedings of SPIE, 2014, , .	0.8	11
1246	A Semi-Quantitative Analysis Model with Parabolic Modelling for DCE-MRI Sequences of Prostate. , 2014, , .		3

#	Article	IF	Citations
1247	Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer. Future Oncology, 2014, 10, 823-833.	1.1	12
1248	Spatial two-tissue compartment model for dynamic contrast-enhanced magnetic resonance imaging. Journal of the Royal Statistical Society Series C: Applied Statistics, 2014, 63, 695-713.	0.5	13
1249	Accelerated pharmacokinetic map determination for dynamic contrast enhanced MRI using frequency-domain based Tofts model., 2014, 2014, 2404-7.		1
1250	A Novel Model-Based Measure for Quality Evaluation of Image Registration Techniques in DCE-MRI. , 2014, , .		12
1251	The History of MR Imaging as Seen through the Pages of <i>Radiology </i> . Radiology, 2014, 273, S181-S200.	3.6	99
1252	Prostate functional magnetic resonance image analysis using multivariate curve resolution methods. Journal of Chemometrics, 2014, 28, 672-680.	0.7	5
1253	A comparison of arterial spin labeling perfusion MRI and DCEâ€MRI in human prostate cancer. NMR in Biomedicine, 2014, 27, 817-825.	1.6	19
1254	Perfusion Imaging. Journal of Magnetic Resonance Imaging, 2014, 40, 269-279.	1.9	12
1255	Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer, 2014, 120, 77-85.	2.0	22
1256	Intratumor distribution and test–retest comparisons of physiological parameters quantified by dynamic contrastâ€enhanced MRI in rat U251 glioma. NMR in Biomedicine, 2014, 27, 1230-1238.	1.6	20
1257	Impact of precontrast T ₁₀ relaxation times on dynamic contrast-enhanced MRI pharmacokinetic parameters: T ₁₀ mapping versus a fixed T ₁₀ reference value. Journal of Magnetic Resonance Imaging, 2014, 39, 1136-1145.	1.9	14
1258	Automated Real-time Needle-Guide Tracking for Fast 3-T MR-guided Transrectal Prostate Biopsy: A Feasibility Study. Radiology, 2014, 273, 879-886.	3.6	20
1259	Breast Cancer: Early Prediction of Response to Neoadjuvant Chemotherapy Using Parametric Response Maps for MR Imaging. Radiology, 2014, 272, 385-396.	3.6	81
1260	Dynamic gadobutrol-enhanced MRI predicts early response to antivascular but not to antiproliferation therapy in a mouse xenograft model. Magnetic Resonance in Medicine, 2014, 71, 1826-1833.	1.9	6
1261	<i>In Vivo</i> Imaging of Tumor Physiological, Metabolic, and Redox Changes in Response to the Anti-Angiogenic Agent Sunitinib: Longitudinal Assessment to Identify Transient Vascular Renormalization. Antioxidants and Redox Signaling, 2014, 21, 1145-1155.	2.5	41
1262	Spatially regularized estimation for the analysis of dynamic contrast-enhanced magnetic resonance imaging data. Statistics in Medicine, 2014, 33, 1029-1041.	0.8	10
1263	<i>In vivo</i> detection of the effects of preconditioning on LNCaP tumors by a TNF-α nanoparticle construct using MRI. NMR in Biomedicine, 2014, 27, 1063-1069.	1.6	8
1264	Dynamic contrast enhanced-MRI in rectal cancer: Inter- and intraobserver reproducibility and the effect of slice selection on pharmacokinetic analysis. Journal of Magnetic Resonance Imaging, 2014, 40, 715-722.	1.9	7

#	Article	IF	CITATIONS
1265	Split dynamic MRI: Single bolus high spatial–temporal resolution and multi contrast evaluation of breast lesions. Journal of Magnetic Resonance Imaging, 2014, 39, 673-682.	1.9	9
1266	Inhibitors of angiogenesis: Ready for prime time?. Best Practice and Research in Clinical Rheumatology, 2014, 28, 637-649.	1.4	20
1267	The Effects of Applying Breast Compression in Dynamic Contrast Material–enhanced MR Imaging. Radiology, 2014, 272, 79-90.	3.6	15
1268	Role of highâ€field MR in studies of localized prostate cancer. NMR in Biomedicine, 2014, 27, 67-79.	1.6	15
1269	Contrast dispersion imaging for cancer localization. , 2014, 2014, 4268-71.		2
1270	Dynamic contrast enhanced MRI parameters and tumor cellularity in a rat model of cerebral glioma at 7 T. Magnetic Resonance in Medicine, 2014, 71, 2206-2214.	1.9	63
1271	Uncertainty in MR tracer kinetic parameters and water exchange rates estimated from <i>T</i> ₁ â€weighted dynamic contrast enhanced MRI. Magnetic Resonance in Medicine, 2014, 72, 534-545.	1.9	13
1273	Detection of prostate cancer in peripheral zone: comparison of MR diffusion tensor imaging, quantitative dynamic contrast-enhanced MRI, and the two techniques combined at 3.0 T. Acta Radiologica, 2014, 55, 239-247.	0.5	23
1275	DCE-MRI assessment of the effect of Epstein-Barr virus-encoded latent membrane protein-1 targeted DNAzyme on tumor vasculature in patients with nasopharyngeal carcinomas. BMC Cancer, 2014, 14, 835.	1.1	14
1276	Multiparametric MRI of Rectal Cancer in the Assessment of Response to Therapy. Diseases of the Colon and Rectum, 2014, 57, 790-799.	0.7	77
1277	Magnetic Resonance Dispersion Imaging for Localization of Angiogenesis and Cancer Growth. Investigative Radiology, 2014, 49, 561-569.	3. 5	27
1278	Magnetic Resonance Imaging Using Gadolinium-Based Contrast Agents. Topics in Magnetic Resonance Imaging, 2014, 23, 51-69.	0.7	23
1279	Improving Bladder Cancer Imaging Using 3-T Functional Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Investigative Radiology, 2014, 49, 390-395.	3.5	18
1280	Imaging Assessment of Lung Tumor Angiogenesis: Insights and Innovations. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 112-128.	0.8	2
1282	Automated Colorectal Tumour Segmentation in DCE-MRI Using Supervoxel Neighbourhood Contrast Characteristics. Lecture Notes in Computer Science, 2014, 17, 609-616.	1.0	18
1283	Quantitative evaluation of hyperbaric oxygen efficacy in experimental traumatic brain injury: an MRI study. Neurological Sciences, 2014, 35, 295-302.	0.9	12
1284	Prostate cancer detection and diagnosis: the role of MR and its comparison with other diagnostic modalities $\hat{a} \in \hat{a}$ a radiologist's perspective. NMR in Biomedicine, 2014, 27, 3-15.	1.6	43
1285	A review of technical aspects of T1-weighted dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in human brain tumors. Physica Medica, 2014, 30, 635-643.	0.4	54

#	Article	IF	CITATIONS
1286	Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Prostate Cancer Clinical Trials: Potential Roles and Possible Pitfalls. Translational Oncology, 2014, 7, 120-129.	1.7	20
1287	Variations of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Evaluation of Breast Cancer Therapy Response: A Multicenter Data Analysis Challenge. Translational Oncology, 2014, 7, 153-166.	1.7	120
1289	A comparison of two methods for estimating DCE-MRI parameters via individual and cohort based AIFs in prostate cancer: A step towards practical implementation. Magnetic Resonance Imaging, 2014, 32, 321-329.	1.0	36
1290	The role of functional imaging in the era of targeted therapy of renal cell carcinoma. World Journal of Urology, 2014, 32, 47-58.	1.2	18
1291	Dynamic contrast-enhanced magnetic resonance imaging can assess vascularity within fracture non-unions and predicts good outcome. European Radiology, 2014, 24, 449-459.	2.3	33
1292	MRI for assessing and predicting response to neoadjuvant treatment in rectal cancer. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 480-488.	8.2	56
1294	A Physiological Perspective on the Use of Imaging to Assess the In Vivo Delivery of Therapeutics. Annals of Biomedical Engineering, 2014, 42, 280-298.	1.3	12
1295	Is there any correlation between model-based perfusion parameters and model-free parameters of time-signal intensity curve on dynamic contrast enhanced MRI in breast cancer patients?. European Radiology, 2014, 24, 1089-1096.	2.3	33
1296	Pancreatic adenocarcinoma: a pilot study of quantitative perfusion and diffusion-weighted breath-hold magnetic resonance imaging. Abdominal Imaging, 2014, 39, 744-752.	2.0	20
1297	Measurement Science in the Circulatory System. Cellular and Molecular Bioengineering, 2014, 7, 1-14.	1.0	23
1298	Markers of cochlear inflammation using MRI. Journal of Magnetic Resonance Imaging, 2014, 39, 150-161.	1.9	28
1299	Dynamic contrastâ€enhanced MRI of nasopharyngeal carcinoma: A preliminary study of the correlations between quantitative parameters and clinical stage. Journal of Magnetic Resonance Imaging, 2014, 39, 940-948.	1.9	33
1300	Association Between Penile Dynamic Contrastâ€Enhanced MRIâ€Derived Quantitative Parameters and Selfâ€Reported Sexual Function in Patients with Newly Diagnosed Prostate Cancer. Journal of Sexual Medicine, 2014, 11, 2581-2588.	0.3	5
1301	DCE and DSC MR perfusion imaging in the differentiation of recurrent tumour from treatment-related changes in patients with glioma. Clinical Radiology, 2014, 69, e264-e272.	0.5	58
1302	Myocardial signal intensity decay after gadolinium injection: a fast and effective method for the diagnosis of cardiac amyloidosis. International Journal of Cardiovascular Imaging, 2014, 30, 1105-1115.	0.7	23
1303	High-field small animal magnetic resonance oncology studies. Physics in Medicine and Biology, 2014, 59, R65-R127.	1.6	13
1304	An investigation into the effects of temporal resolution on hepatic dynamic contrast-enhanced MRI in volunteers and in patients with hepatocellular carcinoma. Physics in Medicine and Biology, 2014, 59, 3187-3200.	1.6	11
1305	Computer-Aided Detection of Prostate Cancer in MRI. IEEE Transactions on Medical Imaging, 2014, 33, 1083-1092.	5.4	338

#	Article	IF	CITATIONS
1306	Abdomen and Thoracic Imaging. , 2014, , .		5
1307	Imageâ€based assessment of microvascular function and structure in collagen XV―and XVIIIâ€deficient mice. Journal of Physiology, 2014, 592, 325-336.	1.3	13
1308	Dynamic contrastâ€enhanced MRI in mouse tumors at 11.7 T: comparison of three contrast agents with different molecular weights to assess the early effects of combretastatin A4. NMR in Biomedicine, 2014, 27, 1403-1412.	1.6	9
1309	Mapping water exchange rates in rat tumor xenografts using the late-stage uptake following bolus injections of contrast agent. Magnetic Resonance in Medicine, 2014, 71, 1874-1887.	1.9	19
1310	An introduction to ASL labeling techniques. Journal of Magnetic Resonance Imaging, 2014, 40, 1-10.	1.9	76
1311	A dialyzer-based flow system for validating dynamic contrast enhanced MR image acquisition. Magnetic Resonance in Medicine, 2014, 72, 41-48.	1.9	6
1312	Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2014, 27, 161-170.	1.1	6
1313	Assessment of blood–brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review. NeuroImage: Clinical, 2014, 6, 262-274.	1.4	285
1314	Accurate Determination of Blood–Brain Barrier Permeability Using Dynamic Contrast-Enhanced T1-Weighted MRI: A Simulation and ⟨i⟩in vivo⟨ i⟩ Study on Healthy Subjects and Multiple Sclerosis Patients. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1655-1665.	2.4	90
1315	Evaluation of a multiple spin- and gradient-echo (SAGE) EPI acquisition with SENSE acceleration: Applications for perfusion imaging in and outside the brain. Magnetic Resonance Imaging, 2014, 32, 1171-1180.	1.0	30
1316	Evaluation of IAUGC indices and two DCE-MRI pharmacokinetic parameters assessed by two different theoretical algorithms in patients with brain tumors. Clinical Imaging, 2014, 38, 808-814.	0.8	5
1317	Cancer Drug Delivery: Considerations in the Rational Design of Nanosized Bioconjugates. Bioconjugate Chemistry, 2014, 25, 2093-2100.	1.8	68
1318	Quantitative Radiology. Advances in Cancer Research, 2014, 124, 1-30.	1.9	1
1319	Measurement of rat brain tumor kinetics using an intravascular MR contrast agent and DCEâ€MRI nested model selection. Journal of Magnetic Resonance Imaging, 2014, 40, 1223-1229.	1.9	15
1320	Correlation between dynamic contrast-enhanced MRI and quantitative histopathologic microvascular parameters in organ-confined prostate cancer. European Radiology, 2014, 24, 2597-2605.	2.3	38
1321	Use of Diffusion-weighted, Intravoxel Incoherent Motion, and Dynamic Contrast-enhanced MR Imaging in the Assessment of Response to Radiotherapy of Lytic Bone Metastases from Breast Cancer. Academic Radiology, 2014, 21, 1286-1293.	1.3	48
1322	Glioma: Application of Histogram Analysis of Pharmacokinetic Parameters from T1-Weighted Dynamic Contrast-Enhanced MR Imaging to Tumor Grading. American Journal of Neuroradiology, 2014, 35, 1103-1110.	1.2	81
1323	Multifunctional Ultrasound Contrast Agents for Imaging Guided Photothermal Therapy. Bioconjugate Chemistry, 2014, 25, 840-854.	1.8	44

#	Article	IF	CITATIONS
1324	Bifunctional Chelates Optimized for Molecular MRI. Inorganic Chemistry, 2014, 53, 6554-6568.	1.9	14
1325	Perfusion Imaging in Liver MRI. Magnetic Resonance Imaging Clinics of North America, 2014, 22, 417-432.	0.6	12
1326	A spatially-distributed computational model to quantify behaviour of contrast agents in MR perfusion imaging. Medical Image Analysis, 2014, 18, 1200-1216.	7.0	24
1327	Dynamic contrast-enhanced MRI to evaluate the therapeutic response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer. Journal of Magnetic Resonance Imaging, 2014, 40, 730-737.	1.9	64
1328	Multiparametric 3 <scp>T MRI</scp> in the evaluation of intraglandular prostate cancer: Correlation with histopathology. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 439-448.	0.9	8
1329	Positron Emission Tomography-Magnetic Resonance Imaging in the Evaluation of Brain Tumors: Current Status and Future Prospects. Seminars in Roentgenology, 2014, 49, 275-289.	0.2	1
1330	The formation of inflammatory demyelinated lesions in cerebral white matter. Annals of Neurology, 2014, 76, 594-608.	2.8	89
1331	Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis. BMC Cancer, 2014, 14, 510.	1.1	23
1332	In silico evaluation of gadofosveset pharmacokinetics in different population groups using the Simcyp $\hat{A}^{@}$ simulator platform. In Silico Pharmacology, 2014, 2, 2.	1.8	9
1333	Multimodal Magnetic Resonance Imaging Evaluation of Primary Brain Tumors. Seminars in Oncology, 2014, 41, 478-495.	0.8	10
1334	Dynamic contrast-enhanced magnetic resonance imaging biomarkers in head and neck cancer: Potential to guide treatment? A systematic review. Oral Oncology, 2014, 50, 963-970.	0.8	74
1336	Pixel-by-pixel analysis of DCE-MRI curve shape patterns in knees of active and inactive juvenile idiopathic arthritis patients. European Radiology, 2014, 24, 1686-1693.	2.3	21
1337	Multiscale and multi-modality visualization of angiogenesis in a human breast cancer model. Angiogenesis, 2014, 17, 695-709.	3.7	28
1338	Regional Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Potential Role for Dynamic Magnetic Resonance Imaging as an Imaging Biomarker and a Survival Update from Two Prospective Clinical Trials. Annals of Surgical Oncology, 2014, 21, 2675-2683.	0.7	38
1339	Using intraoperative dynamic contrast-enhanced T1-weighted MRI to identify residual tumor in glioblastoma surgery. Journal of Neurosurgery, 2014, 120, 60-66.	0.9	23
1340	Connective tissue of cervical carcinoma xenografts: Associations with tumor hypoxia and interstitial fluid pressure and its assessment by DCE-MRI and DW-MRI. Acta Oncol \tilde{A}^3 gica, 2014, 53, 6-15.	0.8	19
1341	Magnetic-resonance imaging for kinetic analysis of permeability changes during focused ultrasound-induced blood–brain barrier opening and brain drug delivery. Journal of Controlled Release, 2014, 192, 1-9.	4.8	54
1342	Advanced Magnetic Resonance Imaging of the Physical Processes in Human Glioblastoma. Cancer Research, 2014, 74, 4622-4637.	0.4	123

#	Article	IF	CITATIONS
1343	DCE-MRI of the hypoxic fraction, radioresponsiveness, and metastatic propensity of cervical carcinoma xenografts. Radiotherapy and Oncology, 2014, 110, 335-341.	0.3	43
1344	Computer-aided diagnosis of breast DCE-MRI using pharmacokinetic model and 3-D morphology analysis. Magnetic Resonance Imaging, 2014, 32, 197-205.	1.0	41
1345	Breast cancer detection from MR images through an auto-probing discrete Fourier transform system. Computers in Biology and Medicine, 2014, 49, 46-59.	3.9	10
1346	Comparison of analytical and numerical analysis of the reference region model for DCE-MRI. Magnetic Resonance Imaging, 2014, 32, 845-853.	1.0	2
1347	Tumor Target Volume for Focal Therapy of Prostate Cancerâ€"Does Multiparametric Magnetic Resonance Imaging Allow for a Reliable Estimation?. Journal of Urology, 2014, 191, 1272-1279.	0.2	77
1348	High-intensity Focused Ultrasound Ablation of Soft-tissue Tumors and Assessment of Treatment Response with Multiparametric Magnetic Resonance Imaging: Preliminary Study Using Rabbit VX2 Tumor Model. Journal of Medical Ultrasound, 2014, 22, 99-105.	0.2	4
1349	Multi-parametric MRI-guided focal tumor boost using HDR prostate brachytherapy: A feasibility study. Brachytherapy, 2014, 13, 137-145.	0.2	41
1350	Spatio-temporal pharmacokinetic model based registration of 4D PET neuroimaging data. NeuroImage, 2014, 84, 225-235.	2.1	12
1351	Chemical reaction engineering methodologies for postâ€contrastographic biomedical imaging analysis. Asia-Pacific Journal of Chemical Engineering, 2014, 9, 354-363.	0.8	0
1352	Multiparametric MRI in prostate cancer management. Nature Reviews Clinical Oncology, 2014, 11, 346-353.	12.5	127
1353	Evaluation of Tumor Microvascular Response to Brivanib by Dynamic Contrast-Enhanced 7-T MRI in an Orthotopic Xenograft Model of Hepatocellular Carcinoma. American Journal of Roentgenology, 2014, 202, W559-W566.	1.0	21
1354	Prostate Stereotactic Ablative Radiation Therapy Using Volumetric Modulated Arc Therapy to Dominant Intraprostatic Lesions. International Journal of Radiation Oncology Biology Physics, 2014, 89, 406-415.	0.4	32
1355	Phase 1 Pharmacogenetic and Pharmacodynamic Study of Sorafenib With Concurrent Radiation Therapy and Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 89, 284-291.	0.4	25
1356	Transport properties of pancreatic cancer describe gemcitabine delivery and response. Journal of Clinical Investigation, 2014, 124, 1525-1536.	3.9	164
1357	In vivo assessment of the vascular disrupting effect of M410 by DCE-MRI biomarker in a rabbit model of liver tumor. Oncology Reports, 2014, 32, 709-715.	1.2	5
1359	Ramucirumab: a promising development in advanced non-small cell lung cancer. Clinical Investigation, 2014, 4, 969-977.	0.0	0
1360	Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Science, 2014, 105, 1334-1342.	1.7	206
1361	Associations between tumor vascularization assessed by in vivo DCEâ€MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis. Journal of Magnetic Resonance Imaging, 2014, 40, 1382-1391.	1.9	9

#	Article	IF	CITATIONS
1362	Assessment of the Early Predictive Power of Quantitative Magnetic Resonance Imaging Parameters During Neoadjuvant Chemotherapy for Uterine Cervical Cancer. International Journal of Gynecological Cancer, 2014, 24, 751-757.	1.2	17
1363	Development of a Multi-Centre Clinical Trial Data Archiving and Analysis Platform for Functional Imaging. Journal of Physics: Conference Series, 2014, 489, 012089.	0.3	0
1364	Distinguishing benign confounding treatment changes from residual prostate cancer on MRI following laser ablation. Proceedings of SPIE, 2014, , .	0.8	0
1365	Highly accelerated dynamic contrast enhanced imaging. Magnetic Resonance in Medicine, 2014, 71, 635-644.	1.9	33
1366	Reproducibility of Dynamic Contrast-Enhanced MRI in Renal Cell Carcinoma. Medicine (United States), 2015, 94, e1529.	0.4	7
1367	The Correlations Between MRI Perfusion, Diffusion Parameters, and 18F-FDG PET Metabolic Parameters in Primary Head-and-Neck Cancer. Medicine (United States), 2015, 94, e2141.	0.4	31
1368	Improved accuracy of quantitative parameter estimates in dynamic contrast-enhanced CT study with low temporal resolution. Medical Physics, 2015, 43, 388-400.	1.6	2
1369	Negative Interactions and Feedback Regulations Are Required for Transient Cellular Response. Scientific Reports, 2015, 4, 3718.	1.6	17
1370	The physics and biology of magnetic resonance imaging: medical miracle anyone?., 0,, 688-707.		0
1371	Semiquantitative and Quantitative Analyses of Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Thyroid Nodules. Journal of Computer Assisted Tomography, 2015, 39, 855-859.	0.5	8
1372	Advanced Hepatocellular Carcinoma. Journal of Computer Assisted Tomography, 2015, 39, 687-696.	0.5	2
1373	Free breathing DCE-MRI with motion correction and its values for benign and malignant liver tumor differentiation. Radiology of Infectious Diseases, 2015, 2, 65-71.	2.4	3
1375	The three glioma rat models C6, F98 and RG2 exhibit different metabolic profiles: in vivo 1H MRS and ex vivo 1H HRMAS combined with multivariate statistics. Metabolomics, 2015, 11, 1834-1847.	1.4	8
1376	Automatic detection of local arterial input functions through Independent Component Analysis on Dynamic Contrast enhanced Magnetic Resonance Imaging., 2015, 2015, 4294-7.		1
1377	Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies. EJNMMI Research, 2015, 5, 62.	1.1	20
1378	Single bolus split dynamic MRI: Is the combination of high spatial and dual-echo high temporal resolution interleaved sequences useful in the differential diagnosis of breast masses?. Journal of Magnetic Resonance Imaging, 2015, 42, 180-187.	1.9	4
1379	Differentiating benign from malignant vertebral fractures using <i>T</i> ₁ â€weighted dynamic contrastâ€enhanced MRI. Journal of Magnetic Resonance Imaging, 2015, 42, 1039-1047.	1.9	23
1380	Assessment of vessel permeability by combining dynamic contrast-enhanced and arterial spin labeling MRI. NMR in Biomedicine, 2015, 28, 642-649.	1.6	5

#	Article	IF	CITATIONS
1381	Cerebrovascular MRI: a review of stateâ€ofâ€theâ€art approaches, methods and techniques. NMR in Biomedicine, 2015, 28, 767-791.	1.6	38
1382	Multiparametric MRI analysis for the evaluation of MRâ€guided high intensity focused ultrasound tumor treatment. NMR in Biomedicine, 2015, 28, 1125-1140.	1.6	14
1383	Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis. Fluids and Barriers of the CNS, 2015, 12, 5.	2.4	27
1384	Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging. BMC Cancer, 2015, 15, 900.	1.1	25
1385	Translational theranostic methodology for diagnostic imaging and the concomitant treatment of malignant solid tumors. Neurovascular Imaging, 2015, 1 , .	2.4	2
1386	Mixedâ€effects modeling of clinical DCEâ€MRI data: Application to colorectal liver metastases treated with bevacizumab. Journal of Magnetic Resonance Imaging, 2015, 41, 132-141.	1.9	9
1387	Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model. Journal of Visualized Experiments, 2015, , .	0.2	7
1388	Three-dimensional dynamic contrast-enhanced MRI for the accurate, extensive quantification of microvascular permeability in atherosclerotic plaques. NMR in Biomedicine, 2015, 28, 1304-1314.	1.6	30
1389	Cluster analysis of DCEâ€MRI data identifies regional tracerâ€kinetic changes after tumor treatment with high intensity focused ultrasound. NMR in Biomedicine, 2015, 28, 1443-1454.	1.6	9
1390	T ₁ in high-grade glioma and the influence of different measurement strategies on parameter estimations in DCE-MRI. Journal of Magnetic Resonance Imaging, 2015, 42, 97-104.	1.9	22
1391	Feasibility of ASL spinal bone marrow perfusion imaging with optimized inversion time. Journal of Magnetic Resonance Imaging, 2015, 42, 1314-1320.	1.9	10
1392	Dynamic contrast-enhanced MRI in mice: An investigation of model parameter uncertainties. Magnetic Resonance in Medicine, 2015, 73, 1979-1987.	1.9	5
1393	Peritumoral tissue compression is predictive of exudate flux in a rat model of cerebral tumor: an MRI study in an embedded tumor. NMR in Biomedicine, 2015, 28, 1557-1569.	1.6	21
1394	Dynamic Contrastâ€Enhanced Perfusion MRI and Diffusionâ€Weighted Imaging in Grading of Gliomas. Journal of Neuroimaging, 2015, 25, 792-798.	1.0	66
1395	Optimized timeâ€resolved imaging of contrast kinetics (TRICKS) in dynamic contrastâ€enhanced MRI after peptide receptor radionuclide therapy in small animal tumor models. Contrast Media and Molecular Imaging, 2015, 10, 413-420.	0.4	6
1396	Imaging of the Posttherapeutic Brain. Topics in Magnetic Resonance Imaging, 2015, 24, 147-154.	0.7	9
1397	Early response to chemoradiotherapy for nasopharyngeal carcinoma treatment: Value of dynamic contrastâ€enhanced 3.0 T MRI. Journal of Magnetic Resonance Imaging, 2015, 41, 1528-1540.	1.9	41
1398	Reproducibility of DCEâ€MRI time–intensity curveâ€shape analysis in patients with knee arthritis: A comparison with qualitative and pharmacokinetic analyses. Journal of Magnetic Resonance Imaging, 2015, 42, 1497-1506.	1.9	8

#	Article	IF	CITATIONS
1399	Dynamic glucose enhanced (DGE) MRI for combined imaging of blood-brain barrier break down and increased blood volume in brain cancer. Magnetic Resonance in Medicine, 2015, 74, 1556-1563.	1.9	94
1400	Optimization of arterial spin labeling MRI for quantitative tumor perfusion in a mouse xenograft model. NMR in Biomedicine, 2015, 28, 988-997.	1.6	5
1401	Magnetic Resonance Imaging of Intraductal Papillomas. Journal of Computer Assisted Tomography, 2015, 39, 176-184.	0.5	8
1402	Response Assessment and Magnetic Resonance Imaging Issues for Clinical Trials Involving High-Grade Gliomas. Topics in Magnetic Resonance Imaging, 2015, 24, 127-136.	0.7	20
1403	Structure and Size-selective Permeability of the Synovial Membrane of the Temporomandibular Joint of the Mouse Measured by MR Imaging at 7T. Magnetic Resonance in Medical Sciences, 2015, 14, 115-122.	1.1	2
1404	Dynamic Contrast-Enhanced MRI Using a Macromolecular MR Contrast Agent (P792): Evaluation of Antivascular Drug Effect in a Rabbit VX2 Liver Tumor Model. Korean Journal of Radiology, 2015, 16, 1029.	1.5	6
1405	Permeability Parameters Measured with Dynamic Contrast-Enhanced MRI: Correlation with the Extravasation of Evans Blue in a Rat Model of Transient Cerebral Ischemia. Korean Journal of Radiology, 2015, 16, 791.	1.5	6
1406	Validation of Perfusion Quantification with 3D Gradient Echo Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using a Blood Pool Contrast Agent in Skeletal Swine Muscle. PLoS ONE, 2015, 10, e0128060.	1.1	10
1407	Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy. PLoS ONE, 2015, 10, e0136725.	1.1	8
1408	Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced MR in Tumor Parenchyma and Peritumoral Area for Distinction of Brain Tumors. PLoS ONE, 2015, 10, e0138573.	1.1	39
1409	DCE-MRI for Pre-Treatment Prediction and Post-Treatment Assessment of Treatment Response in Sites of Squamous Cell Carcinoma in the Head and Neck. PLoS ONE, 2015, 10, e0144770.	1.1	21
1410	A Comparison of Theory-Based and Experimentally Determined Myocardial Signal Intensity Correction Methods in First-Pass Perfusion Magnetic Resonance Imaging. Computational and Mathematical Methods in Medicine, 2015, 2015, 1-9.	0.7	4
1411	Anatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future Implications. BioMed Research International, 2015, 2015, 1-10.	0.9	16
1412	Validation of Microcirculatory Parameters Derived from the Standard Two-Compartment Model with Murine Xenografts Model. Journal of Cancer Research, 2015, 2015, 1-8.	0.7	0
1413	Role of Quantitative Magnetic Resonance Imaging Parameters in the Evaluation of Treatment Response in Malignant Tumors. Chinese Medical Journal, 2015, 128, 1128-1133.	0.9	10
1414	Prognostication and response assessment in liver and pancreatic tumors: The new imaging. World Journal of Gastroenterology, 2015, 21, 6794-6808.	1.4	20
1415	Imaging of Tumor Angiogenesis for Radiologistsâ€"Part 1: Biological and Technical Basis. Current Problems in Diagnostic Radiology, 2015, 44, 407-424.	0.6	45
1416	Intensity-Curvature Measurement Approaches for the Diagnosis of Magnetic Resonance Imaging Brain Tumors. Journal of Advanced Research, 2015, 6, 1045-1069.	4.4	16

#	Article	IF	CITATIONS
1417	Using Single-Channel Blind Deconvolution to Choose the Most Realistic Pharmacokinetic Model in Dynamic Contrast-Enhanced MR Imaging. Applied Magnetic Resonance, 2015, 46, 643-659.	0.6	5
1418	Contrast-Enhanced Ultrasound with Perflubutane in the Assessment of Anti-Angiogenic Effects: Early Prediction of the Anticancer Activity of Bevacizumab in a Mouse Xenografted Model. Ultrasound in Medicine and Biology, 2015, 41, 2497-2505.	0.7	3
1419	1.5-T multiparametric MRI using PI-RADS: a region by region analysis to localize the index-tumor of prostate cancer in patients undergoing prostatectomy. Acta Radiologica, 2015, 56, 500-511.	0.5	33
1420	Quantifying Intracranial Aneurysm Wall Permeability for Risk Assessment Using Dynamic Contrast-Enhanced MRI: A Pilot Study. American Journal of Neuroradiology, 2015, 36, 953-959.	1.2	43
1421	Pixel-by-Pixel Comparison of Volume Transfer Constant and Estimates of Cerebral Blood Volume from Dynamic Contrast-Enhanced and Dynamic Susceptibility Contrast-Enhanced MR Imaging in High-Grade Gliomas. American Journal of Neuroradiology, 2015, 36, 871-876.	1,2	26
1422	High Spatiotemporal Resolution Dynamic Contrast-Enhanced MR Enterography in Crohn Disease Terminal Ileitis Using Continuous Golden-Angle Radial Sampling, Compressed Sensing, and Parallel Imaging. American Journal of Roentgenology, 2015, 204, W663-W669.	1.0	19
1423	Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy ââ,¬â€œ Detecting Illusive Disease, Defining Response. Frontiers in Neurology, 2015, 6, 33.	1,1	139
1424	Multiparametric-MRI and Targeted Biopsies in the Management of Prostate Cancer Patients on Active Surveillance. Frontiers in Oncology, 2015, 5, 4.	1.3	8
1425	A Bloch-McConnell simulator with pharmacokinetic modeling to explore accuracy and reproducibility in the measurement of hyperpolarized pyruvate. , 2015, , .		0
1426	Data-driven selection of motion correction techniques in breast DCE-MRI., 2015,,.		8
1427	Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy—Are We There Yet?. Cancer Journal (Sudbury, Mass), 2015, 21, 337-342.	1.0	8
1428	Short-term pretreatment DCE-MRI in prediction of outcome in locally advanced cervical cancer. Radiotherapy and Oncology, 2015, 115, 379-385.	0.3	23
1429	Multimodal classification of prostate tissue: a feasibility study on combining multiparametric MRI and ultrasound. Proceedings of SPIE, 2015, , .	0.8	3
1430	Advanced Techniques in Musculoskeletal Oncology: Perfusion, Diffusion, and Spectroscopy. Seminars in Musculoskeletal Radiology, 2015, 19, 463-474.	0.4	16
1431	Blood–brain barrier dysfunction following traumatic brain injury: correlation of K ^{trans} (DCE-MRI) and SUVR (99mTc-DTPA SPECT) but not serum S100B. Neurological Research, 2015, 37, 599-606.	0.6	20
1432	T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status. American Journal of Neuroradiology, 2015, 36, 2256-2261.	1.2	46
1433	Assessment of esophageal carcinoma undergoing concurrent chemoradiotherapy with quantitative dynamic contrast-enhanced magnetic resonance imaging. Oncology Letters, 2015, 10, 3607-3612.	0.8	26
1434	Convex Optimization-Based Compartmental Pharmacokinetic Analysis for Prostate Tumor Characterization Using DCE-MRI. IEEE Transactions on Biomedical Engineering, 2015, 63, 1-1.	2.5	12

#	Article	IF	CITATIONS
1435	MRI/MRS in neuroinflammation: methodology and applications. Clinical and Translational Imaging, 2015, 3, 475-489.	1.1	49
1436	4D co-registration of X-ray and MR-mammograms: initial clinical results and potential incremental diagnostic value. Clinical Imaging, 2015, 39, 225-230.	0.8	1
1437	Transperineal In-Bore 3-T MR Imaging–guided Prostate Biopsy: A Prospective Clinical Observational Study. Radiology, 2015, 274, 170-180.	3.6	75
1438	Contrast-enhanced perfusion magnetic resonance imaging for head and neck squamous cell carcinoma: A systematic review. Oral Oncology, 2015, 51, 124-138.	0.8	37
1439	Dynamic contrastâ€enhanced MRI: Use in predicting pathological complete response to neoadjuvant chemoradiation in locally advanced rectal cancer. Journal of Magnetic Resonance Imaging, 2015, 42, 673-680.	1.9	69
1440	Pharmacokinetic Tumor Heterogeneity as a Prognostic Biomarker for Classifying Breast Cancer Recurrence Risk. IEEE Transactions on Biomedical Engineering, 2015, 62, 1585-1594.	2.5	47
1441	Correlation of dynamic contrastâ€enhanced MRI perfusion parameters with angiogenesis and biologic aggressiveness of rectal cancer: Preliminary results. Journal of Magnetic Resonance Imaging, 2015, 41, 474-480.	1.9	76
1442	Simulating the effect of input errors on the accuracy of Tofts' pharmacokinetic model parameters. Magnetic Resonance Imaging, 2015, 33, 222-235.	1.0	28
1443	Nanomaterial Applications in Multiple Sclerosis Inflamed Brain. Journal of NeuroImmune Pharmacology, 2015, 10, 1-13.	2.1	15
1444	Functional MRI and CT biomarkers in oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 562-578.	3.3	19
1445	Establishing implantation uncertainties for focal brachytherapy with I-125 seeds for the treatment of localized prostate cancer. Acta Oncol \tilde{A}^3 gica, 2015, 54, 839-846.	0.8	13
1446	Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy: Differentiation of True Progression from Pseudoprogression with Quantitative Dynamic Contrast-enhanced MR Imaging. Radiology, 2015, 274, 830-840.	3.6	102
1447	Differentiation of tuberculosis and metastatic cancer in the spine using dynamic contrast-enhanced MRI. European Spine Journal, 2015, 24, 1729-1737.	1.0	34
1448	Intravenous Infusion of Nitroglycerine Leads to Increased Permeability on Dynamic Contrast-Enhanced MR Imaging in Pig Brains. American Journal of Neuroradiology, 2015, 36, 1288-1292.	1.2	1
1449	Feasibility Analysis of the Parametric Response Map as an Early Predictor of Treatment Efficacy in Head and Neck Cancer. American Journal of Neuroradiology, 2015, 36, 757-762.	1.2	27
1450	Clinical applications for dual energy CT versus dynamic contrast enhanced CT in oncology. European Journal of Radiology, 2015, 84, 2368-2379.	1.2	16
1451	Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation. Magnetic Resonance Imaging, 2015, 33, 886-894.	1.0	23
1452	Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment. Journal of the National Cancer Institute Monographs, 2015, 2015, 40-46.	0.9	11

#	Article	IF	CITATIONS
1453	Measurement of single-kidney glomerular filtration function from magnetic resonance perfusion renography. European Journal of Radiology, 2015, 84, 1419-1423.	1.2	12
1454	Optimal cut-off value of perfusion parameters for diagnosing prostate cancer and for assessing aggressiveness associated with Gleason score. Clinical Imaging, 2015, 39, 834-840.	0.8	34
1455	Dynamic contrast-enhanced MRI of oral squamous cell carcinoma: a preliminary study of the correlations between quantitative parameters and the clinical stage. British Journal of Radiology, 2015, 88, 20140814.	1.0	15
1456	Validation of functional imaging as a biomarker for radiation treatment response. British Journal of Radiology, 2015, 88, 20150014.	1.0	22
1457	Breast MRI for Diagnosis and Staging of Breast Cancer. , 2015, , 181-200.		2
1458	The assessment of immature microvascular density in brain gliomas with dynamic contrast-enhanced magnetic resonance imaging. European Journal of Radiology, 2015, 84, 1805-1809.	1.2	41
1459	Breast DCE-MRI Kinetic Heterogeneity Tumor Markers: Preliminary Associations With Neoadjuvant Chemotherapy Response. Translational Oncology, 2015, 8, 154-162.	1.7	48
1460	Quantitative analysis of 3-Tesla magnetic resonance imaging in the differential diagnosis of breast lesions. Experimental and Therapeutic Medicine, 2015, 9, 913-918.	0.8	15
1461	Characterization of bone perfusion by dynamic contrastâ€enhanced magnetic resonance imaging and positron emission tomography in the Dunkin–Hartley guinea pig model of advanced osteoarthritis. Journal of Orthopaedic Research, 2015, 33, 366-372.	1.2	25
1462	The Role of Pathology Correlation Approach in Prostate Cancer Index Lesion Detection and Quantitative Analysis with Multiparametric MRI. Academic Radiology, 2015, 22, 548-555.	1.3	32
1463	Dynamic perfusion CT in brain tumors. European Journal of Radiology, 2015, 84, 2386-2392.	1.2	22
1464	Tumor plasma flow determined by dynamic contrast-enhanced MRI predicts response to induction chemotherapy in head and neck cancer. Oral Oncology, 2015, 51, 508-513.	0.8	20
1465	Human cerebral blood volume measurements using dynamic contrast enhancement in comparison to dynamic susceptibility contrast MRI. Neuroradiology, 2015, 57, 671-678.	1.1	16
1466	Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI. European Radiology, 2015, 25, 2665-2672.	2.3	57
1467	Dynamic Contrast-Enhanced MRI in the Study of Brain Tumors. Comparison Between the Extended Tofts-Kety Model and a Phenomenological Universalities (PUN) Algorithm. Journal of Digital Imaging, 2015, 28, 748-754.	1.6	3
1468	Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology, 2015, 121, 373-380.	1.4	43
1469	Diagnosis of brain tumors using dynamic contrast-enhanced perfusion imaging with a short acquisition time. SpringerPlus, 2015, 4, 88.	1.2	41
1470	Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging. Cancer Imaging, 2015, 15, 4.	1.2	97

#	ARTICLE	IF	CITATIONS
1471	Correlation Between F-18 Fluorodeoxyglucose Positron Emission Tomography Metabolic Parameters and Dynamic Contrast-Enhanced MRI-Derived Perfusion Data in Patients with Invasive Ductal Breast Carcinoma. Annals of Surgical Oncology, 2015, 22, 3866-3872.	0.7	18
1472	Tumor metabolism and perfusion ratio assessed by 18F-FDG PET/CT and DCE-MRI in breast cancer patients: Correlation with tumor subtype and histologic prognostic factors. European Journal of Radiology, 2015, 84, 1365-1370.	1.2	29
1473	Efficient Hilbert transform-based alternative to Tofts physiological models for representing MRI dynamic contrast-enhanced images in computer-aided diagnosis of prostate cancer., 2015,,.		0
1474	MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity. British Journal of Cancer, 2015, 112, 504-513.	2.9	25
1475	Radiochemotherapy-induced changes of tumour vascularity and blood supply estimated by dynamic contrast-enhanced CT and fractal analysis in malignant head and neck tumours. British Journal of Radiology, 2015, 88, 20140412.	1.0	8
1476	Enhancement in blood-tumor barrier permeability and delivery of liposomal doxorubicin using focused ultrasound and microbubbles: evaluation during tumor progression in a rat glioma model. Physics in Medicine and Biology, 2015, 60, 2511-2527.	1.6	78
1477	Dynamic Contrast-Enhanced Magnetic Resonance Imaging Measurements in Renal Cell Carcinoma. Investigative Radiology, 2015, 50, 57-66.	3.5	29
1478	Semiautomatic Determination of Arterial Input Functions for Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Non-Small Cell Lung Cancer Patients. Investigative Radiology, 2015, 50, 129-134.	3.5	4
1479	Differentiation of solitary brain metastasis from glioblastoma multiforme: a predictive multiparametric approach using combined MR diffusion and perfusion. Neuroradiology, 2015, 57, 697-703.	1.1	87
1480	Dynamic Contrast-enhanced MR Imaging Curve-type Analysis: Is It Helpful in the Differentiation of Prostate Cancer from Healthy Peripheral Zone?. Radiology, 2015, 275, 448-457.	3.6	71
1481	Prostate Imaging – An Update. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2015, 187, 751-759.	0.7	7
1482	IV Administered Gadodiamide Enters the Lumen of the Prostatic Glands: X-Ray Fluorescence Microscopy Examination of a Mouse Model. American Journal of Roentgenology, 2015, 205, W313-W319.	1.0	6
1483	Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas. Neuroradiology, 2015, 57, 1269-1280.	1.1	37
1484	Effect of \$\$ T_{2}^{*} \$\$ correction on contrast kinetic model analysis using a reference tissue arterial input function at 7ÂT. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2015, 28, 555-563.	1.1	11
1485	Assessing and monitoring intratumor heterogeneity in glioblastoma: how far has multimodal imaging come?. CNS Oncology, 2015, 4, 399-410.	1.2	8
1486	Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. British Journal of Cancer, 2015, 113, 1282-1288.	2.9	29
1487	Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. Oncologist, 2015, 20, 952-959.	1.9	23
1488	Multimodal approach to assess tumour vasculature and potential treatment effect with DCEâ€US and DCEâ€MRI quantification in CWR22 prostate tumour xenografts. Contrast Media and Molecular Imaging, 2015, 10, 428-437.	0.4	5

#	Article	IF	CITATIONS
1489	Quantitative multiparametric MRI in uveal melanoma: increased tumor permeability may predict monosomy 3. Neuroradiology, 2015, 57, 833-840.	1.1	22
1490	Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. Journal of Neuro-Oncology, 2015, 125, 183-190.	1.4	106
1491	Kinetic Modeling and Constrained Reconstruction of Hyperpolarized [1-13C]-Pyruvate Offers Improved Metabolic Imaging of Tumors. Cancer Research, 2015, 75, 4708-4717.	0.4	69
1492	Functional imaging of the human placenta with magnetic resonance. American Journal of Obstetrics and Gynecology, 2015, 213, S103-S114.	0.7	106
1493	MRI reconstruction of multiâ€image acquisitions using a rank regularizer with data reordering. Medical Physics, 2015, 42, 4734-4744.	1.6	2
1494	A Radiation-Induced Hippocampal Vascular Injury Surrogate Marker Predicts Late Neurocognitive Dysfunction. International Journal of Radiation Oncology Biology Physics, 2015, 93, 908-915.	0.4	48
1495	Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging. Journal of Nuclear Medicine, 2015, 56, 1554-1561.	2.8	152
1496	Prospective glioma grading using single-dose dynamic contrast-enhanced perfusion MRI. Clinical Radiology, 2015, 70, 1128-1135.	0.5	32
1497	New Imaging Techniques in the Diagnosis of Inflammatory Bowel Diseases. Visceral Medicine, 2015, 31, 227-234.	0.5	13
1498	Pharmacokinetic analysis of prostate cancer using independent component analysis. Magnetic Resonance Imaging, 2015, 33, 1236-1245.	1.0	5
1499	The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival. American Journal of Neuroradiology, 2015, 36, 2235-2241.	1.2	36
1500	Dynamic Contrast-Enhanced MRI Kinetic Parameters as Prognostic Biomarkers for Prediction of Survival of Patient with Advanced Hepatocellular Carcinoma. Academic Radiology, 2015, 22, 1344-1360.	1.3	10
1501	Accuracy of MRI-Targeted in-Bore Prostate Biopsy According to the Gleason Score with Postprostatectomy Histopathologic Control—a Targeted Biopsy-Only Strategy with Limited Number of Cores. Academic Radiology, 2015, 22, 1409-1418.	1.3	16
1502	Upsampling dynamic contrast enhanced MRI., 2015, , .		2
1503	Blood–brain barrier impairment in dementia: Current and future in vivo assessments. Neuroscience and Biobehavioral Reviews, 2015, 49, 71-81.	2.9	51
1504	Measurement of T ₁ relaxation time of osteochondral specimens using VFA WIFT. Magnetic Resonance in Medicine, 2015, 74, 175-184.	1.9	15
1505	Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers?. Magnetic Resonance Imaging, 2015, 33, 72-80.	1.0	93
1506	Effects of flip angle uncertainty and noise on the accuracy of DCE-MRI metrics: comparison between standard concentration-based and signal difference methods. Magnetic Resonance Imaging, 2015, 33, 166-173.	1.0	6

#	Article	IF	CITATIONS
1507	Simulation study of the effect of golden-angle KWIC with generalized kinetic model analysis on diagnostic accuracy for lesion discrimination. Magnetic Resonance Imaging, 2015, 33, 86-94.	1.0	3
1508	Automated Voxel-Based Analysis of Volumetric Dynamic Contrast-Enhanced CT Data Improves Measurement of Serial Changes in Tumor Vascular Biomarkers. International Journal of Radiation Oncology Biology Physics, 2015, 91, 48-57.	0.4	15
1509	Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy. Acta Radiologica, 2015, 56, 1300-1307.	0.5	13
1510	Modelling of FDG metabolism in liver voxels. Journal of Theoretical Biology, 2015, 365, 390-402.	0.8	3
1511	Optimization of the reference region method for dual pharmacokinetic modeling using Gdâ€DTPA/MRI and ¹⁸ Fâ€FDG/PET. Magnetic Resonance in Medicine, 2015, 73, 740-748.	1.9	7
1512	Breast Cancer Screening and Diagnosis. , 2015, , .		8
1513	A geometrical perspective on the 3TP method in DCE-MRI. Biomedical Signal Processing and Control, 2015, 16, 32-39.	3.5	3
1514	The Application of Dynamic Contrast-Enhanced MRI and Diffusion-Weighted MRI in Patients with Maxillofacial Tumors. Academic Radiology, 2015, 22, 210-216.	1.3	25
1515	A data-driven approach to prostate cancer detection from dynamic contrast enhanced MRI. Computerized Medical Imaging and Graphics, 2015, 41, 37-45.	3.5	22
1516	Dynamic contrastâ€enhanced MRI of gastric cancer: Correlation of the perfusion parameters with pathological prognostic factors. Journal of Magnetic Resonance Imaging, 2015, 41, 1608-1614.	1.9	21
1517	Dynamic contrast enhanced MR imaging for rectal cancer response assessment after neoâ€adjuvant chemoradiation. Journal of Magnetic Resonance Imaging, 2015, 41, 1646-1653.	1.9	82
1518	Boosting in Nonlinear Regression Models with an Application to DCE-MRI Data. Methods of Information in Medicine, 2016, 55, 31-41.	0.7	3
1519	Recent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma Patients. Magnetic Resonance in Medical Sciences, 2016, 15, 165-177.	1.1	15
1520	Assessment of Blood-Brain Barrier Permeability by Dynamic Contrast-Enhanced MRI in Transient Middle Cerebral Artery Occlusion Model after Localized Brain Cooling in Rats. Korean Journal of Radiology, 2016, 17, 715.	1.5	3
1521	Functional magnetic resonance imaging techniques and their development for radiation therapy planning and monitoring in the head and neck cancers. Quantitative Imaging in Medicine and Surgery, 2016, 6, 430-448.	1.1	14
1522	Spotlight on multiparametric magnetic resonance imaging in prostate cancer management: current perspectives. Reports in Medical Imaging, 2016, Volume 9, 7-16.	0.8	0
1523	A practical guideline for $\langle i \rangle T \langle j \rangle \langle sub \rangle 1 \langle sub \rangle$ reconstruction from various flip angles in MRI. Journal of Algorithms and Computational Technology, 2016, 10, 213-223.	0.4	5
1524	Multivariate Curve Resolution for Magnetic Resonance Image Analysis. Data Handling in Science and Technology, 2016, , 519-550.	3.1	1

#	ARTICLE 5 Perfusion imaging dynamic contrast-enhanced T1-weighted magnetic resonance imaging (DCE-MRI)	IF	Citations
1525	perfusionDynamic contrast-enhanced T1-weighted magnetic resonance imaging (DCE-MRI) perfusionDynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)Perfusion Imaging: Dynamic Contrast-Enhanced T1-Weighted MRI (DCE-MRI) Perfusion., 2016,,.		1
1526	Quantitative Myocardial Perfusion with Dynamic Contrast-Enhanced Imaging in MRI and CT: Theoretical Models and Current Implementation. BioMed Research International, 2016, 2016, 1-12.	0.9	23
1527	Diffusion-weighted and dynamic contrast-enhanced MRI of pancreatic adenocarcinoma xenografts: associations with tumor differentiation and collagen content. Journal of Translational Medicine, 2016, 14, 161.	1.8	35
1528	Evaluation of an Automated Analysis Tool for Prostate Cancer Prediction Using Multiparametric Magnetic Resonance Imaging. PLoS ONE, 2016, 11, e0159803.	1.1	14
1529	Dynamic Contrast-Enhanced MRI Perfusion Parameters as Imaging Biomarkers of Angiogenesis. PLoS ONE, 2016, 11, e0168632.	1.1	52
1530	The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse Hepatocarcinoma. Frontiers in Pharmacology, 2016, 7, 506.	1.6	8
1531	Performance of different imaging modalities in assessment of response to neoadjuvant therapy in primary esophageal cancer. Ecological Management and Restoration, 2016, 29, 116-130.	0.2	16
1532	A novel approach to tracerâ€kinetic modeling for (macromolecular) dynamic contrastâ€enhanced MRI. Magnetic Resonance in Medicine, 2016, 75, 1142-1153.	1.9	11
1533	Volumeâ€normalized transfer constant as an imaging biomarker for chronic inflammatory arthritis: A dynamic contrast enhanced MRI study. Magnetic Resonance in Medicine, 2016, 76, 926-934.	1.9	2
1535	Pharmacokinetic modeling of multislice dynamic contrastâ€enhanced MRI in normalâ€healing radial fractures: A pilot study. Journal of Magnetic Resonance Imaging, 2016, 43, 611-619.	1.9	1
1536	Dynamic contrastâ€enhanced MRI for oncology drug development. Journal of Magnetic Resonance Imaging, 2016, 44, 251-264.	1.9	31
1537	Monitoring Combretastatin A4–induced tumor hypoxia and hemodynamic changes using endogenous MR contrast and DCEâ€MRI. Magnetic Resonance in Medicine, 2016, 75, 866-872.	1.9	16
1538	Validation of a T ₁ and T2* leakage correction method based on multiecho dynamic susceptibility contrast MRI using MION as a reference standard. Magnetic Resonance in Medicine, 2016, 76, 613-625.	1.9	17
1539	Effects of transcytolemmal water exchange on the assessment of myocardial extracellular volume with cardiovascular MRI. NMR in Biomedicine, 2016, 29, 499-506.	1.6	4
1540	Measurement of glomerular filtration rate by dynamic contrast-enhanced magnetic resonance imaging using a subject-specific two-compartment model. Physiological Reports, 2016, 4, e12755.	0.7	9
1541	Increased microcirculation detected by dynamic contrastâ€enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma. British Journal of Haematology, 2016, 174, 127-135.	1.2	25
1542	Improving the arterial input function in dynamic contrast enhanced MRI by fitting the signal in the complex plane. Magnetic Resonance in Medicine, 2016, 76, 1236-1245.	1.9	14
1543	Performance of an efficient imageâ€registration algorithm in processing MR renography data. Journal of Magnetic Resonance Imaging, 2016, 43, 391-397.	1.9	6

#	Article	IF	CITATIONS
1544	B ₁ and T ₁ mapping of the breast with a reference tissue method. Magnetic Resonance in Medicine, 2016, 75, 1565-1573.	1.9	23
1545	Perfusion Imaging for Brain Tumor Characterization and Assessment of Treatment Response. , 2016, , 335-351.		2
1546	Comparison of Glioblastomas and Brain Metastases using Dynamic Contrastâ€Enhanced Perfusion MRI. Journal of Neuroimaging, 2016, 26, 240-246.	1.0	46
1547	Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials. Journal of Neuromuscular Diseases, 2016, 3, 1-28.	1.1	129
1548	A DCE-MRI imaging-based model for simulation of vascular tumour growth. , 2016, 2016, 5949-5952.		1
1549	Artificial Neural Networks approach to pharmacokinetic model selection in DCE-MRI studies. Physica Medica, 2016, 32, 1543-1550.	0.4	5
1550	Overexpression of HER-2 in MDA-MB-435/LCC6 Tumours is Associated with Higher Metabolic Activity and Lower Energy Stress. Scientific Reports, 2016, 6, 18537.	1.6	1
1551	Characterization of cervical lymph nodes using DCE-MRI: Differentiation between metastases from SCC of head and neck and benign lymph nodes. Clinical Hemorheology and Microcirculation, 2016, 64, 213-222.	0.9	18
1552	Influence of amplitudeâ€related perfusion parameters in the parotid glands by nonâ€fatâ€saturated dynamic contrastâ€enhanced magnetic resonance imaging. Medical Physics, 2016, 43, 1873-1881.	1.6	2
1553	The role of imaging in the diagnosis of primary prostate cancer. Journal of Clinical Urology, 2016, 9, 11-17.	0.1	6
1555	Mechanistic and quantitative insight into cell surface targeted molecular imaging agent design. Scientific Reports, 2016, 6, 25424.	1.6	27
1556	Functional assessment of glioma pathogenesis by in vivo multi-parametric magnetic resonance imaging and in vitro analyses. Scientific Reports, 2016, 6, 26050.	1.6	9
1557	Functional MRI for the prediction of treatment response in head and neck squamous cell carcinoma: potential and limitations. Cancer Imaging, 2016, 16, 23.	1.2	86
1558	Tumor Growth Estimation via Registration of DCE-MRI Derived Tumor Specific Descriptors. , 2016, , .		0
1559	Exploring Targeted Contrast-Enhanced Ultrasound to Detect Neural Inflammation. Journal of Diagnostic Medical Sonography, 2016, 32, 313-323.	0.1	3
1560	Correlation of quantitative dynamic contrastâ€enhanced MRI with microvascular density in necrotic, partial necrotic, and viable liver tumors in a rabbit model. Journal of Applied Clinical Medical Physics, 2016, 17, 418-427.	0.8	6
1561	High-resolution whole-brain DCE-MRI using constrained reconstruction: Prospective clinical evaluation in brain tumor patients. Medical Physics, 2016, 43, 2013-2023.	1.6	28
1562	Diagnostic value of dynamic contrast-enhanced magnetic resonance imaging in rectal cancer and its correlation with tumor differentiation. Molecular and Clinical Oncology, 2016, 4, 500-506.	0.4	20

#	Article	IF	CITATIONS
1563	DCE-MRI, DW-MRI, and MRS in Cancer. Topics in Magnetic Resonance Imaging, 2016, 25, 245-254.	0.7	36
1564	Soft Null Hypotheses: A Case Study of Image Enhancement Detection in Brain Lesions. Journal of Computational and Graphical Statistics, 2016, 25, 570-588.	0.9	2
1565	High-dose estrogen treatment at reperfusion reduces lesion volume and accelerates recovery of sensorimotor function after experimental ischemic stroke. Brain Research, 2016, 1639, 200-213.	1.1	17
1566	Synovitis assessed on static and dynamic contrast-enhanced magnetic resonance imaging and its association with pain in knee osteoarthritis: A cross-sectional study. European Journal of Radiology, 2016, 85, 1099-1108.	1.2	46
1567	Early Prediction and Evaluation of Breast Cancer Response to Neoadjuvant Chemotherapy Using Quantitative DCE-MRI. Translational Oncology, 2016, 9, 8-17.	1.7	94
1568	Triexponential function analysis of diffusion-weighted MRI for diagnosing prostate cancer. Journal of Magnetic Resonance Imaging, 2016, 43, 138-148.	1.9	28
1569	Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: systematic review and meta-analysis. Skeletal Radiology, 2016, 45, 1235-1242.	1.2	30
1570	Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases. Spine Journal, 2016, 16, 291-298.	0.6	32
1571	Synovial volume vs synovial measurements from dynamic contrast enhanced MRI as measures of response in osteoarthritis. Osteoarthritis and Cartilage, 2016, 24, 1392-1398.	0.6	34
1572	Comparison of actual with default hematocrit value in dynamic contrast enhanced MR perfusion quantification in grading of human glioma. Magnetic Resonance Imaging, 2016, 34, 1071-1077.	1.0	10
1573	A longitudinal study of placental perfusion using dynamic contrast enhanced magnetic resonance imaging in murine pregnancy. Placenta, 2016, 43, 90-97.	0.7	16
1574	Rectal Cancer: Assessment of Neoadjuvant Chemoradiation Outcome based on Radiomics of Multiparametric MRI. Clinical Cancer Research, 2016, 22, 5256-5264.	3.2	322
1575	Potential Role of PET/MRI for Imaging Metastatic Lymph Nodes in Head and Neck Cancer. American Journal of Roentgenology, 2016, 207, 248-256.	1.0	28
1576	Effect of parallel radiofrequency transmission on arterial input function selection in dynamic contrast-enhanced 3 Tesla pelvic MRI. Journal of Magnetic Resonance Imaging, 2016, 43, 229-235.	1.9	0
1577	Brain imaging of neurovascular dysfunction in Alzheimer's disease. Acta Neuropathologica, 2016, 131, 687-707.	3.9	160
1578	Stereological quantification of microvessels using semiautomated evaluation of X-ray microtomography of hepatic vascular corrosion casts. International Journal of Computer Assisted Radiology and Surgery, 2016, 11, 1803-1819.	1.7	12
1579	Pieces-of-parts for supervoxel segmentation with global context: Application to DCE-MRI tumour delineation. Medical Image Analysis, 2016, 32, 69-83.	7.0	20
1580	Time-efficient estimation of the magnetic resonance dispersion model parameters for quantitative assessment of angiogenesis. Biomedical Signal Processing and Control, 2016, 26, 23-33.	3.5	7

#	ARTICLE	IF	CITATIONS
1581	Application of histogram analysis for the evaluation of vascular permeability in glioma by the K2 parameter obtained with the dynamic susceptibility contrast method: Comparisons with Ktrans obtained with the dynamic contrast enhance method and cerebral blood volume. Magnetic Resonance Imaging, 2016, 34, 896-901.	1.0	11
1582	Vascular assessment of liver diseaseâ€"towards a new frontier in MRI. British Journal of Radiology, 2016, 89, 20150675.	1.0	17
1583	Dynamic contrast-enhanced MRI, diffusion-weighted MRI and 18F-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. European Radiology, 2016, 26, 4162-4172.	2.3	55
1584	Dynamic Contrast-Enhanced MRI to Study Atherosclerotic Plaque Microvasculature. Current Atherosclerosis Reports, 2016, 18, 33.	2.0	16
1585	Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis. European Journal of Radiology, 2016, 85, 1147-1156.	1.2	76
1586	A role for dynamic contrast-enhanced magnetic resonance imaging in predicting tumour radiation response. British Journal of Cancer, 2016, 114, 1206-1211.	2.9	11
1587	Computer-aided Detection of Prostate Cancer with MRI. Academic Radiology, 2016, 23, 1024-1046.	1.3	49
1588	Complications from radiotherapy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 219-234.	1.0	16
1589	Simulation of heterogeneous molecular delivery in tumours using \hat{l} /4CT reconstructions and MRI validation. Microvascular Research, 2016, 108, 69-74.	1.1	1
1590	Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. Journal of Neuro-Oncology, 2016, 130, 495-503.	1.4	16
1591	Assessment of DCE–MRI parameters for brain tumors through implementation of physiologically–based pharmacokinetic model approaches for Gd-DOTA. Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43, 529-547.	0.8	7
1592	Cognitive impairment after traumatic brain injury: The role of MRI and possible pathological basis. Journal of the Neurological Sciences, 2016, 370, 244-250.	0.3	44
1593	The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer. Expert Review of Anticancer Therapy, 2016, 16, 1119-1129.	1.1	2
1594	Dynamic contrast-enhanced case-control analysis in 3T MRI of prostate cancer can help to characterize tumor aggressiveness. European Journal of Radiology, 2016, 85, 2119-2126.	1.2	25
1595	Deep Learning and Data Labeling for Medical Applications. Lecture Notes in Computer Science, 2016, , .	1.0	45
1596	Reduced respiratory motion artifacts using structural similarity in fast 2D dynamic contrast enhanced MRI of liver lesions. NMR in Biomedicine, 2016, 29, 1526-1535.	1.6	1
1597	Detecting tumor progression in glioma: current standards and new techniques. Expert Review of Anticancer Therapy, 2016, 16, 1177-1188.	1.1	18
1598	PI-RADS Version 2: A Pictorial Update. Radiographics, 2016, 36, 1354-1372.	1.4	88

#	ARTICLE	IF	CITATIONS
1600	Dynamic Contrastâ€Enhanced Perfusion MRI of High Grade Brain Gliomas Obtained with Arterial or Venous Waveform Input Function. Journal of Neuroimaging, 2016, 26, 124-129.	1.0	17
1601	Cluster analysis of dynamic contrast enhanced MRI reveals tumor subregions related to locoregional relapse for cervical cancer patients. Acta Oncol \tilde{A}^3 gica, 2016, 55, 1294-1298.	0.8	33
1602	A prospective study of DWI, DCE-MRI and FDG PET imaging for target delineation in brachytherapy for cervical cancer. Radiotherapy and Oncology, 2016, 120, 519-525.	0.3	41
1603	Feasibility of free-breathing dynamic contrast-enhanced MRI of the abdomen: a comparison between CAIPIRINHA-VIBE, Radial-VIBE with KWIC reconstruction and conventional VIBE. British Journal of Radiology, 2016, 89, 20160150.	1.0	8
1604	Short-term follow-up MRI after unplanned resection of malignant soft-tissue tumours; quantitative measurements on dynamic contrast enhanced and diffusion-weighted MR images. British Journal of Radiology, 2016, 89, 20160302.	1.0	9
1605	Assessment of a simplified spin and gradient echo (sSAGE) approach for human brain tumor perfusion imaging. Magnetic Resonance Imaging, 2016, 34, 1248-1255.	1.0	17
1606	Kinetic Analysis of Benign and Malignant Breast Lesions With Ultrafast Dynamic Contrast-Enhanced MRI: Comparison With Standard Kinetic Assessment. American Journal of Roentgenology, 2016, 207, 1159-1166.	1.0	98
1607	The Tofts model in frequency domain: fast and robust determination of pharmacokinetic maps for dynamic contrast enhancement MRI. Physics in Medicine and Biology, 2016, 61, 8462-8475.	1.6	4
1608	A DCE-MRI analysis workflow. , 2016, , .		1
1609	Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 705-718.	0.6	25
1610	Blood–Brain Barrier Disruption. , 2016, , 291-311.		2
1611	Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor. European Journal of Radiology, 2016, 85, 1722-1727.	1.2	40
1612	Feasibility of 4D perfusion CT imaging for the assessment of liver treatment response following SBRT and sorafenib. Advances in Radiation Oncology, 2016, 1, 194-203.	0.6	12
1613	Functional MR imaging in gynecologic malignancies: current status and future perspectives. Abdominal Radiology, 2016, 41, 2509-2523.	1.0	8
1614	A novel anthropomorphic flow phantom for the quantitative evaluation of prostate DCE-MRI acquisition techniques. Physics in Medicine and Biology, 2016, 61, 7466-7483.	1.6	8
1615	Focused Ultrasound-Induced Blood-Brain Barrier Opening: Association with Mechanical Index and Cavitation Index Analyzed by Dynamic Contrast-Enhanced Magnetic-Resonance Imaging. Scientific Reports, 2016, 6, 33264.	1.6	93
1616	Translational Biomedical Informatics. Advances in Experimental Medicine and Biology, 2016, , .	0.8	1
1617	Medical Imaging Informatics. Advances in Experimental Medicine and Biology, 2016, 939, 167-224.	0.8	9

#	Article	IF	CITATIONS
1618	Difference in the intratumoral distributions of extracellularâ€fluid and intravascular MR contrast agents in glioblastoma growth. NMR in Biomedicine, 2016, 29, 1688-1699.	1.6	3
1619	Liver DCE-MRI Registration in Manifold Space Based on Robust Principal Component Analysis. Scientific Reports, 2016, 6, 34461.	1.6	17
1620	Noninvasive mapping of endothelial dysfunction in myocardial ischemia by magnetic resonance imaging using an albuminâ€based contrast agent. NMR in Biomedicine, 2016, 29, 1500-1510.	1.6	8
1621	Quantifying hypoxia in human cancers using static PET imaging. Physics in Medicine and Biology, 2016, 61, 7957-7974.	1.6	11
1622	Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients. Neuroradiology, 2016, 58, 1197-1208.	1.1	45
1623	Timeâ€resolved angiography with stochastic trajectories for dynamic contrastâ€enhanced MRI in head and neck cancer: Are pharmacokinetic parameters affected?. Medical Physics, 2016, 43, 6024-6032.	1.6	3
1624	A novel perfused Bloch–McConnell simulator for analyzing the accuracy of dynamic hyperpolarized MRS. Medical Physics, 2016, 43, 854-864.	1.6	8
1625	Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR Images. Biomarkers in Cancer, 2016, 8s2, BIC.S31801.	3.6	11
1626	A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer. BMC Cancer, 2016, 16, 466.	1,1	23
1627	Differential diagnosis of prostate cancer and noncancerous tissue in the peripheral zone and central gland using the quantitative parameters of DCE-MRI. Medicine (United States), 2016, 95, e5715.	0.4	12
1628	Model-Based Characterization of the Transpulmonary Circulation by Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Heart Failure and Healthy Volunteers. Investigative Radiology, 2016, 51, 720-727.	3.5	11
1629	Dynamic contrastâ€enhanced MRI: Study of interâ€software accuracy and reproducibility using simulated and clinical data. Journal of Magnetic Resonance Imaging, 2016, 43, 1288-1300.	1.9	31
1630	Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy. Radiology, 2016, 281, 454-464.	3.6	33
1631	Imaging heterogeneity of peptide delivery and binding in solid tumors using SPECT imaging and MRI. EJNMMI Research, 2016, 6, 3.	1.1	8
1632	Application of Blood-Brain Barrier Permeability Imaging in Global Cerebral Edema. American Journal of Neuroradiology, 2016, 37, 1599-1603.	1,2	18
1633	Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study. European Radiology, 2016, 26, 2771-2778.	2.3	31
1634	4 Perfusion imaging Dynamic susceptibility contrast magnetic resonance perfusion (DSC-MRP) Perfusion Imaging: Dynamic Susceptibility Contrast Magnetic Resonance Perfusion., 2016,,.		0
1635	Diffusion-Related MRI Parameters for Assessing Early Treatment Response of Liver Metastases to Cytotoxic Therapy in Colorectal Cancer. American Journal of Roentgenology, 2016, 207, W26-W32.	1.0	36

#	Article	IF	CITATIONS
1636	Imaging of local recurrence in prostate cancer. Future Oncology, 2016, 12, 2401-2415.	1.1	17
1637	Mathematical Models of Contrast Transport Kinetics for Cancer Diagnostic Imaging: A Review. IEEE Reviews in Biomedical Engineering, 2016, 9, 121-147.	13.1	32
1638	Ultrafast Bilateral DCE-MRI of the Breast with Conventional Fourier Sampling. Academic Radiology, 2016, 23, 1137-1144.	1.3	70
1639	MRI contrast agent concentration and tumor interstitial fluid pressure. Journal of Theoretical Biology, 2016, 406, 52-60.	0.8	4
1640	Apparent Diffusion Coefficient and Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Pancreatic Cancer. Journal of Computer Assisted Tomography, 2016, 40, 709-716.	0.5	33
1641	Neurovascular unit impairment in early Alzheimer's disease measured with magnetic resonance imaging. Neurobiology of Aging, 2016, 45, 190-196.	1.5	146
1642	Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 111-117.	0.4	25
1643	DUSTER: dynamic contrast enhance up-sampled temporal resolution analysis method. Magnetic Resonance Imaging, 2016, 34, 442-450.	1.0	10
1644	Decline of Tumor Vascular Function as AssessedÂby Dynamic Contrast-Enhanced Magnetic Resonance Imaging Is Associated WithÂPoor Responses to Radiation Therapy andÂChemotherapy. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1495-1503.	0.4	7
1645	Relative sensitivities of DCE-MRI pharmacokinetic parameters to arterial input function (AIF) scaling. Journal of Magnetic Resonance, 2016, 269, 104-112.	1.2	33
1646	A novel approach for quantification of time–intensity curves in a DCE-MRI image series with an application to prostate cancer. Computers in Biology and Medicine, 2016, 73, 119-130.	3.9	20
1647	Multi-parametric MRI in the early prediction of response to neo-adjuvant chemotherapy in breast cancer: Value of non-modelled parameters. European Journal of Radiology, 2016, 85, 837-842.	1.2	41
1648	Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinib. Lung Cancer, 2016, 93, 20-27.	0.9	2
1649	Fat suppression techniques for obtaining high resolution dynamic contrast enhanced bilateral breast MR images at 7 T. Magnetic Resonance Imaging, 2016, 34, 462-468.	1.0	4
1650	DCE-MRI and IVIM-MRI of rabbit Vx2 tumors treated with MR-HIFU-induced mild hyperthermia. Journal of Therapeutic Ultrasound, 2016, 4, 9.	2.2	14
1651	Magnetic Resonance Contrast Agents for Neuroradiology. , 2016, , 183-192.		0
1652	Neuroimaging. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 27-50.	1.0	6
1653	MRI Evaluation of Non-Necrotic T2-Hyperintense Foci in Pediatric Diffuse Intrinsic Pontine Glioma. American Journal of Neuroradiology, 2016, 37, 1930-1937.	1.2	7

#	Article	IF	CITATIONS
1654	Distributed capillary adiabatic tissue homogeneity model in parametric multiâ€channel blind AIF estimation using DCEâ€MRI. Magnetic Resonance in Medicine, 2016, 75, 1355-1365.	1.9	13
1655	Dynamic Contrastâ€Enhanced MRI in the Evaluation of Carotid Space Paraganglioma versus Schwannoma. Journal of Neuroimaging, 2016, 26, 618-625.	1.0	24
1656	Dynamic Contrastâ€Enhanced Magnetic Resonance Imaging Using Pharmacokinetic Modeling: Initial Experience in Patients With Early Arthritis. Arthritis and Rheumatology, 2016, 68, 587-596.	2.9	19
1657	Evaluating the Microcirculation of Normal Extraocular Muscles Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Journal of Computer Assisted Tomography, 2016, 40, 419-423.	0.5	3
1658	Assessment of Progression-Free-Survival in Glioblastomas by Intratreatment Dynamic Contrast-Enhanced MRI. Clinical Neuroradiology, 2016, 26, 39-45.	1.0	18
1659	Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results. Breast Cancer Research and Treatment, 2016, 155, 273-284.	1.1	35
1660	Feasibility of test-bolus DCE-MRI using CAIPIRINHA-VIBE for the evaluation of pancreatic malignancies. European Radiology, 2016, 26, 3949-3956.	2.3	14
1661	In vivo prostate cancer detection and grading using restriction spectrum imaging-MRI. Prostate Cancer and Prostatic Diseases, 2016, 19, 168-173.	2.0	16
1662	Application of Dynamic Contrast-Enhanced MRI Parameters for Differentiating Squamous Cell Carcinoma and Malignant Lymphoma of the Oropharynx. American Journal of Roentgenology, 2016, 206, 401-407.	1.0	34
1663	Human Papillomavirus and Epidermal Growth Factor Receptor in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma: Correlation With Dynamic Contrast-Enhanced MRI Parameters. American Journal of Roentgenology, 2016, 206, 408-413.	1.0	17
1664	Practical aspects of prostate MRI: hardware and software considerations, protocols, and patient preparation. Abdominal Radiology, 2016, 41, 817-830.	1.0	12
1665	Measurement of Tumor Hypoxia in Patients with Advanced Pancreatic Cancer Based on 18</sup>F-Fluoroazomyin Arabinoside Uptake">sup>18F-Fluoroazomyin Arabinoside Uptake . Journal of Nuclear Medicine, 2016, 57, 361-366.	2.8	42
1666	DCE-MRI of hepatocellular carcinoma: perfusion quantification with Tofts model versus shutter-speed model—initial experience. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2016, 29, 49-58.	1.1	24
1667	Assessment of Treatment Response With Diffusion-Weighted MRI and Dynamic Contrast-Enhanced MRI in Patients With Early-Stage Breast Cancer Treated With Single-Dose Preoperative Radiotherapy. Technology in Cancer Research and Treatment, 2016, 15, 651-660.	0.8	17
1668	Tracer kinetic modelling for DCE-MRI quantification of subtle blood–brain barrier permeability. Neurolmage, 2016, 125, 446-455.	2.1	138
1669	Prediction of low-risk breast cancer using perfusion parameters and apparent diffusion coefficient. Magnetic Resonance Imaging, 2016, 34, 67-74.	1.0	18
1670	Combining dynamic contrast enhanced magnetic resonance imaging and microvessel density to assess the angiogenesis after PEI in a rabbit VX2 liver tumor model. Magnetic Resonance Imaging, 2016, 34, 177-182.	1.0	17
1671	Bolus arrival time and its effect on tissue characterization with dynamic contrast-enhanced magnetic resonance imaging. Journal of Medical Imaging, 2016, 3, 014503.	0.8	10

#	Article	IF	CITATIONS
1672	Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. European Journal of Cancer, 2016, 59, 65-78.	1.3	26
1673	Improved Parameter-Estimation With MRI-Constrained PET Kinetic Modeling: A Simulation Study. IEEE Transactions on Nuclear Science, 2016, 63, 2464-2470.	1.2	2
1674	Permeability imaging in cerebrovascular diseases: applications and progress in research. Neurovascular Imaging, 2016, 2, .	2.4	6
1675	Perfusion Parameters in Dynamic Contrast-enhanced MRI and Apparent Diffusion Coefficient Value in Diffusion-weighted MRI:. Academic Radiology, 2016, 23, 446-456.	1.3	34
1676	Clinical Diagnostic Biomarkers from the Personalization of Computational Models of Cardiac Physiology. Annals of Biomedical Engineering, 2016, 44, 46-57.	1.3	7
1677	Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 449-456.	1.5	7
1678	Arterial input functions (AIFs) measured directly from arteries with low and standard doses of contrast agent, and AIFs derived from reference tissues. Magnetic Resonance Imaging, 2016, 34, 197-203.	1.0	18
1679	Assessment of Background Parenchymal Enhancement and Lesion Kinetics in Breast MRI of BRCA $1/2$ Mutation Carriers Compared to Matched Controls Using Quantitative Kinetic Analysis. Academic Radiology, 2016, 23, 358-367.	1.3	8
1680	Magnetic resonance imaging for prostate cancer radiotherapy. Physica Medica, 2016, 32, 446-451.	0.4	43
1681	Triple-phase contrast-enhanced MRI for the prediction of preoperative chemotherapeutic effect in patients with osteosarcoma: comparison with 99mTc-MIBI scintigraphy. Skeletal Radiology, 2016, 45, 87-95.	1.2	11
1682	Dynamic Contrast-Enhanced MR Imaging in Head and Neck Cancer: Techniques and Clinical Applications. American Journal of Neuroradiology, 2016, 37, 588-595.	1.2	90
1683	Magnetic Resonance Imaging: Advanced Applications in Breast Cancer. Current Radiology Reports, 2016, 4, 1.	0.4	0
1684	Multiparametric MRI of the anterior prostate gland: clinical–radiological–histopathological correlation. Clinical Radiology, 2016, 71, 405-417.	0.5	19
1685	Quantitative Multiparametric MRI Features and <i>PTEN</i> Expression of Peripheral Zone Prostate Cancer: A Pilot Study. American Journal of Roentgenology, 2016, 206, 559-565.	1.0	48
1686	Assessment of Prostate Cancer Aggressiveness by Use of the Combination of Quantitative DWI and Dynamic Contrast-Enhanced MRI. American Journal of Roentgenology, 2016, 206, 756-763.	1.0	56
1687	Intravoxel incoherent motion MR imaging for breast lesions: comparison and correlation with pharmacokinetic evaluation from dynamic contrast-enhanced MR imaging. European Radiology, 2016, 26, 3888-3898.	2.3	68
1688	Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters. European Radiology, 2016, 26, 4303-4312.	2.3	63
1689	The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth. Angiogenesis, 2016, 19, 229-244.	3.7	30

#	Article	IF	CITATIONS
1690	DCE MRI of prostate cancer. Abdominal Radiology, 2016, 41, 844-853.	1.0	56
1691	PCA-based groupwise image registration for quantitative MRI. Medical Image Analysis, 2016, 29, 65-78.	7.0	118
1692	Effect of Radiofrequency Transmit Field Correction on Quantitative Dynamic Contrast-enhanced MR Imaging of the Breast at 3.0 T. Radiology, 2016, 279, 368-377.	3.6	17
1693	Creating an anthropomorphic digital MR phantomâ€"an extensible tool for comparing and evaluating quantitative imaging algorithms. Physics in Medicine and Biology, 2016, 61, 974-982.	1.6	21
1694	Automatic ROI construction for analyzing time–signal intensity curve in dynamic contrast-enhanced MR imaging of the breast. Radiological Physics and Technology, 2016, 9, 30-36.	1.0	2
1695	Radiographic Imaging. , 2016, , 87-108.		0
1696	MR Imaging Biomarkers in Oncology Clinical Trials. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 11-29.	0.6	33
1697	Role of Multiparametric MR Imaging in Malignancies of the Urogenital Tract. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 187-204.	0.6	11
1698	Multiparametric MR Imaging of Breast Cancer. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 223-238.	0.6	90
1699	Multiparametric MR Imaging in Abdominal Malignancies. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 157-186.	0.6	26
1700	Monitoring Vascular Disrupting Therapy in a Rabbit Liver Tumor Model: Relationship between Tumor Perfusion Parameters at IVIM Diffusion-weighted MR Imaging and Those at Dynamic Contrast-enhanced MR Imaging. Radiology, 2016, 278, 104-113.	3.6	37
1701	Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma. Neuro-Oncology, 2016, 18, 467-478.	0.6	67
1702	Analysis of kinetic curve and model-based perfusion parameters on dynamic contrast enhanced MRI in breast cancer patients: Correlations with dominant stroma type. Magnetic Resonance Imaging, 2016, 34, 60-65.	1.0	17
1703	MRI findings of extranodal malignant lymphoma and squamous cell carcinoma in the head and neck regions. Oral Radiology, 2016, 32, 98-104.	0.9	5
1704	On the Use of DSC-MRI for Measuring Vascular Permeability. American Journal of Neuroradiology, 2016, 37, 80-87.	1.2	25
1705	Fitting the twoâ€compartment model in <scp>DCEâ€MRI</scp> by linear inversion. Magnetic Resonance in Medicine, 2016, 76, 998-1006.	1.9	23
1706	An efficient calculation method for pharmacokinetic parameters in brain permeability study using dynamic contrastâ€enhanced MRI. Magnetic Resonance in Medicine, 2016, 75, 739-749.	1.9	11
1707	Differentiation of Hemangioblastoma from Metastatic Brain Tumor using Dynamic Contrast-enhanced MR Imaging. Clinical Neuroradiology, 2017, 27, 329-334.	1.0	17

#	Article	IF	CITATIONS
1708	Are complex DCEâ€MRI models supported by clinical data?. Magnetic Resonance in Medicine, 2017, 77, 1329-1339.	1.9	40
1709	Contrast-Enhanced Ultrasound Angiogenesis Imaging by Mutual Information Analysis for Prostate Cancer Localization. IEEE Transactions on Biomedical Engineering, 2017, 64, 661-670.	2.5	23
1710	Dynamic contrast-enhanced and diffusion-weighted MRI of estrogen receptor-positive invasive breast cancers: Associations between quantitative MR parameters and Ki-67 proliferation status. Journal of Magnetic Resonance Imaging, 2017, 45, 94-102.	1.9	52
1711	3D Cartesian MRI with compressed sensing and variable view sharing using complementary poissonâ€disc sampling. Magnetic Resonance in Medicine, 2017, 77, 1774-1785.	1.9	36
1712	Clinical translation of ferumoxytolâ€based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population. Magnetic Resonance in Medicine, 2017, 77, 814-825.	1.9	11
1713	Quantification of tumor perfusion using dynamic contrast-enhanced ultrasound: impact of mathematical modeling. Physics in Medicine and Biology, 2017, 62, 1113-1125.	1.6	10
1714	Predicting prostate tumour location from multiparametric MRI using Gaussian kernel support vector machines: a preliminary study. Australasian Physical and Engineering Sciences in Medicine, 2017, 40, 39-49.	1.4	29
1715	Flow versus permeability weighting in estimating the forward volumetric transfer constant (Ktrans) obtained by DCE-MRI with contrast agents of differing molecular sizes. Magnetic Resonance Imaging, 2017, 36, 105-111.	1.0	7
1716	Functional MRI for quantitative treatment response prediction in locally advanced rectal cancer. British Journal of Radiology, 2017, 90, 20151078.	1.0	56
1717	Orbital benign and malignant lymphoproliferative disorders: Differentiation using semi-quantitative and quantitative analysis of dynamic contrast-enhanced magnetic resonance imaging. European Journal of Radiology, 2017, 88, 88-94.	1.2	23
1718	Reproducibility of dynamic contrast-enhanced MRI and dynamic susceptibility contrast MRI in the study of brain gliomas: a comparison of data obtained using different commercial software. Radiologia Medica, 2017, 122, 294-302.	4.7	23
1719	Intravoxel incoherent motion MRI in the brain: Impact of the fitting model on perfusion fraction and lesion differentiability. Journal of Magnetic Resonance Imaging, 2017, 46, 1187-1199.	1.9	32
1720	A continuousâ€infusion dynamic MRI model at 3.0 Tesla for the serial quantitative evaluation of microvascular proliferation in an animal model of glioblastoma multiforme. Magnetic Resonance in Medicine, 2017, 78, 1824-1838.	1.9	0
1721	Repeatability and response to therapy of dynamic contrast-enhanced magnetic resonance imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting. European Radiology, 2017, 27, 3662-3668.	2.3	20
1722	Assessment of micronecrotic tumor tissue using dynamic contrast-enhanced magnetic resonance imaging. Physica Medica, 2017, 34, 38-47.	0.4	4
1723	MR Imaging. Radiologic Clinics of North America, 2017, 55, 553-577.	0.9	7
1724	PET–MR Imaging in Head and Neck. Magnetic Resonance Imaging Clinics of North America, 2017, 25, 315-324.	0.6	8
1725	An extended vascular model for less biased estimation of permeability parameters in DCEâ€₹1 images. NMR in Biomedicine, 2017, 30, e3698.	1.6	12

#	Article	IF	CITATIONS
1726	Diffusionâ€compensated tofts model suggests contrast leakage through aneurysm wall. Magnetic Resonance in Medicine, 2017, 78, 2388-2398.	1.9	7
1727	Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer. European Radiology, 2017, 27, 3733-3743.	2.3	13
1728	Multiresolution imaging using golden angle stack-of-stars and compressed sensing for dynamic MR urography. Journal of Magnetic Resonance Imaging, 2017, 46, 303-311.	1.9	7
1729	Improved multiparametric MRI discrimination between lowâ€risk prostate cancer and benign tissues in a small cohort of 5αâ€reductase inhibitor treated individuals as compared with an untreated cohort. NMR in Biomedicine, 2017, 30, e3696.	1.6	11
1730	Molecular imaging and fusion targeted biopsy of the prostate. Clinical and Translational Imaging, 2017, 5, 29-43.	1.1	12
1731	Acute Temporal Changes of MRI-Tracked Tumor Vascular Parameters after Combined Anti-angiogenic and Radiation Treatments in a Rat Glioma Model: Identifying Signatures of Synergism. Radiation Research, 2017, 187, 79-88.	0.7	15
1732	Water Exchange Rate Constant as a Biomarker of Treatment Efficacy in Patients With Brain Metastases Undergoing Stereotactic Radiosurgery. International Journal of Radiation Oncology Biology Physics, 2017, 98, 47-55.	0.4	12
1733	An adaptive model for rapid and direct estimation of extravascular extracellular space in dynamic contrast enhanced MRI studies. NMR in Biomedicine, 2017, 30, e3682.	1.6	5
1734	Quantitative effects of acquisition duration and temporal resolution on the measurement accuracy of prostate dynamic contrast-enhanced MRI data: a phantom study. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2017, 30, 461-471.	1.1	8
1735	Understanding the Neurophysiology and Quantification of Brain Perfusion. Topics in Magnetic Resonance Imaging, 2017, 26, 57-65.	0.7	12
1736	Bone marrow perfusion measured with dynamic contrast enhanced magnetic resonance imaging is correlated to body mass index in adults. Bone, 2017, 99, 47-52.	1.4	12
1737	Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion. Cancer Research, 2017, 77, 3207-3216.	0.4	60
1738	Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits. Journal of Neuro-Oncology, 2017, 133, 155-163.	1.4	6
1739	Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential. Journal of Computer Assisted Tomography, 2017, 41, 823-827.	0.5	11
1740	Implications of neurovascular uncoupling in functional magnetic resonance imaging (fMRI) of brain tumors. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3475-3487.	2.4	77
1741	A Pilot Study Evaluating the Use of Dynamic Contrast-Enhanced Perfusion MRI to Predict Local Recurrence After Radiosurgery on Spinal Metastases. Technology in Cancer Research and Treatment, 2017, 16, 857-865.	0.8	37
1742	Towards intrinsic R2* imaging in the prostate at 3 and 7 tesla. Magnetic Resonance Imaging, 2017, 42, 16-21.	1.0	8
1743	The prognostic value of dynamic contrast-enhanced MRI contrast agent transfer constant Ktrans in cervical cancer is explained by plasma flow rather than vessel permeability. British Journal of Cancer, 2017, 116, 1436-1443.	2.9	25

#	Article	IF	CITATIONS
1744	Understanding <i>K</i> ^{trans} : a simulation study based on a multiple-pathway model. Physics in Medicine and Biology, 2017, 62, N297-N319.	1.6	3
1745	Biomarker comparison and selection for prostate cancer detection in Dynamic Contrast Enhanced-Magnetic Resonance Imaging (DCE-MRI). Chemometrics and Intelligent Laboratory Systems, 2017, 165, 38-45.	1.8	4
1746	Effects of arterial input function selection on kinetic parameters in brain dynamic contrast-enhanced MRI. Magnetic Resonance Imaging, 2017, 40, 83-90.	1.0	34
1747	Dynamic Contrast-enhanced MR Imaging Parameters in Bone Metastases from Non–Small Cell Lung Cancer: Comparison between Lesions with and Lesions without Epidermal Growth Factor Receptor Mutation in Primary Lung Cancer. Radiology, 2017, 284, 815-823.	3.6	14
1748	Reliable estimation of microvascular flow patterns in patients with disrupted blood–brain barrier using dynamic susceptibility contrast MRI. Journal of Magnetic Resonance Imaging, 2017, 46, 537-549.	1.9	13
1749	Increased robustness in reference region model analysis of <scp>DCE MRI</scp> using twoâ€step constrained approaches. Magnetic Resonance in Medicine, 2017, 78, 1547-1557.	1.9	2
1750	Role of pharmacokinetic parameters derived with high temporal resolution DCE MRI using simultaneous PET/MRI system in breast cancer: A feasibility study. European Journal of Radiology, 2017, 86, 261-266.	1.2	20
1751	Differentiation between Treatment-Induced Necrosis and Recurrent Tumors in Patients with Metastatic Brain Tumors: Comparison among ¹¹ C-Methionine-PET, FDG-PET, MR Permeability Imaging, and MRI-ADC—Preliminary Results. American Journal of Neuroradiology, 2017, 38, 1520-1527.	1.2	47
1752	Imaging Studies in Immunotherapy. , 2017, , 149-179.		1
1753	An Update on the Approach to the Imaging of Brain Tumors. Current Neurology and Neuroscience Reports, 2017, 17, 53.	2.0	11
1754	Prognostic Role of Conventional and Dynamic Contrastâ€Enhanced MRI in Optic Pathway Gliomas. Journal of Neuroimaging, 2017, 27, 594-601.	1.0	9
1755	Contrast-enhanced 3T MR Perfusion of Musculoskeletal Tumours: T1 Value Heterogeneity Assessment and Evaluation of the Influence of T1 Estimation Methods on Quantitative Parameters. European Radiology, 2017, 27, 4903-4912.	2.3	5
1756	Validation of Interstitial Fractional Volume Quantification by Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Porcine Skeletal Muscles. Investigative Radiology, 2017, 52, 66-73.	3.5	8
1757	Differential diagnosis of oligodendroglial and astrocytic tumors using imaging results: the added value of perfusion MR imaging. Neuroradiology, 2017, 59, 665-675.	1.1	11
1758	Chapter 8 On the Horizon: Advanced Imaging Techniques to Improve Noninvasive Assessment of Cervical Lymph Nodes. Seminars in Ultrasound, CT and MRI, 2017, 38, 542-556.	0.7	1
1759	Simultaneous measurement of <i>T</i> ₁ / <i>B</i> ₁ and pharmacokinetic model parameters using active contrast encoding (ACE)â€MRI. NMR in Biomedicine, 2017, 30, e3737.	1.6	7
1760	An empirical method for reducing variability and complexity of myocardial perfusion quantification by dual bolus cardiac MRI. Magnetic Resonance in Medicine, 2017, 77, 2347-2355.	1.9	4
1761	Repeatability of dose painting by numbers treatment planning in prostate cancer radiotherapy based on multiparametric magnetic resonance imaging. Physics in Medicine and Biology, 2017, 62, 5575-5588.	1.6	21

#	Article	IF	Citations
1762	T1-weighted dynamic contrast-enhanced brain magnetic resonance imaging: A preliminary study with low infusion rate in pediatric patients. Neuroradiology Journal, 2017, 30, 429-436.	0.6	3
1763	DCEâ€MRI prediction of survival time for patients with glioblastoma multiforme: using an adaptive neuroâ€fuzzyâ€based model and nested model selection technique. NMR in Biomedicine, 2017, 30, e3739.	1.6	16
1764	Assessment of pharmacokinetics for microvessel proliferation by DCE-MRI for early detection of physeal bone bridge formation in an animal model. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2017, 30, 417-427.	1.1	2
1765	Quantitative magnetic resonance imaging biomarkers in oncological clinical trials: Current techniques and standardization challenges. Chronic Diseases and Translational Medicine, 2017, 3, 8-20.	0.9	9
1766	Multiparametric approach with diffusion-weighted imaging and dynamic contrast-enhanced MRI: a comparison study for differentiating between benign and malignant bone lesions in adults. Clinical Radiology, 2017, 72, 552-559.	0.5	12
1767	Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI. Clinical Cancer Research, 2017, 23, 4233-4241.	3.2	33
1768	Dynamic Contrast-Enhanced Magnetic Resonance Enterography and Dynamic Contrast-Enhanced Ultrasonography in Crohn's Disease: An Observational Comparison Study. Ultrasound International Open, 2017, 03, E13-E24.	0.3	15
1769	Intravoxel incoherent motion diffusion-weighted magnetic resonance imaging of focal vertebral bone marrow lesions: initial experience of the differentiation of nodular hyperplastic hematopoietic bone marrow from malignant lesions. Skeletal Radiology, 2017, 46, 675-683.	1.2	28
1770	Value of Dynamic Contrast-enhanced and Diffusion-weighted MR Imaging in the Detection of Pathologic Complete Response in Cervical Cancer after Neoadjuvant Therapy: A Retrospective Observational Study. Radiology, 2017, 284, 432-442.	3.6	49
1771	Pharmacokinetic analysis and drug delivery efficiency of the focused ultrasound-induced blood-brain barrier opening in non-human primates. Magnetic Resonance Imaging, 2017, 37, 273-281.	1.0	26
1772	Perfusion Parameters on Breast Dynamic Contrast-Enhanced MRI Are Associated With Disease-Specific Survival in Patients With Triple-Negative Breast Cancer. American Journal of Roentgenology, 2017, 208, 687-694.	1.0	12
1773	Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in assessing glioblastoma microvasculature. European Journal of Radiology, 2017, 87, 120-124.	1.2	14
1774	Dynamic multi-echo DCE- and DSC-MRI in rectal cancer: Low primary tumor K ^{trans} and Î"R2* peak are significantly associated with lymph node metastasis. Journal of Magnetic Resonance Imaging, 2017, 46, 194-206.	1.9	21
1775	Multicenter validation of prostate tumor localization using multiparametric <scp>MRI</scp> and prior knowledge. Medical Physics, 2017, 44, 949-961.	1.6	23
1776	Dynamic contrast-enhanced magnetic resonance imaging of osseous spine metastasis before and 1 hour after high-dose image-guided radiation therapy. Neurosurgical Focus, 2017, 42, E9.	1.0	24
1777	Haematopoietic prolyl hydroxylase†deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis. Journal of Pathology, 2017, 241, 547-558.	2.1	32
1778	Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced–MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma. American Journal of Neuroradiology, 2017, 38, 485-491.	1.2	71
1779	Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. European Radiology, 2017, 27, 3069-3079.	2.3	18

#	Article	IF	Citations
1780	T2-weighted MRI-derived textural features reflect prostate cancer aggressiveness: preliminary results. European Radiology, 2017, 27, 3050-3059.	2.3	116
1781	Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study. European Radiology, 2017, 27, 3156-3166.	2.3	27
1782	Quantitative analysis of permeability for glioma grading using dynamic contrastâ€'enhanced magnetic resonance imaging. Oncology Letters, 2017, 14, 5418-5426.	0.8	25
1783	Assessment of Concurrent Stereotactic Radiosurgery and Bevacizumab Treatment of Recurrent Malignant Gliomas Using Multiparametric MRI Imaging and Radiomics Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 99, E734.	0.4	7
1784	Imaging Neoadjuvant Therapy Response in Breast Cancer. Radiology, 2017, 285, 358-375.	3.6	159
1785	Microcirculation at the supraspinatus tendon and shoulder external rotation explosive strength and fatigue are correlated. Isokinetics and Exercise Science, 2017, 25, 9-15.	0.2	0
1786	Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma. Journal of Computer Assisted Tomography, 2017, 41, 898-903.	0.5	23
1787	MR-Derived Biomarkers for Cancer Characterization. , 2017, , 409-431.		O
1788	Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity. Nature Communications, 2017, 8, 552.	5 . 8	24
1789	T1-Weighted Dynamic Contrast-Enhanced MR Perfusion Imaging Characterizes Tumor Response to Radiation Therapy in Chordoma. American Journal of Neuroradiology, 2017, 38, 2210-2216.	1.2	18
1790	MRI protocol optimization for quantitative DCE-MRI of the spine. Magnetic Resonance Imaging, 2017, 44, 96-103.	1.0	5
1791	Reproducibility and relative stability in magnetic resonance imaging indices of tumor vascular physiology over a period of 24 h in a rat 9L gliosarcoma model. Magnetic Resonance Imaging, 2017, 44, 131-139.	1.0	7
1792	Clinical pharmacology of anti-angiogenic drugs in oncology. Critical Reviews in Oncology/Hematology, 2017, 119, 75-93.	2.0	13
1793	A Multi-Institutional Comparison of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Parameter Calculations. Scientific Reports, 2017, 7, 11185.	1.6	29
1794	DCE―and DWâ€MRI as early imaging biomarkers of treatment response in a preclinical model of triple negative breast cancer. NMR in Biomedicine, 2017, 30, e3799.	1.6	17
1795	Molecular MR imaging of fibrosis in a mouse model of pancreatic cancer. Scientific Reports, 2017, 7, 8114.	1.6	30
1796	Contribution of Circulatory Disturbances in Subchondral Bone to the Pathophysiology of Osteoarthritis. Current Rheumatology Reports, 2017, 19, 49.	2.1	22
1797	Hypoxia in cervical cancer: from biology to imaging. Clinical and Translational Imaging, 2017, 5, 373-388.	1.1	40

#	Article	IF	CITATIONS
1798	T2*-Correction in Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Glioblastoma From a Half Dose of High-Relaxivity Contrast Agent. Journal of Computer Assisted Tomography, 2017, 41, 916-921.	0.5	5
1799	Quantitative dynamic contrast-enhanced magnetic resonance imaging in a VX2 rabbit liver tumour model using different gadolinium-based contrast agents: comparison of DCE-MRI quantitative results between Magnevist and Eovist. BJR case Reports, 2017, 3, 20160099.	0.1	2
1800	Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research, 2017, 23, 6062-6069.	3.2	7
1801	Ensemble of expert deep neural networks for spatio-temporal denoising of contrast-enhanced MRI sequences. Medical Image Analysis, 2017, 42, 145-159.	7.0	67
1802	Permeability Surface of Deep Middle Cerebral Artery Territory on Computed Tomographic Perfusion Predicts Hemorrhagic Transformation After Stroke. Stroke, 2017, 48, 2412-2418.	1.0	20
1803	A non-invasive magnetic resonance imaging approach for assessment of real-time microcirculation dynamics. Scientific Reports, 2017, 7, 7468.	1.6	17
1804	Comparison of region-of-interest-averaged and pixel-averaged analysis of DCE-MRI data based on simulations and pre-clinical experiments. Physics in Medicine and Biology, 2017, 62, N445-N459.	1.6	6
1805	Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform. British Journal of Cancer, 2017, 117, 791-800.	2.9	9
1806	Quantitative Methods in Abdominal MRI. Topics in Magnetic Resonance Imaging, 2017, 26, 251-258.	0.7	13
1807	Impact of hybrid PET/MR technology on multiparametric imaging and treatment response assessment of cervix cancer. Radiotherapy and Oncology, 2017, 125, 420-425.	0.3	25
1808	Integrated radiomic framework for breast cancer and tumor biology using advanced machine learning and multiparametric MRI. Npj Breast Cancer, 2017, 3, 43.	2.3	121
1809	Radiomic Phenotyping in Brain Cancer to Unravel Hidden Information in Medical Images. Topics in Magnetic Resonance Imaging, 2017, 26, 43-53.	0.7	32
1810	Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts. Acta Oncol \tilde{A}^3 gica, 2017, 56, 1754-1762.	0.8	22
1811	MR-guided radiation therapy: transformative technology and its role in the central nervous system. Neuro-Oncology, 2017, 19, ii16-ii29.	0.6	49
1812	Temporal evolution of perfusion parameters in brain metastases treated with stereotactic radiosurgery: comparison of intravoxel incoherent motion and dynamic contrast enhanced MRI. Journal of Neuro-Oncology, 2017, 135, 119-127.	1.4	8
1813	The potential of multiparametric MRI of the breast. British Journal of Radiology, 2017, 90, 20160715.	1.0	110
1814	Differentiation of focal indeterminate marrow abnormalities with multiparametric MRI. Journal of Magnetic Resonance Imaging, 2017, 46, 49-60.	1.9	21
1815	Quantification of antiangiogenic treatment effects on tissue heterogeneity in glioma tumour xenograft model using a combination of DCE-MRI and 3D-ultramicroscopy. European Radiology, 2017, 27, 2894-2902.	2.3	3

#	Article	IF	CITATIONS
1816	Image Processing and Analysis of PET and Hybrid PET Imaging., 2017,, 285-301.		O
1817	Evaluation of extracapsular extension in prostate cancer using qualitative and quantitative multiparametric MRI. Journal of Magnetic Resonance Imaging, 2017, 45, 1760-1770.	1.9	18
1818	Value of dynamic MRI using the Ktrans technique for assessment of native kidneys in pre-emptive renal transplantation. Acta Radiologica, 2017, 58, 1005-1011.	0.5	5
1819	Direct estimation of tracerâ€kinetic parameter maps from highly undersampled brain dynamic contrast enhanced MRI. Magnetic Resonance in Medicine, 2017, 78, 1566-1578.	1.9	42
1820	Brain capillary transit time heterogeneity in healthy volunteers measured by dynamic contrastâ€enhanced T ₁ â€weighted perfusion MRI. Journal of Magnetic Resonance Imaging, 2017, 45, 1809-1820.	1.9	16
1821	Correlation study between intravoxel incoherent motion MRI and dynamic contrast-enhanced MRI in head and neck squamous cell carcinoma: Evaluation in primary tumors and metastatic nodes. Magnetic Resonance Imaging, 2017, 37, 1-8.	1.0	16
1822	The association between histological, macroscopic and magnetic resonance imaging assessed synovitis in end-stage knee osteoarthritis: a cross-sectional study. Osteoarthritis and Cartilage, 2017, 25, 272-280.	0.6	31
1823	Dynamic contrast-enhanced MRI for automatic detection of foci i»¿of residual or recurrent disease after prostatectomy. Strahlentherapie Und Onkologie, 2017, 193, 13-21.	1.0	4
1824	Characterization of $\langle \sup 11 \rangle C$ -GSK1482160 for Targeting the P2X7 Receptor as a Biomarker for Neuroinflammation. Journal of Nuclear Medicine, 2017, 58, 458-465.	2.8	109
1825	Imaging Biomarkers. , 2017, , .		7
1826	B ₁ Field Correction of T1 Estimation Should Be Considered for Breast Dynamic Contrast-enhanced MR Imaging Even at 1.5 T. Radiology, 2017, 282, 55-62.	3.6	15
1827	Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model. European Radiology, 2017, 27, 2086-2094.	2.3	13
1828	Reduction of Longitudinal Vertebral Blood Perfusion and Its Likely Causes: A Quantitative Dynamic Contrast-enhanced MR Imaging Study of a Rat Osteoporosis Model. Radiology, 2017, 282, 369-380.	3.6	22
1829	Prostatic Tumors. , 2017, , 95-167.		0
1830	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	12.5	792
1831	Patterns of Vasculature in Mouse Models of Lung Cancer Are Dependent on Location. Molecular Imaging and Biology, 2017, 19, 215-224.	1.3	15
1832	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clinical Genitourinary Cancer, 2017, 15, 207-212.	0.9	10
1833	Quantitative diffusionâ€weighted imaging and dynamic contrastâ€enhanced characterization of the index lesion with multiparametric MRI in prostate cancer patients. Journal of Magnetic Resonance Imaging, 2017, 45, 908-916.	1.9	19

#	Article	IF	CITATIONS
1834	Antiâ€angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between micro–computed tomography angiography and dynamic contrast enhanced MRI. Magnetic Resonance in Medicine, 2017, 78, 1513-1522.	1.9	12
1835	Dynamic contrast-enhanced MRI of gastric cancer: Correlations of the pharmacokinetic parameters with histological type, Lauren classification, and angiogenesis. Magnetic Resonance Imaging, 2017, 37, 27-32.	1.0	31
1836	Quantifying Intracranial Plaque Permeability with Dynamic Contrast-Enhanced MRI: A Pilot Study. American Journal of Neuroradiology, 2017, 38, 243-249.	1.2	12
1837	Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck. British Journal of Cancer, 2017, 116, 28-35.	2.9	20
1838	Comparison of linear and nonlinear implementation of the compartmental tissue uptake model for dynamic contrast-enhanced MRI. Magnetic Resonance in Medicine, 2017, 77, 2414-2423.	1.9	13
1839	Parameter estimation of perfusion models in dynamic contrast-enhanced imaging: a unified framework for model comparison. Medical Image Analysis, 2017, 35, 360-374.	7.0	13
1840	Dynamic contrast-enhanced MRI of the prostate: An intraindividual assessment of the effect of temporal resolution on qualitative detection and quantitative analysis of histopathologically proven prostate cancer. Journal of Magnetic Resonance Imaging, 2017, 45, 1464-1475.	1.9	22
1841	Prognostic aspects of dynamic contrast-enhanced magnetic resonance imaging in synchronous distant metastatic rectal cancer. European Radiology, 2017, 27, 1840-1847.	2.3	20
1842	Automatic Approaches for CE-MRI Examination of the Breast: A Survey. , 2017, , .		2
1843	The value of DCE-MRI in assessing histopathological and molecular biological features in induced rat epithelial ovarian carcinomas. Journal of Ovarian Research, 2017, 10, 65.	1.3	7
1844	Influence of B1-Inhomogeneity on Pharmacokinetic Modeling of Dynamic Contrast-Enhanced MRI: A Simulation Study. Korean Journal of Radiology, 2017, 18, 585.	1.5	4
1845	Oxygen Enhanced Optoacoustic Tomography (OE-OT) Reveals Vascular Dynamics in Murine Models of Prostate Cancer. Theranostics, 2017, 7, 2900-2913.	4.6	83
1846	Quantification of Tumor Vascular Permeability and Blood Volume by Positron Emission Tomography. Theranostics, 2017, 7, 2363-2376.	4.6	23
1847	Automatic Detection and Quantitative DCE-MRI Scoring of Prostate Cancer Aggressiveness. Frontiers in Oncology, 2017, 7, 259.	1.3	12
1848	Quantitative Evaluation of Temporal Regularizers in Compressed Sensing Dynamic Contrast Enhanced MRI of the Breast. International Journal of Biomedical Imaging, 2017, 2017, 1-11.	3.0	10
1849	Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Regional Nodal Metastasis in Nasopharyngeal Carcinoma: Correlation with Nodal Staging. Contrast Media and Molecular Imaging, 2017, 2017, 1-6.	0.4	6
1850	Validation of Blood Volume Fraction Quantification with 3D Gradient Echo Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Porcine Skeletal Muscle. PLoS ONE, 2017, 12, e0170841.	1.1	20
1851	Magnetic resonance imaging of the hand and wrist in a randomized, double-blind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis: Comparison of dynamic contrast enhanced assessments with semi-quantitative scoring. PLoS ONE, 2017, 12, e0187397.	1.1	6

#	Article	IF	Citations
1852	High-permeability region size on perfusion CT predicts hemorrhagic transformation after intravenous thrombolysis in stroke. PLoS ONE, 2017, 12, e0188238.	1.1	15
1853	Evaluation of B1 inhomogeneity effect on DCE-MRI data analysis of brain tumor patients at 3T. Journal of Translational Medicine, 2017, 15, 242.	1.8	13
1854	Multiparametric magnetic resonance imaging in mucosal primary head and neck cancer: a prospective imaging biomarker study. BMC Cancer, 2017, 17, 475.	1.1	11
1855	Study protocol: multi-parametric magnetic resonance imaging for therapeutic response prediction in rectal cancer. BMC Cancer, 2017, 17, 465.	1.1	29
1856	Comparison of semi-quantitative and quantitative dynamic contrast-enhanced MRI evaluations of vertebral marrow perfusion in a rat osteoporosis model. BMC Musculoskeletal Disorders, 2017, 18, 446.	0.8	3
1857	Dynamics of angiogenesis and cellularity in rabbit VX2 tumors using contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging. Oncology Letters, 2018, 15, 2978-2984.	0.8	4
1858	Delineation of Tumor Habitats based on Dynamic Contrast Enhanced MRI. Scientific Reports, 2017, 7, 9746.	1.6	48
1859	Cancer Metabolism and Tumor Heterogeneity: Imaging Perspectives Using MR Imaging and Spectroscopy. Contrast Media and Molecular Imaging, 2017, 2017, 1-18.	0.4	39
1860	Intravoxel incoherent motion MR imaging in nasopharyngeal carcinoma: comparison and correlation with dynamic contrast enhanced MR imaging. Oncotarget, 2017, 8, 68472-68482.	0.8	11
1861	Accuracy of dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate cancer: systematic review and meta-analysis. Oncotarget, 2017, 8, 77975-77989.	0.8	10
1862	How Can New Imaging Modalities Help in the Practice of Radiology?. Eurasian Journal of Medicine, 2017, 48, 213-221.	0.2	21
1863	TumourMetrics: a comprehensive clinical solution for the standardization of DCE-MRI analysis in research and routine use. Quantitative Imaging in Medicine and Surgery, 2017, 7, 496-510.	1.1	10
1864	DCE-MRI Texture Features for Early Prediction of Breast Cancer Therapy Response. Tomography, 2017, 3, 23-32.	0.8	56
1865	Inhibition of astrocytic activity alleviates sequela in acute stages of intracerebral hemorrhage. Oncotarget, 2017, 8, 94850-94861.	0.8	24
1866	Estimating extraction fraction and blood flow by combining first-pass myocardial perfusion and T1 mapping results. Quantitative Imaging in Medicine and Surgery, 2017, 7, 480-495.	1.1	4
1867	Measurement of bloodâ€brain barrier permeability using dynamic contrastâ€enhanced magnetic resonance imaging with reduced scan time. Magnetic Resonance in Medicine, 2018, 80, 1686-1696.	1.9	7
1868	Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1205-1217.	3.3	35
1869	Imaging in neuro-oncology. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641875986.	1.5	41

#	Article	IF	CITATIONS
1870	Image-Guided Focused-Ultrasound CNS Molecular Delivery: An Implementation via Dynamic Contrast-Enhanced Magnetic-Resonance Imaging. Scientific Reports, 2018, 8, 4151.	1.6	14
1871	Novel Imaging Techniques in Rheumatic Diseases. Seminars in Musculoskeletal Radiology, 2018, 22, 237-244.	0.4	2
1872	Differentiating Atypical Hemangiomas and Metastatic Vertebral Lesions: The Role of T1-Weighted Dynamic Contrast-Enhanced MRI. American Journal of Neuroradiology, 2018, 39, 968-973.	1.2	49
1873	Dynamic magnetic resonance imaging of the breast: Comparison of gadobutrol vs. Gd-DTPA. Radiologia, 2018, 60, 49-56.	0.3	4
1874	Noninvasive prediction of portal pressure with MR elastography and DCEâ€MRI of the liver and spleen: Preliminary results. Journal of Magnetic Resonance Imaging, 2018, 48, 1091-1103.	1.9	33
1875	Dynamic contrast-enhanced (DCE) MRI derived kinetic perfusion indices may help predicting seizure control in single calcified neurocysticercosis. Magnetic Resonance Imaging, 2018, 49, 55-62.	1.0	4
1876	Quantifying bone structure, micro-architecture, and pathophysiology with MRI. Clinical Radiology, 2018, 73, 221-230.	0.5	17
1877	Multiparametric (mp) MRI of prostate cancer. Progress in Nuclear Magnetic Resonance Spectroscopy, 2018, 105, 23-40.	3.9	29
1878	The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib. European Radiology, 2018, 28, 2281-2290.	2.3	28
1879	Pilot study for supervised target detection applied to spatially registered multiparametric MRI in order to non-invasively score prostate cancer. Computers in Biology and Medicine, 2018, 94, 65-73.	3.9	12
1880	Meningioma assessment: Kinetic parameters in dynamic contrast-enhanced MRI appear independent from microvascular anatomy and VEGF expression. Journal of Neuroradiology, 2018, 45, 242-248.	0.6	7
1881	Brain Gliomas: Multicenter Standardized Assessment of Dynamic Contrast-enhanced and Dynamic Susceptibility Contrast MR Images. Radiology, 2018, 287, 933-943.	3.6	70
1882	Robust and efficient pharmacokinetic parameter non-linear least squares estimation for dynamic contrast enhanced MRI of the prostate. Magnetic Resonance Imaging, 2018, 48, 50-61.	1.0	8
1883	Resonancia magnética dinámica de mama: estudio comparativo de gadobutrol y Gd-DTPA. Radiologia, 2018, 60, 49-56.	0.3	5
1884	Assessment of the need for DCE MRI in the detection of dominant lesions in the whole gland: Correlation between histology and MRI of prostate cancer. NMR in Biomedicine, 2018, 31, e3882.	1.6	10
1885	Numerical Study of Transport of Anticancer Drugs in Heterogeneous Vasculature of Human Brain Tumors Using Dynamic Contrast Enhanced-Magnetic Resonance Imaging. Journal of Biomechanical Engineering, 2018, 140, .	0.6	14
1886	Improved Evaluation of Antivascular Cancer Therapy Using Constrained Tracer-Kinetic Modeling for Multiagent Dynamic Contrast-Enhanced MRI. Cancer Research, 2018, 78, 1561-1570.	0.4	12
1887	Correlation of dynamic contrastâ€enhanced MRI derived volume transfer constant with histological angiogenic markers in highâ€grade gliomas. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 464-470.	0.9	8

#	Article	IF	CITATIONS
1888	Performance of Ultrafast DCE-MRI for Diagnosis of Prostate Cancer. Academic Radiology, 2018, 25, 349-358.	1.3	28
1889	What Have We Learned from Perfusion MRI in Multiple Sclerosis?. American Journal of Neuroradiology, 2018, 39, 994-1000.	1.2	53
1890	Use of diffusion kurtosis imaging and quantitative dynamic contrastâ€enhanced MRI for the differentiation of breast tumors. Journal of Magnetic Resonance Imaging, 2018, 48, 1358-1366.	1.9	41
1891	Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium. Investigative Radiology, 2018, 53, 609-615.	3.5	19
1892	Interval Change in Diffusion and Perfusion MRI Parameters for the Assessment of Pseudoprogression in Cerebral Metastases Treated With Stereotactic Radiation. American Journal of Roentgenology, 2018, 211, 168-175.	1.0	29
1893	Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis. Magnetic Resonance in Medical Sciences, 2018, 17, 42-49.	1.1	21
1894	Multi-modal characterization of vasculature and nanoparticle accumulation in five tumor xenograft models. Journal of Controlled Release, 2018, 279, 292-305.	4.8	34
1895	Voxel-wise prostate cell density prediction using multiparametric magnetic resonance imaging and machine learning. Acta Oncol \hat{A}^3 gica, 2018, 57, 1540-1546.	0.8	19
1896	Dynamic contrast-enhanced MRI of orbital and anterior visual pathway lesions. Magnetic Resonance Imaging, 2018, 51, 44-50.	1.0	12
1897	ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models. Molecular Cancer Therapeutics, 2018, 17, 1039-1050.	1.9	35
1898	Variability induced by the MR imager in dynamic contrast-enhanced imaging of the prostate. Diagnostic and Interventional Imaging, 2018, 99, 255-264.	1.8	8
1899	A simulation study comparing nine mathematical models of arterial input function for dynamic contrast enhanced MRI to the Parker model. Australasian Physical and Engineering Sciences in Medicine, 2018, 41, 507-518.	1.4	7
1900	Real-time monitoring of tumor vascular disruption induced by radiofrequency assisted gadofullerene. Science China Materials, 2018, 61, 1101-1111.	3.5	11
1901	Perfusion MR imaging at 3-Tesla: Can it predict tumor grade and histologic necrosis rate of musculoskeletal sarcoma?. Diagnostic and Interventional Imaging, 2018, 99, 473-481.	1.8	12
1902	A DCE-MRI Driven 3-D Reaction-Diffusion Model of Solid Tumor Growth. IEEE Transactions on Medical Imaging, 2018, 37, 724-732.	5.4	37
1903	Propagation of error from parameter constraints in quantitative MRI: Example application of multiple spin echo <i>T</i> ₂ mapping. Magnetic Resonance in Medicine, 2018, 79, 673-682.	1.9	8
1904	Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion. Clinical Neuroradiology, 2018, 28, 421-428.	1.0	52
1905	Response assessment of stereotactic body radiation therapy using dynamic contrastâ€enhanced integrated MRâ€PET in nonâ€small cell lung cancer patients. Journal of Magnetic Resonance Imaging, 2018, 47, 191-199.	1.9	19

#	Article	IF	Citations
1906	Parameter estimation using weighted total least squares in the twoâ€compartment exchange model. Magnetic Resonance in Medicine, 2018, 79, 561-567.	1.9	2
1907	Modeling Dynamic Contrast-Enhanced MRI Data with a Constrained Local AIF. Molecular Imaging and Biology, 2018, 20, 150-159.	1.3	5
1908	A oneâ€step biomarker quantification methodology for DCEâ€MRI of adnexal masses: Capturing kinetic pattern from early to late enhancement. Magnetic Resonance in Medicine, 2018, 79, 1165-1171.	1.9	5
1909	Review of dynamic contrastâ€enhanced MRI: Technical aspects and applications in the musculoskeletal system. Journal of Magnetic Resonance Imaging, 2018, 47, 875-890.	1.9	51
1910	Dynamic Contrast-Enhanced MR Imaging in Head and Neck Cancer. Magnetic Resonance Imaging Clinics of North America, 2018, 26, 135-149.	0.6	21
1911	Early posttreatment assessment of MRI perfusion biomarkers can predict long-term response of lung cancer brain metastases to stereotactic radiosurgery. Neuro-Oncology, 2018, 20, 567-575.	0.6	27
1912	Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-Oncology, 2018, 20, 184-191.	0.6	443
1913	Differentiating between benign and malignant sinonasal lesions using dynamic contrast-enhanced MRI and intravoxel incoherent motion. European Journal of Radiology, 2018, 98, 7-13.	1.2	16
1914	Semi-parametric arterial input functions for quantitative dynamic contrast enhanced magnetic resonance imaging in mice. Magnetic Resonance Imaging, 2018, 46, 10-20.	1.0	3
1915	Quantitative free-breathing dynamic contrast-enhanced MRI in hepatocellular carcinoma using gadoxetic acid: correlations with Ki67 proliferation status, histological grades, and microvascular density. Abdominal Radiology, 2018, 43, 1393-1403.	1.0	24
1916	Combined ¹⁸ F-Fluciclovine PET/MRI Shows Potential for Detection and Characterization of High-Risk Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 762-768.	2.8	27
1917	Multiparametric MRI for Differentiation of Radiation Necrosis From Recurrent Tumor in Patients With Treated Glioblastoma. American Journal of Roentgenology, 2018, 210, 18-23.	1.0	56
1918	Differentiation of grade II and III oligodendrogliomas from grade II and III astrocytomas: a histogram analysis of perfusion parameters derived from dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) MRI. Acta Radiologica, 2018, 59, 723-731.	0.5	16
1919	Discrimination between benign and malignant breast lesions using volumetric quantitative dynamic contrast-enhanced MR imaging. European Radiology, 2018, 28, 982-991.	2.3	24
1920	A novel framework for evaluating the image accuracy of dynamic MRI and the application on accelerated breast DCE MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2018, 31, 309-320.	1.1	1
1921	Dynamic contrastâ€enhanced MRI in orbital lymphoproliferative disorders: Effects of region of interest selection methods on time efficiency, measurement reproducibility, and diagnostic ability. Journal of Magnetic Resonance Imaging, 2018, 47, 1298-1305.	1.9	11
1922	A Survey on Multimodal Medical Data Visualization. Computer Graphics Forum, 2018, 37, 413-438.	1.8	39
1923	Magnetic Resonance Imaging (MRI). , 2018, , 51-83.		0

#	Article	IF	CITATIONS
1924	MRI measurements of Blood-Brain Barrier function in dementia: A review of recent studies. Neuropharmacology, 2018, 134, 259-271.	2.0	108
1925	Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 759-767.	3.3	35
1926	Quantitating whole lesion tumor biology in rectal cancer MRI: taking a lesson from FDG-PET tumor metrics. Abdominal Radiology, 2018, 43, 1575-1582.	1.0	5
1927	Linearization improves the repeatability of quantitative dynamic contrast-enhanced MRI. Magnetic Resonance Imaging, 2018, 47, 16-24.	1.0	11
1928	Dynamic Contrast-Enhanced MRI–Derived Intracellular Water Lifetime (݄i): A Prognostic Marker for Patients with Head and Neck Squamous Cell Carcinomas. American Journal of Neuroradiology, 2018, 39, 138-144.	1.2	24
1929	Quantitative Evaluation of Vertebral Microvascular Permeability and Fat Fraction in Alloxan-induced Diabetic Rabbits. Radiology, 2018, 287, 128-136.	3.6	25
1930	Clinical role of breast MRI now and going forward. Clinical Radiology, 2018, 73, 700-714.	0.5	83
1931	Spatiotemporal features of DCE-MRI for breast cancer diagnosis. Computer Methods and Programs in Biomedicine, 2018, 155, 153-164.	2.6	31
1932	Rectal perfusion parameters normalised to tumour-free rectal wall can predict response to neoadjuvant chemoradiotherapy. Clinical Radiology, 2018, 73, 151-157.	0.5	4
1933	Estimating the arterial input function from dynamic contrastâ€enhanced MRI data with compensation for flow enhancement (II): Applications in spine diagnostics and assessment of crohn's disease. Journal of Magnetic Resonance Imaging, 2018, 47, 1197-1204.	1.9	4
1934	The effects of intravoxel contrast agent diffusion on the analysis of DCEâ€MRI data in realistic tissue domains. Magnetic Resonance in Medicine, 2018, 80, 330-340.	1.9	8
1935	Evaluation of dynamic contrast-enhanced MRI biomarkers for stratified cancer medicine: How do permeability and perfusion vary between human tumours?. Magnetic Resonance Imaging, 2018, 46, 98-105.	1.0	20
1936	Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Acta Radiologica, 2018, 59, 1010-1017.	0.5	33
1937	Role of magnetic resonance imaging in the management of perianal Crohn's disease. Insights Into Imaging, 2018, 9, 47-58.	1.6	13
1938	Histogram analysis of T2*-based pharmacokinetic imaging in cerebral glioma grading. Computer Methods and Programs in Biomedicine, 2018, 155, 19-27.	2.6	5
1939	Assessment of the zonal variation of perfusion parameters in the femoral head: a 3-T dynamic contrast-enhanced MRI pilot study. Skeletal Radiology, 2018, 47, 261-270.	1.2	5
1940	Fatâ€based registration of breast dynamic contrast enhanced water images. Magnetic Resonance in Medicine, 2018, 79, 2408-2414.	1.9	1
1941	Vessel wall characterization using quantitative MRI: what's in a number?. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2018, 31, 201-222.	1.1	35

#	ARTICLE	IF	CITATIONS
1942	Intravoxel Incoherent Motion Diffusion-Weighted Imaging Versus Dynamic Contrast-Enhanced Magnetic Resonance Imaging: Comparison of the Diagnostic Performance of Perfusion-Related Parameters in Breast. Journal of Computer Assisted Tomography, 2018, 42, 6-11.	0.5	12
1943	Dynamic contrast-enhanced magnetic resonance imaging may act as a biomarker for vascular damage in normal appearing brain tissue after radiotherapy in patients with glioblastoma. Acta Radiologica Open, 2018, 7, 205846011880881.	0.3	6
1944	Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Scientific Reports, 2018, 8, 17062.	1.6	11
1946	CRF-Based Clustering of Pharmacokinetic Curves from Dynamic Contrast-Enhanced MR Images. , 2018, , .		0
1947	Detectability of radiation-induced changes in magnetic resonance biomarkers following stereotactic radiosurgery: A pilot study. PLoS ONE, 2018, 13, e0207933.	1.1	5
1948	Feasibility study of dual parametric 2D histogram analysis of breast lesions with dynamic contrast-enhanced and diffusion-weighted MRI. Journal of Translational Medicine, 2018, 16, 325.	1.8	8
1949	Metabolic Volumetric Parameters in 11C-Choline PET/MR Are Superior PET Imaging Biomarkers for Primary High-Risk Prostate Cancer. Contrast Media and Molecular Imaging, 2018, 2018, 1-10.	0.4	11
1950	6 Abbreviated Breast Magnetic Resonance Imaging Protocols and Clinical Implementation. , 2018, , .		0
1951	Role of perfusion parameters on DCE-MRI and ADC values on DWMRI for invasive ductal carcinoma at 3.0 Tesla. World Journal of Surgical Oncology, 2018, 16, 239.	0.8	25
1952	Investigating the correlation of arterial spin labeling and dynamic contrast enhanced perfusion in primary tumor of nasopharyngeal carcinoma. European Journal of Radiology, 2018, 108, 222-229.	1.2	19
1953	The potential for remodelling the tumour vasculature in glioblastoma. Advanced Drug Delivery Reviews, 2018, 136-137, 49-61.	6.6	15
1954	<i>In vitro</i> pharmacokinetic phantom for two-compartment modeling in DCE-MRI. Physics in Medicine and Biology, 2018, 63, 205012.	1.6	1
1955	Radiation-induced parotid changes in oropharyngeal cancer patients: the role of early functional imaging and patientâ°/treatment-related factors. Radiation Oncology, 2018, 13, 189.	1.2	27
1956	Evaluation of Dispersion MRI for Improved Prostate Cancer Diagnosis in a Multicenter Study. American Journal of Roentgenology, 2018, 211, W242-W251.	1.0	7
1957	Monocyte and Macrophage Dynamics in the Cardiovascular System. Journal of the American College of Cardiology, 2018, 72, 2198-2212.	1,2	47
1958	Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage. Contrast Media and Molecular Imaging, 2018, 2018, 1-7.	0.4	11
1959	The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1219-1235.	0.4	30
1960	Blood-Brain Barrier Permeability in Aneurysmal Subarachnoid Hemorrhage: Correlation With Clinical Outcomes. American Journal of Roentgenology, 2018, 211, 891-895.	1.0	22

#	Article	IF	Citations
1961	Histogram Analysis of Perfusion Parameters from Dynamic Contrast-Enhanced MR Imaging with Tumor Characteristics and Therapeutic Response in Locally Advanced Rectal Cancer. BioMed Research International, 2018, 2018, 1-9.	0.9	14
1962	Texture features and pharmacokinetic parameters in differentiating benign and malignant breast lesions by dynamic contrast enhanced magnetic resonance imaging. Oncology Letters, 2018, 16, 4607-4613.	0.8	13
1963	Dynamic contrast-enhanced MRI perfusion of normal muscle in adult hips: Variation of permeability and semi-quantitative parameters. European Journal of Radiology, 2018, 108, 92-98.	1.2	4
1964	Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer. European Radiology, 2018, 28, 4860-4870.	2.3	9
1965	Accuracy and precision of quantitative DCE-MRI parameters: How should one estimate contrast concentration?. Magnetic Resonance Imaging, 2018, 52, 16-23.	1.0	22
1966	Modeling hyperoxia-induced BOLD signal dynamics to estimate cerebral blood flow, volume and mean transit time. Neurolmage, 2018, 178, 461-474.	2.1	25
1967	Investigating the role of functional imaging in the management of soft-tissue sarcomas of the extremities. Physics and Imaging in Radiation Oncology, 2018, 6, 53-60.	1.2	4
1968	Advanced magnetic resonance imaging (MRI) techniques of the spine and spinal cord in children and adults. Insights Into Imaging, 2018, 9, 549-557.	1.6	29
1969	In vivo MR in the drug pipeline. Journal of Magnetic Resonance, 2018, 292, 117-128.	1.2	4
1970	Correlation of human papilloma virus status with quantitative perfusion/diffusion/metabolic imaging parameters in the oral cavity and oropharyngeal squamous cell carcinoma: comparison of primary tumour sites and metastatic lymph nodes. Clinical Radiology, 2018, 73, 757.e21-757.e27.	0.5	17
1971	DCE-MRI of Sunitinib-Induced Changes in Tumor Microvasculature and Hypoxia: A Study of Pancreatic Ductal Adenocarcinoma Xenografts. Neoplasia, 2018, 20, 734-744.	2.3	18
1972	A light-fluence-independent method for the quantitative analysis of dynamic contrast-enhanced multispectral optoacoustic tomography (DCE MSOT). Photoacoustics, 2018, 10, 54-64.	4.4	21
1973	The Role of Advanced Brain Tumor Imaging in the Care of Patients with Central Nervous System Malignancies. Current Treatment Options in Oncology, 2018, 19, 40.	1.3	7
1974	Preoperative dynamic breast magnetic resonance imaging kinetic features using computer-aided diagnosis: Association with survival outcome and tumor aggressiveness in patients with invasive breast cancer. PLoS ONE, 2018, 13, e0195756.	1.1	19
1975	Imaging biomarkers in oncology: Basics and application to MRI. Journal of Magnetic Resonance Imaging, 2018, 48, 13-26.	1.9	39
1976	MRI Study on the Changes of Bone Marrow Microvascular Permeability and Fat Content after Total-Body X-Ray Irradiation. Radiation Research, 2018, 189, 205-212.	0.7	7
1977	Role of Magnetic Resonance in Drug Development. , 2018, , 199-218.		0
1978	Multi-parameter MRI to investigate vasculature modulation and photo-thermal ablation combination therapy against cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 2179-2189.	1.7	4

#	Article	IF	Citations
1979	Fast Temporal Resolution Dynamic Contrast-Enhanced MRI: Histogram Analysis Versus Visual Analysis for Differentiating Benign and Malignant Breast Lesions. American Journal of Roentgenology, 2018, 211, 933-939.	1.0	15
1980	Application of a Simplified Method for Estimating Perfusion Derived from Diffusion-Weighted MR Imaging in Glioma Grading. Frontiers in Aging Neuroscience, 2017, 9, 432.	1.7	27
1981	Combining Perfusion and High B-value Diffusion MRI to Inform Prognosis and Predict Failure Patterns in Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2018, 102, 757-764.	0.4	16
1982	Impact of contrast agent injection duration on dynamic contrastâ€enhanced MRI quantification in prostate cancer. NMR in Biomedicine, 2018, 31, e3946.	1.6	4
1983	Blood-Brain Barrier Disruption and Perivascular Beta-Amyloid Accumulation in the Brain of Aged Rats with Spontaneous Hypertension: Evaluation with Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Korean Journal of Radiology, 2018, 19, 498.	1.5	22
1984	A Supervised Learning Tool for Prostate Cancer Foci Detection and Aggressiveness Identification using Multiparametric magnetic resonance imaging/magnetic resonance spectroscopy imaging. Cancer Informatics, 2018, 17, 117693511878626.	0.9	3
1985	Clinical Value of Vascular Permeability Estimates Using Dynamic Susceptibility Contrast MRI: Improved Diagnostic Performance in Distinguishing Hypervascular Primary CNS Lymphoma from Glioblastoma. American Journal of Neuroradiology, 2018, 39, 1415-1422.	1.2	10
1986	Image-guided chemotherapy with specifically tuned blood brain barrier permeability in glioma margins. Theranostics, 2018, 8, 3126-3137.	4.6	50
1987	Could perfusion heterogeneity at dynamic contrast-enhanced MRI be used to predict rectal cancer sensitivity to chemoradiotherapy?. Clinical Radiology, 2018, 73, 911.e1-911.e7.	0.5	13
1988	Early Prediction of Response to Neoadjuvant Chemotherapy Using Dynamic Contrast-Enhanced MRI and Ultrasound in Breast Cancer. Korean Journal of Radiology, 2018, 19, 682.	1.5	44
1989	Dynamic glucose enhanced MRI of the placenta in a mouse model of intrauterine inflammation. Placenta, 2018, 69, 86-91.	0.7	9
1990	Incorporating drug delivery into an imaging-driven, mechanics-coupled reaction diffusion model for predicting the response of breast cancer to neoadjuvant chemotherapy: theory and preliminary clinical results. Physics in Medicine and Biology, 2018, 63, 105015.	1.6	41
1991	Pseudoprogression of brain tumors. Journal of Magnetic Resonance Imaging, 2018, 48, 571-589.	1.9	199
1992	An extended reference region model for DCEâ€MRI that accounts for plasma volume. NMR in Biomedicine, 2018, 31, e3924.	1.6	8
1993	Late normal tissue response in the rat spinal cord after carbon ion irradiation. Radiation Oncology, 2018, 13, 5.	1.2	18
1994	Contouring of prostate tumors on multiparametric MRI: Evaluation of clinical delineations in a multicenter radiotherapy trial. Radiotherapy and Oncology, 2018, 128, 321-326.	0.3	36
1995	Use of Diffusional Kurtosis Imaging and Dynamic Contrast-Enhanced MR Imaging to Predict Posttraumatic Epilepsy in Rabbits. American Journal of Neuroradiology, 2018, 39, 1068-1073.	1.2	3
1996	Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma. PLoS ONE, 2018, 13, e0202387.	1.1	15

#	Article	IF	CITATIONS
1997	Applying dynamic contrast enhanced MSOT imaging to intratumoral pharmacokinetic modeling. Photoacoustics, 2018, 11, 28-35.	4.4	11
1998	A novel approach to monitoring the efficacy of anti-tumor treatments in animal models: combining functional MRI and texture analysis. BMC Cancer, 2018, 18, 833.	1.1	3
1999	Cluster versus ROI analysis to assess combined antiangiogenic therapy and radiotherapy in the F98 ratâ€glioma model. NMR in Biomedicine, 2018, 31, e3933.	1.6	6
2000	Dynamic MRI reconstruction from undersampled data with an anatomical prescan. Inverse Problems, 2018, 34, 074001.	1.0	16
2001	Influence of arterial input function (AIF) on quantitative prostate dynamic contrast-enhanced (DCE) MRI and zonal prostate anatomy. Magnetic Resonance Imaging, 2018, 53, 28-33.	1.0	12
2002	Grading of pancreatic neuroendocrine neoplasms using pharmacokinetic parameters derived from dynamic contrastâ€enhanced MRI. Oncology Letters, 2018, 15, 8349-8356.	0.8	9
2003	Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiating Between Primary Tumor, Metastatic Node and Normal Tissue in Head and Neck Cancer. Current Medical Imaging, 2018, 14, 416-421.	0.4	10
2004	Can dynamic contrast-enhanced MRI evaluate VEGF expression in brain glioma? An MRI-guided stereotactic biopsy study. Journal of Neuroradiology, 2019, 46, 186-192.	0.6	18
2005	Rapid dynamic contrastâ€enhanced <scp>MRI</scp> for small animals at 7 <scp>T</scp> using 3 <scp>D</scp> ultraâ€short echo time and goldenâ€angle radial sparse parallel <scp>MRI</scp> . Magnetic Resonance in Medicine, 2019, 81, 140-152.	1.9	21
2006	Multiparametric MRI Characterization of Funaki Types of Uterine Fibroids Considered for MR-Guided High-Intensity Focused Ultrasound (MR-HIFU) Therapy. Academic Radiology, 2019, 26, e9-e17.	1.3	10
2007	Quantitative dynamic contrast-enhanced MR imaging shows widespread blood-brain barrier disruption in mild traumatic brain injury patients with post-concussion syndrome. European Radiology, 2019, 29, 1308-1317.	2.3	26
2008	Histogram analysis of dynamic contrast-enhanced magnetic resonance imaging for differentiating malignant from benign orbital lymphproliferative disorders. Acta Radiologica, 2019, 60, 239-246.	0.5	10
2009	DCE-MR imaging of orbital lesions: diagnostic performance of the tumor flow residence time Ï,, calculated by a multi-compartmental pharmacokinetic tumor model based on individual factors. Acta Radiologica, 2019, 60, 643-652.	0.5	12
2010	Perfusion-sensitive parameters of intravoxel incoherent motion MRI in rectal cancer: evaluation of reproducibility and correlation with dynamic contrast-enhanced MRI. Acta Radiologica, 2019, 60, 569-577.	0.5	12
2011	Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle. Clinical Pharmacology and Therapeutics, 2019, 106, 148-163.	2.3	60
2012	A correlative study between diffusion and perfusion MR imaging parameters on peripheral arterial disease data. Magnetic Resonance Imaging, 2019, 55, 26-35.	1.0	10
2013	Imaging vascular and hemodynamic features of the brain using dynamic susceptibility contrast and dynamic contrast enhanced MRI. Neurolmage, 2019, 187, 32-55.	2.1	45
2014	Reliability of dynamic contrast-enhanced magnetic resonance imaging data in primary brain tumours: a comparison of Tofts and shutter speed models. Neuroradiology, 2019, 61, 1375-1386.	1.1	11

#	Article	IF	CITATIONS
2015	Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. Theranostics, 2019, 9, 5085-5104.	4.6	29
2016	A multiparametric analysis based on DCE-MRI to improve the accuracy of parotid tumor discrimination. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2228-2234.	3.3	34
2017	Spatially regularized estimation of the tissue homogeneity model parameters in DCEâ€MRI using proximal minimization. Magnetic Resonance in Medicine, 2019, 82, 2257-2272.	1.9	2
2018	Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nature Communications, 2019, 10, 3170.	5.8	113
2019	Stateâ€ofâ€theâ€Art Report: Visual Computing in Radiation Therapy Planning. Computer Graphics Forum, 2019, 38, 753-779.	1.8	9
2020	Monitoring radiotherapy induced tissue changes in localized prostate cancer by multi-parametric magnetic resonance imaging (MP-MRI). Diagnostic and Interventional Imaging, 2019, 100, 699-708.	1.8	7
2021	In vivo magnetic resonance imaging and spectroscopy. Technological advances and opportunities for applications continue to abound. Journal of Magnetic Resonance, 2019, 306, 55-65.	1,2	10
2022	Estimation of cellularâ€interstitial water exchange in dynamic contrast enhanced MRI using two flip angles. NMR in Biomedicine, 2019, 32, e4135.	1.6	10
2023	Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Brain Tumors., 2019,, 405-428.		0
2024	Applications of Neuroimaging Biomarkers in CNS Drug Development. Handbook of Behavioral Neuroscience, 2019, , 115-158.	0.7	0
2025	Use of Indicator Dilution Principle to Evaluate Accuracy of Arterial Input Function Measured With Low-Dose Ultrafast Prostate Dynamic Contrast-Enhanced MRI. Tomography, 2019, 5, 260-265.	0.8	1
2026	Localized Blood–Brain Barrier Opening in Ovine Model Using Image-Guided Transcranial Focused Ultrasound. Ultrasound in Medicine and Biology, 2019, 45, 2391-2404.	0.7	20
2027	Classification of Breast Lesions Using Quantitative Dynamic Contrast Enhanced-MRI. Lecture Notes in Computer Science, 2019, , 108-119.	1.0	1
2028	On Computer-Aided Diagnosis of Prostate Cancer from MRI using Machine Intelligence Techniques. , 2019, , .		0
2029	Assessing Microcirculation in Resectable Oesophageal Squamous Cell Carcinoma with Dynamic Contrast-enhanced MRI for Identifying Primary tumour and Lymphatic Metastasis. Scientific Reports, 2019, 9, 124.	1.6	4
2030	Non-invasive MR assessment of the microstructure and microcirculation in regional lymph nodes for rectal cancer: a study of intravoxel incoherent motion imaging. Cancer Imaging, 2019, 19, 70.	1.2	6
2031	Evaluating differential nanoparticle accumulation and retention kinetics in a mouse model of traumatic brain injury via Ktrans mapping with MRI. Scientific Reports, 2019, 9, 16099.	1.6	21
2032	The Utility of Diffusion-Weighted Imaging and Perfusion Magnetic Resonance Imaging Parameters for Detecting Clinically Significant Prostate Cancer. Canadian Association of Radiologists Journal, 2019, 70, 441-451.	1.1	1

#	ARTICLE	IF	CITATIONS
2033	Does Moxa Smoke Have Significant Effect on the Acupuncturist's Respiratory System? A Population-Based Study. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-10.	0.5	8
2034	3-D Microwave Tomography Using the Soft Prior Regularization Technique: Evaluation in Anatomically Realistic MRI-Derived Numerical Breast Phantoms. IEEE Transactions on Biomedical Engineering, 2019, 66, 2566-2575.	2.5	30
2035	Bayesian pharmacokinetic modeling of dynamic contrast-enhanced magnetic resonance imaging: validation and application. Physics in Medicine and Biology, 2019, 64, 18NT02.	1.6	6
2036	Blood-Brain Barrier Permeability in Patients with Systemic Lupus Erythematosus. American Journal of Neuroradiology, 2019, 40, E41-E41.	1.2	0
2037	Do DWI and quantitative DCE perfusion MR have a prognostic value in high-grade serous ovarian cancer?. Radiologia Medica, 2019, 124, 1315-1323.	4.7	7
2038	Multiparametric MRI Tumor Probability Model for the Detection of Locally Recurrent Prostate Cancer After Radiation Therapy: Pathologic Validation and Comparison With Manual Tumor Delineations. International Journal of Radiation Oncology Biology Physics, 2019, 105, 140-148.	0.4	7
2039	Imaging Tumor Angiogenesis. , 2019, , 277-290.		1
2040	Diagnostic performance of diffusionâ€weighted (DWI) and dynamic contrastâ€enhanced (DCE) MRI for the differentiation of benign from malignant softâ€issue tumors. Journal of Magnetic Resonance Imaging, 2019, 50, 798-809.	1.9	41
2041	Blood-brain barrier at the interface of air pollution-associated neurotoxicity and neuroinflammation. Advances in Neurotoxicology, 2019, , 295-337.	0.7	3
2042	Dynamics of blood brain barrier permeability and tissue microstructure following controlled cortical impact injury in rat: A dynamic contrast-enhanced magnetic resonance imaging and diffusion kurtosis imaging study. Magnetic Resonance Imaging, 2019, 62, 1-9.	1.0	14
2043	MRI biomarkers in osseous tumors. Journal of Magnetic Resonance Imaging, 2019, 50, 702-718.	1.9	14
2044	Convolutional Neural Networks for Direct Inference of Pharmacokinetic Parameters: Application to Stroke Dynamic Contrast-Enhanced MRI. Frontiers in Neurology, 2018, 9, 1147.	1.1	43
2046	Improved repeatability of dynamic contrastâ€enhanced MRI using the complex MRI signal to derive arterial input functions: a testâ€retest study in prostate cancer patients. Magnetic Resonance in Medicine, 2019, 81, 3358-3369.	1.9	10
2047	Advanced Magnetic Resonance Imaging Techniques in Management of Brain Metastases. Frontiers in Oncology, 2019, 9, 440.	1.3	42
2048	A compact solution for estimation of physiological parameters from ultrafast prostate dynamic contrast enhanced MRI. Physics in Medicine and Biology, 2019, 64, 155012.	1.6	3
2049	3D nonrigid motion correction for quantitative assessment of hepatic lesions in DCEâ€MRI. Magnetic Resonance in Medicine, 2019, 82, 1753-1766.	1.9	14
2050	Imaging of Central Nervous System Tumors. , 2019, , 111-142.		0
2052	Association between high-resolution MRI-detected extramural vascular invasion and tumour microcirculation estimated by dynamic contrast-enhanced MRI in rectal cancer: preliminary results. BMC Cancer, 2019, 19, 498.	1.1	20

#	Article	IF	CITATIONS
2053	Monitoring tumour microenvironment changes during anti-angiogenesis therapy using functional MRI. Angiogenesis, 2019, 22, 457-470.	3.7	43
2054	Basic concepts and applications of functional magnetic resonance imaging for radiotherapy of prostate cancer. Physics and Imaging in Radiation Oncology, 2019, 9, 50-57.	1.2	10
2055	DCEâ€MRI protocol for constraining absolute pharmacokinetic modeling errors within specific accuracy limits. Medical Physics, 2019, 46, 3592-3602.	1.6	1
2056	NCTN Assessment on Current Applications of Radiomics in Oncology. International Journal of Radiation Oncology Biology Physics, 2019, 104, 302-315.	0.4	44
2057	Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non–small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 3818-3829.	3.2	51
2058	Early stage of diffusional kurtosis imaging and dynamic contrast-enhanced magnetic resonance imaging correlated with long-term neurocognitive function after experimental traumatic brain injury. Neuroscience Letters, 2019, 705, 206-211.	1.0	8
2059	Quantifying bloodâ€brain barrier leakage in small vessel disease: Review and consensus recommendations. Alzheimer's and Dementia, 2019, 15, 840-858.	0.4	134
2060	Cancer imaging in preclinical models. , 2019, , 373-400.		1
2061	Qualityâ€based pharmacokinetic model selection on DCEâ€MRI for characterizing orbital lesions. Journal of Magnetic Resonance Imaging, 2019, 50, 1514-1525.	1.9	14
2062	Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model. Acta Oncol \tilde{A}^3 gica, 2019, 58, 828-837.	0.8	7
2064	Dynamic Contrast-Enhanced MRI for Measuring Pancreatic Perfusion in Acute Pancreatitis: A Preliminary Study. Academic Radiology, 2019, 26, 1641-1649.	1.3	7
2065	3â€T MR perfusion of solid pancreatic lesions using dynamic contrast-enhanced DISCO sequence: Usefulness of qualitative and quantitative analyses in a pilot study. Magnetic Resonance Imaging, 2019, 59, 105-113.	1.0	9
2066	Whole-tumour histogram analysis of pharmacokinetic parameters from dynamic contrast-enhanced MRI in resectable oesophageal squamous cell carcinoma can predict T-stage and regional lymph node metastasis. European Journal of Radiology, 2019, 112, 112-120.	1,2	13
2067	Functional MRI: DWI and DCE-MRI. Pediatric Oncology, 2019, , 91-106.	0.5	3
2069	Functional Cross-Sectional Imaging Techniques in Crohn's Disease. , 2019, , 93-123.		0
2070	DCE-MRI and Quantitative Histology Reveal Enhanced Vessel Maturation but Impaired Perfusion and Increased Hypoxia in Bevacizumab-Treated Cervical Carcinoma. International Journal of Radiation Oncology Biology Physics, 2019, 104, 666-676.	0.4	14
2071	Influence of temporal parameters of DCEâ€MRI on the quantification of heterogeneity in tumor vascularization. Journal of Magnetic Resonance Imaging, 2019, 50, 1773-1788.	1.9	19
2072	Comparison of T1 mapping and fixed T1 method for dynamic contrast-enhanced MRI perfusion in brain gliomas. European Radiology, 2019, 29, 3467-3479.	2.3	22

#	Article	IF	CITATIONS
2073	Comparison of transport of chemotherapeutic drugs in voxelized heterogeneous model of human brain tumor. Microvascular Research, 2019, 124, 76-90.	1.1	20
2074	Resonancia magnética funcional de la próstata. EMC - UrologÃa, 2019, 51, 1-11.	0.0	0
2075	Revisiting quantitative multi-parametric MRI of benign prostatic hyperplasia and its differentiation from transition zone cancer. Abdominal Radiology, 2019, 44, 2233-2243.	1.0	30
2076	Complementary Roles of Dynamic Contrast-Enhanced MR Imaging and Postcontrast Vessel Wall Imaging in Detecting High-Risk Intracranial Aneurysms. American Journal of Neuroradiology, 2019, 40, 490-496.	1.2	18
2077	Methodologic Concerns on the Reported Values for Assessing Permeability of the Blood-Brain Barrier in the Hippocampus. American Journal of Neuroradiology, 2019, 40, E65-E66.	1.2	3
2078	Correlation of DWI and DCE MRI Markers for the Study of Perfusion of the Lower Limb in Patients with Peripheral Arterial Disease., 2019, , .		0
2079	A Comparative Study of Two-Compartment Exchange Models for Dynamic Contrast-Enhanced MRI in Characterizing Uterine Cervical Carcinoma. Contrast Media and Molecular Imaging, 2019, 2019, 1-13.	0.4	7
2080	Emerging quantitative MR imaging biomarkers in inflammatory arthritides. European Journal of Radiology, 2019, 121, 108707.	1.2	6
2081	Impact of Single Dose Photons and Carbon Ions on Perfusion and Vascular Permeability: A Dynamic Contrast-Enhanced MRI Pilot Study in the Anaplastic Rat Prostate Tumor R3327-AT1. Radiation Research, 2019, 193, 34.	0.7	8
2082	Evaluating the scope of intramedullary invasion of malignant bone tumor by DCE-MRI quantitative parameters in an animal study. Journal of Bone Oncology, 2019, 19, 100269.	1.0	2
2083	Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Point-of-Care Perfusion Phantom. Investigative Radiology, 2019, 54, 16-22.	3.5	19
2084	Ultra-early changes in vascular parameters from dynamic contrast enhanced MRI of breast cancer xenografts following systemic therapy with doxorubicin and liver X receptor agonist. Cancer Imaging, 2019, 19, 88.	1.2	6
2085	Advances in Diffusion and Perfusion MRI for Quantitative Cancer Imaging. Current Pathobiology Reports, 2019, 7, 129-141.	1.6	3
2086	Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with ⁹⁰ Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI. Contrast Media and Molecular Imaging, 2019, 2019, 1-12.	0.4	15
2087	<p>Perfusion, Diffusion, Or Brain Tumor Barrier Integrity: Which Represents The Glioma Features Best?</p> . Cancer Management and Research, 2019, Volume 11, 9989-10000.	0.9	10
2088	Textural features on 18F-FDG PET/CT and dynamic contrast-enhanced MR imaging for predicting treatment response and survival of patients with hypopharyngeal carcinoma. Medicine (United States), 2019, 98, e16608.	0.4	10
2089	Radiomics Analysis of Multiparametric MRI Evaluates the Pathological Features of Cervical Squamous Cell Carcinoma. Journal of Magnetic Resonance Imaging, 2019, 49, 1141-1148.	1.9	48
2090	Comparison of 18F-Choline PET/CT and MRI functional parameters in prostate cancer. Annals of Nuclear Medicine, 2019, 33, 47-54.	1.2	0

#	Article	IF	CITATIONS
2091	Comparing diagnostic accuracy of luminal water imaging with diffusionâ€weighted and dynamic contrastâ€enhanced MRI in prostate cancer: A quantitative MRI study. NMR in Biomedicine, 2019, 32, e4048.	1.6	13
2092	Investigating the Correlation of Ktrans With Semi-Quantitative MRI Parameters Towards More Robust and Reproducible Perfusion Imaging Biomarkers in Three Cancer Types. IEEE Journal of Biomedical and Health Informatics, 2019, 23, 1855-1862.	3.9	14
2093	Correlation of Preoperative Von Willebrand Factor with Magnetic Resonance Imaging Perfusion and Permeability Parameters as Predictors of Prognosis in Glioblastoma. World Neurosurgery, 2019, 122, e226-e234.	0.7	2
2094	Magnetic resonance imaging-guided radiation therapy using animal models of glioblastoma. British Journal of Radiology, 2019, 92, 20180713.	1.0	5
2095	Quantitative assessment of dynamic ¹⁸ F-flumethycholine PET and dynamic contrast enhanced MRI in high risk prostate cancer. British Journal of Radiology, 2019, 92, 20180568.	1.0	0
2096	Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models. Cancer Research, 2019, 79, 220-230.	0.4	67
2097	Functional magnetic resonance imaging of head and neck cancer: Performance and potential. Neuroradiology Journal, 2019, 32, 36-52.	0.6	25
2098	Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCEâ€MRI derived biomarkers in multicenter oncology trials. Journal of Magnetic Resonance Imaging, 2019, 49, e101-e121.	1.9	241
2099	A machine learning approach for distinguishing uterine sarcoma from leiomyomas based on perfusion weighted MRI parameters. European Journal of Radiology, 2019, 110, 203-211.	1.2	24
2100	Quantitative parameters correlated well with differentiation of squamous cell carcinoma at head and neck: a study of dynamic contrast-enhanced MRI. Acta Radiologica, 2019, 60, 962-968.	0.5	10
2101	Selection of Fitting Model and Arterial Input Function for Repeatability in Dynamic Contrast-Enhanced Prostate MRI. Academic Radiology, 2019, 26, e241-e251.	1.3	12
2102	Future Perspectives in Multiparametric Prostate MR Imaging. Magnetic Resonance Imaging Clinics of North America, 2019, 27, 117-130.	0.6	6
2103	Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma. Magnetic Resonance Imaging, 2019, 57, 156-164.	1.0	21
2104	Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer. Neoplasia, 2019, 21, 17-29.	2.3	20
2105	Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance–positron-emission tomography. Strahlentherapie Und Onkologie, 2019, 195, 707-718.	1.0	10
2106	Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival. Neurocirugia, 2019, 30, 11-18.	0.2	10
2107	Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival. NeurocirugÃa (English Edition), 2019, 30, 11-18.	0.1	2
2108	Optimizing Texture Retrieving Model for Multimodal MR Imageâ€Based Support Vector Machine for Classifying Glioma. Journal of Magnetic Resonance Imaging, 2019, 49, 1263-1274.	1.9	31

#	Article	IF	CITATIONS
2109	Guiding the first biopsy in glioma patients using estimated Ki-67 maps derived from MRI: conventional versus advanced imaging. Neuro-Oncology, 2019, 21, 527-536.	0.6	41
2110	Ultrafast Dynamic Contrast-Enhanced Breast MRI: Kinetic Curve Assessment Using Empirical Mathematical Model Validated with Histological Microvessel Density. Academic Radiology, 2019, 26, e141-e149.	1.3	31
2111	Role of Quantitative Dynamic Contrast-Enhanced MRI in Evaluating Regional Lymph Nodes With a Short-Axis Diameter of Less Than 5 mm in Rectal Cancer. American Journal of Roentgenology, 2019, 212, 77-83.	1.0	15
2112	Quantitative 3D dynamic contrastâ€enhanced (DCE) MR imaging of carotid vessel wall by fast T1 mapping using Multitasking. Magnetic Resonance in Medicine, 2019, 81, 2302-2314.	1.9	30
2113	Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma. Neuro-Oncology, 2019, 21, 314-325.	0.6	59
2114	Effect of Tumor Volume on Drug Delivery in Heterogeneous Vasculature of Human Brain Tumors. Journal of Engineering and Science in Medical Diagnostics and Therapy, 2019, 2, .	0.3	8
2115	Voxelâ€wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework. BJU International, 2019, 123, 1020-1030.	1.3	9
2116	The Use of Dynamic Contrast-Enhanced Perfusion MRI in Differentiating Benign and Malignant Thyroid Nodules. Indian Journal of Otolaryngology and Head and Neck Surgery, 2019, 71, 706-711.	0.3	6
2117	Epac1 â^'/â^' mice have elevated baseline permeability and do not respond to histamine as measured with dynamic contrastâ€enhanced magnetic resonance imaging with contrast agents of different molecular weights. Acta Physiologica, 2019, 225, e13199.	1.8	7
2118	Unified platform for multimodal voxel-based analysis to evaluate tumour perfusion and diffusion characteristics before and after radiation treatment evaluated in metastatic brain cancer. British Journal of Radiology, 2019, 92, 20170461.	1.0	6
2119	Shutterâ€speed dynamic contrastâ€enhanced MRI: Is it fit for purpose?. Magnetic Resonance in Medicine, 2019, 81, 976-988.	1.9	13
2120	Machine learning improves classification of preclinical models of pancreatic cancer with chemical exchange saturation transfer MRI. Magnetic Resonance in Medicine, 2019, 81, 594-601.	1.9	6
2121	Correlation Between Intravoxel Incoherent Motion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Parameters in Rectal Cancer. Academic Radiology, 2019, 26, e134-e140.	1.3	12
2122	Hypoenhancing prostate cancers on dynamic contrast-enhanced MRI are associated with poor outcomes in high-risk patients: results of a hypothesis generating study. Abdominal Radiology, 2019, 44, 723-731.	1.0	3
2123	Quantitative subchondral bone perfusion imaging in knee osteoarthritis using dynamic contrast enhanced MRI. Seminars in Arthritis and Rheumatism, 2020, 50, 177-182.	1.6	11
2124	Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clinical Cancer Research, 2020, 26, 206-212.	3.2	48
2125	Automatic inâ€line quantitative myocardial perfusion mapping: Processing algorithm and implementation. Magnetic Resonance in Medicine, 2020, 83, 712-730.	1.9	27
2126	Pharmacokinetic modeling of dynamic contrastâ€enhanced MRI using a reference region and input function tail. Magnetic Resonance in Medicine, 2020, 83, 286-298.	1.9	1

#	Article	IF	Citations
2127	Gastric cancer and image-derived quantitative parameters: Part 2—a critical review of DCE-MRI and 18F-FDG PET/CT findings. European Radiology, 2020, 30, 247-260.	2.3	33
2128	Whole-lesion histogram and texture analyses of breast lesions on inline quantitative DCE mapping with CAIPIRINHA-Dixon-TWIST-VIBE. European Radiology, 2020, 30, 57-65.	2.3	26
2129	Validating an Empirical Mathematical Model for Dynamic Contrast-enhanced MR Imaging of Hand and Wrist Synovitis in Rheumatoid Arthritis: Correlation of Model Parameters with Clinical Disease Activity. Magnetic Resonance in Medical Sciences, 2020, 19, 176-183.	1.1	8
2130	Intravoxel Incoherent Motion Diffusionâ∈Weighted Imaging for Evaluation of the Cell Density and Angiogenesis of Cirrhosisâ∈Related Nodules in an Experimental Rat Model: Comparison and Correlation With Dynamic Contrastâ∈Enhanced MRI. Journal of Magnetic Resonance Imaging, 2020, 51, 812-823.	1.9	11
2131	Breast MRI in the era of diffusion weighted imaging: do we still need signal-intensity time curves?. European Radiology, 2020, 30, 47-56.	2.3	23
2132	Renal perfusion imaging by MRI. Journal of Magnetic Resonance Imaging, 2020, 52, 369-379.	1.9	32
2133	Reference region extraction by clustering for the pharmacokinetic analysis of dynamic contrast-enhanced MRI in prostate cancer. Magnetic Resonance Imaging, 2020, 66, 185-192.	1.0	4
2134	Dynamic contrastâ€enhanced MRI model selection for predicting tumor aggressiveness in papillary thyroid cancers. NMR in Biomedicine, 2020, 33, e4166.	1.6	19
2135	Soft tissue sarcoma: DWI and DCE-MRI parameters correlate with Ki-67 labeling index. European Radiology, 2020, 30, 914-924.	2.3	42
2136	DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy. Journal of Neuro-Oncology, 2020, 146, 339-346.	1.4	17
2137	Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer–A Pilot Study. Academic Radiology, 2020, 27, 1432-1439.	1.3	9
2138	Perfusion parameters of intravoxel incoherent motion based on tumor edge region of interest in cervical cancer: evaluation of differentiation and correlation with dynamic contrast-enhanced MRI. Acta Radiologica, 2020, 61, 1087-1095.	0.5	6
2139	Esophagus and Stomach. Magnetic Resonance Imaging Clinics of North America, 2020, 28, 1-15.	0.6	8
2140	Combined dynamic DCE-MRI and diffusion-weighted imaging to evaluate the effect of neoadjuvant chemotherapy in cervical cancer. Tumori, 2020, 106, 155-164.	0.6	13
2141	DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: Comparisons of single versus three fraction schemes and two different imaging time delays post-SABR. Clinical and Translational Radiation Oncology, 2020, 21, 25-31.	0.9	12
2142	Magnetic resonance-guided high-intensity focused ultrasound of uterine fibroids: whole-tumor quantitative perfusion for prediction of immediate ablation response. Acta Radiologica, 2020, 61, 1125-1133.	0.5	12
2143	Less Severe Preoperative Synovitis is Associated With Higher Self-reported Pain Intensity 12 Months After Total Knee Arthroplasty—An Exploratory Prospective Observational Study. Clinical Journal of Pain, 2020, 36, 34-40.	0.8	3
2144	CT and MR perfusion techniques to assess diffuse liver disease. Abdominal Radiology, 2020, 45, 3496-3506.	1.0	13

#	Article	IF	CITATIONS
2145	Volume-based histogram analysis of dynamic contrast-enhanced MRI for estimation of gliomas IDH1 mutation status. European Journal of Radiology, 2020, 131, 109247.	1.2	2
2146	Exploring the Inter-voxel Information in Pharmacokinetic Maps for Cervical Carcinoma Prediction. , 2020, 2020, 1477-1480.		0
2147	Application of hierarchical clustering to multi-parametric MR in prostate: Differentiation of tumor and normal tissue with high accuracy. Magnetic Resonance Imaging, 2020, 74, 90-95.	1.0	8
2148	Quantitative dynamic contrast-enhanced MR imaging can be used to predict the pathologic stages of oral tongue squamous cell carcinoma. BMC Medical Imaging, 2020, 20, 117.	1.4	7
2149	MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study. Lancet Rheumatology, The, 2020, 2, e666-e676.	2.2	15
2150	Quantitative perfusion parameters of benign inflammatory breast pathologies: A descriptive study. Clinical Imaging, 2020, 68, 249-256.	0.8	2
2151	Multiparametric quantitative analysis of tumor perfusion and diffusion with 3T MRI: differentiation between benign and malignant soft tissue tumors. British Journal of Radiology, 2020, 93, 20191035.	1.0	16
2152	Relevance of dynamic studies with magnetic resonance enterography in Crohn's disease. GastroenterologÃa Y HepatologÃa (English Edition), 2020, 43, 179-187.	0.0	O
2153	Intraprocedural Transcatheter Intraarterial Perfusion (TRIP)-MRI for Evaluation of Irreversible Electroporation Therapy Response in a Rabbit Liver Tumor Model. Clinical and Experimental Gastroenterology, 2020, Volume 13, 543-553.	1.0	1
2154	Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. Neuro-Oncology Advances, 2020, 2, vdaa157.	0.4	8
2155	Quantitative DCE-MRI: an efficient diagnostic technique for evaluating early micro-environment permeability changes in ankylosing spondylitis. BMC Musculoskeletal Disorders, 2020, 21, 774.	0.8	1
2156	Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Contrast Media and Molecular Imaging, 2020, 2020, 1-11.	0.4	3
2157	Magnetic Resonance Methods for Focused Ultrasound-Induced Blood-Brain Barrier Opening. Frontiers in Physics, 2020, 8, .	1.0	6
2158	The Effect of Registration on Voxel-Wise Tofts Model Parameters and Uncertainties from DCE-MRI of Early-Stage Breast Cancer Patients Using 3DSlicer. Journal of Digital Imaging, 2020, 33, 1065-1072.	1.6	6
2159	Convolutional neural networks for head and neck tumor segmentation on 7-channel multiparametric MRI: a leave-one-out analysis. Radiation Oncology, 2020, 15, 181.	1.2	19
2160	Ultrasmall Mixed Eu–Gd Oxide Nanoparticles for Multimodal Fluorescence and Magnetic Resonance Imaging of Passive Accumulation and Retention in TBI. ACS Omega, 2020, 5, 16220-16227.	1.6	17
2161	Comparison of iterative parametric and indirect deep learningâ€based reconstruction methods in highly undersampled DCEâ€MR Imaging of the breast. Medical Physics, 2020, 47, 4838-4861.	1.6	5
2162	BONE PERFUSION AND ADIPOSITY BEYOND THE NECROTIC ZONE IN FEMORAL HEAD OSTEONECROSIS: A QUANTITATIVE MRI STUDY. European Journal of Radiology, 2020, 131, 109206.	1.2	5

#	Article	IF	CITATIONS
2163	DCE-MRI of Tumor Hypoxia and Hypoxia-Associated Aggressiveness. Cancers, 2020, 12, 1979.	1.7	16
2164	Biomarkers of Brain Damage Induced by Radiotherapy. Dose-Response, 2020, 18, 155932582093827.	0.7	10
2165	Assessment of pelvic lymph node metastasis in FIGO IB and IIA cervical cancer using quantitative dynamic contrast-enhanced MRI parameters. Diagnostic and Interventional Radiology, 2020, 26, 382-389.	0.7	3
2166	Patient-Centric Head and Neck Cancer Radiation Therapy. Neuroimaging Clinics of North America, 2020, 30, 341-357.	0.5	1
2167	Dynamic Electron Paramagnetic Resonance Imaging: Modern Technique for Biodistribution and Pharmacokinetic Imaging. Journal of Physical Chemistry C, 2020, 124, 19743-19752.	1.5	4
2168	Magnetic resonance enterography perfusion parameters reveal complex changes in affected and unaffected segments in Crohn's disease. Scandinavian Journal of Gastroenterology, 2020, 55, 1041-1048.	0.6	6
2169	The role of MRI and clinicopathologic features in predicting the invasive component of biopsy-confirmed ductal carcinoma in situ. BMC Medical Imaging, 2020, 20, 95.	1.4	17
2170	Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas. European Radiology, 2020, 30, 6475-6484.	2.3	29
2171	Functional Imaging to Predict Treatment Response in Head and Neck Cancer: How Close are We to Biologically Adaptive Radiotherapy?. Clinical Oncology, 2020, 32, 861-873.	0.6	7
2172	T1-weighted Dynamic Contrast-enhanced MRI to Differentiate Nonneoplastic and Malignant Vertebral Body Lesions in the Spine. Radiology, 2020, 297, 382-389.	3.6	18
2173	Nanometre-Scale Visualization of Chemical Parameter Changes by T1-Weighted ODMR Imaging Using a Fluorescent Nanodiamond. Chemosensors, 2020, 8, 68.	1.8	1
2174	Slice profile effects on quantitative analysis of hyperpolarized pyruvate. NMR in Biomedicine, 2020, 33, e4373.	1.6	10
2175	Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for pretreatment prediction of neoadjuvant chemotherapy response in locally advanced hypopharyngeal cancer. British Journal of Radiology, 2020, 93, 20200751.	1.0	2
2176	Variability and Standardization of Quantitative Imaging. Investigative Radiology, 2020, 55, 601-616.	3.5	89
2177	Pharmacokinetic Analysis of Dynamic Contrast-Enhanced Magnetic Resonance Imaging at 7T for Breast Cancer Diagnosis and Characterization. Cancers, 2020, 12, 3763.	1.7	3
2179	PET-MRI nanoparticles imaging of blood–brain barrier damage and modulation after stroke reperfusion. Brain Communications, 2020, 2, fcaa193.	1.5	18
2180	FASTRACK II magnetic resonance imaging sub-study Diffusion and perfusion biomarkers for renal SABR response. Journal of Physics: Conference Series, 2020, 1662, 012018.	0.3	0
2181	Permeability Measures Predict Hemorrhagic Transformation after Ischemic Stroke. Annals of Neurology, 2020, 88, 466-476.	2.8	20

#	Article	IF	CITATIONS
2182	Dynamic contrast-enhanced MRI in oncology: how we do it. Radiologia Medica, 2020, 125, 1288-1300.	4.7	62
2183	<p>Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging</p> . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 77-89.	1.8	44
2184	Does multiparametric imaging with 18F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma?. British Journal of Cancer, 2020, 123, 46-53.	2.9	13
2185	Feasibility and safety of focused ultrasound-enabled liquid biopsy in the brain of a porcine model. Scientific Reports, 2020, 10, 7449.	1.6	40
2186	Slow blood-to-brain transport underlies enduring barrier dysfunction in American football players. Brain, 2020, 143, 1826-1842.	3.7	42
2187	Assessment of tumor treatment response using active contrast encoding (ACE)-MRI: Comparison with conventional DCE-MRI. PLoS ONE, 2020, 15, e0234520.	1.1	5
2188	Comparative study of preclinical mouse models of high-grade glioma for nanomedicine research: the importance of reproducing blood-brain barrier heterogeneity. Theranostics, 2020, 10, 6361-6371.	4.6	27
2189	Wholeâ€heart, ungated, freeâ€breathing, cardiacâ€phaseâ€resolved myocardial perfusion MRI by using Continuous Radial Interleaved simultaneous Multiâ€slice acquisitions at sPoiled steadyâ€state (CRIMP). Magnetic Resonance in Medicine, 2020, 84, 3071-3087.	1.9	12
2190	Prostate MRI Essentials. , 2020, , .		1
2191	Computational Modeling of Interstitial Fluid Pressure and Velocity in Non-small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery. Frontiers in Neurology, 2020, 11, 402.	1.1	9
2192	Shutterâ€Speed DCEâ€MRI Analyses of Human Glioblastoma Multiforme (GBM) Data. Journal of Magnetic Resonance Imaging, 2020, 52, 850-863.	1.9	18
2193	Imaging and histopathologic correlates of plasma cell-free DNA concentration and circulating tumor DNA in adult patients with newly diagnosed glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa016.	0.4	15
2194	BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2020, 107, 478-486.	0.4	6
2195	Quantitative pharmacokinetic analysis of high-temporal-resolution dynamic contrast-enhanced MRI to differentiate the normal-appearing pituitary gland from pituitary macroadenoma. Japanese Journal of Radiology, 2020, 38, 649-657.	1.0	5
2196	Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors. Neuro-Oncology, 2020, 22, 1658-1666.	0.6	27
2197	Feasibility of using dynamic contrast-enhanced MRI for differentiating thymic carcinoma from thymic lymphoma based on semi-quantitative and quantitative models. Clinical Radiology, 2020, 75, 560.e19-560.e25.	0.5	4
2198	Detection of Mesenteric Tumor Using Dynamic Contrast Enhanced MRI. Annals of Surgical Oncology, 2020, 27, 2525-2536.	0.7	2
2199	Gastrointestinal vascular permeability changes following spinal cord injury. Neurogastroenterology and Motility, 2020, 32, e13834.	1.6	6

#	Article	IF	CITATIONS
2200	Correlation between histogram-based DCE-MRI parameters and 18F-FDG PET values in oropharyngeal squamous cell carcinoma: Evaluation in primary tumors and metastatic nodes. PLoS ONE, 2020, 15, e0229611.	1.1	7
2201	The inflammatory microenvironment in vestibular schwannoma. Neuro-Oncology Advances, 2020, 2, vdaa023.	0.4	35
2202	MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer. Cancer Research, 2020, 80, 3993-4003.	0.4	26
2203	Characterization of parotid gland tumors: added value of permeability MR imaging to DWI and DCE-MRI. European Radiology, 2020, 30, 6402-6412.	2.3	25
2204	Prediction of survival and progression in glioblastoma patients using temporal perfusion changes during radiochemotherapy. Magnetic Resonance Imaging, 2020, 68, 106-112.	1.0	17
2205	Multiparametric Analysis of Longitudinal Quantitative MRI Data to Identify Distinct Tumor Habitats in Preclinical Models of Breast Cancer. Cancers, 2020, 12, 1682.	1.7	28
2206	Late changes in blood–brain barrier permeability in a rat tMCAO model of stroke detected by gadolinium-enhanced MRI. Neurological Research, 2020, 42, 844-852.	0.6	6
2207	Toward precise arterial input functions derived from DCEâ€MRI through a novel extracorporeal circulation approach in mice. Magnetic Resonance in Medicine, 2020, 84, 1404-1415.	1.9	6
2208	Imaging breast cancer using hyperpolarized carbon-13 MRI. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 2092-2098.	3.3	138
2209	Quantitative DCE-MRI demonstrates increased blood perfusion in Hoffa's fat pad signal abnormalities in knee osteoarthritis, but not in patellofemoral pain. European Radiology, 2020, 30, 3401-3408.	2.3	19
2210	Transcatheter Intraarterial Perfusion MRI Approaches to Differentiate Reversibly Electroporated Penumbra From Irreversibly Electroporated Zones in Rabbit Liver. Academic Radiology, 2020, 27, 1727-1733.	1.3	3
2211	Multimodal imaging reveals transient liver metabolic disturbance and sinusoidal circulation obstruction after a single administration of ketamine/xylazine mixture. Scientific Reports, 2020, 10, 3657.	1.6	3
2212	Quantitative evaluation of Crohn's disease using dynamic contrast-enhanced MRI in children and young adults. European Radiology, 2020, 30, 3168-3177.	2.3	13
2213	The Usefulness of Bayesian Network in Assessing the Risk of Triple-Negative Breast Cancer. Academic Radiology, 2020, 27, e282-e291.	1.3	4
2214	Optimal Mass Transport with Lagrangian Workflow Reveals Advective and Diffusion Driven Solute Transport in the Glymphatic System. Scientific Reports, 2020, 10, 1990.	1.6	75
2215	Decreased Hand Motor Resting-State Functional Connectivity in Patients with Glioma: Analysis of Factors including Neurovascular Uncoupling. Radiology, 2020, 294, 610-621.	3.6	18
2216	Prognostication of anaplastic astrocytoma patients: application of contrast leakage information of dynamic susceptibility contrast-enhanced MRI and dynamic contrast-enhanced MRI. European Radiology, 2020, 30, 2171-2181.	2.3	7
2217	Sixâ€dimensional quantitative DCE MR Multitasking of the entire abdomen: Method and application to pancreatic ductal adenocarcinoma. Magnetic Resonance in Medicine, 2020, 84, 928-948.	1.9	16

#	Article	IF	CITATIONS
2218	Quantifying Reoxygenation in Pancreatic Cancer During Stereotactic Body Radiotherapy. Scientific Reports, 2020, 10, 1638.	1.6	16
2219	DCE-MRI pharmacokinetic parameter maps for cervical carcinoma prediction. Computers in Biology and Medicine, 2020, 118, 103634.	3.9	12
2221	Imageâ€guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1628.	3.3	24
2222	Predicting clinically significant prostate cancer from quantitative image features including compressed sensing radial MRI of prostate perfusion using machine learning: comparison with PI-RADS v2 assessment scores. Quantitative Imaging in Medicine and Surgery, 2020, 10, 808-823.	1.1	16
2223	Diffusion kurtosis imaging in head and neck cancer: A correlation study with dynamic contrast enhanced MRI. Physica Medica, 2020, 73, 22-28.	0.4	9
2224	DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses. Radiation Oncology, 2020, 15, 79.	1.2	10
2225	Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma. Clinical Cancer Research, 2020, 26, 3135-3144.	3.2	7
2226	Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value. American Journal of Neuroradiology, 2020, 41, 49-56.	1.2	11
2227	MRI of the Pancreas. Journal of Magnetic Resonance Imaging, 2021, 53, 347-359.	1.9	23
2228	Portable Perfusion Phantom Offers Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Accurate Prostate Cancer Grade Stratification: A Pilot Study. Academic Radiology, 2021, 28, 405-413.	1.3	2
2229	Dynamic contrast-enhanced MRI analysis for prognosis of intracranial dissecting aneurysm with intramural haematoma after endovascular treatment: an observational registry study. Stroke and Vascular Neurology, 2021, 6, 133-138.	1.5	3
2230	Prognostic value of tumoral and peritumoral magnetic resonance parameters in osteosarcoma patients for monitoring chemotherapy response. European Radiology, 2021, 31, 3518-3529.	2.3	19
2231	Radiomics derived from dynamic contrast-enhanced MRI pharmacokinetic protocol features: the value of precision diagnosis ovarian neoplasms. European Radiology, 2021, 31, 368-378.	2.3	32
2232	Hypoxia and perfusion in breast cancer: simultaneous assessment using PET/MR imaging. European Radiology, 2021, 31, 333-344.	2.3	32
2233	Morphological and functional assessment of the uterus: "one-stop shop imaging―using a compressed-sensing accelerated, free-breathing T1-VIBE sequence. Acta Radiologica, 2021, 62, 695-704.	0.5	3
2234	Contribution of perfusion to the 11 Câ€acetate signal in brown adipose tissue assessed by DCEâ€MRI and 68 Gaâ€DOTA PET in a rat model. Magnetic Resonance in Medicine, 2021, 85, 1625-1642.	1.9	5
2235	Patient-derived orthotopic xenograft models of medulloblastoma lack a functional blood-brain barrier. Neuro-Oncology, 2021, 23, 732-742.	0.6	12
2236	Value of dynamic contrast-enhanced magnetic resonance imaging for determining the plasma Epstein-Barr virus status and staging of nasopharyngeal carcinoma. Clinical Imaging, 2021, 72, 1-7.	0.8	5

#	Article	IF	CITATIONS
2237	Improved discrimination of molecular subtypes in invasive breast cancer: Comparison of multiple quantitative parameters from breast MRI. Magnetic Resonance Imaging, 2021, 77, 148-158.	1.0	20
2238	A Comprehensive View on MRI Techniques for Imaging Blood-Brain Barrier Integrity. Investigative Radiology, 2021, 56, 10-19.	3.5	23
2239	Comparison of dataâ€driven and general temporal constraints on compressed sensing for breast DCE MRI. Magnetic Resonance in Medicine, 2021, 85, 3071-3084.	1.9	3
2240	Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial. Neuro-Oncology, 2021, 23, 314-323.	0.6	18
2241	Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer. European Radiology, 2021, 31, 864-874.	2.3	8
2242	Differentiation of recurrent diffuse glioma from treatment-induced change using amide proton transfer imaging: incremental value to diffusion and perfusion parameters. Neuroradiology, 2021, 63, 363-372.	1.1	24
2243	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts. Molecular Imaging and Biology, 2021, 23, 70-83.	1.3	1
2244	Quantitative kinetic parameters of primary tumor can be used to predict pelvic lymph node metastasis in early-stage cervical cancer. Abdominal Radiology, 2021, 46, 1129-1136.	1.0	6
2245	Multiparametric functional MRI and 18F-FDG-PET for survival prediction in patients with head and neck squamous cell carcinoma treated with (chemo)radiation. European Radiology, 2021, 31, 616-628.	2.3	33
2246	Magnetic resonance imaging for assessing treatment response in bone marrow metastases. Acta Radiologica, 2021, 62, 483-499.	0.5	2
2247	Dynamic Contrast Enhancement (DCE) MRI–Derived Renal Perfusion and Filtration: Basic Concepts. Methods in Molecular Biology, 2021, 2216, 205-227.	0.4	3
2248	Dynamic Contrast Enhanced MRI and Intravoxel Incoherent Motion to Identify Molecular Subtypes of Breast Cancer with Different Vascular Normalization Gene Expression. Korean Journal of Radiology, 2021, 22, 1021.	1.5	4
2249	Kinetic Modeling of Enzymatic Reactions in Analyzing Hyperpolarized NMR Data., 2021,, 103-121.		0
2250	Algorithms applied to spatially registered multi-parametric MRI for prostate tumor volume measurement. Quantitative Imaging in Medicine and Surgery, 2021, 11, 119-132.	1.1	8
2251	Application of T1 Map Information Based on Synthetic MRI for Dynamic Contrast-Enhanced Imaging: A Comparison Study with the Fixed Baseline T1 Value Method. Korean Journal of Radiology, 2021, 22, 1352.	1.5	0
2252	Tumor Vasculature. , 2021, , 831-867.		1
2253	Advances in Myocardial Perfusion MR Imaging: Physiological Implications, the Importance of Quantitative Analysis, and Impact on Patient Care in Coronary Artery Disease. Magnetic Resonance in Medical Sciences, 2022, 21, 195-211.	1.1	6
2254	Magnetic Resonance Imaging for Drug Development. Advances in Experimental Medicine and Biology, 2021, 1310, 187-209.	0.8	0

#	Article	IF	CITATIONS
2255	Imaging Hypoxia., 2021,, 869-895.		0
2256	Neural Machine Registration for Motion Correction in Breast DCE-MRI. , 2021, , .		1
2257	Comparison of DCE-MRI of murine model cancers with a low dose and high dose of contrast agent. Physica Medica, 2021, 81, 31-39.	0.4	4
2258	Value of quantitative dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging in predicting extramural venous invasion in locally advanced gastric cancer and prognostic significance. Quantitative Imaging in Medicine and Surgery, 2021, 11, 328-340.	1.1	17
2259	Neuronavigation-guided focused ultrasound for transcranial blood-brain barrier opening and immunostimulation in brain tumors. Science Advances, 2021, 7, .	4.7	70
2260	Quantifying lumbar vertebral perfusion by a Tofts model on DCE-MRI using segmental versus aortic arterial input function. Scientific Reports, $2021, 11, 2920$.	1.6	2
2261	Dynamic contrast-enhanced MRI of synovitis in knee osteoarthritis: repeatability, discrimination and sensitivity to change in a prospective experimental study. European Radiology, 2021, 31, 5746-5758.	2.3	12
2262	Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study. Annals of Palliative Medicine, 2021, 10, 1589-1598.	0.5	5
2263	Intravital microscopy of tumor vessel morphology and function using a standard fluorescence microscope. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3089-3100.	3.3	9
2264	Utilizing Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Analyze Interstitial Fluid Flow and Transport in Glioblastoma and the Surrounding Parenchyma in Human Patients. Pharmaceutics, 2021, 13, 212.	2.0	11
2265	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro-Oncology, 2021, 23, 1056-1071.	0.6	68
2266	Data-Driven Regularization Parameter Selection in Dynamic MRI. Journal of Imaging, 2021, 7, 38.	1.7	1
2267	Early response assessment after CyberKnife stereotactic radiosurgery for symptomatic vertebral hemangioma by quantitative parameters from dynamic contrast-enhanced MRI. European Spine Journal, 2021, 30, 2867-2873.	1.0	2
2268	Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging. Neuroradiology, 2021, 63, 1811-1822.	1.1	7
2269	Effects of artery input function on dynamic contrast-enhanced MRI for determining grades of gliomas. British Journal of Radiology, 2021, 94, 20200699.	1.0	1
2270	Pharmacokinetic Modelling. , 2021, , 47-67.		0
2271	Revisiting DCE-MRI. Investigative Radiology, 2021, 56, 553-562.	3.5	7
2272	An A.I. classifier derived from 4D radiomics of dynamic contrast-enhanced breast MRI data: potential to avoid unnecessary breast biopsies. European Radiology, 2021, 31, 5866-5876.	2.3	18

#	Article	IF	CITATIONS
2273	Nongaussian Intravoxel Incoherent Motion Diffusion Weighted and Fast Exchange Regime Dynamic Contrast-Enhanced-MRI of Nasopharyngeal Carcinoma: Preliminary Study for Predicting Locoregional Failure. Cancers, 2021, 13, 1128.	1.7	4
2274	Investigating the blood–spinal cord barrier in preclinical models: a systematic review of in vivo imaging techniques. Spinal Cord, 2021, 59, 596-612.	0.9	5
2275	Enhancement degree of brain metastases: correlation analysis between enhanced T2 FLAIR and vascular permeability parameters of dynamic contrast-enhanced MRI. European Radiology, 2021, 31, 5595-5604.	2.3	6
2276	Respiratory motion correction for enhanced quantification of hepatic lesions in simultaneous PET and DCE-MR imaging. Physics in Medicine and Biology, 2021, 66, 095012.	1.6	8
2277	DCE-MRI in Glioma, Infiltration Zone and Healthy Brain to Assess Angiogenesis: AÂBiopsy Study. Clinical Neuroradiology, 2021, 31, 1049-1058.	1.0	10
2278	MRI Dynamic Contrast Imaging of Oral Cavity and Oropharyngeal Tumors. Topics in Magnetic Resonance Imaging, 2021, 30, 97-104.	0.7	1
2279	Improved Minimum-Volume Enclosing Simplex Algorithm for Prostate DCE-MRI Analysis. , 2021, , .		0
2280	Imaging acute effects of bevacizumab on tumor vascular kinetics in a preclinical orthotopic model of U251 glioma. NMR in Biomedicine, 2021, 34, e4516.	1.6	7
2281	The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review. Cancer Imaging, 2021, 21, 36.	1.2	3
2282	Permeability of the Blood–Brain Barrier after Traumatic Brain Injury: Radiological Considerations. Journal of Neurotrauma, 2022, 39, 20-34.	1.7	16
2283	Diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging after radiation therapy for bone metastases in patients with hepatocellular carcinoma. Scientific Reports, 2021, 11, 10459.	1.6	10
2284	The LEGATOS technique: A new tissueâ€validated dynamic contrastâ€enhanced MRI method for wholeâ€brain, highâ€spatial resolution parametric mapping. Magnetic Resonance in Medicine, 2021, 86, 2122-2136.	1.9	7
2285	The microenvironment in sporadic and neurofibromatosis type II–related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study. Journal of Neurosurgery, 2021, 134, 1419-1429.	0.9	23
2286	Sparse precontrast T ₁ mapping for highâ€resolution wholeâ€brain DCEâ€MRI. Magnetic Resonance in Medicine, 2021, 86, 2234-2249.	1.9	3
2287	Assessment of Hypoxic Tissue Fraction and Prediction of Survival in Cervical Carcinoma by Dynamic Contrast-Enhanced MRI. Frontiers in Oncology, 2021, 11, 668916.	1.3	4
2288	Artificial intelligence and imaging biomarkers for prostate radiation therapy during and after treatment. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 612-626.	0.9	3
2289	Diagnostic Performance of Vascular Permeability and Texture Parameters for Evaluating the Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 604480.	1.3	1
2290	A Review of Mathematics Determining Solute Uptake at the Blood–Brain Barrier in Normal and Pathological Conditions. Pharmaceutics, 2021, 13, 756.	2.0	2

#	Article	IF	Citations
2291	Non-Invasive Evaluation of Cerebral Microvasculature Using Pre-Clinical MRI: Principles, Advantages and Limitations. Diagnostics, 2021, 11, 926.	1.3	11
2292	Motion correction of free-breathing magnetic resonance renography using model-driven registration. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2021, 34, 805-822.	1.1	2
2293	Mathematical model for histogram analysis of dynamic contrast-enhanced MRI: A method to evaluate the drug treatment response in rheumatoid arthritis. European Journal of Radiology, 2021, 141, 109831.	1.2	9
2294	Comparison between high-frequency irreversible electroporation and irreversible electroporation ablation of small swine liver: follow-up of DCE-MRI and pathological observations. Chinese Medical Journal, 2021, 134, 2081-2090.	0.9	3
2295	Modelâ€free leakage index estimation of the bloodâ€brain barrier using dual dynamic susceptibility contrast MRI acquisition. NMR in Biomedicine, 2021, 34, e4570.	1.6	1
2296	Automated synthesis of gadopentetate dimeglumine through solid-liquid reaction in femtosecond laser fabricated microfluidic chips. Chinese Chemical Letters, 2022, 33, 1077-1080.	4.8	3
2297	7T dynamic contrastâ€enhanced MRI for the detection of subtle blood–brain barrier leakage. Journal of Neuroimaging, 2021, 31, 902-911.	1.0	7
2298	An automatic framework for evaluating the vascular permeability of bone metastases from prostate cancer. Physics in Medicine and Biology, 2021, 66, 125006.	1.6	0
2299	Differentiating Glioblastomas from Solitary Brain Metastases: An Update on the Current Literature of Advanced Imaging Modalities. Cancers, 2021, 13, 2960.	1.7	13
2300	Imaging biomarkers in the diagnosis of salivary gland tumors: the value of lesion/parenchyma ratio of perfusion-MR pharmacokinetic parameters. Radiologia Medica, 2021, 126, 1345-1355.	4.7	14
2301	Quantitative magnetic resonance imaging for focal liver lesions: bridging the gap between research and clinical practice. British Journal of Radiology, 2021, 94, 20210220.	1.0	9
2302	3D MRI in Osteoarthritis. Seminars in Musculoskeletal Radiology, 2021, 25, 468-479.	0.4	5
2303	Imaging biomarkers for evaluating tumor response: RECIST and beyond. Biomarker Research, 2021, 9, 52.	2.8	55
2304	Diagnosis of transition zone prostate cancer by multiparametric MRI: added value of MR spectroscopic imaging with sLASER volume selection. Journal of Biomedical Science, 2021, 28, 54.	2.6	10
2305	Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer. Cancers, 2021, 13, 3511.	1.7	4
2306	Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats. Molecular Pharmaceutics, 2021, 18, 2997-3009.	2.3	10
2307	Drug transport kinetics of intravascular triggered drug delivery systems. Communications Biology, 2021, 4, 920.	2.0	26
2308	Operator dependency of arterial input function in dynamic contrast-enhanced MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2021, , $1.$	1.1	3

#	ARTICLE	IF	CITATIONS
2309	The diagnostic efficiency of the perfusion-related parameters in assessing the vascular disrupting agent (CA4P) response in a rabbit VX2 liver tumor model. Acta Radiologica, 2021, , 028418512110324.	0.5	1
2310	Intelligent Computer-Aided Prostate Cancer Diagnosis Systems: State-of-the-Art and Future Directions. Mathematical Problems in Engineering, 2021, 2021, 1-17.	0.6	1
2311	Quantitative dynamic contrast-enhanced MRI and readout segmentation of long variable echo-trains diffusion-weighted imaging in differentiating parotid gland tumors. Neuroradiology, 2021, 63, 1709-1719.	1.1	6
2312	Blood–brain barrier leakage and hemorrhagic transformation: The Reperfusion Injury in Ischemic StroKe (RISK) study. European Journal of Neurology, 2021, 28, 3147-3154.	1.7	39
2313	Dynamic contrast-enhanced MRI predicts PTEN protein expression which can function as a prognostic measure of progression-free survival in NPC patients. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1771-1780.	1.2	3
2314	Consistency of Pituitary Adenoma: Prediction by Pharmacokinetic Dynamic Contrast-Enhanced MRI and Comparison with Histologic Collagen Content. Cancers, 2021, 13, 3914.	1.7	6
2315	Emerging methods for prostate cancer imaging: evaluating cancer structure and metabolic alterations more clearly. Molecular Oncology, 2021, 15, 2565-2579.	2.1	5
2316	Spatial Resolution versus Reproducibility for Dynamic MRI of High-Grade Gliomas. Radiology, 2021, 300, 421-422.	3.6	1
2317	Detection of early changes in the post-radiosurgery vestibular schwannoma microenvironment using multinuclear MRI. Scientific Reports, 2021, 11, 15712.	1.6	8
2318	Longitudinal Monitoring of Simulated Interstitial Fluid Pressure for Pancreatic Ductal Adenocarcinoma Patients Treated with Stereotactic Body Radiotherapy. Cancers, 2021, 13, 4319.	1.7	2
2319	Role of MRI-Based Functional Imaging in Improving the Therapeutic Index of Radiotherapy in Cancer Treatment. Frontiers in Oncology, 2021, 11, 645177.	1.3	8
2320	Multiâ€parametric MRI (mpMRI) for treatment response assessment of radiation therapy. Medical Physics, 2022, 49, 2794-2819.	1.6	3
2321	Use of dynamic contrast-enhanced MRI for the early assessment of outcome of CyberKnife stereotactic radiosurgery for patients with spinal metastases. Clinical Radiology, 2021, 76, 864.e1-864.e6.	0.5	3
2322	What's Hot in Breast MRI. Canadian Association of Radiologists Journal, 2022, 73, 125-140.	1.1	6
2323	How tissue T1-variability influences DCE-MRI perfusion parameters estimation of recurrent high-grade glioma after surgery followed by radiochemotherapy. Acta Radiologica, 2021, , 028418512110359.	0.5	1
2324	[18F]NaF PET-MRI provides direct in-vivo evidence of the association between bone metabolic activity and adjacent synovitis in knee osteoarthritis: a cross-sectional study. Osteoarthritis and Cartilage, 2021, 29, 1155-1162.	0.6	19
2325	Multiparametric MRI Evaluation of Oropharyngeal Squamous Cell Carcinoma. A Mono-Institutional Study. Journal of Clinical Medicine, 2021, 10, 3865.	1.0	6
2326	The Utility of Magnetic Resonance Imaging in the Multidisciplinary Treatment of Patients with Rectal Cancer., 0, , .		0

#	Article	IF	CITATIONS
2327	Quantitative diffusion and perfusion MRI in the evaluation of endometrial cancer: validation with histopathological parameters. British Journal of Radiology, 2021, 94, 20210054.	1.0	29
2328	Assessment of quantitative dynamic contrast-enhanced MRI in distinguishing different histologic grades of breast phyllode tumor. European Radiology, 2021, , 1.	2.3	1
2329	Dynamic biomarker and imaging changes from a phase II study of pre―and postâ€surgical sunitinib. BJU International, 2022, 130, 244-253.	1.3	5
2330	Assessment of Intratumor Heterogeneity in Parametric Dynamic Contrast-Enhanced MR Images: A Comparative Study of Novel and Established Methods. Frontiers in Oncology, 2021, 11, 722773.	1.3	1
2331	Monitoring the therapeutic efficacy of CA4P in the rabbit VX2 liver tumor using dynamic contrast-enhanced MRI., 2021, 27, 587-594.		0
2332	DCE-MRI quantitative transport mapping for noninvasively detecting hypoxia inducible factor-1α, epidermal growth factor receptor overexpression, and Ki-67 in nasopharyngeal carcinoma patients. Radiotherapy and Oncology, 2021, 164, 146-154.	0.3	11
2333	Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies. Cancer Journal (Sudbury, Mass), 2021, 27, 395-403.	1.0	2
2334	Differentiation of Jugular Foramen Paragangliomas versus Schwannomas Using Golden-Angle Radial Sparse Parallel Dynamic Contrast-Enhanced MRI. American Journal of Neuroradiology, 2021, 42, 1847-1852.	1.2	3
2335	DCE-MRI of Brain Fluid Barriers: <i>In Vivo</i> Water Cycling at the Human Choroid Plexus. Tissue Barriers, 2022, 10, 1963143.	1.6	6
2336	Effectiveness of Dynamic Contrast Enhanced MRI with a Split Dose of Gadoterate Meglumine for Detection of Prostate Cancer. Academic Radiology, 2022, 29, 796-803.	1.3	2
2337	Multiscale computational modeling of cancer growth using features derived from microCT images. Scientific Reports, 2021, 11, 18524.	1.6	11
2338	Blood-Brain Barrier Permeability in Patients With Reversible Cerebral Vasoconstriction Syndrome Assessed With Dynamic Contrast-Enhanced MRI. Neurology, 2021, 97, e1847-e1859.	1.5	11
2339	Cerebral and tumoral blood flow in adult gliomas: a systematic review of results from magnetic resonance imaging. British Journal of Radiology, 2021, 94, 20201450.	1.0	7
2340	Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer. Cancers, 2021, 13, 4869.	1.7	7
2341	Liver DCEâ€MRI registration based on sparse recovery of contrast agent curves. Medical Physics, 2021, 48, 6916-6929.	1.6	4
2342	Gadoliniumâ€free assessment of synovitis using diffusion tensor imaging. NMR in Biomedicine, 2022, 35, e4614.	1.6	9
2343	Correlation of prostate tumor eccentricity and Gleason scoring from prostatectomy and multi-parametric-magnetic resonance imaging. Quantitative Imaging in Medicine and Surgery, 2021, 11, 4235-4244.	1.1	8
2344	Advances in Imaging for HPV-Related Oropharyngeal Cancer: Applications to Radiation Oncology. Seminars in Radiation Oncology, 2021, 31, 371-388.	1.0	16

#	Article	IF	CITATIONS
2345	Descriptive analysis of MRI functional changes occurring during reduced dose radiotherapy for myxoid liposarcomas. British Journal of Radiology, 2021, 94, 20210310.	1.0	1
2346	Prognostic and therapeutic evaluation of nasopharyngeal carcinoma by dynamic contrast-enhanced (DCE), diffusion-weighted (DW) magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). Magnetic Resonance Imaging, 2021, 83, 50-56.	1.0	11
2347	Blood-brain barrier dysfunction significantly correlates with serum matrix metalloproteinase-7 (MMP-7) following traumatic brain injury. NeuroImage: Clinical, 2021, 31, 102741.	1.4	12
2348	Regional Differences in Blood-Brain Barrier Permeability in Cognitively Normal Elderly Subjects: A Dynamic Contrast-Enhanced MRI-Based Study. Korean Journal of Radiology, 2021, 22, 1152.	1.5	11
2349	Difference of DCE-MRI Parameters at Different Time Points and Their Predictive Value for Axillary Lymph Node Metastasis of Breast Cancer. Academic Radiology, 2022, 29, S79-S86.	1.3	8
2351	Convolutional neural network for accelerating the computation of the extended Tofts model in <scp>dynamic contrastâ€enhanced magnetic resonance imaging < /scp>. Journal of Magnetic Resonance Imaging, 2021, 53, 1898-1910.</scp>	1.9	17
2352	Accuracy, repeatability, and interplatform reproducibility of T ₁ quantification methods used for DCEâ€MRI: Results from a multicenter phantom study. Magnetic Resonance in Medicine, 2018, 79, 2564-2575.	1.9	75
2353	Dynamic Breast Magnetic Resonance Imaging. , 2005, , 79-139.		10
2354	Applications of Dynamic Contrast-Enhanced MRI in Oncology Drug Development., 2005,, 281-297.		7
2355	Imaging bio-markers predictive of disease/therapy outcome: ischemic stroke and drug development. , 2005, 62, 319-356.		6
2356	Physical Principles of MR Perfusion and Permeability Imaging: Gadolinium Bolus Technique. , 2011, , 53-59.		4
2357	Clinical Applications of MR Perfusion Imaging. , 2011, , 71-105.		2
2358	Lessons from Animal Imaging in Preclinical Models. , 2010, , 95-116.		1
2359	Quantitative Evaluation of Liver Function Within MR Imaging. , 2014, , 233-251.		5
2360	Applications of Small-Animal Molecular Imaging in Drug Development., 2014,, 715-752.		1
2361	Tumor Blood Vessel Visualization. Methods in Molecular Biology, 2016, 1464, 163-173.	0.4	1
2362	Angiogenic Signalling Pathways. Methods in Molecular Biology, 2009, 467, 25-51.	0.4	26
2363	Measuring the Integrity of the Human Blood–Brain Barrier Using Magnetic Resonance Imaging. Methods in Molecular Biology, 2011, 686, 229-245.	0.4	24

#	Article	IF	CITATIONS
2364	Advanced Physiologic Imaging: Perfusion– Theory and Applications. , 2020, , 61-91.		3
2365	Kinetic Textural Biomarker for Predicting Survival of Patients with Advanced Hepatocellular Carcinoma After Antiangiogenic Therapy by Use of Baseline First-Pass Perfusion CT. Lecture Notes in Computer Science, 2014, , 48-61.	1.0	1
2366	LBP-TOP for Volume Lesion Classification in Breast DCE-MRI. Lecture Notes in Computer Science, 2015, , 647-657.	1.0	7
2367	De-noising of Contrast-Enhanced MRI Sequences by an Ensemble of Expert Deep Neural Networks. Lecture Notes in Computer Science, 2016, , 95-110.	1.0	13
2368	Imaging in Diabetes. , 2018, , 175-197.		2
2369	Look-Up Tables for Efficient Non-Linear Parameters Estimation. Springer Proceedings in Mathematics and Statistics, 2017, , 49-57.	0.1	1
2371	Automatic Determination of Arterial Input Function for Dynamic Contrast Enhanced MRI in Tumor Assessment. Lecture Notes in Computer Science, 2008, 11, 594-601.	1.0	21
2372	Model Selection in Dynamic Contrast Enhanced MRI: The Akaike Information Criterion. IFMBE Proceedings, 2009, , 356-358.	0.2	1
2373	Automated Calibration for Computerized Analysis of Prostate Lesions Using Pharmacokinetic Magnetic Resonance Images. Lecture Notes in Computer Science, 2009, 12, 836-843.	1.0	9
2374	Computer Aided Detection of Prostate Cancer Using T2, DWI and DCE MRI: Methods and Clinical Applications. Lecture Notes in Computer Science, 2010, , 4-14.	1.0	1
2375	Imaging as a Surrogate for the Early Prediction and Assessment of Treatment Response through the Analysis of 4-D Texture Ensembles (ISEPARATE). Lecture Notes in Computer Science, 2011, , 164-173.	1.0	1
2377	Perfusion Imaging by Magnetic Resonance. , 2014, , 341-376.		1
2378	Registration of Free-Breathing 3D+t Abdominal Perfusion CT Images via Co-segmentation. Lecture Notes in Computer Science, 2013, 16, 99-107.	1.0	1
2379	The Impact of Heterogeneity and Uncertainty on Prediction of Response to Therapy Using Dynamic MRI Data. Lecture Notes in Computer Science, 2013, 16, 316-323.	1.0	2
2381	Imaging of Hepatic Metastases. Cancer Metastasis - Biology and Treatment, 2011, , 307-351.	0.1	3
2382	Imaging Biomarkers in Preclinical Studies on Brain Tumors. Biomarkers in Disease, 2015, , 391-413.	0.0	1
2383	MRI of blood-brain barrier permeability in cerebral ischemia. Translational Stroke Research, 2012, 3, 56-64.	2.3	11
2384	MODERN NEURORADIOLOGY RELEVANT TO ANESTHETIC AND PERIOPERATIVE MANAGEMENT. , 2010, , 95-114.		1

#	Article	IF	CITATIONS
2385	Perfusion Imaging for Brain Tumor Characterization and Assessment of Treatment Response. , 2008, , 264-277.		3
2386	Evaluation of chronic lead effects in the blood brain barrier system by DCE-CT. Journal of Trace Elements in Medicine and Biology, 2020, 62, 126648.	1.5	11
2387	Repeatability of arterial input functions and kinetic parameters in muscle obtained by dynamic contrast enhanced MR imaging of the head and neck. Magnetic Resonance Imaging, 2020, 68, 1-8.	1.0	19
2388	MR Molecular Imaging of Tumor Vasculature and Vascular Targets. Advances in Genetics, 2010, 69, 1-30.	0.8	27
2389	A facile synthesis of a theranostic nanoparticle by oxidation of dopamine-DTPA-Gd conjugates. Journal of Materials Chemistry B, 2017, 5, 8754-8760.	2.9	4
2390	PET Imaging of Tumor Perfusion: A Potential Cancer Biomarker?. Seminars in Nuclear Medicine, 2020, 50, 549-561.	2.5	9
2391	18F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data. EJNMMI Research, 2020, 10, 88.	1.1	7
2392	Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours. British Journal of Radiology, 2011, 84, S127-S144.	1.0	52
2393	Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma. PLoS ONE, 2011, 6, e23062.	1.1	81
2394	Early Detection of Lewis Lung Carcinoma Tumor Control by Irradiation Using Diffusion-Weighted and Dynamic Contrast-Enhanced MRI. PLoS ONE, 2013, 8, e62762.	1.1	9
2395	Novel Nano-Sized MR Contrast Agent Mediates Strong Tumor Contrast Enhancement in an Oncogene-Driven Breast Cancer Model. PLoS ONE, 2014, 9, e107762.	1.1	7
2396	Dynamic Contrast Enhanced MRI Detects Early Response to Adoptive NK Cellular Immunotherapy Targeting the NG2 Proteoglycan in a Rat Model of Glioblastoma. PLoS ONE, 2014, 9, e108414.	1.1	27
2397	Unsupervised Deconvolution of Dynamic Imaging Reveals Intratumor Vascular Heterogeneity and Repopulation Dynamics. PLoS ONE, 2014, 9, e112143.	1.1	15
2398	Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Gd-EOB-DTPA for the Evaluation of Liver Fibrosis Induced by Carbon Tetrachloride in Rats. PLoS ONE, 2015, 10, e0129621.	1.1	16
2399	Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma. PLoS ONE, 2015, 10, e0144488.	1.1	6
2400	Hyperthermic Laser Ablation of Recurrent Glioblastoma Leads to Temporary Disruption of the Peritumoral Blood Brain Barrier. PLoS ONE, 2016, 11, e0148613.	1.1	146
2401	Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer. PLoS ONE, 2016, 11, e0154009.	1.1	27
2402	MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. PLoS ONE, 2016, 11, e0155289.	1.1	21

#	Article	IF	Citations
2403	Use of Myometrium as an Internal Reference for Endometrial and Cervical Cancer on Multiphase Contrast-Enhanced MRI. PLoS ONE, 2016, 11, e0157820.	1.1	7
2404	Computer aided detection in prostate cancer diagnostics: A promising alternative to biopsy? A retrospective study from 104 lesions with histological ground truth. PLoS ONE, 2017, 12, e0185995.	1.1	22
2405	Monitoring tumor response to the vascular disrupting agent CKD-516 in a rabbit VX2 intramuscular tumor model using PET/MRI: Simultaneous evaluation of vascular and metabolic parameters. PLoS ONE, 2018, 13, e0192706.	1.1	3
2406	Ultra-high resolution, 3-dimensional magnetic resonance imaging of the atherosclerotic vessel wall at clinical 7T. PLoS ONE, 2020, 15, e0241779.	1.1	3
2407	Evaluation of metronomic chemotherapy response using diffusion and dynamic contrast-enhanced MRI. PLoS ONE, 2020, 15, e0241916.	1.1	4
2408	Time-Efficient Perfusion Imaging Using DCE- and DSC-MRI. Measurement Science Review, 2018, 18, 262-271.	0.6	3
2409	High Doses of Photons and Carbon Ions Comparably Increase Vascular Permeability in R3327-HI Prostate Tumors: A Dynamic Contrast-Enhanced MRI Study. Radiation Research, 2020, 194, 465-475.	0.7	1
2410	Ornamental plants architectural characteristics in relation to visual sensory attributes: a new approach on the rose bush for objective evaluation of the visual quality. European Journal of Horticultural Science, 2018, 83, 187-201.	0.3	6
2411	The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge. Tomography, 2016, 2, 56-66.	0.8	70
2412	Comparison of Voxel-Wise Tumor Perfusion Changes Measured with Dynamic Contrast-Enhanced (DCE) MRI and Volumetric DCE CT in Patients with Metastatic Brain Cancer Treated with Radiosurgery. Tomography, 2016, 2, 325-333.	0.8	13
2413	Temporal Feature Extraction from DCE-MRI to Identify Poorly Perfused Subvolumes of Tumors Related to Outcomes of Radiation Therapy in Head and Neck Cancer. Tomography, 2016, 2, 341-352.	0.8	8
2414	Spiral Perfusion Imaging with Consecutive Echoes (SPICEâ,,¢) for the Simultaneous Mapping of DSC- and DCE-MRI Parameters in Brain Tumor Patients: Theory and Initial Feasibility. Tomography, 2016, 2, 295-307.	0.8	35
2415	The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge, Part II. Tomography, 2019, 5, 99-109.	0.8	44
2416	Real-Time Quantitative Assessment of Accuracy and Precision of Blood Volume Derived from DCE-MRI in Individual Patients during a Clinical Trial. Tomography, 2019, 5, 61-67.	0.8	7
2417	Developing a Pipeline for Multiparametric MRI-Guided Radiation Therapy: Initial Results from a Phase II Clinical Trial in Newly Diagnosed Glioblastoma. Tomography, 2019, 5, 118-126.	0.8	22
2418	Early Prediction of Breast Cancer Therapy Response using Multiresolution Fractal Analysis of DCE-MRI Parametric Maps. Tomography, 2019, 5, 90-98.	0.8	25
2419	Accuracy and Performance of Functional Parameter Estimation Using a Novel Numerical Optimization Approach for GPU-Based Kinetic Compartmental Modeling. Tomography, 2019, 5, 209-219.	0.8	2
2420	Automatic Tumor Segmentation With a Convolutional Neural Network in Multiparametric MRI: Influence of Distortion Correction. Tomography, 2019, 5, 292-299.	0.8	11

#	Article	IF	CITATIONS
2421	Test–Retest Performance of a 1-Hour Multiparametric MR Image Acquisition Pipeline With Orthotopic Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts. Tomography, 2019, 5, 320-331.	0.8	9
2422	R2* Relaxation Affects Pharmacokinetic Analysis of Dynamic Contrast-Enhanced MRI in Cancer and Underestimates Treatment Response at 7 T. Tomography, 2019, 5, 308-319.	0.8	4
2423	Discrimination of Malignant and Benign Breast Lesions Using Quantitative Multiparametric MRI: A Preliminary Study. Tomography, 2020, 6, 148-159.	0.8	12
2424	Computational Modeling of Interstitial Fluid Pressure and Velocity in Head and Neck Cancer Based on Dynamic Contrast-Enhanced Magnetic Resonance Imaging: Feasibility Analysis. Tomography, 2020, 6, 129-138.	0.8	14
2425	Diffusion-Weighted and Dynamic Contrast-Enhanced MRI Derived Imaging Metrics for Stereotactic Body Radiotherapy of Pancreatic Ductal Adenocarcinoma: Preliminary Findings. Tomography, 2020, 6, 261-271.	0.8	10
2426	Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies. Oncotarget, 2016, 7, 53362-53376.	0.8	90
2427	Multiparametric imaging using 18F-FDG PET/CT heterogeneity parameters and functional MRI techniques: prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. Oncotarget, 2017, 8, 62606-62621.	0.8	30
2428	Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P. Oncotarget, 2017, 8, 55204-55215.	0.8	7
2429	Quantitative parameters in dynamic contrast-enhanced magnetic resonance imaging for the detection and characterization of prostate cancer. Oncotarget, 2018, 9, 15997-16007.	0.8	28
2430	Increasing aggressiveness of patient-derived xenograft models of cervix carcinoma during serial transplantation. Oncotarget, 2018, 9, 21036-21051.	0.8	12
2431	A pilot study using dynamic contrast enhanced-MRI as a response biomarker of the radioprotective effect of memantine in patients receiving whole brain radiotherapy. Oncotarget, 2016, 7, 50986-50996.	0.8	21
2432	DATforDCEMRI: AnRPackage for Deconvolution Analysis and Visualization of DCE-MRI Data. Journal of Statistical Software, 2011, 44, .	1.8	7
2433	Prostate cancer radiomics and the promise of radiogenomics. Translational Cancer Research, 2016, 5, 432-447.	0.4	111
2434	Dynamic contrast-enhanced MRI in cancer. Imaging in Medicine, 2009, 1, 173-186.	0.0	5
2435	Coregistration of Ultrasonography and Magnetic Resonance Imaging with a Preliminary Investigation of the Spatial Colocalization of Vascular Endothelial Growth Factor Receptor 2 Expression and Tumor Perfusion in a Murine Tumor Model. Molecular Imaging, 2009, 8, 7290.2009.00018.	0.7	10
2436	Machine learning for radiomics-based multimodality and multiparametric modeling. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 323-338.	0.4	33
2437	Prognostic role of diffusion weighted and dynamic contrast-enhanced MRI in loco-regionally advanced head and neck cancer treated with concomitant chemoradiotherapy. Radiology and Oncology, 2019, 53, 39-48.	0.6	8
2438	Differentiation of Benign from Malignant Adnexal Masses by Dynamic Contrast-Enhanced MRI (DCE-MRI): Quantitative and Semi-quantitative analysis at 3-Tesla MRI. Asian Pacific Journal of Cancer Prevention, 2019, 20, 1073-1079.	0.5	15

#	Article	IF	CITATIONS
2439	Comparison of Qualitative (Time Intensity Curve Analysis), Semi-Quantitative, and Quantitative Multi-Phase 3T DCEMRI Parameters as Predictors of Malignancy in Adnexal. Asian Pacific Journal of Cancer Prevention, 2019, 20, 1603-1611.	0.5	9
2440	Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 3652.	1.4	20
2441	Dynamic contrast-enhanced magnetic resonance imaging: fundamentals and application to the evaluation of the peripheral perfusion. Cardiovascular Diagnosis and Therapy, 2014, 4, 147-64.	0.7	75
2442	Quantitative evaluation of dual-flip-angle T1 mapping on DCE-MRI kinetic parameter estimation in head and neck. Quantitative Imaging in Medicine and Surgery, 2012, 2, 245-53.	1.1	31
2443	Dosimetric and Radiobiological Evaluation of Multiparametric MRI-Guided Dose Painting in Radiotherapy of Prostate Cancer. Journal of Medical Signals and Sensors, 2017, 7, 114.	0.5	5
2444	Magnetic Resonance Perfusion in Brain Tumors: Comparison of Different Evaluation Approaches in Dual-Echo and Multi-Echo Techniques. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 2017, 06, 174-192.	0.3	2
2445	Magnetic Resonance Perfusion Imaging in the Diagnosis of High-Grade Glioma Progression and Treatment-Related Changes: A Systematic Review. Open Journal of Modern Neurosurgery, 2018, 08, 282-305.	0.0	4
2446	Local staging of prostate cancer with MRI. Diagnostic and Interventional Radiology, 2011, 18, 365-73.	0.7	29
2447	Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer. World Journal of Radiology, 2011, 3, 1.	0.5	17
2448	Dynamic contrast-enhanced MR imaging findings of bone metastasis in patients with prostate cancer. World Journal of Radiology, 2011, 3, 241.	0.5	24
2449	Texture analysis on parametric maps derived from dynamic contrast-enhanced magnetic resonance imaging in head and neck cancer. World Journal of Radiology, 2016, 8, 90.	0.5	42
2450	Dynamic contrast-enhanced magnetic resonance imaging of prostate cancer: A review of current methods and applications. World Journal of Radiology, 2017, 9, 416-425.	0.5	36
2451	Title is missing!. Journal of Medical and Biological Engineering, 2014, 34, 157.	1.0	9
2452	Review of treatment assessment using DCE-MRI in breast cancer radiation therapy. World Journal of Methodology, 2014, 4, 46.	1.1	40
2453	Assessment of the Characteristics of Different Kinds of MS Lesions Using Multi-Parametric MRI. Archives of Neuroscience, 2020, 7, .	0.1	2
2454	Prostate tumor eccentricity predicts Gleason score better than prostate tumor volume. Quantitative Imaging in Medicine and Surgery, 2022, 12, 1096-1108.	1.1	6
2455	RBF level-set based fully-nonlinear fluorescence photoacoustic pharmacokinetic tomography. Inverse Problems in Science and Engineering, 2021, 29, 3227-3260.	1.2	1
2456	Diffusion kurtosis imaging and dynamic contrast-enhanced MRI for the differentiation of parotid gland tumors. European Radiology, 2022, 32, 2748-2759.	2.3	8

#	Article	IF	CITATIONS
2457	Stress Cardiac Magnetic Resonance Myocardial Perfusion Imaging. Journal of the American College of Cardiology, 2021, 78, 1655-1668.	1.2	57
2458	Blood–Brain Barrier Repair of Bevacizumab and Corticosteroid as Prediction of Clinical Improvement and Relapse Risk in Radiation-Induced Brain Necrosis: A Retrospective Observational Study. Frontiers in Oncology, 2021, 11, 720417.	1.3	5
2459	The history of magnetic resonance imaging and its reflections in <i>Acta Radiologica</i> Li>. Acta Radiologica, 2021, 62, 1481-1498.	0.5	2
2460	Added-value of dynamic contrast-enhanced MRI on prediction of tumor recurrence in locally advanced cervical cancer treated with chemoradiotherapy. European Radiology, 2022, 32, 2529-2539.	2.3	7
2461	Predicting T and N Staging of Resectable Gastric Cancer According to Whole Tumor Histogram Analysis About a Non-Cartesian k-Space Acquisition DCE-MRI: A Feasibility Study. Cancer Management and Research, 2021, Volume 13, 7951-7960.	0.9	0
2462	Prediction of the effects of radiation therapy in esophageal cancer using diffusion and perfusion MRI. Cancer Science, 2021, 112, 5046-5054.	1.7	1
2463	DCE-MRI detected vascular permeability changes in the rat spinal cord do not explain shorter latency times for paresis after carbon ions relative to photons. Radiotherapy and Oncology, 2021, 165, 126-134.	0.3	2
2464	Incorporating cross-voxel exchange into the analysis of dynamic contrast-enhanced imaging data: theory, simulations and experimental results. Physics in Medicine and Biology, 2021, 66, 205018.	1.6	5
2465	New and Advanced Magnetic Resonance Imaging Diagnostic Imaging Techniques in the Evaluation of Cranial Nerves and the Skull Base. Neuroimaging Clinics of North America, 2021, 31, 665-684.	0.5	3
2466	Four functional magnetic resonance imaging techniques for skeletal muscle exploration, a systematic review. European Journal of Radiology, 2021, 144, 109995.	1.2	9
2467	Microvascular Dynamics in the Nailfolds of Scleroderma Patients Studied Using Na-Fluorescein dye. Lecture Notes in Computer Science, 2001, , 204-210.	1.0	0
2468	Measurement of Blood-Brain Barrier Permeability in Multiple Sclerosis. , 2004, , 9-22.		O
2470	MRI measures of changes in the transfer constant of gadomer after dexamethasone in 9L rat cerebral tumor. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S268-S268.	2.4	0
2471	IMAGING OF PHARMACODYNAMIC END POINTS IN CLINICAL TRIALS. , 2006, , 299-336.		0
2472	SU-FF-I-65: Assessment of Advanced Algorithm in Non-Linear Curve Fitting for DSC in Human Brain. Medical Physics, 2006, 33, 2011-2011.	1.6	0
2474	Influence of Organ Motion and Contrast Enhancement on Image Registration. Lecture Notes in Computer Science, 2008, 11, 948-955.	1.0	5
2475	Imaging of Angiogenesis., 2008,, 321-332.		1
2476	Monitoring Therapy in Bone and Soft Tissue Tumors. , 2008, , 1860-1879.		1

#	Article	IF	CITATIONS
2477	Contrast Agents in Neuroradiological MRI: Current Status., 2008, , 150-157.		0
2478	Pharmacokinetic Perfusion Curves Estimation for Liver Tumor Diagnosis from DCE-MRI. Lecture Notes in Computer Science, 2008, , 789-797.	1.0	O
2480	Perfusion Imaging: Physical Principles and Applications in the Brain., 2008, , 273-308.		0
2481	Biotinoyl Domain of Human Acetyl-CoA Carboxylase;Structural Insights into the Carboxyl Transfer Mechanism. Journal of the Korean Magnetic Resonance Society, 2008, 12, 1-13.	0.1	1
2482	Analysis of in vitro 2D-COSY on Human Brain Metabolites for Molecular Stereochemistry. Journal of the Korean Magnetic Resonance Society, 2008, 12, 14-25.	0.1	0
2484	Impact of the Blood–Brain Barrier on Brain Tumor Imaging and Therapy. , 2009, , 789-811.		0
2485	Dynamic Contrast Enhancement. , 2009, , 392-406.		1
2486	Quantitative Assessment of Colorectal Cancer Perfusion: Perfusion Computed Tomography and Dynamic Contrast Enhanced Magnetic Resonance Imaging., 2009,, 183-205.		0
2487	Delay And dispersion correction for simultaneous quantification of perfusion And permeability in the prostate using DCE-MRI with a dual-contrast sequence. IFMBE Proceedings, 2009, , 14-15.	0.2	0
2489	Estudo da permeabilidade vascular e volume extracelular na diferenciação das lesões nodulares benignas e malignas da mama. Radiologia Brasileira, 2009, 42, 406-406.	0.3	0
2490	Kinetic Models for Cancer Imaging. Advances in Experimental Medicine and Biology, 2010, 680, 549-557.	0.8	1
2491	Dynamic Contrast-Enhanced and Diffusion-Weighted MRI of the Gastrointestinal Tract. Medical Radiology, 2010, , 51-63.	0.0	1
2492	Molecular Imaging of Angiogenesis. , 2010, , 105-115.		0
2493	MRI to Assess Vascular Disruptive Agents. , 2010, , 137-163.		0
2494	Contrast Ultrasound in Imaging Tumor Angiogenesis. , 2010, , 165-179.		0
2495	The Use of Animal Models in the Assessment of Tumour Vascular Disrupting Agents (VDAs). , 2010, , 49-75.		2
2498	Principles of Radiological Imaging of the Urinary Tract. , 2010, , 83-102.		0
2500	Imaging Efficacy in Tumor Models. , 2011, , 215-241.		1

#	Article	IF	Citations
2501	Quantitative DCE-MRI modeling on tumor diagnosis and treatment effect evaluation. , 2011, , .		0
2502	Dynamic Contrast-Enhanced Magnetic Resonance Imaging. , 2011, , 1173-1176.		0
2503	Simultaneous PET and MR Imaging of the Human Brain. , 2011, , 867-892.		0
2504	Brain Tumor Angiogenesis and Glioma Grading: Role of Tumor Blood Volume and Permeability Estimates Using Perfusion CT., 2011,, 81-91.		O
2505	Renal functional MRI in mice evaluated with a dual bolus of intravascular and diffusible contrast agents. Journal of Biomedical Science and Engineering, 2011, 04, 315-319.	0.2	0
2506	Clinical Applications of Dynamic Contrast-Enhanced (DCE) Permeability Imaging., 2011, , 117-137.		O
2507	Advances in Prostate Imaging: Implications for Prostate Cancer Diagnosis and Treatment. , 2012, , 219-235.		0
2509	Targeting Tumor Perfusion and Oxygenation Modulates Hypoxia and Cancer Sensitivity to Radiotherapy and Systemic Therapies. , 0, , .		1
2510	Tracer Kinetic Modeling by Morales-Smith Hypothesis in Hepatic Perfusion CT. Lecture Notes in Computer Science, 2012, , 292-302.	1.0	2
2511	Spatial-temporal Pharmacokinetic Model Based Registration of 4D Brain PET Data. Lecture Notes in Computer Science, 2012, , 100-112.	1.0	2
2512	Pharmacokinetic Analysis for Tumor Characterization Using MR-Guided Dynamic Contrast Enhanced Diffuse Optical Tomography. , 2012, , .		1
2513	The Relative Contributions of Muscle Deformation and Ischemia to Pressure Ulcer Development. , 2012, , .		1
2514	Dynamic Contrast-Enhanced Magnetic Resonance Imaging. , 2012, , 1-20.		1
2515	Magnetic Resonance Imaging of Atherosclerosis. , 2012, , 1-50.		0
2516	New Horizons in Molecular Imaging of Prostate Cancer. , 2013, , 219-234.		0
2517	A Multi-task Learning Approach for Compartmental Model Parameter Estimation in DCE-CT Sequences. Lecture Notes in Computer Science, 2013, 16, 271-278.	1.0	1
2519	Pharmacokinetics and Bio-distribution of New Gd-complexes of DTPA-bis (amide) (L3) in a Rat Model. Journal of the Korean Society of Magnetic Resonance in Medicine, 2013, 17, 259.	0.1	1
2520	Continuous-Time Flow-Limited Modeling by Convolution Area Property and Differentiation Product Rule in 4-Phase Liver Dynamic Contrast-Enhanced CT. Lecture Notes in Computer Science, 2013, , 259-269.	1.0	0

#	Article	IF	Citations
2521	MR Perfusion Imaging: ASL, T2*-Weighted DSC, and T1-Weighted DCE Methods., 2014, , 3-25.		O
2523	Bone Malignancies. , 2014, , 1369-1388.		O
2524	Bone Metastasis. , 2014, , 1389-1410.		0
2525	Multiple Myeloma and Other Hematological Malignancies. , 2014, , 1335-1354.		O
2526	Feasibility of Single-Input Tracer Kinetic Modeling with Continuous-Time Formalism in Liver 4-Phase Dynamic Contrast-Enhanced CT. Lecture Notes in Computer Science, 2014, 8676, 62-73.	1.0	0
2527	Solutions for Missing Parameters in Computer-Aided Diagnosis with Multiparametric Imaging Data. Lecture Notes in Computer Science, 2014, , 289-296.	1.0	О
2528	Distribution of Intravascular and Extravascular Extracellular Volume Fractions by Total Area under Curve for Neovascularization Assessment by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Journal of Medical Signals and Sensors, 2014, 4, 159.	0.5	0
2529	Parameter Comparison Between Fast-Water-Exchange-Limit-Constrained Standard and Water-Exchange-Modified Dual-Input Tracer Kinetic Models for DCE-MRI in Advanced Hepatocellular Carcinoma. Lecture Notes in Computer Science, 2014, , 33-47.	1.0	0
2530	New Imaging Modalities. Current Clinical Urology, 2014, , 43-63.	0.0	0
2531	Haemodynamics and Oxygenation of the Tumour Microcirculation. , 2014, , 125-141.		1
2532	Imaging Biomarkers in Preclinical Studies on Brain Tumors. , 2014, , 1-19.		0
2533	Prostate Imaging. , 2015, , 635-654.		0
2534	Dynamic Contrast-Enhanced Magnetic Resonance Imaging. , 2015, , 1-5.		0
2535	Dynamic Contrast-Enhanced Magnetic Resonance Imaging. , 2015, , 1439-1443.		0
2537	Quantitative Assessment of the Effect of Nitric Oxide Synthase Inhibition on Tumor Vascular Activity Using Dynamic Contrast-Enhanced Computed Tomography. Open Journal of Medical Imaging, 2016, 06, 42-52.	0.1	0
2538	Factors that Influence the Permeability Analysis in Magnetic Resonance Studies of the Prostate. Colorectal Cancer Open Access, 2016, 2, .	0.0	0
2539	Imagerie et spectroscopie par résonance magnétique nucléaire du muscle strié squelettique. Les Cahiers De Myologie, 2016, , 34-67.	0.0	1
2540	Multiparametric Magnetic Resonance Imaging of Prostate Cancer: Association of Quantitative Magnetic Resonance Parameters with Histopathologic Findings. Iranian Journal of Radiology, 2016, In press, .	0.1	0

#	Article	IF	CITATIONS
2541	Use Case III: Imaging Biomarkers in Breast Tumours. Development and Clinical Integration. , 2017, , 195-251.		0
2542	Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Symptomatic Uterine Fibroids and Normal Uterus: A Feasibility Study. Iranian Journal of Radiology, 2016, inpress, .	0.1	1
2543	Magnetic Resonance Imaging: Advanced Imaging Techniques., 2017,, 85-113.		3
2544	Multiparametric Imaging: Cutting-Edge Sequences and Techniques Including Diffusion-Weighted Imaging, Magnetic Resonance Spectroscopy, and PET/CT or PET/MRI., 2017,, 283-320.		0
2545	Imaging Tumor Angiogenesis. , 2017, , 1-14.		0
2546	Role of Magnetic Resonance in Drug Development. , 2017, , 1-20.		0
2547	Bildgebende Diagnostik von Gliomen. , 2018, , 29-44.		0
2548	Automatic Liver Tumor Characterization Using LAVA DCE-MRI Images. Lecture Notes in Computational Vision and Biomechanics, 2018, , 388-395.	0.5	0
2549	Tumor image signatures and habitats: a processing pipeline of multimodality metabolic and physiological images. Journal of Medical Imaging, 2017, 5, 1.	0.8	3
2551	Correlations among Apparent Diffusion Coefficient and Permeability Parameters from Dynamic Contrast-enhanced MR in Brain Tumor Parenchyma and Peritumoral Area. Journal of Neurology & Neurophysiology, 2018, 09, .	0.1	0
2552	Parameterized level-set based pharmacokinetic fluorescence optical tomography using the regularized Gauss–Newton filter. Journal of Biomedical Optics, 2018, 24, 1.	1.4	6
2553	CT Brain Perfusion: A Clinical Perspective. Lecture Notes in Computer Science, 2019, , 15-24.	1.0	0
2556	Computed Tomography and Magnetic Resonance Imaging. Recent Results in Cancer Research, 2020, 216, 31-110.	1.8	1
2557	Relevance of dynamic studies with magnetic resonance enterography in Crohn's disease. GastroenterologÃa Y HepatologÃa, 2020, 43, 179-187.	0.2	1
2559	A scalable solver for a stochastic, hybrid cellular automaton model of personalized breast cancer therapy. International Journal for Numerical Methods in Biomedical Engineering, 2021, , e3542.	1.0	2
2560	Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma. PLoS ONE, 2021, 16, e0258988.	1.1	4
2561	Parameter Selection in Dynamic Contrast-Enhanced Magnetic Resonance Tomography. Springer Proceedings in Mathematics and Statistics, 2020, , 73-89.	0.1	0
2562	Evaluation of Mesorectal Microcirculation With Quantitative Dynamic Contrast-Enhanced MRI. American Journal of Roentgenology, 2020, 215, 1370-1376.	1.0	8

#	ARTICLE	IF	Citations
2563	Evaluation of Golden-Angle-Sampled Dynamic Contrast-Enhanced MRI Reconstruction Using Objective Image Quality Measures: A Simulated Phantom Study. Tomography, 2020, 6, 362-372.	0.8	0
2564	Is quantitative DCE-MRI useful in differentiation of indolent and significant prostate cancers?. Journal of Surgery and Medicine, 2020, 4, 1186-1189.	0.0	0
2565	Dynamic Contrast-Enhanced MRI: Basic Physics, Pulse Sequences, and Modeling. Advances in Magnetic Resonance Technology and Applications, 2020, 1, 321-344.	0.0	1
2566	Alzheimer Dementia and Microvascular Pathology: Blood-Brain Barrier Permeability Imaging. Journal of the Korean Society of Radiology, 2020, 81, 488.	0.1	3
2567	Dynamic Contrast-Enhanced Imaging. , 2020, , 75-87.		0
2568	The Role of Advanced Imaging in Spinal Metastases. , 2020, , 523-534.		0
2569	CAD and Machine Learning for Breast MRI. , 2020, , 97-111.		4
2570	Applications of Quantitative Perfusion and Permeability in the Body. Advances in Magnetic Resonance Technology and Applications, 2020, , 427-454.	0.0	0
2571	Increased aneurysm wall permeability colocalized with low wall shear stress in unruptured saccular intracranial aneurysm. Journal of Neurology, 2022, 269, 2715-2719.	1.8	1
2572	Quantitative transport mapping (QTM) for differentiating benign and malignant breast lesion: Comparison with traditional kinetics modeling and semi-quantitative enhancement curve characteristics Magnetic Resonance Imaging, 2022, 86, 86-93.	1.0	8
2573	Dynamic Contrast-Enhanced MRI in Cerebral Tumours. , 2005, , 117-143.		2
2574	Angiogenesis and Lung Cancer. , 2005, , 13-30.		0
2576	Magnetic Resonance Measurement of Tumor Perfusion and Vascularity., 2007,, 73-84.		2
2577	Prostate Carcinoma – Cross-Sectional Imaging Techniques. , 2009, , 229-247.		0
2578	Molecular Imaging of Targets and Therapeutics in Tumour Angiogenesis. , 2008, , 511-528.		0
2579	Clinical Development of the VEGFR Signalling Inhibitor AZD2171., 2008,, 673-688.		0
2580	Imaging the Effect of Anti-Angiogenic Tumor Therapy in Clinical Studies. , 2008, , 717-739.		0
2581	Estimating Local Cellular Density in Glioma Using MR Imaging Data. American Journal of Neuroradiology, 2021, 42, 102-108.	1.2	9

#	Article	IF	CITATIONS
2583	Coregistration of ultrasonography and magnetic resonance imaging with a preliminary investigation of the spatial colocalization of vascular endothelial growth factor receptor 2 expression and tumor perfusion in a murine tumor model. Molecular Imaging, 2009, 8, 187-98.	0.7	6
2586	Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging. Molecular Imaging, 2011, 10, 153-67.	0.7	18
2587	Kinetic modeling in PET imaging of hypoxia. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 490-506.	1.0	17
2588	Distribution of Intravascular and Extravascular Extracellular Volume Fractions by Total Area under Curve for Neovascularization Assessment by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Journal of Medical Signals and Sensors, 2014, 4, 159-70.	0.5	0
2589	Recent developments in imaging of pancreatic neuroendocrine tumors. Annals of Gastroenterology, 2015, 28, 193-202.	0.4	38
2590	Prediction of radiosensitivity in primary central nervous system germ cell tumors using dynamic contrast-enhanced magnetic resonance imaging. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 231-8.	0.7	3
2591	Usefulness of dynamic contrast-enhanced magnetic resonance imaging for predicting treatment response to vinorelbine-cisplatin with or without recombinant human endostatin in bone metastasis of non-small cell lung cancer. American Journal of Cancer Research, 2016, 6, 2890-2900.	1.4	3
2592	Dosimetric and Radiobiological Evaluation of Multiparametric MRI-Guided Dose Painting in Radiotherapy of Prostate Cancer. Journal of Medical Signals and Sensors, 2017, 7, 114-121.	0.5	3
2594	Variability in Quantitative DCE-MRI: Sources and Solutions. Journal of Nature and Science, 2018, 4, .	1.1	18
2595	Reperfusion Injury after ischemic Stroke Study (RISKS): single-centre (Florence, Italy), prospective observational protocol study. BMJ Open, 2018, 8, e021183.	0.8	5
2596	Assessment of concurrent stereotactic radiosurgery and bevacizumab treatment of recurrent malignant gliomas using multi-modality MRI imaging and radiomics analysis. Journal of Radiosurgery and SBRT, 2018, 5, 171-181.	0.2	7
2597	DWI and DCE-MRI approaches for differentiating reversibly electroporated penumbra from irreversibly electroporated ablation zones in a rabbit liver model. American Journal of Cancer Research, 2019, 9, 1982-1994.	1.4	4
2598	Quantitative analyses of the correlation between dynamic contrast-enhanced MRI and intravoxel incoherent motion DWI in thyroid nodules. American Journal of Translational Research (discontinued), 2020, 12, 3984-3992.	0.0	1
2599	Assessment of metastatic cervical adenopathy using dynamic contrast-enhanced MR imaging. American Journal of Neuroradiology, 2003, 24, 301-11.	1.2	91
2600	Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. American Journal of Neuroradiology, 2004, 25, 746-55.	1.2	383
2601	Dynamic susceptibility contrast-enhanced perfusion and conventional MR imaging findings for adult patients with cerebral primitive neuroectodermal tumors. American Journal of Neuroradiology, 2004, 25, 997-1005.	1.2	16
2602	Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas?. American Journal of Neuroradiology, 2005, 26, 2455-65.	1.2	109
2603	Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. American Journal of Neuroradiology, 2006, 27, 1975-82.	1.2	77

#	Article	IF	Citations
2604	Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma?. American Journal of Neuroradiology, 2006, 27, 853-8.	1.2	109
2605	Comparison of microvascular permeability measurements, K(trans), determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. American Journal of Neuroradiology, 2006, 27, 409-17.	1.2	94
2606	Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. American Journal of Neuroradiology, 2005, 26, 1446-54.	1.2	128
2607	Development and testing quantitative metrics from multi-parametric magnetic resonance imaging that predict Gleason score for prostate tumors. Quantitative Imaging in Medicine and Surgery, 2021, 12, 0-0.	1.1	6
2608	The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol. BMC Cancer, 2021, 21, 1238.	1.1	4
2609	Disposable pointâ€ofâ€care portable perfusion phantom for quantitative DCEâ€MRI. Medical Physics, 2022, 49, 271-281.	1.6	3
2610	Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma. Frontiers in Immunology, 2021, 12, 790674.	2.2	14
2611	FLUID study: study protocol for an open-label, single-centre pilot study to investigate the effect of Lemborexant on sleep management in Japanese subjects aged 50 years and older with Insomnia Disorder. BMJ Open, 2021, 11, e054885.	0.8	6
2612	Recent Advances in Functional MRI to Predict Treatment Response for Locally Advanced Rectal Cancer. Current Colorectal Cancer Reports, 0 , , 1 .	1.0	0
2613	Radiomic Analysis of Pharmacokinetic Heterogeneity Within Tumor Based on the Unsupervised Decomposition of Dynamic Contrastâ€Enhanced ⟨scp⟩MRI⟨/scp⟩ for Predicting Histological Characteristics of Breast Cancer. Journal of Magnetic Resonance Imaging, 2022, 55, 1636-1647.	1.9	8
2614	Dynamic contrast-enhanced magnetic resonance perfusion volumetrics can differentiate tuberculosis of the spine and vertebral malignancy. Acta Radiologica, 2021, , 028418512110438.	0.5	2
2615	Differential diagnosis of parotid gland tumours: Application of SWI combined with DWI and DCE-MRI. European Journal of Radiology, 2022, 146, 110094.	1.2	6
2616	Extracellular volume fraction with MRI: As an alternative predictive biomarker to dynamic contrast-enhanced MRI for chemotherapy response of pancreatic ductal adenocarcinoma. European Journal of Radiology, 2021, 145, 110036.	1.2	11
2617	Repeatability of tumor perfusion kinetics from dynamic contrast-enhanced MRI in glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab174.	0.4	3
2618	Contrast agent-based perfusion MRI methods. Advances in Magnetic Resonance Technology and Applications, 2021, 4, 195-209.	0.0	0
2619	Early Response Prediction of Multiparametric Functional MRI and 18F-FDG-PET in Patients with Head and Neck Squamous Cell Carcinoma Treated with (Chemo)Radiation. Cancers, 2022, 14, 216.	1.7	14
2620	Data Learning: Integrating Data Assimilation and Machine Learning. Journal of Computational Science, 2022, 58, 101525.	1.5	35
2621	Validación de un algoritmo de obtención de biomarcadores de imágenes dinámicas de perfusión en tomografÃa computarizada. Revista Española De FÃsica Médica, 2020, 21, 53-65.	0.1	0

#	Article	IF	Citations
2622	Radiomic combination of spatial and temporal features extracted from DCE-MRI for prostate cancer detection * ., 2021, 2021, 3153-3156.		0
2623	Intravoxel Incoherent Motion Imaging on Sacroiliitis in Patients With Axial Spondyloarthritis: Correlation With Perfusion Characteristics Based on Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Frontiers in Medicine, 2021, 8, 798845.	1.2	0
2624	Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition. International Journal of Molecular Sciences, 2022, 23, 679.	1.8	O
2625	Association Between DCE-MRI Perfusion Histogram Parameters and EGFR and VEGF Expressions in Different Lauren Classifications of Advanced Gastric Cancer. Pathology and Oncology Research, 2021, 27, 1610001.	0.9	4
2626	Medical Imaging Biomarker Discovery and Integration Towards Al-Based Personalized Radiotherapy. Frontiers in Oncology, 2021, 11, 764665.	1.3	4
2627	Changes in Magnetic Resonance Imaging Radiomic Features in Response to Androgen Deprivation Therapy in Patients with Intermediate- and High-risk Prostate Cancer. Clinical Oncology, 2022, , .	0.6	2
2628	Estimation of Contrast Agent Concentration in DCE-MRI Using 2 Flip Angles. Investigative Radiology, 2022, Publish Ahead of Print, .	3.5	2
2629	Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance. , 2022, 234, 108119.		38
2630	Estimation of the capillary level input function for dynamic contrastâ€enhanced MRI of the breast using a deep learning approach. Magnetic Resonance in Medicine, 2022, , .	1.9	1
2631	Modified Maximum Entropy Method and Estimating the AIF via DCE-MRI Data Analysis. Entropy, 2022, 24, 155.	1.1	1
2632	Critical Review of the simple theoretical models in Dynamic Imaging: Up-Slope Method and Graphical Analysis. Current Radiopharmaceuticals, 2022, 15, .	0.3	0
2633	Response prediction of vestibular schwannoma after gamma-knife radiosurgery using pretreatment dynamic contrast-enhanced MRI: a prospective study. European Radiology, 2022, 32, 3734-3743.	2.3	2
2634	PET/MR Imaging of Somatostatin Receptor Expression and Tumor Vascularity in Meningioma: Implications for Pathophysiology and Tumor Outcomes. Frontiers in Oncology, 2021, 11, 820287.	1.3	1
2635	Follow-Up of High-Grade Clial Tumor; Differentiation of Posttreatment Enhancement and Tumoral Enhancement by DCE-MR Perfusion. Contrast Media and Molecular Imaging, 2022, 2022, 1-9.	0.4	3
2636	Quantitative evaluation of simultaneous spatial and temporal regularization in dynamic contrast-enhanced MRI of the liver using Gd-EOB-DTPA. Magnetic Resonance Imaging, 2022, 88, 25-37.	1.0	1
2637	Fractal analysis of perfusion imaging in synovitis: a novel imaging biomarker for grading inflammatory activity based on assessing angiogenesis. RMD Open, 2022, 8, e002078.	1.8	2
2638	Reperfusion Injury after ischemic Stroke Study (RISKS): single-centre (Florence, Italy), prospective observational protocol study. BMJ Open, 2018, 8, e021183.	0.8	13
2639	Correlation of histopathology and multi-modal magnetic resonance imaging in childhood osteosarcoma: Predicting tumor response to chemotherapy. PLoS ONE, 2022, 17, e0259564.	1.1	12

#	Article	IF	Citations
2640	Assessing Tumour Haemodynamic Heterogeneity and Response to Choline Kinase Inhibition Using Clustered Dynamic Contrast Enhanced MRI Parameters in Rodent Models of Glioblastoma. Cancers, 2022, 14, 1223.	1.7	3
2641	Bridging the macro to micro resolution gap with angiographic optical coherence tomography and dynamic contrast enhanced MRI. Scientific Reports, 2022, 12, 3159.	1.6	1
2642	Multi-parameter diffusion and perfusion magnetic resonance imaging and radiomics nomogram for preoperative evaluation of aquaporin-1 expression in rectal cancer. Abdominal Radiology, 2022, 47, 1276-1290.	1.0	9
2643	Pretreatment DCE-MRI-Based Deep Learning Outperforms Radiomics Analysis in Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Frontiers in Oncology, 2022, 12, 846775.	1.3	12
2644	Evaluation of dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging for predicting muscular hyperplasia/hypertrophy in Crohn's disease. Abdominal Radiology, 2022, 47, 1714-1724.	1.0	2
2645	Deep learning quantification of vascular pharmacokinetic parameters in mouse brain tumor models. Frontiers in Bioscience, 2022, 27, 099.	0.8	5
2646	Quantification of Blood-Brain-Barrier Permeability Dysregulation and Inflammatory Activity in MS Lesions by Dynamic-Contrast Enhanced MR Imaging. Basic and Clinical Neuroscience, 2022, 13, 117-128.	0.3	3
2647	The Potential of Photoacoustic Imaging in Radiation Oncology. Frontiers in Oncology, 2022, 12, 803777.	1.3	11
2648	Breast Cancer Subtypes and Quantitative Magnetic Resonance Imaging: A Systemic Review. Life, 2022, 12, 490.	1.1	10
2649	Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma. NMR in Biomedicine, 2022, 35, e4719.	1.6	11
2650	Magnetic Resonance Imaging (MRI) and MR Spectroscopic Methods in Understanding Breast Cancer Biology and Metabolism. Metabolites, 2022, 12, 295.	1.3	17
2651	Dynamic contrastâ€enhanced MRI parametric mapping using high spatiotemporal resolution Goldenâ€angle RAdial Sparse Parallel MRI and iterative joint estimation of the arterial input function and pharmacokinetic parameters. NMR in Biomedicine, 2022, , e4718.	1.6	1
2652	Tumor Connectomics: Mapping the Intra-Tumoral Complex Interaction Network Using Machine Learning. Cancers, 2022, 14, 1481.	1.7	1
2653	Reproducibility of dynamic contrast enhanced MRI derived transfer coefficient Ktrans in lung cancer. PLoS ONE, 2022, 17, e0265056.	1.1	3
2654	Simple Change Improves the Arterial Input Function in Dynamic Contrast Enhanced MRI. Academic Radiology, 2022, , .	1.3	0
2655	High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques. Frontiers in Oncology, 2022, 12, 810263.	1.3	29
2656	Evaluation of Dynamic <scp>Contrastâ€Enhanced MRI</scp> Measures of Lung Congestion and Endothelial Permeability in Heart Failure: A Prospective Method Validation Study. Journal of Magnetic Resonance Imaging, 2022, , .	1.9	1
2657	A multi-modality medical imaging head and neck phantom: Part 2. Medical imaging. Physica Medica, 2022, 96, 179-197.	0.4	2

#	Article	IF	CITATIONS
2658	An Anthropomorphic Digital Reference Object (DRO) for Simulation and Analysis of Breast DCE MRI Techniques. Tomography, 2022, 8, 1005-1023.	0.8	1
2659	Multi-parametric PET/MRI for enhanced tumor characterization of patients with cervical cancer. European Journal of Hybrid Imaging, 2022, 6, 7.	0.6	3
2660	The value of multi-parameter diffusion and perfusion magnetic resonance imaging for evaluating epithelial-mesenchymal transition in rectal cancer. European Journal of Radiology, 2022, 150, 110245.	1.2	6
2661	Synovial signal intensity on static contrast-enhanced MRI for evaluation of disease activity in juvenile idiopathic arthritis $\hat{a} \in A$ look at the bright side of the knee. Clinical Imaging, 2022, 86, 53-60.	0.8	2
2662	Vascularity and Dynamic Contrast-Enhanced Breast Magnetic Resonance Imaging. Frontiers in Radiology, 2021, 1 , .	1,2	2
2663	Introducing a New Biomarker Named <scp>R2</scp> *â€ <scp>BOLDâ€MRI</scp> Parameter to Assess Treatment Response in Osteosarcoma. Journal of Magnetic Resonance Imaging, 2022, 56, 538-546.	1.9	5
2664	An Attention Based Deep Learning Model for Direct Estimation of Pharmacokinetic Maps from DCE-MRI Images., 2021,,.		0
2665	The Role of Patient- and Treatment-Related Factors and Early Functional Imaging in Late Radiation-Induced Xerostomia in Oropharyngeal Cancer Patients. Cancers, 2021, 13, 6296.	1.7	1
2666	The diagnostic performance of dynamic contrast-enhanced MRI and its correlation with subtypes of breast cancer. Medicine (United States), 2021, 100, e28109.	0.4	1
2670	Sciatic nerve microvascular permeability in type 2 diabetes decreased in patients with neuropathy. Annals of Clinical and Translational Neurology, 2022, 9, 830-840.	1.7	10
2671	Subchondral involvement in osteonecrosis of the femoral head: insight on local composition, microstructure and vascularization. Osteoarthritis and Cartilage, 2022, 30, 1103-1115.	0.6	7
2672	Evaluation of the Effects of <scp>Antiâ€PD</scp> â€1 Therapy on <scp>Tripleâ€Negative</scp> Breast Cancer in Mice by Diffusion Kurtosis Imaging and Dynamic <scp>Contrastâ€Enhanced</scp> Imaging. Journal of Magnetic Resonance Imaging, 2022, 56, 1912-1923.	1.9	4
2673	Association of dynamic susceptibility contrast- and dynamic contrast-enhanced magnetic resonance imaging parameters with molecular marker status in lower-grade gliomas: A retrospective study. Neuroradiology Journal, 2023, 36, 49-58.	0.6	3
2674	Intraoperative Real-Time Near-Infrared Image-Guided Surgery to Identify Intracranial Meningiomas via Microscope. Frontiers in Neuroscience, 2022, 16, .	1.4	4
2675	New Cluster Analysis Method for Quantitative Dynamic Contrastâ€Enhanced <scp>MRI</scp> Assessing Tumor Heterogeneity Induced by a Tumorâ€Microenvironmental Ameliorator (<scp>E7130</scp>) Treatment to a Breast Cancer Mouse Model. Journal of Magnetic Resonance Imaging, 2022, 56, 1820-1831.	1.9	3
2676	Troponin T Is Negatively Associated With 3 Tesla Magnetic Resonance Peripheral Nerve Perfusion in Type 2 Diabetes. Frontiers in Endocrinology, 2022, 13, .	1.5	5
2677	Consideration of transmembrane water exchange in pharmacokinetic model significantly improves the accuracy of DCE-MRI in estimating cellular density: A pilot study in glioblastoma multiforme. Magnetic Resonance Letters, 2022, 2, 243-254.	0.7	0
2678	Monitoring Gastrointestinal Tumor Response to Therapy. , 2015, , 2295-2305.		0

#	Article	IF	CITATIONS
2679	The Blood–Cerebrospinal Fluid Barrier May Play a Role in Alzheimer Disease Pathogenesis. Radiology, 2022, 304, 646-647.	3.6	1
2680	Pediatric Osteosarcoma: Correlation of Imaging Findings with Histopathologic Features, Treatment, and Outcome. Radiographics, 2022, 42, 1196-1213.	1.4	14
2681	Sequential multiblock partial least squares discriminant analysis for assessing prostate cancer aggressiveness with multiparametric magnetic resonance imaging. Chemometrics and Intelligent Laboratory Systems, 2022, 226, 104588.	1.8	2
2682	Surrogate vascular input function measurements from the superior sagittal sinus are repeatable and provide tissue-validated kinetic parameters in brain DCE-MRI. Scientific Reports, 2022, 12, .	1.6	6
2683	Review of functional magnetic resonance imaging in the assessment of nasopharyngeal carcinoma treatment response. Precision Radiation Oncology, 2022, 6, 177-185.	0.4	1
2684	Predictors of Outcome after (Chemo)Radiotherapy for Node-Positive Oropharyngeal Cancer: The Role of Functional MRI. Cancers, 2022, 14, 2477.	1.7	5
2685	A finite element based optimization algorithm to include diffusion into the analysis of DCE-MRI. Engineering With Computers, 2022, 38, 3849-3865.	3.5	4
2686	Combining and analyzing novel multi-parametric magnetic resonance imaging metrics for predicting Gleason score. Quantitative Imaging in Medicine and Surgery, 2022, 12, 3844-3859.	1.1	5
2688	Longitudinal Correlations Between Intravoxel Incoherent Motion (IVIM) and Dynamic Contrast-Enhanced (DCE) MRI During Radiotherapy in Prostate Cancer Patients. Frontiers in Oncology, 0, 12, .	1.3	9
2689	Dynamic Contrast Enhanced Study in Multiparametric Examination of the Prostate—Can We Make Better Use of It?. Tomography, 2022, 8, 1509-1521.	0.8	1
2690	Deep learning DCE-MRI parameter estimation: Application in pancreatic cancer. Medical Image Analysis, 2022, 80, 102512.	7.0	17
2692	The optimal 18F-fluoromisonidazole PET threshold to define tumor hypoxia in preclinical squamous cell carcinomas using pO2 electron paramagnetic resonance imaging as reference truth. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4014-4024.	3.3	7
2693	Exploratory Analysis of Serial 18F-fluciclovine PET-CT and Multiparametric MRI during Chemoradiation for Glioblastoma. Cancers, 2022, 14, 3485.	1.7	1
2694	Advances in the imaging of gastroenteropancreatic neuroendocrine neoplasms. World Journal of Gastroenterology, 2022, 28, 3008-3026.	1.4	3
2695	Emerging MR methods for improved diagnosis of prostate cancer by multiparametric MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 587-608.	1.1	3
2696	Selecting ideal drugs for encapsulation in thermosensitive liposomes and other triggered nanoparticles. International Journal of Hyperthermia, 2022, 39, 998-1009.	1.1	3
2698	Advanced magnetic resonance imaging of brain tumours. , 2022, , 185-201.		0
2699	Dynamic contrast-enhanced and diffusion-weighted MR imaging in early prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer. Abdominal Radiology, 2022, 47, 3394-3405.	1.0	6

#	Article	IF	CITATIONS
2700	Liquid biopsies for early diagnosis of brain tumours: $\langle i \rangle i / i \rangle \langle i \rangle silico \langle i \rangle$ mathematical biomarker modelling. Journal of the Royal Society Interface, 2022, 19, .	1.5	2
2701	Potential 18F-RGD PET/CT and DCE-MRI Imaging-Based Biomarkers for Postoperative Survival Prediction Among Patients With Newly Diagnosed Glioblastoma Treated With Bevacizumab and Chemoradiotherapy. Frontiers in Oncology, 0, 12, .	1.3	O
2702	Modeling Blood–Brain Barrier Permeability to Solutes and Drugs In Vivo. Pharmaceutics, 2022, 14, 1696.	2.0	3
2703	ADC and kinetic parameter of primary tumor: Surrogate imaging markers for fertility-sparing vaginal radical trachelectomy in patients with stage IB cervical cancer. European Journal of Radiology, 2022, 155, 110467.	1.2	3
2704	Quantification of pulmonary functional MRI: state-of-the-art and emerging image processing methods and measurements. Physics in Medicine and Biology, 2022, 67, 22TR01.	1.6	5
2705	Correlations of tumour permeability parameters with apparent diffusion coefficient in nasopharyngeal carcinoma. Physics and Imaging in Radiation Oncology, 2022, 24, 30-35.	1.2	0
2706	Advances in Molecular, Functional, and Anatomical Head and Neck Imaging., 2022, , 73-90.		0
2707	Perfusion magnetic resonance imaging for brain tumour characterisation and assessment of treatment response., 2022,, 395-414.		0
2708	Quantitative DCE-MRI of the Breast. Advances in Magnetic Resonance Technology and Applications, 2022, , 425-458.	0.0	0
2709	DCE-MRI radiomics models predicting the expression of radioresistant-related factors of LRP-1 and survivin in locally advanced rectal cancer. Frontiers in Oncology, 0, 12, .	1.3	4
2710	Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy. Npj Breast Cancer, 2022, 8, .	2.3	3
2711	Longitudinal Changes and Predictive Value of Multiparametric MRI Features for Prostate Cancer Patients Treated with MRI-Guided Lattice Extreme Ablative Dose (LEAD) Boost Radiotherapy. Cancers, 2022, 14, 4475.	1.7	4
2712	Transport Phenomena with Reactions in Drug Delivery: Towards a Quantitative Description. Canadian Journal of Chemical Engineering, 0, , .	0.9	0
2713	Selfâ€gated, dynamic contrastâ€enhanced magnetic resonance imaging with compressedâ€sensing reconstruction for evaluating endothelial permeability in the aortic root of atherosclerotic mice. NMR in Biomedicine, 2023, 36, .	1.6	3
2714	Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	3.3	0
2715	<scp>MR</scp> multitaskingâ€based dynamic imaging for cerebrovascular evaluation (<scp>MTâ€DICE</scp>): Simultaneous quantification of permeability and leakageâ€insensitive perfusion by dynamic T1/T2* mapping. Magnetic Resonance in Medicine, 2023, 89, 161-176.	1.9	1
2716	Breast <scp>PET</scp> / <scp>MRI</scp> Hybrid Imaging and Targeted Tracers. Journal of Magnetic Resonance Imaging, 2023, 57, 370-386.	1.9	5
2717	Latest models for the discovery and development of rheumatoid arthritis drugs. Expert Opinion on Drug Discovery, 0, , .	2.5	0

#	Article	IF	CITATIONS
2718	Dynamic contrastâ€enhanced <scp>MRI</scp> and Doppler sonography in patients with squamous cell carcinoma of head and neck treated with induction chemotherapy. Journal of Clinical Ultrasound, 2022, 50, 1353-1359.	0.4	1
2719	Effect of magnetic resonance imaging pre-processing on the performance of model-based prostate tumor probability mapping. Physics in Medicine and Biology, 0, , .	1.6	0
2720	Editorial for "Influence of Different Measurement Methods of Arterial Input Function on Quantitative Dynamic Contrastâ€Enhanced <scp>MRI</scp> Parameters in Head and Neck Cancer― Journal of Magnetic Resonance Imaging, 2023, 58, 133-134.	1.9	1
2721	Evaluation of tracer kinetic parameters in cervical cancer using dynamic contrast-enhanced MRI as biomarkers in terms of biological relevance, diagnostic performance and inter-center variability. Frontiers in Oncology, 0, 12, .	1.3	0
2722	Amide proton transfer imaging of Alzheimer's disease and Parkinson's disease. Magnetic Resonance Letters, 2022, , .	0.7	1
2723	Influence of Different Measurement Methods of Arterial Input Function on Quantitative Dynamic Contrastâ€Enhanced <scp>MRI</scp> Parameters in Head and Neck Cancer. Journal of Magnetic Resonance Imaging, 2023, 58, 122-132.	1.9	2
2724	Prediction of Lung Shunt Fraction for Yttrium-90 Treatment of Hepatic Tumors Using Dynamic Contrast Enhanced MRI with Quantitative Perfusion Processing. Tomography, 2022, 8, 2687-2697.	0.8	1
2725	Diametrical Effects of Glucose Levels on Microvascular Permeability of Peripheral Nerves in Patients With Type 2 Diabetes With and Without Diabetic Neuropathy. Diabetes, 2023, 72, 290-298.	0.3	5
2726	VTDCEâ€Net: A time invariant deep neural network for direct estimation of pharmacokinetic parameters from undersampled DCE MRI data. Medical Physics, 2023, 50, 1560-1572.	1.6	2
2727	Quantitative dynamic contrast-enhanced MRI of bone marrow perfusion at the proximal femur: influence of femoral head osteonecrosis risk factor and overt osteonecrosis. European Radiology, 2023, 33, 2340-2349.	2.3	3
2729	Non-human primates models of stroke: Imaging studies in cerebral ischemia in Macaca fascicularis. , 2023, , 641-653.		0
2730	In vivo methods for imaging blood–brain barrier function and dysfunction. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1051-1083.	3.3	14
2732	Semi-quantitative and quantitative dynamic contrast-enhanced (DCE) MRI parameters as prostate cancer imaging biomarkers for biologically targeted radiation therapy. Cancer Imaging, 2022, 22, .	1.2	3
2733	Quantifying the changes in the tumour vascular micro-environment in spinal metastases treated with stereotactic body radiotherapy - a single arm prospective study. Radiology and Oncology, 2022, 56, 525-534.	0.6	3
2734	Imaging in translational cancer research. Cancer Biology and Medicine, 2022, 19, 1565-1585.	1.4	2
2735	Incorporating cross-voxel exchange for the analysis of dynamic contrast-enhanced imaging data: pre-clinical results. Physics in Medicine and Biology, 2022, 67, 245013.	1.6	0
2736	Clinical indications and acquisition protocol for the use of dynamic contrast-enhanced MRI in head and neck cancer squamous cell carcinoma: recommendations from an expert panel. Insights Into Imaging, 2022, 13, .	1.6	2
2737	Microenvironmental Factors in Oral Cavity Squamous Cell Carcinoma Undergoing Surgery: Correlation with Diffusion Kurtosis Imaging and Dynamic Contrast-Enhanced MRI. Cancers, 2023, 15, 15.	1.7	2

#	ARTICLE	IF	CITATIONS
2738	DCE-MRI and DWI can differentiate benign from malignant prostate tumors when serum PSA is $\hat{a}\%$ ¥10 ng/ml. Frontiers in Oncology, 0, 12, .	1.3	1
2740	Quantitative magnetic resonance imaging (qMRI) in axial spondyloarthritis. British Journal of Radiology, 2023, 96, .	1.0	5
2741	Diagnostic efficacy of diffusion-weighted imaging and semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging in salivary gland tumors. World Journal of Radiology, 0, 15, 20-31.	0.5	0
2742	Assessing and testing anomaly detection for finding prostate cancer in spatially registered multi-parametric MRI. Frontiers in Oncology, 0, 12, .	1.3	1
2743	Outcomes and imaging features of microinvasive carcinoma and ductal carcinoma in situ: Matched cohort study. Clinical Imaging, 2023, 96, 64-70.	0.8	3
2744	Multi-parametric MRI without artificial erection for preoperative assessment of primary penile carcinoma: A pilot study on the correlation between imaging and histopathological findings. European Journal of Radiology Open, 2023, 10, 100478.	0.7	2
2745	Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Measuring Perfusion in Pancreatic Ductal Adenocarcinoma and Different Tumor Grade: A Preliminary Single Center Study. Diagnostics, 2023, 13, 521.	1.3	1
2746	Pilot study for generating and assessing nomograms and decision curves analysis to predict clinically significant prostate cancer using only spatially registered multi-parametric MRI. Frontiers in Oncology, 0, 13, .	1.3	2
2747	A proof-of-concept pipeline to guide evaluation of tumor tissue perfusion by dynamic contrast-agent imaging: Direct simulation and inverse tracer-kinetic procedures. Frontiers in Bioinformatics, 0, 3, .	1.0	0
2748	Assessing the identifiability of model selection frameworks for the prediction of patient outcomes in the clinical breast cancer setting. Journal of Computational Science, 2023, 69, 102006.	1.5	0
2749	The arterial input function: Spatial dependence within the imaging volume and its influence on 3D quantitative dynamic contrast-enhanced MRI for head and neck cancer. Magnetic Resonance Imaging, 2023, 101, 40-46.	1.0	0
2750	Dynamic Contrast-Enhanced MRI and Its Applications in Various Central Nervous System Diseases. Investigative Magnetic Resonance Imaging, 2022, 26, 256.	0.2	1
2751	Magnetic Resonance Imagingâ€Derived Microvascular Perfusion Modeling to Assess Peripheral Artery Disease. Journal of the American Heart Association, 2023, 12, .	1.6	1
2752	Evaluation of Blood-Brain Barrier Integrity by the Analysis of Dynamic Contrast-Enhanced MRI $\hat{a}\in$ a Comparison of Quantitative and Semi-Quantitative Methods. Physiological Research, 2022, 71, S259-S275.	0.4	2
2753	Multiple parameters from ultrafast dynamic contrast-enhanced magnetic resonance imaging to discriminate between benign and malignant breast lesions: Comparison with apparent diffusion coefficient. Diagnostic and Interventional Imaging, 2023, 104, 275-283.	1.8	3
2754	Predictive model based on DCE-MRI and clinical features for the evaluation of pain response after stereotactic body radiotherapy in patients with spinal metastases. European Radiology, 0, , .	2.3	0
2755	Sex-based differences of antioxidant enzyme nanoparticle effects following traumatic brain injury. Journal of Controlled Release, 2023, 355, 149-159.	4.8	6
2757	Contributions of blood–brain barrier imaging to neurovascular unit pathophysiology of Alzheimer's disease and related dementias. Frontiers in Aging Neuroscience, 0, 15, .	1.7	4

#	Article	IF	CITATIONS
2758	Advances in PET and MRI imaging of tumor hypoxia. Frontiers in Medicine, 0, 10, .	1.2	3
2760	Characterizing the Bone Marrow Environment in Advanced-Stage Myelofibrosis during Ruxolitinib Treatment Using PET/CT and MRI: A Pilot Study. Tomography, 2023, 9, 459-474.	0.8	O
2761	Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	25
2762	Advanced <scp>MR</scp> Techniques for Preoperative Glioma Characterization: Part 1. Journal of Magnetic Resonance Imaging, 2023, 57, 1655-1675.	1.9	18
2763	Advances in Bone Marrow Imaging: Strengths and Limitations from a Clinical Perspective. Seminars in Musculoskeletal Radiology, 2023, 27, 003-021.	0.4	2
2764	Blood–brain barrier damage and new onset refractory status epilepticus: An exploratory study using dynamic contrastâ€enhanced magnetic resonance imaging. Epilepsia, 2023, 64, 1594-1604.	2.6	6
2765	Intraoperative Real-Time Near-Infrared Image-Guided Endoscopic Endonasal Surgery for Pituitary Tumors. World Neurosurgery, 2023, 175, e218-e229.	0.7	2
2766	Novel magnetic resonance KTRANS measurement of blood-brain barrier permeability correlated with covert HE. Hepatology Communications, 2023, 7, .	2.0	1
2767	The clinical value of DCE-MRI for differentiating secondary laryngeal cartilage lesions. Medicine (United States), 2023, 102, e33352.	0.4	0
2768	Delay of Aortic Arterial Input Function Time Improves Detection of Malignant Vertebral Body Lesions on Dynamic Contrast-Enhanced MRI Perfusion. Cancers, 2023, 15, 2353.	1.7	0
2769	High-temporal resolution DCE-MRI improves assessment of intra- and peri-breast lesions categorized as BI-RADS 4. BMC Medical Imaging, 2023, 23, .	1.4	3
2776	Clinical Applications of MR Perfusion Imaging. , 2023, , 119-160.		0
2777	Simultaneous PET and MR Imaging of the Human Brain. , 2023, , 1165-1201.		0
2778	Clinical Applications of Dynamic Contrast-Enhanced (DCE) Permeability Imaging. , 2023, , 175-200.		1
2787	Physical Principles of Dynamic Contrast-Enhanced and Dynamic Susceptibility Contrast MRI., 2023, , 15-34.		0
2798	MRI of skeletal muscle perfusion. Advances in Magnetic Resonance Technology and Applications, 2023, , 513-540.	0.0	0
2804	Monitoring Therapy in Bone and Soft Tissue Tumors. , 2023, , 1-29.		0
2806	Dynamic contrast-enhanced MRI. Advances in Magnetic Resonance Technology and Applications, 2023, , 17-40.	0.0	0

#	Article	IF	CITATIONS
2807	Practical considerations for water exchange modeling in DCE-MRI. Advances in Magnetic Resonance Technology and Applications, 2023, , 211-252.	0.0	0
2808	MR contrast agents for perfusion imaging. Advances in Magnetic Resonance Technology and Applications, 2023, , 135-151.	0.0	0
2833	Staging Bone and Soft Tissue Tumors. , 2023, , 1-17.		0
2839	Imaging Biomarkers in Oncology. , 2023, , 551-571.		0
2840	Imaging of the Orbit: "Current Concepts― , 2023, , 121-139.		0
2850	Comparison Between MRI Pseudo-Diffusion and Perfu-Sion Techniques in Prostate Protocol. IFMBE Proceedings, 2024, , 149-152.	0.2	0
2851	Correlation Between Molecular Techniques at Breast Multiparametric MRI Protocol. IFMBE Proceedings, 2024, , 145-148.	0.2	0